



**HAL**  
open science

## Intérêt de l'étude des HSP70-exosomes dans le diagnostic et le suivi du cancer

Gaetan Chanteloup

► **To cite this version:**

Gaetan Chanteloup. Intérêt de l'étude des HSP70-exosomes dans le diagnostic et le suivi du cancer. Médecine humaine et pathologie. Université Bourgogne Franche-Comté, 2020. Français. NNT : 2020UBFCI009 . tel-03123320

**HAL Id: tel-03123320**

**<https://theses.hal.science/tel-03123320v1>**

Submitted on 27 Jan 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**UNIVERSITE DE BOURGOGNE FRANCHE-COMTE**  
**U.F.R DES SCIENCES DE SANTE**  
**Ecole Doctorale Environnements-Santé-E2S**

**THESE**

Présentée pour l'obtention du titre de  
**DOCTEUR DE L'UNIVERSITE DE BOURGOGNE FRANCHE-COMTE**  
**Mention : Biochimie, Biologie Cellulaire et Moléculaire**

Présentée et soutenue publiquement le Mardi 01 Septembre 2020

Par :

**Gaëtan Chanteloup**

**INTERET DE L'ETUDE DES HSP70-EXOSOMES DANS LE DIAGNOSTIC ET  
LE SUIVI DU CANCER**

**Membres du jury :**

Dr Patrick Mehlen.....Rapporteur  
Dr Laura Senovilla.....Rapporteur  
Dr Cédric Rebé.....Examineur  
Dr Wilfrid Boireau.....Examineur  
Dr Carmen GARRIDO.....Directrice de thèse  
Dr Jessica Gobbo.....Co-encadrante

## Remerciements

Je tiens tout d'abord à remercier vivement les membres du Jury qui m'ont fait l'honneur de juger ce travail malgré leurs nombreuses obligations professionnelles : Je remercie les membres du jury pour leurs disponibilités, le **Dr Patrick Mehlen** et le **Dr Laura Senovilla** d'avoir accepté d'être rapporteurs de ce travail et le **Dr Cédric Rebé** ainsi que le **Dr Wilfrid Boireau** d'avoir accepté d'être examinateurs.

Je tiens à remercier en premier lieu le **Dr Carmen Garrido** de m'avoir si chaleureusement accueilli dans son équipe. Je ne vous remercierai jamais assez de la confiance que vous m'avez accordée au cours de ma thèse. Grâce à vous j'ai pu participer à différents projets, différentes réunions, à la rédaction de nombreux appels à projets et articles, à des événements de vulgarisation, à des congrès, à un gala de charité et bien d'autres. Ma thèse a ainsi été extrêmement formatrice à tout point de vue. Vous m'avez également toujours soutenu dans mes projets. Pour tout cela, je vous suis éternellement reconnaissant.

Je remercie également le **Dr Jessica Gobbo** pour son co-encadrement.

Un grand merci également aux **Dr Dominique Thuringer** et **Dr Gaëtan Jego** de m'avoir fait participer à vos projets respectifs. Ma vision de la recherche est à votre image, faite de partage et de collaborations.

Je souhaite tout particulièrement remercier **Marine**, mon binôme. Tu as été un rouage essentiel à ma thèse, tu as su m'accompagner, me soutenir, me motiver, me canaliser, me supporter aussi ! Ma thèse est intimement liée à toi, je ne peux l'évoquer sans y faire référence. Nos discussions, aussi bien professionnelles que personnelles vont me manquer et je doute de retrouver un jour une collègue si parfaite. J'admire ton abnégation, ta détermination à réussir ce que tu entreprends. Je n'ai aucun doute sur le fait que tu parviendras à tes fins ! Je te souhaite tout le meilleur, rien que le meilleur. A bientôt !

Je veux également dire merci à mes collègues et amis depuis plusieurs années maintenant, **Burhan** et **Killian**. Tout ce chemin parcouru ensemble depuis les premiers jours sur les bancs de l'université... Le temps révolu où vous aviez respectivement encore des cheveux et trois poils sur le menton ! **Burhan** merci pour toute ton aide, ton incomparable générosité, tes talents de cuisinier et ton humour... Particulier ! Tu feras un excellent médecin j'en suis sûr ! Tous mes vœux de bonheur et de réussite pour la suite. **Killian**, merci de ta gentillesse, de ton humour, des nombreux débats plus ou moins sérieux, de tes « allez juste un verre », de tes avoirs de compotes... Je te souhaite plein de bonheur professionnellement mais aussi personnellement avec ta petite Adélie comme tu le dis si souvent.

**François, Elise**, je ne peux vous distinguer l'un de l'autre ! Merci pour l'aide et toutes les discussions scientifiques que nous avons pu avoir. Merci pour les fou rire, les soirées raclettes, les mercredis foot ! François je vais poursuivre ton rêve... A toi de faire le job maintenant ! Je vous souhaite sincèrement de réussir vos projets professionnels et de vous épanouir dans votre vie future.

Mes amis, nous avons ensemble noué des liens forts, vécu des moments qui marquent une vie, et vous ferez toujours partie de la mienne.

Un grand merci également à la team football de l'unité 1231 avec qui j'ai pu partager ma passion chaque mercredi soir.

Je souhaite aussi remercier les anciens doctorants **Margaux, Guillaume, Christophe, Alex** notamment pour leur accueil et leurs conseils à mon arrivée au laboratoire.

Merci également à tous les **membres actuels et passés par l'équipe HSP-pathies** pour les échanges scientifiques mais aussi plus personnels.

Je veux également dire merci à tous les **membres de l'unité INSERM U1231**. Pour moi, les relations humaines sont très importantes et vous avez tous, de près ou de loin, participé au déroulement de ma thèse.

Merci bien évidemment à mes **amis aubois**. Vous m'avez toujours soutenu dans la poursuite de mes études.

Enfin je veux remercier **ma famille**, et plus particulièrement **mes parents** pour tout le soutien, aussi bien moral que financier. Si j'en suis là aujourd'hui c'est grâce à vous, grâce à votre éducation. Merci d'avoir fait de moi ce que je suis aujourd'hui. Sentir votre fierté me pousse à aller toujours plus loin. Merci, merci, merci.

## Résumé

Le cancer est aujourd'hui une maladie qui fait malheureusement partie de notre quotidien, et bien qu'il soit de mieux en mieux traité, de plus en plus de gens en sont atteints. La recherche s'oriente sur deux pans : la thérapie et le diagnostic. Les nouvelles thérapies présentent des résultats spectaculaires jamais atteints à ce jour, mais l'amélioration du diagnostic peut aussi sauver des vies. Il est établi que plus un cancer est diagnostiqué tôt, plus le patient a de chances de guérir. Idem pour le suivi de la maladie. Dans ce contexte de précision et de précocité, la biopsie liquide émerge et possède un avenir très prometteur. Elle consiste en l'étude d'analytes présents dans les fluides corporels, particulièrement la circulation sanguine. On y retrouve principalement, mais pas exclusivement, l'ADN tumoral circulant, les cellules tumorales circulantes (CTCs) et les exosomes.

Ce manuscrit a pour objectif de replacer mon travail de recherche, qui porte sur les exosomes, dans le contexte de la biopsie liquide, afin de laisser libre court aux comparaisons et à la compréhension de leur potentiel diagnostique. Les exosomes sont des nanovésicules libérées par les cellules dans le sang. Elles contiennent du matériel génétique, des lipides et des protéines. Une étape clé pour leur utilisation en tant que biomarqueur est de différencier les exosomes dérivés de tumeur de ceux dérivés d'autres cellules de l'organisme.

La protéine de stress Heat shock protein-70 (HSP70) a été décrite comme étant surexprimée dans les cellules cancéreuses et associée à un mauvais pronostic. Nous avons précédemment démontré que seuls les exosomes dérivés de cellules cancéreuses portaient HSP70 à la membrane. Dans ce travail, nous avons ouvert une étude clinique pilote prospective incluant des patients atteints d'un cancer du sein et du poumon afin de déterminer s'il était possible de détecter et quantifier les HSP70-exosomes dans le sang de patients atteints de tumeurs solides malignes.

Nous avons montré que le taux de HSP70 dans les exosomes, contrairement à la forme soluble, reflétait le contenu en HSP70 dans la biopsie tumorale. Le taux de HSP70-exosomes circulants est augmenté chez les patients atteints d'un cancer à un stade métastatique comparé aux non-métastatique et aux donneurs sains. Nous avons ensuite démontré que les niveaux de HSP70-exosomes étaient corrélés au statut de la maladie, et étaient potentiellement de meilleurs marqueurs que les CTCs. Enfin, nous avons indiqué que le taux de HSP70-exosomes étaient inversement corrélés à la réponse au traitement, et, par conséquent, que le suivi du taux de HSP70 dans les exosomes pourrait être utile dans la prédiction de la réponse au traitement.

## Table des matières

Liste des figures.....	7
Liste des tableaux.....	7
Liste des abréviations.....	8
ETAT DE L'ART .....	10
1. Epidémiologie des cancers : .....	11
2. Diagnostic :.....	12
2.1. La biopsie tumorale :.....	12
2.2. La biopsie liquide :.....	14
3. L'ADN tumoral circulant :.....	15
3.1. Généralités : .....	15
3.2. Détection de l'ADNtc :.....	16
3.3. Intérêt clinique de l'ADNtc :.....	18
3.3.1. Diagnostic et profilage moléculaire :.....	18
3.3.2. Suivi du cancer :.....	19
4. Les cellules tumorales circulantes (CTCs) :.....	22
4.1. Généralités : .....	22
4.2. Détection des CTCs :.....	23
4.3. Intérêt clinique des CTCs :.....	24
4.3.1. Valeur pronostique :.....	24
4.3.2. Un outil pour guider la thérapie :.....	25
5. Les vésicules extracellulaires :.....	27
6. Les exosomes :.....	28
6.1. Généralités : .....	28
6.2. Biogenèse des exosomes :.....	29
6.2.1. Formation des vésicules intraluminales :.....	30
6.2.2. Trafic intracellulaire des corps multivésiculaires jusqu'à l'exocytose : .....	31
6.3. Composition : .....	32
6.3.1. Contenu protéique : .....	32
6.3.2. Contenu lipidique : .....	33
6.3.3. Contenu en acide nucléiques : .....	33
6.4. Hétérogénéité des exosomes :.....	34
6.5. Interaction avec la cellule réceptrice : .....	35
6.5.1. Fixation à la surface des cellules cibles : .....	35
6.5.2. Signalisation intercellulaire médiée par les exosomes : .....	36
6.6. Fonction des exosomes dans le cancer :.....	37

6.6.1.	Induction de lésions néoplasiques : .....	37
6.6.2.	Rôle dans la progression tumorale : .....	37
6.7.	Utilisation des exosomes en tant que biomarqueur : .....	41
6.7.1.	Le contenu protéique des exosomes en tant que biomarqueur : .....	42
6.7.2.	Le contenu en acide nucléiques des exosomes en tant que biomarqueur : .....	43
7.	Les protéines de choc thermique (HSPs) : .....	45
7.1.	La réponse au stress cellulaire : .....	45
7.2.	Classification des HSPs : .....	46
7.3.	Structure des principales HSPs : .....	47
7.3.1.	HSP27 : .....	47
7.3.2.	HSP90 : .....	48
7.3.3.	HSP110 : .....	48
7.3.4.	HSP70 : .....	48
7.4.	Fonctions de HSP70 : .....	50
7.4.1.	Rôle de chaperon moléculaire : .....	50
7.4.2.	Rôle anti-apoptotique : .....	52
8.	HSP70 et cancer : .....	53
8.1.	HSP70 : tumorigénicité et résistance des cellules cancéreuses : .....	53
8.2.	Rôle de HSP70 extracellulaire soluble : .....	54
8.3.	Rôle de HSP70 extracellulaire lié aux membranes : .....	55
	PROJET DE RECHERCHE .....	57
	RESULTATS.....	59
	DISCUSSION ET PERSPECTIVES .....	75
	CONCLUSION GENERALE .....	80
	BIBLIOGRAPHIE.....	81
	ANNEXES.....	101

## Liste des figures

<b>Figure 1 : Incidence et mortalité des 10 cancers les plus fréquents dans le monde, en 2018.</b>	<b>12</b>
<b>Figure 2 : Hétérogénéité tumorale et évolution clonale.</b>	<b>13</b>
<b>Figure 3 : Principe de la biopsie liquide.</b>	<b>14</b>
<b>Figure 4 : Origine et types d'altérations de l'ADNtc.</b>	<b>15</b>
<b>Figure 5 : Analyse de l'ADNtc.</b>	<b>17</b>
<b>Figure 6 : Applications cliniques de l'analyse de l'ADNtc.</b>	<b>21</b>
<b>Figure 7 : Analyse des CTCs.</b>	<b>24</b>
<b>Figure 8 : Mécanismes de la biogenèse des exosomes.</b>	<b>29</b>
<b>Figure 9 : Composition des exosomes.</b>	<b>32</b>
<b>Figure 10 : Hétérogénéité des exosomes.</b>	<b>35</b>
<b>Figure 11 : Interactions des exosomes avec la cellule réceptrice.</b>	<b>37</b>
<b>Figure 12 : Rôle des exosomes dérivés de tumeur.</b>	<b>41</b>
<b>Figure 13 : Représentation schématique de la réponse au stress par HSF1 chez les vertébrés.</b>	<b>46</b>
<b>Figure 14 : Structure des principales HSPs.</b>	<b>49</b>
<b>Figure 15 : Cycle allostérique chaperon de HSP70.</b>	<b>51</b>
<b>Figure 16 : Rôles de HSP70 dans la cellule.</b>	<b>51</b>
<b>Figure 17 : Rôle anti-apoptotique de HSP70.</b>	<b>53</b>
<b>Figure 18: Rôle des HSP70-exosomes sur le système immunitaire.</b>	<b>56</b>
<b>Figure 19 : Résultats préliminaires de l'étude des HSP70-exosomes dans le cancer colorectal.</b>	<b>58</b>
<b>Figure 20 : Résultats préliminaires de l'étude des HSP70-exosomes dans le cancer colorectal.</b>	<b>78</b>

## Liste des tableaux

<b>Tableau 1 : Nomenclature des principales familles des HSPs chez l'Homme. D'après Kampinga et al, Cell stress and chaperones, 2009.</b>	<b>47</b>
---	-----------



## Liste des abréviations

<b>ABD</b>	ATP Binding Domain	<b>EGFR</b>	Epidermal Growth Factor Receptor
<b>ALIX</b>	ALG-2 interacting protein X	<b>EPHB2</b>	Ephrin type-B receptor 2
<b>ATP</b>	Adénosine Tri-Phosphate	<b>EPCAM</b>	Epithelial Cell Adhesion Molecule
<b>ADNcf</b>	ADN cell-free	<b>ER</b>	Estrogen Receptor
<b>ADNtc</b>	ADN tumoral circulant	<b>ESCRT</b>	Endosomal Sorting Complex Responsible for Transport
<b>AR</b>	Androgen Receptor	<b>FAC</b>	Fibroblaste associé au cancer
<b>ARF6</b>	ADP-ribosylation factor 6	<b>FADD</b>	Fas Associated Death Domain
<b>ARNcf</b>	ARN cell-free	<b>FAS-L</b>	Fas ligand
<b>ARv7</b>	Androgen Receptor Variant 7	<b>FDA</b>	Food and Drug Administration
<b>BCL-2</b>	B-cell lymphoma 2	<b>GAPDH</b>	Glycéraldéhyde-3-phosphate déshydrogénase
<b>CAD</b>	Caspase Activated DNase	<b>GiS1P</b>	inhibitory G protein (Gi)-coupled sphingosine 1-phosphate (S1P)
<b>circARN</b>	ARN circulaire	<b>GPC1</b>	Glypican-1
<b>CK</b>	Cytokératine	<b>GTPase</b>	Guanosine Tri-Phosphatase
<b>CMH</b>	Complexe Majeur d'Histocompatibilité	<b>HER2</b>	Human Epidermal Growth Factor Receptor-2
<b>CMV</b>	Corps Multivésiculaire	<b>HSE</b>	Heat Shock Element
<b>CNV</b>	Copy Number Variation	<b>HSF</b>	Heat Shock Factor
<b>CPA</b>	Cellule Présentatrice d'Antigène	<b>HSP</b>	Heat Shock Protein
<b>CRPC</b>	Castration-Resistant Prostate Cancer	<b>ICAM</b>	Intercellular Adhesion Molecule
<b>CTC</b>	Cellule Tumorale Circulante	<b>IHC</b>	Immunohistochemistry
<b>CTLA-4</b>	Cytotoxic T-Lymphocyte-Associated protein 4	<b>ISEV</b>	International Society of Extracellular Vesicle
<b>DAPI</b>	4',6-diamidino-2-phénylindole	<b>JAK2</b>	Janus kinase 2
<b>ddPCR</b>	Droplet Digital PCR	<b>JNK</b>	c-Jun N-terminal kinase
<b>DIABLO</b>	Direct IAP Binding protein with Low pI	<b>LFA-1</b>	Lymphocyte function-associated antigen 1
<b>DISC</b>	Death-Inducing Signaling Complex		
<b>dsDNA</b>	Double Stranded DNA		

<b>IncARN</b>	Long ARN non codant	<b>SMAC</b>	Second Mitochondria-derived Activator of Caspases
<b>MCF-7</b>	Michigan Cancer Foundation-7	<b>SNAP23</b>	Synaptosomal-Associated Protein 23
<b>MEC</b>	Matrice Extracellulaire	<b>SNARE</b>	Soluble N-éthylmaleimide-sensitive-factor Attachment protein REceptor
<b>MISEV</b>	Minimal information for studies of extracellular vesicles	<b>snARN</b>	small nuclear ARN
<b>MDSC</b>	Myeloid Derived Supressor Cell	<b>snoARN</b>	small nucleolar ARN
<b>MMP</b>	Matrix Metallo-Proteinase	<b>STAT3</b>	Signal Transducer and Activator of Transcription 3
<b>NGS</b>	Next Generation Sequencing	<b>TGF</b>	Tumor Growth Factor
<b>NES</b>	Nuclear Export Signal	<b>TLR</b>	Toll-Like receptor
<b>NLS</b>	Nuclear Localization Signal	<b>TNF</b>	Tumor Necrosis Factor
<b>NK</b>	Natural Killer	<b>TRAIL</b>	Tumor necosis factor-Related Apoptosis-Inducing Ligand
<b>NKG2D</b>	Natural Killer Group 2D	<b>TRPC-5</b>	short Transient Receptor Potential Channel 5
<b>PARP</b>	Poly (ADP-ribose) polymerase	<b>tsARN</b>	tRNA-derived small ARN
<b>PBD</b>	Peptide Binding Domain	<b>TSG101</b>	Tumor Susceptibility Gene 101
<b>PCR</b>	Polymerase Chain Reaction	<b>TYRP-2</b>	Tyrosinase-Related Protein-2
<b>PD1</b>	Programmed cell Death-1	<b>VAMP7</b>	Vesicle Associated Membrane Protein 7
<b>PD-L1</b>	Programmed death-ligand 1	<b>VE</b>	Vésicule Extracellulaire
<b>piARN</b>	Piwi-interacting ARN	<b>VEGF</b>	Vascular Endothelial Growth Factor
<b>PI3KCA</b>	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha	<b>VIL</b>	Vésicule Intra-Luminale
<b>PLD2</b>	Phospholipase D2	<b>VLA-4</b>	Very Late Antigen-4
<b>PSA</b>	Prostate Specific Antigen		
<b>PSMA</b>	Prostate-Specific Membrane Antigen		
<b>SIGLEC</b>	Sialic Acid-Binding Immunoglobulin-like Lectin		

# ETAT DE L'ART

## 1. Epidémiologie des cancers :


Dans le monde, en 2018, on estime à 18,1 millions le nombre de nouveaux cas et 9,6 millions le nombre de décès par cancer (Figure 1)<sup>1</sup>. En France métropolitaine, on estime à 382 000 le nombre de nouveaux cas de cancer (204 600 hommes et 177 400 femmes) avec un âge médian au diagnostic de 68 ans chez l'homme et de 67 ans chez la femme. Le nombre de décès par cancer est quant à lui estimé à 157 400, parmi lesquels 89 600 hommes et 67 800 femmes, en légère hausse par rapport à 2017 (84 041 hommes et 66 000 femmes), avec un âge médian au décès de 73 ans chez l'homme et de 77 ans chez la femme<sup>2,3</sup>.

Chez l'homme, le cancer de la prostate reste de loin le plus fréquent (50 430 nouveaux cas estimés en 2015), devant le cancer du poumon (31 231 cas estimés en 2018) et le cancer colorectal (23 216 cas estimés en 2018). Le cancer le plus meurtrier est le cancer du poumon avec 22 761 décès en 2018, devant le cancer colorectal (9 209 décès) et le cancer de la prostate (8 115 décès)<sup>2,3</sup>.

Chez la femme, le cancer du sein se situe au premier rang avec 58 459 cas estimés en 2018, devant le cancer colorectal (20 120 cas) et le cancer du poumon (15 132 cas). Le cancer du sein est la première cause de décès par cancer (12 146 décès), devant le cancer du poumon (10 356 décès) et le cancer colorectal (7 908 décès)<sup>2,3</sup>.

Il est désormais acquis que plus un cancer est diagnostiqué à un stade précoce, plus les chances de guérison sont importantes. Certains cancers peuvent être repérés par des tests simples permettant d'identifier dans une population les sujets qui ont un cancer mais n'en présentent pas les symptômes. En France des programmes nationaux de dépistage ont été mis en place pour trois cancers : sein (2004), colorectal (2008-2009) et col de l'utérus (2018-2019). Ainsi, toutes les femmes de 50 à 74 ans ne présentant aucun symptôme sont invitées à réaliser tous les deux ans une mammographie de dépistage, et pour les hommes et femmes du même profil, un test de recherche de sang occulte dans les selles. Pour le cancer du col de l'utérus il est recommandé de réaliser un dépistage tous les trois ans chez les femmes de 25 à 65 ans y compris chez les femmes vaccinées contre différents papillomavirus humains (HPV) car la vaccination ne protège pas contre tous les HPV liés au cancer du col de l'utérus.

Néanmoins, le dépistage ne constitue pas un diagnostic, le seul moyen étant l'analyse sur des prélèvements tissulaires : une biopsie.



**Figure 1 : Incidence et mortalité des 10 cancers les plus fréquents dans le monde, en 2018.** Lung = poumon, Breast = sein, Colorectum = colorectal, Prostate = prostate, Stomach = estomac, Liver = foie, Esophagus = œsophage, Cervix uteri = utérus, Thyroid = thyroïde, Bladder = vessie, Leukaemia = leucémie, Pancreas = pancréas, other = autre. D'après Bray et al, CA cancer J Clin, 2018.

## 2. Diagnostic :

### 2.1. La biopsie tumorale :


A ce jour, la technique de référence utilisée pour le diagnostic des cancers reste la biopsie tumorale, malgré l'apparition d'alternatives à fort potentiel. En effet, l'analyse anatomo-pathologique permet de préciser le stade de la maladie, son type histologique, et définit certaines caractéristiques biologiques, le tout permettant d'adopter le régime thérapeutique approprié ou encore de fournir des estimations pronostiques. L'apparition de technologies de pointe a permis de révéler les caractéristiques moléculaires des tumeurs et d'évoluer vers une médecine de précision, toujours plus personnalisée. Les traitements actuels consistent ainsi de plus en plus en des thérapies ciblant des altérations biologiques propres au cancer telles que la surexpression ou la mutation d'une protéine, l'amplification ou la mutation de gènes spécifiques ou encore sur la modulation du système immunitaire et du microenvironnement tumoral<sup>4</sup>. Ces altérations peuvent alors être identifiées par l'intermédiaire d'analyses anatomo-pathologiques ou de séquençage nouvelle génération (NGS) à partir du matériel issu de la biopsie tumorale.

Cependant, et bien que la biopsie tumorale soit toujours la technique privilégiée pour un diagnostic, elle présente plusieurs inconvénients :

- Le premier provient du fait que c'est un acte chirurgical invasif pour le patient, qui en plus n'est pas toujours réalisable. En effet, certaines tumeurs peuvent être localisées dans des endroits difficilement accessibles. De plus, le risque est parfois trop important lorsque l'acte doit être

réalisé à proximité d'un vaisseau sanguin majeur ou lorsque le patient possède d'autres comorbidités.

- Le deuxième réside dans l'hétérogénéité tumorale. La tumeur est ainsi composée de différents clones exprimant certaines protéines ou certaines mutations dans des endroits différents. Ce processus est dynamique et peut évoluer au cours de la croissance de la tumeur avec la dominance de certains clones dans certaines régions. De plus, chaque patient possède une hétérogénéité tumorale propre, y compris ceux porteurs d'une tumeur de même nature. Les métastases peuvent également présenter un profil génétique différent de celui de la tumeur primitive. Enfin, le stress thérapeutique, et plus particulièrement les thérapies ciblées, entraîne une pression de sélection clonale qui modifie le paysage génétique de la tumeur<sup>5-9</sup> (Figure 2). Par conséquent, l'étude des caractéristiques de la tumeur via la biopsie ne reflète pas toute l'hétérogénéité tumorale, voire du corps entier s'il y a des métastases, et peut donc fausser la prise de décision thérapeutique.



**Figure 2 : Hétérogénéité tumorale et évolution clonale.** Puisque les tumeurs cancéreuses présentent des variations au sein des cellules qui la constituent, certains types de clones peuvent dominer un site spécifique de la tumeur (dominance of clone) ou être retrouvé de façon relativement équitable (mixed dominance). L'évolution clonale a lieu au cours de la progression tumorale (tumor development) ou à la suite de traitements spécifiques (treatment). Intratumoral heterogeneity = hétérogénéité intratumorale, heterogeneous tumor = tumeur hétérogène, cancer patient = patient cancéreux, clonal evolution = évolution clonale. D'après Oliveira et al, *Molecular cancer research*, 2020.


- La troisième raison est sous-jacente aux deux premières : elle ne permet pas d'étudier la dynamique de la tumeur au cours de la ligne de traitement.

Ainsi, ces dernières années, la médecine de précision et notamment la recherche en cancérologie s'est focalisée sur la biopsie liquide puisqu'elle permet des prélèvements répétés de façon peu invasive. Elle offre également la possibilité d'une détection précoce contrairement à la biopsie tumorale<sup>5-7</sup>.

## 2.2. La biopsie liquide :

Le terme « biopsie liquide » a été utilisé pour la 1<sup>e</sup> fois en 2010 par Klaus Pantel et Catherine Alix-Panabières, pionniers en la matière, pour décrire une méthode basée sur une prise de sang et capable de fournir les mêmes informations que la biopsie tumorale<sup>8</sup>. Il se réfère au prélèvement et à l'analyse de tous les fluides biologiques corporels, principalement le sang, mais aussi l'urine, le liquide cébro-spinal, la salive ou encore les effusions pleurales<sup>9,10</sup>. Le sang périphérique constitue la principale source d'analytes pour la biopsie liquide. Il contient notamment des cellules tumorales circulantes (CTCs), de l'ADN circulant libre (*ADN cell-free*, ADNcf) ou tumoral circulant (ADNtc), de l'ARN circulant libre (*ARN cell-free*, ARNcf), principalement des petits ARNs non codants mais aussi de l'ARN messenger, des vésicules extracellulaires, majoritairement des exosomes, mais aussi des protéines et de nombreux métabolites<sup>5,6,9-13</sup>. Ainsi, ensemble, ces analytes ont le potentiel de refléter les caractéristiques de la tumeur, habituellement fournies par la biopsie tumorale. Par exemple, les données sur les altérations génomiques peuvent être fournies par les CTCs ou l'ADNtc, tandis que d'autres analytes circulants fournissent des informations sur la transcriptomique<sup>14</sup>, l'épigénomique<sup>15</sup>, la protéomique<sup>16</sup> ou encore la métabolomique<sup>17</sup> des tumeurs (Figure 3).

Ainsi, la biopsie liquide, au travers de ses composants, émerge comme un outil prometteur pour la médecine de précision grâce à sa capacité à refléter de façon globale l'hétérogénéité tumorale.



**Figure 3 : Principe de la biopsie liquide.** 1) Des cellules sont capables de se détacher de la tumeur primitive ou des lésions métastatiques (primary tumour or metastatic lesion) et d'entrer dans la circulation sanguine (bloodstream) : les cellules tumorales circulantes (CTC). 2) les exosomes sont libérés par les cellules tumorales et saines. 3) Les cellules apoptotiques ou nécrotiques (apoptotic or necrotic cell) libèrent de l'ADNtc (ctDNA) dans la circulation sanguine. Les CTCs sont ensuite capables de contribuer au pool d'exosomes (4) et d'ADNtc (5). Des prises de sang (blood sample) répétées peuvent être réalisées pour stratifier les patients, évaluer l'efficacité thérapeutique, identifier des cibles thérapeutiques, et détecter l'émergence de mécanismes de résistance du cancer. Personalized treatment = traitement personnalisé. D'après Alix-Panabières et al, Nature Biomedical Engineering, 2017.

### 3. L'ADN tumoral circulant :


#### 3.1. Généralités :

On appelle ADN tumoral circulant (ADNtc), l'ADN dérivé de tumeur primaires ou métastatiques qui se retrouve dans les fluides biologiques et notamment la circulation sanguine. Il provient des cellules tumorales apoptotiques<sup>18,19</sup> et nécrotiques<sup>20</sup> mais également de la sécrétion de cellules intactes sous forme libre<sup>21</sup> ou associées à des vésicules extracellulaires<sup>22,23</sup> (Figure 4). L'ADNtc se distingue de l'ADN dit « cell-free » (ADNcf) qui, lui, correspond à l'ADN libéré dans le milieu extracellulaire mais qui ne provient pas de cellules tumorales. Il provient des cellules non malignes qui meurent, mais aussi des tissus sains affectés par certaines thérapies chez les patients atteints de cancer telles que la chimiothérapie ou la radiothérapie, ce qui a pour effet de diluer l'ADNtc. Il est caractérisé par des altérations tumorales telles que des mutations ponctuelles, des réarrangements chromosomiques, des « copy-number variation » (CNV), et une méthylation propre<sup>24-26</sup> (Figure 4).

De façon intéressante, l'ADNtc possède une faible demi-vie dans la circulation sanguine, environ 2h, ce qui permet de suivre en temps réel la dynamique de la tumeur tout au long du traitement<sup>24</sup>. L'avancée des technologies de pointe a permis de montrer que l'ADNtc reflète le génome tumoral puisque l'ADN libéré provient de différentes régions de la tumeur<sup>27-29</sup> ou des foyers tumoraux<sup>30</sup>. En



effet, des études ont révélé la présence de mutations dans le sang qui n'étaient pas présentes dans les tissus correspondants mettant ainsi en lumière l'hétérogénéité tumorale<sup>31</sup> ainsi que la détection de mutations sous-clonales<sup>32-35</sup>. Elles ont aussi révélé la présence de sous-types moléculaires spécifiques avec des signatures génomiques distinctes<sup>36,37</sup>. La découverte de ces nouvelles données a donc très vite suggéré leur utilisation potentielle en tant que biomarqueur ; il s'en est suivi une explosion des études démontrant un fort intérêt dans le diagnostic, le pronostic et le suivi de la réponse au traitement des patients atteints de tumeurs solides<sup>11,24,38</sup>. L'analyse de l'ADNtc est aujourd'hui fréquemment utilisée en clinique puisqu'il constitue une alternative sérieuse à la biopsie tissulaire, en particulier dans les cas où cette dernière est impossible à réaliser, ou lorsque le risque est trop important. Il permet également un suivi constant, presque en temps réel de la réponse au traitement, ce qui est impossible avec une biopsie classique.




**Figure 4 : Origine et types d'altérations de l'ADNtc.** Les cellules libèrent de l'ADN qui provient d'une combinaison de sécrétion (secretion), d'apoptose (apoptosis) et de nécrose (necrosis). Dans la circulation sanguine, l'ADNtc circulant peut être libre ou dans les exosomes (exosomal DNA). On retrouve différents types d'altérations génétiques : des mutations ponctuelles (point mutations), des variations du nombre de copies (copy number alterations), des réarrangements (rearrangements), ou encore des méthylations particulières (methylation changes). D'après Wan et al, Nature reviews cancer, 2017.

### 3.2. Détection de l'ADNtc :

L'ADNtc est présent à faible concentration dans la circulation et se retrouve noyé dans l'ADNcf. La capacité de détection des mutations est ainsi directement corrélée à la charge tumorale ; plus la tumeur est grosse, plus le taux d'ADNtc libéré dans la circulation sanguine est important<sup>39</sup>. Il y a néanmoins une variabilité inter-individuelle puisqu'il existe des patients avec un stade avancé et peu d'ADNtc dans le sang, y compris des patients atteints d'une même tumeur<sup>33,40,40</sup>. Il est donc nécessaire d'avoir des technologies suffisamment sensibles et spécifiques pour détecter des mutants pouvant être présent à une fréquence de 0,01%<sup>25,39</sup> (Figure 5).

Il existe aujourd'hui une multitude de technologies de pointe qui font preuve d'une innovation constante afin d'en améliorer la sensibilité et la spécificité ; elles reposent soit sur le principe de la PCR (*Polymerase Chain Reaction*), ou du NGS (*Next Generation Sequencing*)<sup>11,25,41</sup>. Pour la détection de mutations ponctuelles, des techniques spécifiques de l'analyse de mutations basée sur la PCR ont été développées telles que le BEAMing (beads, emulsion, amplification, and magnetics)<sup>42</sup> ou la ddPCR (droplet digital PCR)<sup>43</sup>. Elles sont capables d'identifier et quantifier avec une grande précision les altérations génétiques circulantes, mais ne permettent pas ou peu l'analyse de plusieurs cibles en parallèle. Des techniques de NGS ont également été adaptées à l'analyse de l'ADNtc, en passant du séquençage du génome entier ou de l'exome<sup>44</sup>, au séquençage ciblé<sup>45</sup> sur un panel de gènes plus restreint<sup>46,47</sup>. Néanmoins, bien que ces techniques de séquençage permettent une analyse multiplexée, elles sont moins sensibles et moins spécifiques que les techniques basées sur la PCR, du fait du taux d'erreur de l'ADN polymérase et du séquençage. Ainsi, afin de contourner ces inconvénients, des approches nouvelles ont intégré des méthodes de séquençage ultrasensibles, des code-barres moléculaires ou encore des algorithmes de suppression d'erreurs afin d'en améliorer la limite de détection<sup>35,48,49</sup>. Il existe donc aujourd'hui une grande variété de techniques permettant d'analyser très précisément les altérations génétiques circulantes, chacune ayant des caractéristiques différentes au niveau de la sensibilité de la spécificité et du multiplexage. Il est donc nécessaire d'adapter le choix de l'analyse à réaliser en fonction de la nature de l'altération, de sa fréquence dans la circulation et de l'information que l'on souhaite en tirer (Figure 5).



**Figure 5 : Analyse de l'ADNtc.** Une fois extrait du plasma, l'ADNtc est analysé pour détection des altérations associées au cancer. Les différentes méthodes de détection ont chacune une limite de sensibilité (limit of detection), qui régit son utilité clinique (clinical relevance). Molecular techniques = techniques moléculaires, diagnosis = diagnostic, monitoring = suivi, tumor burden = volume tumoral, metastatic disease = maladie métastatique. D'après Oliveira et al, *Molecular cancer research*, 2020.

### 3.3. Intérêt clinique de l'ADNtc :

#### 3.3.1. Diagnostic et profilage moléculaire :

La connaissance précise de l'hétérogénéité tumorale est aujourd'hui fondamentale dans la médecine oncologique puisqu'elle permet notamment de sélectionner les thérapies à administrer aux patients. La potentielle utilisation de la biopsie liquide afin de réaliser le profilage moléculaire de la tumeur de façon peu invasive a fait de l'ADNtc un outil attractif.

Une grande majorité des études réalisées sur des cohortes importantes montrent une grande concordance entre la tumeur et le plasma (80 à 90%)<sup>44,50-52</sup>. Ainsi, plusieurs équipes se sont intéressées à la pertinence de l'analyse de l'ADNtc dans la détection précoce des cancers. Les résultats sont encourageants pour les tumeurs avancées mais moins pour les cancers primaires, notamment parce que l'ADNtc y est extrêmement rare et que l'on atteint la limite de détection des technologies d'analyse<sup>29,33</sup>.

Malgré ces données encourageantes, la biopsie tumorale reste à ce jour l'option majoritaire pour plusieurs raisons ; la première réside dans le fait qu'elle permet une analyse histologique et d'autres marqueurs, en particulier protéiques, très utiles pour le diagnostic, la stratification des patients ainsi que la prise de décision thérapeutique. Ensuite, plusieurs études ont démontré que certains patients ne possédaient pas suffisamment d'ADNtc en dépit de la nature de la tumeur et du stade de la maladie<sup>33,52</sup>.

Néanmoins, l'analyse de l'ADNtc peut être une alternative pertinente lorsque que la biopsie tumorale n'est pas possible ou trop dangereuse à réaliser, c'est pourquoi elle est de plus en plus utilisée en clinique pour la sélection des traitements de ces patients<sup>51,53</sup>. D'un point de vue du suivi, la possibilité de suivre en temps réel l'évolution de la tumeur via des prélèvements réguliers au cours de la ligne de traitement permet, par exemple, de détecter l'apparition d'altérations génétiques responsables de la résistance aux thérapies (Figure 6)<sup>54-60</sup>. Le meilleur exemple d'utilisation de l'analyse de l'ADNtc en clinique concerne la détection de l'apparition de la mutation EGFR-T790M chez les patients atteints d'un cancer du poumon non à petites cellules EGFR muté, traités par des anti-EGFR. Des études clés ont démontré une très grande concordance dans la détection de la mutation T790M circulante et dans la tumeur, qui répondent à l'osimertinib, un inhibiteur de EGFR de troisième génération<sup>61,62</sup>. Ainsi, le « cobas EGFR Mutation Test » a été approuvé par la FDA en tant que test diagnostique de complément pour le choix des thérapies EGFR<sup>63</sup>.

### 3.3.2. Suivi du cancer :

#### 3.3.2.1. Suivi de la réponse au traitement :

De nombreuses études ont montré la corrélation entre le volume tumoral et le taux d'ADNtc, qui chute après un traitement tel qu'une chirurgie ou une thérapie à base de drogues suggérant ainsi la potentielle utilisation en tant que biomarqueur<sup>24,42,45,57</sup>. Le gros avantage de l'ADNtc est son court temps de demi-vie, approximativement 2h, qui permet une analyse en temps réel de la tumeur comparativement aux marqueurs tumoraux classiques, qui ont une demi-vie de plusieurs jours à plusieurs heures, et à l'imagerie médicale. En effet, des études ont montré une pauvre sensibilité et spécificité des marqueurs tumoraux comparé à l'ADNtc<sup>57,64</sup>, qui, lui, permet de détecter une progression tumorale de façon plus précoce que la radiographie<sup>32,57-59</sup>.

#### 3.3.2.2. Détection de la résistance au traitement et de l'hétérogénéité tumorale :

La résistance au traitement se définit par une inefficacité de la thérapie. Celle-ci peut être « primaire » lorsque le patient, d'emblée, ne répond pas au traitement, ou « secondaire » lorsque le patient répond dans un premier temps jusqu'à ce que la drogue devienne inefficace à un moment donné de la ligne de traitement. Ceci s'explique par la création de nouvelles mutations induites par les drogues dans certains clones qui prolifèrent et qui permettent à la tumeur de croître via d'autres voies de signalisations<sup>54,56,59,60,65</sup>. Sachant qu'il existe une grande hétérogénéité au sein de la tumeur chez un même individu, y compris dans les sites métastatiques, la biopsie solide, qui ne permet d'analyser qu'une partie de la tumeur primitive, peut potentiellement fausser le diagnostic. De plus, on sait dorénavant que l'ADNtc reflète complètement l'hétérogénéité tumorale du corps entier<sup>54,56,66</sup>. Ces données permettent donc aux cliniciens de déterminer avec précision le moment à partir duquel le patient devient réfractaire à la thérapie, mais aussi le type de thérapie à adopter pour contrer cette résistance secondaire (Figure 6). Une étude menée sur des patients atteints d'un cancer colorectal et traités aux anti-EGFR a par exemple détecté pas moins de 13 mutations de résistance différentes via l'ADNtc, avec moins d'un dixième des patients seulement présentant une seule mutation de résistance<sup>52</sup>.

Ainsi, en plus de la détection de l'émergence de la résistance au traitement, l'ADNtc peut être utilisé pour son suivi. Un exemple marquant est celui discuté précédemment de la mutation EGFR T790M dans le cancer du poumon non à petites cellules<sup>61,62,65</sup>. D'autres études sur le cancer colorectal ont démontré que l'apparition de mutations du gène KRAS, KRAS G12R et KRAS G13D notamment, engendraient une résistance aux anti-EGFR<sup>32,58,59</sup>. L'arrêt de ce type de traitement entraîne quant à lui une chute du taux de mutations du gène RAS circulant, ce qui suggère au clinicien la possibilité de réintroduire les anti-EGFR dans la ligne de traitement<sup>32</sup>. Des recherches similaires ont été menées dans différents cancers tels que le cancer du sein<sup>47</sup> ou encore le cancer de la prostate<sup>67,68</sup>.


Ces études indiquent donc que l'évolution clonale durant les thérapies peut être suivie via l'analyse de l'ADNtc.

### *3.3.2.3. Détection du risque de rechute :*

L'ADNtc concentre aussi de nombreux espoirs dans la détection précoce du risque de rechute. Le traitement initial pour une majorité de tumeurs est la chirurgie, qui est suivie ou non d'une thérapie adjuvante afin d'éliminer les éventuelles cellules cancéreuses restantes et donc de diminuer le risque de rechute. Néanmoins, il est difficile pour les cliniciens de discriminer les patients avec un grand risque de rechute.

Ainsi, dans certains cas bien particuliers comme le cancer colorectal de stade II, les patients avec un faible risque clinique ne se voient pas tous administrer une thérapie adjuvante alors que 15% environ rechutent<sup>24</sup>. Une étude menée par Diehl et ses collègues a montré que la détection d'ADNtc chez les patients atteints d'un cancer colorectal quelques semaines après une chirurgie rechutaient dans les 1an<sup>69</sup>. Une autre étude également réalisée dans ce même cancer a montré que de grandes concentrations d'ADNtc, et notamment des mutants KRAS, étaient un indicateur précis du risque de rechute<sup>70</sup>. Des résultats similaires ont été publiés dans le cancer du sein<sup>71,72</sup>, du poumon<sup>73</sup> et du pancréas<sup>74</sup> soulignant ainsi toute l'importance que pourrait avoir l'ADNtc dans le suivi du cancer (Figure 7). Des études cliniques sont actuellement en cours pour démontrer sa valeur clinique.

L'analyse de l'ADNtc a donc connu un bond en avant conséquent ces dernières années, et ce de manière extrêmement rapide au vu des applications cliniques potentielles extrêmement prometteuses. Il faut néanmoins un consensus méthodologique afin de l'introduire complètement en clinique. Bien qu'elle soit déjà utilisée pour certaines applications, l'analyse de l'ADNtc possède le potentiel de transformer plus encore la prise en charge des patients atteints de cancer.



**Figure 6 : Applications cliniques de l'analyse de l'ADNtc.** L'analyse de l'ADNtc à de potentielles applications cliniques à différentes étapes cliniques du cancer. Des méthodes de détection précoce (early detection) de tumeurs naissantes sont en cours de développement. La biopsie liquide est capable d'identifier des cancers à un stade précoce, lorsqu'il est cliniquement détectable (clinically detectable). Après la chirurgie (surgical resection), l'ADNtc peut être analysé pendant des mois afin de détecter la présence éventuelle d'altérations présentes dans la tumeur réséquée, c'est-à-dire détecter la maladie résiduelle (minimal residual disease). Puisque la demi-vie de l'ADNtc est très courte, la détection de mutations de plasma post-chirurgical peut fournir une preuve directe d'une possible rechute. De plus, la détection d'ADNtc rapidement après la chirurgie peut permettre de stratifier les patients selon le risque de récurrence et peut offrir une opportunité pour une intervention précoce. Dans le contexte d'un cancer métastatique (metastatic disease), le profilage moléculaire (molecular profiling) par séquençage de l'ADNtc peut identifier de potentielles altérations génétiques qui peuvent être ciblées par des thérapies de précision. Des études ont montré que le taux d'ADNtc corrélait avec le volume tumoral et peut être utilisé comme un moyen précis de suivre la réponse au traitement (response monitoring) et l'apparition d'une résistance (resistance mechanisms). Lorsque la maladie progresse, l'analyse de l'ADNtc a prouvé son efficacité pour identifier des altérations génétiques émergentes qui entraînent une résistance à la thérapie, et peut donc guider la prise de décision thérapeutique. Enfin, l'analyse de l'ADNtc a été utilisée pour suivre la dynamique d'évolution clonale (monitoring of clonal dynamics) de différents sous clones au cours de la thérapie. D'après Corcoran et al, NEJM, 2018.

## 4. Les cellules tumorales circulantes (CTCs) :

### 4.1. Généralités :

Les cellules tumorales circulantes sont des cellules émergent de carcinomes, c'est-à-dire de cancers d'origine épithéliale, qui ont la capacité de migrer de la tumeur primaire et des sites métastatiques dans la circulation sanguine afin de coloniser un autre organe<sup>75</sup>. Lors de leur intravasation ces cellules sont soumises à des conditions de sélection difficiles. En effet, leur temps de demi-vie est estimé de 1 à 2,4 heures<sup>76</sup>. De plus, des CTCs apoptotiques ou fragmentées sont fréquemment retrouvées dans le sang périphérique de patients atteints de cancer ; ainsi la clairance des cellules cancéreuses circulantes survivantes intervient au moment de l'extravasation dans les organes secondaires<sup>77</sup>.

La détection et l'analyse des CTCs ont été corrélées à différents paramètres cliniques et démontrées comme étant utile dans le diagnostic et le suivi de nombreuses tumeurs solides, notamment le cancer du sein, le cancer colorectal et de la prostate dont la technique de détection CellSearch® est approuvée par l'administration fédérale de l'alimentation et de médicaments américaine (*Food and Drug Administration, FDA*)<sup>11,78-80</sup>. Il y a cependant quelques inconvénients à la détection des CTCs, le principal étant que ces cellules sont rares ; on estime qu'il y a 1 à 10 cellules pour dix millilitre de sang, soit une cellule pour  $10^{6-7}$  leucocytes<sup>81,82</sup>. Il faut donc avoir des technologies capables de détecter avec suffisamment de sensibilité et de spécificité une CTC parmi les millions d'autres cellules présentes dans le sang. L'autre obstacle majeur provient du phénotype même de ces cellules ; elles sont caractérisées biologiquement par la présence du marqueur d'adhésion cellulaire épithélial EPCAM ainsi que des membres de la famille des cytokératines tels que CK8, CK18 et CK19, et physiquement par leur taille plus importante, leur forme irrégulière ainsi que leur morphologie subcellulaire particulière<sup>75,83</sup>. Cependant, ce n'est pas toujours le cas ; en effet, les CTCs sont capables de procéder à un mécanisme appelé transition épithélio-mésenchymateuse qui consiste en la perte de ses caractéristiques épithéliales au profit d'un phénotype mésenchymateux<sup>84</sup>. Il en résulte une augmentation de la plasticité ainsi que de la capacité de migration et d'invasion, de résistance à l'anoïkis et à l'apoptose ; autant de paramètres qui font de ces CTCs les plus à même de parvenir à coloniser un organe secondaire<sup>84,85</sup>. Enfin ces cellules sont capables de former des clusters avec un potentiel métastatique 25 à 50 fois supérieur<sup>86</sup>.


Il apparaît donc que ces cellules existent avec différents phénotypes ce qui rend leur utilisation en tant que biomarqueur plus complexe. Les progrès technologiques des dernières années permettent de mieux étudier la biologie des CTCs, notamment les approches « single cell », qui ont révélé de nouvelles approches possibles pour leur utilisation en tant que biomarqueur circulant<sup>11,87,88</sup>.

## 4.2. Détection des CTCs :

Les CTCs sont essentielles pour la compréhension de la biologie des métastases et représentent un fort potentiel en tant que biomarqueur non invasif pour évaluer la progression tumorale et la réponse au traitement. Néanmoins, cette méthode qui présente certains avantages tels que la robustesse et la reproductibilité comporte aussi de nombreuses limites<sup>84,89</sup>. La première difficulté réside dans le fait de pouvoir différencier ces cellules extrêmement rares au milieu des millions d'autres cellules présentes dans un échantillon sanguin. Il existe ainsi deux grands types d'approches qui tirent parti de l'aspect biologique de ces cellules, ou de leur aspect physique mais à ce jour une seule est approuvée par la FDA : le système CellSearch® (Figure 7)<sup>84</sup>. Cette approche basée sur la biologie des CTCs consiste en premier lieu en une étape d'enrichissement par sélection positive des cellules exprimant EPCAM. Le prélèvement de sang périphérique (7,5mL) est suivi d'une étape de capture immunomagnétique avec des nanoparticules de fer recouverte d'un polymère de biotine, couplé avec des anticorps anti-EPCAM. Des réactifs fluorescents sont ensuite ajoutés pour la détection des CTCs : le DAPI pour la coloration du noyau cellulaire, des anticorps dirigés contre les cytokératines 8, 18 et 19 (marqueurs spécifiques des cellules épithéliales) et contre CD45 (un marqueur spécifique des leucocytes). Le mélange réactifs/échantillon est ensuite déposé à l'intérieur d'une cartouche qui est insérée dans un dispositif comprenant un champ magnétique attirant les cellules épithéliales marquées magnétiquement à la surface de la cartouche. Un microscope fluorescent couplé à un logiciel permet ensuite la lecture automatique et le décompte des cellules tumorales circulantes, c'est-à-dire les cellules positives pour le marquage au DAPI et aux cytokératines et négatives pour le marquage CD45. Des kits de réactifs de phénotypage HER2 et EGFR sont également commercialisés et permettent de mettre en évidence les CTC surexprimant ces récepteurs.

Il existe actuellement d'autres techniques de détection des CTCs en cours de développement ou de validation clinique qui tirent parti de leurs différences phénotypiques et moléculaires, qui pourraient accélérer leur utilisation en clinique<sup>84</sup>(Figure 7)<sup>11,84</sup>.





**Figure 7 : Analyse des CTCs.** Les CTCs peuvent être enrichies à partir du sang grâce à des techniques utilisant des marqueurs biologiques (enrichment) : sélection positive in vitro ou in vivo en utilisant des anticorps dirigés contre des protéines épithéliales et/ou mésenchymateuses (antibody to epithelial or mesenchymal marker), ou négativement à travers la déplétion de leucocytes avec des anticorps anti-CD45 (anti-CD45 antibody). Un enrichissement positif peut aussi être réalisé in vitro grâce à des méthodes basées sur les caractéristiques physiques des CTCs tels que la taille (size), la déformabilité (deformability), la densité (density) et la charge électrique (electric charge). Ensuite, les CTCs peuvent être détectées (CTC detection) par des techniques qui reposent sur l'immunocytologie (immunocytology), la biologie moléculaire (molecular biology) ou des essais fonctionnels (fonctionnal assays). Concernant l'immunocytologie, les CTCs sont identifiées par des anticorps dirigés contre des marqueurs épithéliaux, mésenchymateux, spécifiques de la tumeur (tumour-associated marker) ou des tissus (tissue-specific marker). Les méthodes moléculaires utilisent des essais basés sur l'analyse de l'ARN tels que la RT-qPCR, le NGS ou l'hybridation ARN in situ. Les essais fonctionnels sont eux principalement des tests EPISPOT ou EPIDROP. Enfin, la caractérisation des CTCs (CTC characterization) est réalisée en étudiant son génome, son protéome et son transcriptome ainsi qu'en testant ses propriétés in vivo, par xénogreffe (xenograft). D'après Pantel et al, Nature Review clinical oncology, 2019.

### 4.3. Intérêt clinique des CTCs :

#### 4.3.1. Valeur pronostique :

De nombreuses études démontrent l'intérêt pronostique des CTCs chez des patients atteints de différentes tumeurs solides, particulièrement dans le cancer du sein<sup>80,86,90,91</sup>. Une étude de Rack et ses collègues réalisée sur 2026 patients avec un cancer du sein à un stade précoce avant chimiothérapie et chez 1492 patients après chimiothérapie a démontré que la présence des CTCs était associée à une faible survie sans maladie (DFS : *Disease Free Survival*) et une survie globale (OS : *Overall Survival*)<sup>91</sup>. De plus, les chercheurs ont remarqué que le pronostic des patients avec au moins 5 CTCs/30mL de sang était plus mauvais et que la persistance de ces cellules au cours du traitement

chimiothérapeutique avait une influence pronostique négative. Ainsi, la détection des CTCs à la fois avant et après la chimiothérapie adjuvante est liée à un risque plus élevé de rechute du cancer du sein primaire. Une autre étude très complète publiée par Zhang et ses collègues portant sur la méta-analyse de 49 études incluant 6825 patients a démontré à grande échelle que la présence des CTCs était significativement associée à une survie plus courte à la fois dans les cancers du sein précoces et métastatiques<sup>90</sup>.

D'autres travaux prometteurs ont démontré des corrélations significatives entre le nombre de CTCs, le pronostic, et la rechute métastatique dans différents types de tumeurs tels que le cancer de la prostate<sup>79,82,92-94</sup>, le cancer colorectal<sup>82,95</sup>, le cancer du rein<sup>96</sup>, du foie<sup>97</sup>, de l'œsophage<sup>98</sup> ou encore de la tête et du cou<sup>99</sup>. Néanmoins, ces études se doivent d'être confirmées à plus large échelle avec des tests plus sensibles afin d'explorer la pertinence clinique réelle des CTCs, particulièrement dans le suivi des patients où l'on ne connaît pas pour l'instant la cinétique d'expression de ceux qui rechutent.

#### 4.3.2. Un outil pour guider la thérapie :

Actuellement, les prises de décisions thérapeutiques sont majoritairement basées sur l'analyse de la tumeur primitive tandis que les prélèvements des lésions métastatiques restent compliqués cliniquement car elles sont invasives pour les patients. Ainsi, les CTCs apparaissent comme un bon moyen de contourner la biopsie solide, tout en permettant un suivi de la réponse au traitement en temps réel. Le développement de technologies sophistiquées du type « single cell » ont permis une meilleure compréhension des mécanismes de résistance aux thérapies et d'ouvrir des pistes dans le cadre d'une médecine personnalisée.

##### 4.3.2.1. Analyse de l'ADN :

Des études d'analyse génomique comparative de CTCs, de tumeurs primaires ainsi que de métastases chez des patients atteints d'un cancer colorectal ou de la prostate ont montré que des mutations présentes dans les CTCs étaient les mêmes que ceux détectées dans la tumeur primaire et les métastases ouvrant ainsi de nouvelles perspectives d'utilisation en tant que biomarqueur liquide, notamment pour la réponse au traitement<sup>25,93</sup>. En effet, des mutations dans des protéines cibles (ou en aval de la voie de signalisation) affectent l'efficacité des molécules dirigées contre ces protéines. Par exemple, des mutations du gène KRAS sont fréquemment retrouvées dans les cancers colorectaux et conduisent généralement à une activation de la voie de signalisation de l'EGFR. Deux études séparées sur le cancer colorectal ont révélé une grande hétérogénéité des mutations KRAS dans les CTCs des patients, suggérant ainsi que la détection précoce des CTCs porteuses de la mutation KRAS pourrait aider les cliniciens dans le choix d'administrer ou non une thérapie à base d'anti-EGFR<sup>100,101</sup>. De la même manière, dans le cancer de la prostate des mutations du récepteur aux androgènes (AR :

*Androgen Receptor*), qui confèrent aux cellules tumorales une résistance aux thérapies de blocage des récepteurs androgéniques, ont été retrouvées dans les CTCs de patients<sup>102</sup>. Autres exemples, la détection des mutations PI3KCA et BRAF dans les CTCs des patients atteints d'un cancer du sein HER2+ et du mélanome, respectivement<sup>103,104</sup>.

#### 4.3.2.2. Analyse de l'ARN :

Au niveau de l'ARNm, des études se focalisant sur le cancer de la prostate ont révélé que l'analyse de l'ARNm des CTCs pouvait aussi révéler des informations sur la résistance aux traitements. Le cancer de la prostate résistant à la castration (CRPC : *Castration-Resistant Prostate Cancer*) se définit par une croissance tumorale continue malgré la prise d'anti-androgènes. Une étude de Antonarakis et ses collègues ont mis en lumière la présence d'une forme tronquée de l'ARNm du récepteur aux androgènes dans les CTCs, appelée ARv7 (*androgen-receptor variant 7*), qui pourrait prédire l'échec d'une thérapie aux anti-androgènes suggérant ainsi la potentielle utilisation en tant que marqueur de sélection des patients pour ce type de traitement<sup>105</sup>.

#### 4.3.2.3. Analyse protéique :

Un autre moyen d'utiliser les CTCs pour guider la décision thérapeutique consiste à combiner la détection de ces cellules avec l'analyse de certaines protéines qu'elles contiennent. Par exemple, dans le cancer du sein le récepteur aux oestrogène (ER : *Estrogen Receptor*) est une cible clé. On estime les patients comme étant ER+ lorsque au moins 1% des cellules tumorales expriment le récepteur ; ils vont alors être traités par thérapie hormonale. Cependant 1% représente un seuil faible, ainsi les tumeurs du sein ER+ peuvent présenter des CTCs ER- et donc engendrer une résistance au traitement anti-hormonal<sup>106</sup>. Une équipe de chercheur a mis au point un test multiparamétrique, le CTC-ETI (*CTC-Endocrine Therapy Index*), qui pourrait être capable de prédire la résistance à la thérapie hormonale chez les patients atteints d'un cancer du sein ER+ métastatique<sup>107</sup>. Ce test combine le comptage des CTCs avec l'expression dans ces cellules de quatre marqueurs : ER, HER2, BCL2 et KI67. Il est actuellement utilisé dans le cadre d'un essai clinique dont les résultats sont attendus très prochainement (COMETI P2, NCT 01701050). De la même manière, d'autres recherches se sont concentrées sur une autre cible importante dans le cancer du sein à savoir l'oncogène HER2<sup>108,109</sup>.

Plus récemment, les inhibiteurs des points de contrôles immunitaires tels que ceux de la voie PD1/PD-L1 ont révolutionné la prise en charge des patients atteints d'un cancer avec des résultats spectaculaires, le taux de réponse objective aux anti-PD1 étant d'environ 28 % tous cancers confondus. Fort de ces résultats encourageants, ces traitements sont prescrits à tous les patients, sans sélection. Au vu des effets secondaires importants et du coup pour la société, il est urgent de trouver des biomarqueurs. Dans cette optique, Mazel et ses collègues ont fourni la première preuve de

l'expression fréquente du ligand PD-L1 à la surface des CTCs de patients atteints d'un cancer du sein, ce qui suggère une potentielle utilisation dans la réponse à l'immunothérapie<sup>110,111</sup>. Depuis, deux études ont démontré leur valeur pronostique dans les cancers de la tête et du cou ainsi que du poumon non à petites cellules<sup>99,112</sup>.

Dans le CRCP, la prise inefficace d'anti-androgènes est souvent suivie d'autres thérapies hormonales ciblant la voie d'activation du récepteur aux androgènes, qui a cependant des effets variables. Myiamoto et ses collègues ont mis au point une technologie à base de microfluidique afin de détecter et analyser l'activation de cette voie de signalisation dans les CTCs via l'analyse de la PSA et PSMA (*prostate-specific membrane antigen*). Les chercheurs ont démontré que les patients traités possédaient des CTCs avec des signaux d'activation mixtes suggérant ainsi l'intérêt de leur technologie dans l'aide à la prise de décision thérapeutique pour ce genre de traitement hormonal<sup>113</sup>.

Ainsi, l'ensemble de ces données démontre que l'analyse des CTCs et de son contenu en ADN, ARN et en protéines pourrait avoir un impact important sur la compréhension des mécanismes de résistance à la thérapie des patients atteints d'un cancer et donc dans leur utilisation en tant que biomarqueur.

## 5. Les vésicules extracellulaires :

L'étude des vésicules extracellulaires (VE) a connu une croissance impressionnante ces 10 dernières années, notamment au vu de leur potentielles applications cliniques pour de nombreuses pathologies telle que le cancer. Cet engouement a abouti à une incroyable quantité de publications sur le sujet, avec parfois un manque clair de consensus que ce soit au niveau de la nomenclature, de la caractérisation ou encore des technologies d'analyse. Pour contourner ce manque d'homogénéité, la communauté de chercheurs s'est réunie pour encadrer le domaine de l'étude des VEs et créer « *l'International Society of Extracellular Vesicle* » (ISEV). Elle édifie les règles à suivre pour l'étude rigoureuse des VEs : les « *Minimal information for studies of extracellular vesicles* » (MISEV), qui sont mises à jour tous les 4 ans<sup>114</sup>. L'engouement est tel qu'il a abouti à la fois à la création d'un journal spécialisé, le « *Journal of Extracellular Vesicle* » dont le facteur d'impact est passé de 4 à 11 en 2020, ainsi que d'un congrès internationalement renommé. Ceci a notamment permis de mieux connaître la biologie et la fonction des VEs. Ainsi, leur sécrétion par les cellules semble être bien plus qu'un simple mécanisme de recyclage des protéines, tel que cela a été décrit pour la 1<sup>e</sup> fois<sup>115,116</sup>. On sait dorénavant que les VEs sont capables d'échanger des composants entre cellules, aussi bien des protéines que des acides nucléiques ou des lipides, et d'agir comme un moyen de communication à part entière<sup>117,118</sup>. De

plus, elles sont retrouvées dans la grande majorité des fluides biologiques c'est pourquoi elles concentrent beaucoup d'intérêts dans le domaine de la biopsie liquide.

La classification des vésicules extracellulaires évolue constamment<sup>114</sup>. Néanmoins, on peut les diviser en deux catégories avec d'un côté les ectosomes (ou microvésicules), et de l'autre les exosomes<sup>119</sup>. Les ectosomes sont formés par bourgeonnement de la membrane plasmique pour former des microvésicules, des microparticules ou encore des vésicules de grande taille, qui mesurent de 50nm jusqu'à 1µM de diamètre. Au contraire, les exosomes ont une origine endosomale et ont une taille comprise entre 40 et 160nm. Les différentes VEs se distinguent par leur origine subcellulaire, leurs propriétés physico-chimiques et leur composition spécifique<sup>117-119</sup>.

Nous nous intéresserons ici plus particulièrement aux exosomes qui concentrent l'essentiel des recherches sur les VEs.

## 6. Les exosomes :

### 6.1. Généralités :


Le terme « exosomes » a été utilisé pour la première fois en 1981 par Trams et ses collègues pour désigner de petites vésicules d'origine inconnue sécrétées par différents types de cellules<sup>120</sup>. En 1983, Pan et Johnstone découvrent que ces vésicules ont une origine endosomale<sup>121</sup>. A l'époque, les chercheurs ont pensé que c'était un moyen pour les cellules d'éliminer les protéines obsolètes, c'est pourquoi pendant une longue période les exosomes n'ont généré que peu d'intérêt. Ce n'est qu'à la fin des années 1990 qu'ils ont suscité l'attention des chercheurs, après la découverte de la sécrétion d'exosomes par les lymphocytes B, par Raposo et ses collègues en 1996<sup>122</sup>, puis par les cellules dendritiques en 1998 par Zitvogel et al<sup>123</sup>, qui étaient capables d'induire une réponse immunitaire<sup>124</sup>. Dès lors, il s'en est suivi une multitude de travaux portant sur de nombreux types cellulaires différents, et leur implication dans les mécanismes de communication intercellulaire en condition pathologiques<sup>117,118,125,126</sup>. Il est ainsi décrit que la grande majorité des types cellulaires sont capable de sécréter des exosomes tels que les cellules épithéliales<sup>127</sup>, les neurones<sup>128</sup> et les cellules tumorales<sup>124</sup>, les cellules immunitaires<sup>117,129</sup>, la quantité et la composition des exosomes étant dépendante de l'état physiologique de la cellule<sup>118</sup>. Ils peuvent être isolés à partir de surnageant de culture cellulaire et ont été retrouvés dans de nombreux fluides biologiques tels que le sang<sup>130</sup>, l'urine<sup>131</sup>, la salive<sup>132</sup>, le liquide bronchoalvéolaire<sup>133</sup>, ou encore le liquide cerebro-spinal<sup>134</sup>.

## 6.2. Biogenèse des exosomes :

La biogenèse des exosomes débute par une étape d'endocytose au cours de laquelle les cellules internalisent diverses molécules. Ensuite, une deuxième invagination de la membrane va avoir lieu dans les endosomes, avant d'être libérés par un processus d'exocytose.

La première étape consiste en l'invagination de la membrane plasmique qui forme une structure contenant des protéines membranaires et des protéines solubles du milieu extracellulaire. Cette structure va aboutir à la formation d'un endosome précoce qui, dans certains cas, va fusionner avec d'autres endosomes précoces. Il est important de noter que le réticulum endoplasmique ainsi que le système de Golgi peuvent, ici, participer à la formation et au contenu de ces endosomes précoces<sup>135-137</sup>. Ensuite, ces endosomes précoces vont mûrir et former des endosomes tardifs, puis des corps multivésiculaires (CMVs). Ces CMVs sont formés par invagination de la membrane de l'endosome tardif et former des petites vésicules appelées vésicules intraluminales (VILs) ; les futurs exosomes. Enfin, les CMVs, contenant les VILs, peuvent soit fusionner avec les autophagosomes et/ou les lysosomes et être recyclés et/ou dégradés, soit fusionner avec la membrane plasmique et libérer les exosomes (Figure 8)<sup>136,138-140</sup>.

Les mécanismes précis de formation des exosomes sont encore mal connus. Néanmoins plusieurs études suggèrent l'implication de différentes molécules laissant à penser qu'il n'y a pas de mécanisme universel, mais plutôt différents systèmes dont l'activité dépend de plusieurs paramètres tels que le type cellulaire et son état physiologique.



**Figure 8 : Mécanismes de la biogenèse des exosomes.** Les exosomes sont générés à l'intérieur des CMVs (MVB), qui, lors de leur maturation, vont fusionner avec la membrane plasmique. Ce mécanisme multi-étape est étroitement régulé et inclue un acheminement via les microtubules, une fixation à la membrane (MVB docking) et la fusion médiée par les protéines SNAREs. D'après Bebelman et al, *Pharmacology & Therapeutics*, 2018.

### 6.2.1. Formation des vésicules intraluminales :

#### 6.2.1.1. Le complexe protéique ESCRT (*Endosomal Sorting Complex Responsible for Transport*) :

Le complexe ESCRT est un acteur majeur de la plasticité des membranes biologiques, en particulier dans la formation des CMVs et des VILs<sup>141</sup>. Cette machinerie moléculaire agit en plusieurs étapes : les sous-unités ESCRT-0 et ESCRT-1 vont d'abord rassembler des protéines transmembranaires ubiquitinylées de la membrane des CMVs, puis recruter via les sous-unités ESCRT-II et ESCRT-III des complexes moléculaires qui vont entraîner le bourgeonnement et la fission du microdomaine néoformé pour créer les VILs<sup>141-144</sup>. Parmi ces protéines, on retrouve notamment TSG101 (*Tumor Susceptibility Gene 101*) qui est présent dans les exosomes et très régulièrement utilisé comme marqueur.

Néanmoins, il existe d'autres mécanismes de formation des exosomes qui sont indépendants du complexe ESCRT<sup>145</sup>.

#### 6.2.1.2. Les céramides :

Les céramides sont une classe de lipides en forme de cônes, générés par le clivage de la sphingomyéline par les sphingomyélinases. Cette forme particulière leur permet notamment d'être les principaux acteurs de la courbure des membranes. Par conséquent les céramides jouent un rôle important dans la formation des VILs. Une étude a par exemple montré que l'inhibition de la nSMAse-2 (*neutral Sphingomyélinase 2*) empêchait le bourgeonnement des VILs dans les CMVs ainsi que la libération des exosomes, via un mécanisme indépendant de la machinerie ESCRT<sup>146</sup>. De plus, les céramides peuvent être métabolisées en sphingosine-1 phosphate qui activent les récepteurs GiS1P [(*inhibitory G protein (Gi)-coupled sphingosine 1-phosphate (S1P)*)] à la membrane des CMVs, régulant ainsi la formation et le tri dans les VILs<sup>147</sup>.

#### 6.2.1.3. L'axe Syndécane-Synténine-ALIX :

Le tri sélectif de protéines transmembranaires dans les VILs des CMVs peut également avoir lieu via des interactions protéiques. C'est notamment le cas des protéines Syndécane, Synténine et ALIX. En effet, la syndécane se fixe à la synténine-1 et forme un complexe qui recrute la protéine ALIX (*ALG-2 interacting protein X*) qui, ensemble, vont permettre l'invagination de la membrane des CMVs pour former les VILs (Figure 8)<sup>148</sup>. Elles sont donc présentes au sein des exosomes. Ces mécanismes sont régulés par d'autres protéines telles que SRC<sup>149,150</sup>, ARF6 et PLD2<sup>151</sup>.

#### 6.2.1.4. Les tétraspanines :

Les tétraspanines sont une famille de glycoprotéines transmembranaires possédant une forme conique, avec une cavité qui leur confère la capacité de fixer des molécules de cholestérol<sup>152</sup>. Ceci

leur permet notamment de se regrouper pour former des « tetraspanin-enriched microdomains », sorte de plateforme de signalisation au niveau de la membrane plasmique. Ainsi, les tétraspanines jouent un rôle dans différents processus tels que l'adhésion cellulaire, la modulation du système immunitaire ou encore le cancer<sup>153</sup>. Parmi elles, CD63 est particulièrement enrichie à la surface des exosomes. Des études ont montré que cette protéine était capable de réguler le tri des protéines dans les exosomes de mélanocytes<sup>154</sup> et de cellules de mélanome<sup>155</sup>. Une autre publication révèle un rôle de CD63 dans la biogenèse de ces nanovésicules dans les fibroblastes de patients atteints du syndrome de Down<sup>156</sup>. Les tétraspanines CD9 et CD81, également enrichies dans les exosomes, sont aussi impliquées directement dans le tri de leur contenu<sup>157,158</sup>.

## 6.2.2. Trafic intracellulaire des corps multivésiculaires jusqu'à l'exocytose :

### 6.2.2.1. Les Rab GTPases :

Les Rab GTPases sont des petites protéines G appartenant à la superfamille des protéines Rab et qui possèdent une activité GTPase. Elles régulent plusieurs processus tels que le trafic membranaire, notamment la formation de vésicules, et leur mouvement sur les réseaux du cytosquelette que sont l'actine et la tubuline<sup>159</sup>. Enfin, elles jouent également un rôle dans la fusion des membranes et par conséquent dans la libération des exosomes dans le milieu extracellulaire<sup>160,161</sup>. Il a par exemple été démontré que Rab27a et Rab27b jouent un rôle dans la morphologie des CMVs ainsi qu'à sa fixation à la membrane, en vue d'une libération des exosomes (Figure 8)<sup>160</sup>. De fait, l'utilisation d'ARN interférant dirigé contre ces protéines a été utilisée dans différentes études afin de démontrer le rôle spécifique des exosomes<sup>162,163</sup>. D'autres Rab GTPases sont également capables de réguler la sécrétion des exosomes tels que Rab7, Rab11 et Rab35<sup>148,159,161</sup>.

### 6.2.2.2. Les protéines SNAREs :

Les SNAREs (*Soluble N-éthylmaleimide-sensitive-factor Attachment protein REceptor*) sont des protéines majoritairement transmembranaires responsables de la fusion et du trafic membranaire au sein des cellules eucaryotes. Elles vont ainsi agir sous forme de complexe au niveau des CMVs fixés à la membrane pour permettre la libération des exosomes (Figure 8). Plusieurs protéines SNAREs ont été décrites comme étant impliquées dans ce mécanisme telles que YKT6<sup>164</sup>, VAMP7<sup>165</sup>, SNAP23<sup>166</sup> ou encore la syntaxin-1a<sup>167</sup>. Cette activité est régulée par différents mécanismes parmi lesquels la concentration en Ca<sup>2+</sup> ou encore leur état de phosphorylation<sup>168-170</sup>.


Il est important de noter ici que toutes ces protéines n'ont pas un rôle exclusif à la biogenèse des exosomes. En effet, elles sont pour la plupart engagées dans de nombreux processus moléculaires responsables du trafic intravésiculaire et membranaire. Il semblerait donc que les exosomes soient



produits via différentes voies de signalisation interconnectées qui sont activées en fonction de différents paramètres tels que le type cellulaire ou les conditions physiologiques, et en régisse ainsi la composition.

### 6.3.Composition :

Les exosomes ont une composition particulière qui les distingue des autres VEs (Figure 9)<sup>171,172</sup>. Cette composition spécifique leur confère des fonctions propres qui sont régulées par la dynamique de libération de ces nanovésicules. Le contenu des exosomes est référencé sur le site internet Exocarta (<http://www.exocarta.org/>).



**Figure 9 : Composition des exosomes.** Ces nanovésicules sont constituées d'un bicouche lipidique enrichie en cholestérol. Des récepteurs et des ligands sont incorporés dans cette membrane. A l'intérieur, on retrouve également des protéines diverses et variées et du matériel génétique. MVB formation = Formation des CMV, immunostimulatory molecules = molécules immunostimulantes, intracellular signaling = signalisation intracellulaire, HSPs = Protéines de choc thermique, Lipid raft associated proteins = protéines associées aux radeaux lipidiques, Lipids = lipides, Ligands = ligands, Adhesion proteins = protéines d'adhésion, membrane trafficking proteins = protéine du trafic membranaire, cytoskeleton molecules = molécules du cytosquelette, genetic material = matériel génétique, enzymes = enzymes. Adapté de Cordonnier & Chanteloup et al, Cell Adh Migr, 2017.

#### 6.3.1. Contenu protéique :

Des études montrent qu'une des voies possibles pour le chargement des protéines à l'intérieur des exosomes est via l'interaction avec les composants de la machinerie de biogenèse des exosomes<sup>131,172</sup>. On y retrouve donc des protéines du trafic membranaire telles que Rab 5 et l'annexine, des protéines impliquées dans la formation des CMVs comme Alix, TSG101 ou la syntenin-1 ou encore des molécules du cytosquelette avec par exemple l'actine ou la tubuline (Figure 9)<sup>172</sup>.

De la même manière, l'association des protéines membranaires avec les tétraspanines facilitent leur incorporation dans les exosomes et plus précisément CD9, CD63 et CD81. On peut aussi noter la

présence d'intégrines telles que LFA-1 ou des ligands de récepteurs comme FAS-L ou PD-L1. On y retrouve différents récepteurs capables d'induire une réponse physiologique comme le CMH I/II, ou encore des enzymes telles que la pyruvate kinase ou la GAPDH (Figure 9)<sup>172</sup>.

Enfin, plusieurs protéines de choc thermique (HSPs : *Heat Shock Protein*) sont présentes dans la lumière des exosomes parmi lesquelles HSP27, HSP60, HSP70, HSP90, dont certaines sont retrouvées à leur surface (HSP70, HSP60 et HSP90)<sup>126</sup> (Figure 9).

Cette composition particulière permet d'identifier les VEs comme exosomes, en plus de leur taille. Ainsi, les MISEVs préconisent de révéler la présence d'au moins 3 marqueurs des exosomes parmi lesquels 2 tétraspanines et 1 molécule impliquée dans la biogenèse telle que TSG101 ou ALIX, et l'absence d'un marqueur négatif comme une protéine du réticulum endoplasmique (Grp94)<sup>114</sup>.

### 6.3.2. Contenu lipidique :

Les lipides sont des composants essentiels de la membrane des exosomes. Il est désormais bien décrit dans la littérature que ces nanovésicules possèdent une double membrane lipidique dont la composition est identique à celle de la cellule mère, mais avec certains enrichissements<sup>173</sup>. Les exosomes sont donc enrichis en phospholipides saturés (phosphatidyl-éthanolamine, phosphatidyl-sérine, phosphatidyl-coline), en sphingolipides (céramides) et en cholestérol (Figure 9). Cette composition particulière leur confère une grande rigidité qui leur permet de protéger leur contenu de la dégradation et d'être plus stable dans le milieu extracellulaire.

### 6.3.3. Contenu en acide nucléiques :

#### 6.3.3.1. Les ARNs :

En 2007, Valadi et ses collègues ont démontré pour la première fois que les cellules étaient capables de procéder à un transfert horizontal d'ARN fonctionnel<sup>174</sup>. Cette étude pionnière a été à l'origine d'intenses efforts de la part des chercheurs pour étudier l'expression et le rôle de différents types d'ARN présents dans ces nanovésicules.

Outre l'ARNm, les exosomes sont hautement enrichis en petits ARNs non codants, ce qui suggère un rôle important dans la régulation des gènes. On y retrouve ainsi majoritairement des micro-ARNs sous leur forme de précurseur ou mature, mais aussi des snARN (*small nuclear* ARN) et snoARN (*small nucleolar* ARN), des Y-ARNs, des piARN (*piwi-interacting* ARN), ou encore des tsARN (*tRNA-derived small* ARN). On retrouve également des longs ARNs non codants (lncARN, *long non coding* ARN) et des ARNs circulaires (cirARN). Enfin, de l'ARN mitochondrial est présent au sein des exosomes<sup>139,171,175,176</sup>. Tous ces ARNs ont été identifiés comme des ARNs non codants capables de modifier la physiologie des cellules, notamment dans le cadre du cancer. Leur chargement au sein des exosomes est lié à un

processus sélectif ce qui entraîne une différence d'expression entre la cellule mère et l'exosome<sup>176</sup>. Leur détection au sein des exosomes circulants représente ainsi un grand espoir dans le diagnostic non invasif de cette pathologie<sup>177-179</sup>.


#### 6.3.3.2. L'ADN :

La présence d'ADN au sein des exosomes a longtemps été mise en doute mais il est aujourd'hui prouvé qu'ils contiennent bien de l'ADN. Kahlert et ses collègues ont montré pour la première fois que les exosomes dérivés de sérum de patients atteints d'un cancer du pancréas contenaient de longs fragments d'ADN double brin (dsADN, *double stranded* ADN), en l'occurrence les mutations KRAS et p53<sup>22</sup>. Cette étude a été confirmée quelques années plus tard lorsque Thakur et ses collègues ont affirmé que la majorité de l'ADN associé aux exosomes étaient double brin<sup>23</sup>. D'autres types d'ADN sont également retrouvés au sein des exosomes tels que de l'ADN simple brin, de l'ADN viral ou encore de l'ADN mitochondrial<sup>180</sup>. Cet ADN est constitué de fragments plus longs que le ADNcf ce qui permet de les différencier<sup>180</sup>.

#### 6.4. Hétérogénéité des exosomes :

La diversité des voies de signalisation et de régulation de la biogenèse des exosomes, ainsi que l'impact de l'environnement cellulaire, entraînent une hétérogénéité phénotypique des exosomes. En effet, il existe des sous-populations de tailles différentes, provenant de sources différentes, au contenu différent et donc qui exercent une fonction différente<sup>139,181</sup> (Figure 10). Cette hétérogénéité a notamment été révélée par des analyses de protéomique qui ont permis d'identifier des signatures protéiques spécifiques d'un type de cellule par exemple, tandis que des études de séquençage ont soulignées les différences d'expression avec la cellule mère, suggérant ainsi un mécanisme de tri spécifique<sup>172,176,182</sup>.

Les fonctions des exosomes sur les cellules réceptrices peuvent donc varier en fonction de leur taille, du type de récepteurs exprimés à leur surface, de la nature et de la quantité du matériel qu'ils contiennent et enfin de la façon dont ils vont interagir avec la cellule réceptrice (Figure 10).



**Figure 10 : Hétérogénéité des exosomes.** Ces nanovésicules peuvent être très hétérogènes et ainsi engendrer des réponses biologiques complexes. Cette hétérogénéité (heterogeneity) des exosomes peut être conceptualisée sur la base de leur taille (size), leur contenu (content), leur fonction sur les cellules réceptrices (functional), et la cellule d'origine (source). Des combinaisons distinctes de ces caractéristiques soulignent toute la complexité de l'hétérogénéité des exosomes. D'après Kalluri et al, Science, 2020.

### 6.5. Interaction avec la cellule réceptrice :

Une fois libérés dans le milieu extracellulaire, les exosomes peuvent atteindre les cellules réceptrices et y délivrer leur contenu, qui va engendrer une réponse fonctionnelle et modifier leur état physiologique. Ils peuvent interagir différemment à la suite de la fixation à la membrane de la cellule réceptrice, mais ces mécanismes sont encore mal connus. On ne sait pas, par exemple, si un mode d'interaction différent agit sur le devenir de l'exosome.

#### 6.5.1. Fixation à la surface des cellules cibles :

Le ciblage des cellules semble avoir lieu via des interactions spécifiques entre des protéines enrichies à la surface des exosomes et des récepteurs au niveau de la membrane plasmique de la cellule. Bien que ces processus ne soient pas clairement décrits, plusieurs acteurs majeurs sont identifiés parmi lesquels les tétraspanines, les lipides, les lectines, les protéoglycanes ou encore les composants de la matrice extracellulaire (MEC). Ainsi, les intégrines présentes dans la membrane des exosomes peuvent par exemple à la fois interagir avec les molécules d'adhésion à la surface de la cellule réceptrice telle que les ICAMs (*intercellular adhesion molecules*)<sup>183</sup>, et les composants de la MEC pour effectuer une

fixation<sup>184</sup>. Hoshino et ses collègues ont également montré que la composition spécifique des exosomes en certaines intégrines définissait le lieu de formation des métastases dans le cancer, induites par ces mêmes exosomes<sup>185</sup>. Les tétraspanines ont également été identifiées comme partenaires d'interaction des intégrines de façon à promouvoir la fixation des exosomes sur les cellules cibles<sup>186,187</sup>. Enfin, d'autres molécules ont un rôle dans ce processus, telle que les lectines<sup>188</sup> ou la composition lipidique des exosomes, notamment la phosphatidyl-sérine<sup>189</sup> (Figure 11).

Cependant, on ne sait pas à ce jour si le ciblage des cellules par un sous-type particulier d'exosomes résulte d'un processus spécifique ou non, la littérature décrivant les 2 hypothèses<sup>137</sup>.

#### 6.5.2. Signalisation intercellulaire médiée par les exosomes :


Une fois fixés à la cellule réceptrice, les exosomes peuvent soit (i) rester à la membrane et engendrer une signalisation<sup>157</sup>, (ii) être internalisés par différents processus de dynamique des membranes à savoir l'endocytose dépendante de la clathrine ou non, la macropinocytose<sup>190</sup> et la phagocytose<sup>191</sup> ou l'endocytose via la caveole et les radeaux lipidiques<sup>192</sup>, (iii) ou encore par fusion des membranes<sup>193</sup> (Figure 11).

Les exosomes sont donc capables de se fixer puis d'activer des récepteurs présents à la surface des cellules. Les premiers exemples de ce processus ont été décrit auparavant et concernent les travaux de Raposo et Zitvogel qui démontrent que les exosomes dérivés de lymphocytes B et de cellules dendritiques, respectivement, sont capables d'induire une réponse immunitaire spécifique<sup>122,123</sup>. Dès lors, de nombreuses études ont révélé un mécanisme similaire et seront détaillées dans le chapitre suivant.

Une fois fixés, les exosomes peuvent également pénétrer dans la cellule par l'intermédiaire des processus évoqués ci-dessus. Ils vont ensuite pénétrer dans un endosome précoce puis un CMV, qui contient possiblement des exosomes néoformés. Il y a alors plusieurs possibilités ; (i) les exosomes vont être dirigés vers le lysosome où ils vont être dégradés<sup>194</sup>, (ii) fusionner avec la membrane du CMV et libérer leur contenu dans le cytoplasme ou vers le réticulum endoplasmique<sup>195</sup>, (iii) ou être resécrétés via la fusion du CMV avec la membrane plasmique<sup>196</sup> (Figure 11).

Enfin, la fusion des membranes entraîne le transfert des composants de la membrane de l'exosome dans celle de la cellule réceptrice, et libère son contenu à l'intérieur (Figure 11).

Ainsi, l'hétérogénéité phénotypique des exosomes impacte la manière dont ils interagissent avec la cellule réceptrice qui, à son tour, régit sa fonction.



**Figure 11 : Interactions des exosomes avec la cellule réceptrice.** En fonction du type cellulaire, les exosomes peuvent rester fixés à la membrane (surface binding) et initier une signalisation intracellulaire. Les exosomes peuvent également être internalisés via différentes voies (uptake). L'internalisation de ces nanovésicules mène à l'endosome précoce (early endosome) qui va se différencier en CMV dans lequel les vésicules internalisées vont être mixées avec les VILs (ILVs). La fusion des CMVs avec le lysosome entraîne la dégradation des exosomes et le recyclage du contenu pour alimenter le métabolisme cellulaire. Les exosomes peuvent également libérer leur contenu (release of vesicle content) dans le cytoplasme de la cellule réceptrice via fusion avec la membrane plasmique (membrane fusion) ou des CMVs (back fusion). Enfin, les exosomes peuvent être re-sécrétés (re-secretion). D'après Niel et al, Nat Rev Mol Cell Biol, 2018.

## 6.6. Fonction des exosomes dans le cancer :

Dans le contexte tumoral, la communication cellulaire est un processus dynamique majeur. Il est désormais acquis que les exosomes en font partie intégrante. Les conditions physiologiques particulières dans le microenvironnement modifient l'état des cellules cancéreuses qui, de fait, libèrent plus d'exosomes que les cellules saines<sup>197</sup>. De plus, leur contenu est également différent de la cellule mère ce qui suggère un processus de tri spécifique qui permet de promouvoir la croissance tumorale.

### 6.6.1. Induction de lésions néoplasiques :

Différentes études ont démontré que les exosomes étaient capables d'induire la formation d'un cancer. Ainsi, il a récemment été démontré que les exosomes dérivés de cancer du pancréas possèdent la capacité de transformer les cellules NIH/3T3 en y induisant des mutations<sup>198</sup>. De la même manière, les exosomes dérivés de cancer du sein et de la prostate semblent être capable d'induire des lésions néoplasiques via le transfert de leur contenu en micro-ARNs<sup>199,200</sup>. Plus précisément, les miR-125b, miR-130 et mir-155, ainsi que l'ARNm HRAS et KRAS des exosomes de cellules de cancer de la prostate semblent pouvoir initier la reprogrammation néoplasique et la formation d'une tumeur des cellules souches adipocytaires<sup>200</sup>.

### 6.6.2. Rôle dans la progression tumorale :

Une des premières études démontrant le fait que les exosomes dérivés de tumeur étaient capables de promouvoir la croissance tumorale fût celle de Liu et ses collègues en 2006. Les auteurs ont démontré

que l'injection d'exosomes dérivés de lignées de cancer du sein murin 4T1 et TS/A *in vivo* entraînait une augmentation de la croissance cellulaire<sup>201</sup>. Depuis, de nombreuses études portent sur l'étude de la fonction des exosomes dérivés de tumeur sur le stroma, notamment les composants de la MEC, les fibroblastes et les cellules immunitaires.

#### *6.6.2.1. Effets sur la matrice extracellulaire :*

Les exosomes dérivés de tumeurs sont capables de remodeler la MEC afin d'augmenter la capacité migratoire des cellules cancéreuses<sup>202</sup> (Figure 12). En effet, ils interagissent avec les composants de cette matrice via des molécules d'adhésion et libèrent des protéines qui vont la dégrader telles que des métalloprotéinases (MMPs) ou des cathepsines<sup>202</sup>. Ce remodelage de la MEC permet la libération de cytokines et de facteurs de croissance qui vont affecter d'autres composants du microenvironnement tumoral afin de favoriser la croissance tumorale, comme les fibroblastes. Ainsi, il a été démontré *in vivo* que les exosomes tumoraux, via la sécrétion de TGF- $\beta$  peuvent induire la différenciation de ces derniers en fibroblastes associés au cancer (FAC), qui possèdent un phénotype mésenchymateux<sup>203,163</sup>. Enfin, les exosomes semblent être capable de libérer des signaux chimiotactiques<sup>184,204</sup>.

#### *6.6.2.2. Effets sur le système immunitaire :*

Des études précoces s'intéressant aux fonctions biologiques des exosomes tumoraux ont révélé un rôle sur le système immunitaire<sup>117,205,206</sup> (Figure 12). Depuis, de nombreux mécanismes ont été identifiés, notamment dans la suppression de l'immunité anti-tumorale. Ainsi, les exosomes sont capables d'inhiber l'activité des lymphocytes T via l'expression à leur surface de points de contrôles du système immunitaire tels que CTLA-4 et PD-L1, qui, une fois liés à leur récepteurs sur les lymphocytes T, les rendent anergiques<sup>207-209</sup>. Poggio et ses collègues ont récemment démontré que PD-L1 exosomal était capable d'induire une immunosuppression à lui seul, renforçant un peu plus le rôle des exosomes dans le cancer<sup>210</sup>. Ces nanovésicules sont aussi capables d'induire l'apoptose des cellules T, notamment via l'expression de ligands tel que Fas<sup>211,212</sup> mais aussi via leur contenu en micro-ARNs<sup>213</sup>. Ils sont également capables de recruter d'autres acteurs du système immunitaire comme les cellules T régulatrices, via l'expression de la chemokine CCL20, puis d'induire leur expansion, ce qui augmente leurs fonctions immunosuppressives<sup>214</sup>. Notre équipe a aussi démontré que les exosomes dérivés de tumeurs pouvaient activer les cellules myéloïdes suppressives (MDSCs) via la forme membranaire de HSP70, et de promouvoir la croissance tumorale<sup>215</sup>. Un autre effet immunosuppresseur des exosomes réside dans leur capacité à inhiber les cellules NK, via l'inhibition de l'expression de son récepteur NKG2D<sup>216,217</sup>. Enfin, les exosomes peuvent affecter la fonction et la différenciation des cellules dendritiques et des macrophages<sup>218</sup>. Ainsi, il existe une large diversité de mécanismes qui soulignent les différents effets des exosomes sur le système immunitaire dans la littérature<sup>129,218</sup>.

#### *6.6.2.3. Effets sur l'angiogenèse et l'hypoxie :*

La néoangiogenèse accompagne la croissance tumorale ; elle permet d'acheminer les nutriments et autres métabolites nécessaires à la croissance des cellules cancéreuses. Elle constitue également une voie privilégiée de la formation des métastases. Des études ont montré que les exosomes dérivés de tumeurs favorisaient la vascularisation de la tumeur (Figure 12). Par exemple, la tétraspanine 8 contribue au recrutement sélectif de protéines et d'ARNm dans les exosomes tumoraux qui, une fois absorbés par les cellules endothéliales, induit une augmentation de la prolifération, de la migration et de la maturation des progéniteurs endothéliaux, favorisant ainsi la néoangiogenèse au niveau de la tumeur<sup>186</sup>. De la même manière, dans le mélanome, la protéine WNT5A entraîne la libération d'exosomes contenant des facteurs proangiogéniques tels que le VEGF ou MMP2<sup>219</sup>, tandis que dans le cancer de la tête et du cou, les exosomes contiennent la protéine EPHB2 et contribuent à l'angiogenèse tumorale<sup>220</sup>.

L'hypoxie est un phénomène particulièrement présent au cœur des tumeurs solides, de même que la néoangiogenèse. Ainsi, les exosomes dérivés de glioblastome sont enrichis en facteurs de régulation de l'hypoxie et reprogramment les cellules endothéliales afin de stimuler la formation de nouveaux vaisseaux sanguins<sup>221</sup>. De la même manière, les exosomes dérivés de tumeur du poumon hypoxique libèrent le miR-23a qu'ils contiennent, dans les cellules endothéliales afin de favoriser l'angiogenèse<sup>222</sup>.

Les cellules cancéreuses sont donc capables d'utiliser les exosomes pour stimuler l'angiogenèse et favoriser la croissance tumorale.

#### *6.6.2.4. Effets sur la formation des métastases :*

Plusieurs études ont également démontré un rôle des exosomes dérivés de tumeurs au niveau de différentes étapes de la formation des métastases (Figure 12). Ainsi, dans un modèle de cancer mammaire murin, Tominaga et ses collègues ont révélé que le miR-181c exosomal entraînait la dégradation de la barrière hémato-encéphalique et promouvait ainsi la formation de métastases cérébrales<sup>223</sup>. De façon similaire, le miR-105 contenu dans les exosomes dérivés de cancer du sein entraîne la formation de métastases pulmonaires et cérébrales via la dégradation de l'ARNm codant pour la protéine ZO-1, constituant important de la perméabilité vasculaire<sup>224</sup>.

Dans le mélanome, deux études ont souligné le rôle des exosomes contenant la protéine MET dans la formation des métastases<sup>225,226</sup>. Ces derniers sont capables de recruter et d'éduquer des progéniteurs de la moelle osseuse vers un phénotype pro-métastatique via le transfert du récepteur de tyrosine kinase MET, et ainsi d'initier la formation d'une niche pré-métastatique<sup>226</sup>. Dans le cancer du pancréas, les exosomes dérivés de tumeur sont enrichis en la protéine MIF qui, une fois assimilés par les cellules de Kupffer du foie, induit une libération de TGF- $\beta$  qui crée un environnement favorable à la formation




de métastases dans ce même organe<sup>227</sup>. De plus, Hoshino et ses collègues ont démontré que le profil en intégrines des exosomes dictait l'organotropisme, c'est-à-dire l'endroit où les métastases vont préférentiellement se développer<sup>185</sup>.

Ainsi, les exosomes semblent être une voie de communication importante dans l'établissement de foyer métastatiques. Il est néanmoins nécessaire de poursuivre les recherches afin de déterminer dans quelles mesures les exosomes sont importants dans ce processus. Des techniques d'imageries innovantes ont été développées dans cette optique<sup>228,229</sup>.

#### *6.6.2.5. Rôles dans la résistance à la thérapie :*

Plusieurs études ont indiqué que les exosomes peuvent médier la résistance à la thérapie, notamment au travers de l'export des drogues chimiothérapeutiques en dehors de la cellule (Figure 12). Par exemple, les cellules de carcinome ovarien humain résistantes au cisplatine possèdent un dérèglement du fonctionnement lysosomal qui aboutit à une sécrétion accrue d'exosomes contenant du cisplatine<sup>230</sup>. Ensuite, les exosomes tumoraux sont capables de transférer des protéines associées à la résistance aux drogues. Parmi ces protéines, TRPC5, présente dans les exosomes dérivés de cellules MCF-7 résistantes à la doxorubicine, est capable de transférer la résistance à la chimiothérapie dans les cellules réceptrices<sup>231</sup>. Mais les exosomes peuvent aussi agir via le transfert de matériel génétique. Ainsi, des chercheurs ont montré que les exosomes étaient capables de transférer la capacité de résistance aux drogues via le transfert du miR-100-5p dans le cancer du poumon<sup>232</sup>, ou le long ARN non codant ARSR dans le cancer du rein<sup>233</sup>. De plus, ces nanovésicules dérivées de tumeur peuvent transférer des molécules anti-apoptotiques ou qui favorisent la survie cellulaire. C'est par exemple le cas des exosomes dérivés de cancer du foie qui inhibent l'apoptose induite par le Sorafenib<sup>234</sup>. Enfin, les exosomes sont capables d'agir comme des leurres afin de tromper les thérapies ; dans le cancer du sein, les exosomes porteurs de la protéine HER2 sont capables de fixer le trastuzumab et par conséquent d'empêcher son action contre les cellules cancéreuses<sup>235</sup>. De la même manière, dans le lymphome B malin les exosomes porteurs de CD20 protègent les cellules cancéreuses des anticorps dirigés contre cette protéine<sup>236</sup>.

Ces études soulignent ainsi l'importance de l'étude des exosomes dans les mécanismes de résistance aux thérapies et constituent, de fait, des cibles thérapeutiques.



**Figure 12 : Rôle des exosomes dérivés de tumeur.** Les exosomes dérivés de cellules tumorales peuvent influencer le microenvironnement local mais aussi systémique. Ils peuvent interagir avec le microenvironnement tumoral pour promouvoir l'angiogenèse (angiogenesis), en activant les cellules endothéliales (endothelial cell) et en augmentant la formation de capillaires (capillary formation) via une sécrétion accrue de VEGF. Les exosomes sont également capables d'induire un environnement immunosuppresseur via l'activation des MDSCs et des Treg, qui aboutit à l'inhibition de la fonction cytotoxique des cellules T (inhibition of cytotoxic effector function). De plus, les exosomes modulent la formation de niche pré-métastatique et déterminent l'organotropisme en y altérant le comportement des cellules. Enfin, via le transfert de transporteurs de drogues ou via son action en tant que leurre (decoy), les exosomes favorisent la progression tumorale, la survie (promotion of survival) et la résistance aux drogues (drug resistance). D'après Dassler-Plenker, *Biochim Biophys Acta Rev Cancer*, 2020.

### 6.7. Utilisation des exosomes en tant que biomarqueur :

La biologie des exosomes dans le cancer est encore un sujet émergent et le nombre de travaux sur leur utilisation en tant que biomarqueur ne cesse de croître. Sachant de plus en plus que ces nanovésicules jouent un rôle important dans le cancer, les chercheurs tentent de tirer parti du contenu biologique des exosomes afin d'établir des biomarqueurs circulants robustes, notamment via des analyses multiparamétriques. Il existe ainsi pléthore de publications suggérant l'utilisation d'une ou plusieurs molécules particulières présentes dans les exosomes pour le diagnostic, le pronostic ou le suivi du cancer<sup>139,237-239</sup>. Le but de cette partie n'est pas d'être exhaustif mais d'illustrer les potentielles applications cliniques des exosomes à l'aide de quelques exemples marquants.

### 6.7.1. Le contenu protéique des exosomes en tant que biomarqueur :

De nombreuses équipes de recherche ont révélé la surexpression d'une ou plusieurs protéines au sein des exosomes et leur corrélation avec la présence ou le stade de la maladie. Par exemple, en 2012, Peinado et ses collègues ont identifié une signature protéique spécifique dans les exosomes circulants de patients atteints de mélanome métastatique, composée de MET, VLA-4 et TYRP-2<sup>226</sup>. Une autre étude suggère l'utilisation des protéines MIA et S100B pour le diagnostic et le pronostic du mélanome<sup>240</sup>. Moon *et al* ont quant à eux identifié dans deux études différentes l'utilité potentielle des protéines Del-1 et de la fibronectine dans les exosomes pour la détection précoce du cancer du sein<sup>241,242</sup>. Des techniques à haut débit ont également permis de révéler une utilité potentielle en tant que biomarqueur, notamment la spectrométrie de masse. Ainsi, Arbelaiz et ses collègues ont identifié une combinaison de protéines dans les exosomes capable de diagnostiquer un cancer du foie avec une précision correcte<sup>243</sup>. De la même manière, une équipe a démontré que le phosphoprotéome des exosomes pouvait avoir une utilité diagnostique dans le cancer du sein<sup>244</sup>.

Mais les exosomes semblent aussi utiles dans le suivi du cancer. Ainsi, des chercheurs ont montré que les patients atteints d'un cancer des ovaires qui possèdent un taux élevé de E-cadhérine dans les exosomes circulants, avaient une probabilité de survie statistiquement inférieure<sup>245</sup>. Mais une des protéines exosomales qui concentre le plus d'espoir reste PD-L1, dont le ciblage par des anticorps monoclonaux a révolutionné la prise en charge des patients atteints de cancer. L'intérêt est d'autant plus grand que la détection de la présence de cette protéine par IHC présente plusieurs inconvénients. Ainsi, Chen et ses collègues ont récemment démontré que le dosage de PD-L1 dans les exosomes circulants de patients atteints de mélanome était capable de prédire la réponse à l'immunothérapie<sup>246</sup>. Notre équipe a également obtenu les mêmes résultats et démontré son utilité en tant que facteur pronostique puisque le taux de PD-L1 dans les exosomes corrèle également avec la probabilité de survie globale et sans progression<sup>207</sup>. D'autres études ont aussi mis en valeur l'utilité de cette protéine en tant que marqueur circulant dans d'autres cancers<sup>208,209,247</sup>. Enfin, une autre possibilité réside dans l'étude du profil des intégrines présentes dans les exosomes afin d'identifier précocement l'organe où les métastases vont préférentiellement se développer<sup>185</sup>.

La recherche sur les exosomes s'orientent cependant vers l'étude de sous-populations d'exosomes particulières, en vue d'une médecine toujours plus personnalisée<sup>144,181</sup>. Melo et ses collègue ont par exemple démontré l'utilité des exosomes porteurs de la protéine glypican-1 (GPC1) dans le diagnostic précoce et le suivi du cancer du pancréas<sup>248</sup>. En effet, les auteurs ont révélé que la détection d'exosomes GPC1+ circulants permettait non seulement de diagnostiquer un cancer du pancréas avec une parfaite précision, mais également de prédire la survie globale et sans progression des patients<sup>248</sup>. Cette étude a également été réalisée par des laboratoires indépendants dans le cancer du sein et du

colon<sup>249-251</sup>. D'autres chercheurs ont identifié des sous-populations particulières d'exosomes au potentiel biomarqueur ; Yoshioka et ses collègues ont par exemple mis au point une technologie basée sur l'immunocapture des exosomes et identifié que les exosomes CD147+ pouvaient être utiles pour diagnostiquer un cancer colorectal<sup>252</sup>.

L'étude des protéines exosomales, qu'elles soient dans la lumière ou membranaires, présente donc un fort potentiel en tant que biomarqueur. Néanmoins, les exosomes contiennent également du matériel génétique qui possède aussi une valeur clinique potentielle.

#### 6.7.2. Le contenu en acide nucléiques des exosomes en tant que biomarqueur :

Les exosomes tumoraux contiennent des acides nucléiques fonctionnels dont l'expression est altérée vis-à-vis de la cellule hôte. On y retrouve ainsi différents types d'ARN et d'ADN<sup>23,171,238</sup>.

En 2016, Yuan et ses collègues ont réalisé une analyse transcriptomique des exosomes qui a révélé la composition en ARN des exosomes. On retrouve ainsi majoritairement des micro-ARNs (40,4%), des piARNs (40%), des pseudo-gènes (3,7%), des lncARNs (2,4%), des ARNt (2,1%) et de l'ARNm (2,1), chacun présentant un potentiel biomarqueur<sup>253</sup>. D'autres types d'ARNs sont également présents comme les ARNs circulaires<sup>254</sup>.

La très grande majorité des études sur le matériel génétique dans les exosomes concerne les micro-ARNs ; on trouve ainsi une grande quantité de publications traitant de la potentielle utilisation d'un ou plusieurs micro-ARNs en tant que biomarqueur de diagnostic, de pronostic ou de suivi du cancer<sup>255,256</sup>. Un des micro-ARNs des exosomes circulants les plus décrits dans la littérature est le miR-21, dont la surexpression a été identifiée dans de nombreux cancers tels que le glioblastome, le pancréas, le cancer colorectal, du foie, du sein, des ovaires ou encore les cancers oraux, mais aussi dans les exosomes dérivés d'urine de patient atteints d'un cancer de la vessie et de la prostate<sup>255-257</sup>. La surexpression du miR-1246 a été quant à elle corrélée aux différents stades et à la probabilité de survie globale des patients atteints d'un cancer de la prostate<sup>258</sup>. Il a également été décrit comme étant surexprimé dans d'autres cancers<sup>259,260</sup>. Les miR-155 et 17-92 ont eux aussi été identifiés comme des oncomirs, c'est-à-dire des micro-ARNs qui favorisent la croissance tumorale, et associés avec différents paramètres cliniques dans plusieurs types de cancers<sup>256</sup>. Mais il est également possible de cibler l'expression de micro-ARNs suppresseurs de tumeurs comme le miR-143 dont la sous-expression a été associée aux cancers du foie, du sein, du colon ou encore du pancréas<sup>256</sup>. Une autre stratégie utilisée par certaines équipes de recherche vise à utiliser une combinaison de micro-ARNs afin d'améliorer la précision clinique de ces biomarqueurs. Différentes études ont ainsi été publiées sur le potentiel clinique d'une signature particulière de micro-ARNs des exosomes dans différents cancers, notamment pour le diagnostic et le pronostic<sup>261-263</sup>.

La détection de mutations au niveau de l'ARNm semble également être pertinente en clinique. Ainsi, McKiernan et ses collègues ont mis au point un test d'expression génique des exosomes dérivés d'urine capable de prédire un cancer de la prostate<sup>264-266</sup>. Enfin, l'avancée des technologies a récemment permis aux chercheurs d'étudier l'expression d'autres types d'ARN dans les exosomes tels que les lncARNs ou les ARNs circulants et leur potentielle utilisation en tant que biomarqueur du cancer<sup>178,267-270</sup>.

Des études ont également suggéré que de petites quantités d'ADN pouvaient être détectées dans les exosomes et permettait d'identifier des mutations associées au cancer<sup>22,23,271</sup>. Ainsi, plusieurs équipes sont parvenues à détecter des mutations des gènes KRAS et TP53 dans les exosomes, dont la fréquence permettrait de diagnostiquer un cancer du pancréas<sup>22,271-274</sup>.

Les exosomes, au travers de leur composition, présentent donc de nombreuses applications potentielles en tant que biomarqueur dans le diagnostic et le suivi du cancer. La recherche s'oriente désormais vers une approche combinatoire qui vise à analyser des marqueurs de nature différente afin d'améliorer la spécificité et la sensibilité des tests. C'est par exemple le cas de l'étude de Melo et ses collègues qui a détecté la mutation KRAS<sup>G12D</sup> dans les exosomes GPC1+ uniquement, et dont la combinaison permet de détecter des lésions intra-épithéliales pancréatiques avant l'imagerie<sup>248</sup>. Une autre équipe a démontré que la détection des mutations du gène EGFR à partir de l'ARN et de l'ADN des exosomes, combiné à l'ADNtc permettait d'améliorer la sensibilité du test diagnostic<sup>275</sup>. Cependant, malgré les nombreuses recherches menées à ce jour, les exosomes ne sont pas encore utilisés en clinique, faute d'études cliniques démontrant un gain réel chez un grand nombre de patients. C'est ce vers quoi doit désormais se tourner la recherche sur les exosomes ; il y a ainsi actuellement 32 essais cliniques en cours dans le monde qui visent à étudier l'utilité des exosomes en tant que biomarqueur du cancer (<https://clinicaltrials.gov/>).

## 7. Les protéines de choc thermique (HSPs) :

### 7.1. La réponse au stress cellulaire :


L'homéostasie se définit par la capacité que peut avoir un système quelconque à conserver son équilibre de fonctionnement en dépit des contraintes qui lui sont extérieures. Ainsi, l'homéostasie cellulaire consiste en un mécanisme d'autorégulation dynamique, mis en place par les cellules afin de répondre à tout type de stress. Ces stimuli peuvent être de nature environnementale (stress oxydatif, hypoxie, température élevée), chimique (chimiothérapies, alcool) ou encore physiologique (inflammation). Les cellules sont donc capables de s'accommoder à ces types de stress afin de résister et de survivre.

Le concept de réponse cellulaire au stress a été décrit pour la première fois en 1962 par Ritossa et ses collègues<sup>276</sup>. Les chercheurs ont en effet observé une boursoufflure des chromosomes géants de glandes salivaires de drosophile suite à un choc thermique ou à un agent chimique, qui se traduisait par une synthèse d'ARN très rapidement augmentée<sup>276,277</sup>. C'est la naissance du concept de réponse au choc thermique. Douze ans après ces premières observations, Tissières et ses collègues ont démontré que ces boursoufflures des chromosomes en réponse à un choc thermique s'accompagnait d'une plus grande production de protéines, qu'ils vont appeler les « protéines de choc thermique » (Heat Shock Proteins, HSPs)<sup>278</sup>. Depuis, on a découvert que ces protéines sont très conservées et présentes dans la grande majorité des espèces<sup>279,280</sup>.

La réponse au stress se caractérise par la surexpression des HSPs en réponse à un stress aigu ou chronique<sup>280</sup>. Cette augmentation de l'expression protéique a lieu grâce à un facteur de transcription appelé « Heat shock factor » (HSF) qui, une fois activé, se lie sur une région particulière de l'ADN appelée « Heat shock element » (HSE). Cette fixation va déclencher la transcription des gènes des HSPs inductibles, puis entraîner leur traduction dans la cellule<sup>280</sup>. Chez les vertébrés, il existe plusieurs membres de la famille des HSF (HSF1-4). De façon générale, HSF1 est le facteur de transcription majoritaire chez les vertébrés. HSF1 et HSF3 sont activés en réponse à différents types de stress, alors que HSF2 est induit lors de processus de différenciation<sup>279,281,282</sup> et HSF4 comme un modulateur dans le développement et la maintenance des organes sensoriels<sup>283,284</sup>.

HSF1 reste donc l'acteur majeur de la réponse au stress chez l'Homme. En réponse à un stimuli, HSF1 va passer de sa forme monomérique inactive dans le cytoplasme, à une forme trimérique active qui va subir de nombreuses modifications post-traductionnelles régulant son activité et sa stabilité. Cette trimérisation est suivie d'une translocation dans le noyau dans lequel les trimères de HSF1 vont se lier aux HSE, dans le promoteur des gènes des HSPs<sup>285</sup>. Cette fixation déclenche alors la synthèse des HSPs

qui vont avoir au sein de la cellule un rôle de chaperon moléculaire qui permet de maintenir l'homéostasie cellulaire, favoriser la survie et réparer les dommages protéiques<sup>279</sup>. Le retour à une situation normale se fait via l'acétylation du domaine de liaison à l'ADN de HSF1 ainsi que par les protéines de choc thermique HSP90 et HSP70 qui vont maintenir HSF1 sous forme de monomère inactif (Figure 13). Un stress trop sévère ou trop long entraîne quant à lui des dommages trop importants pour les capacités de réparation de la cellule, qui entrera alors dans un processus de mort par apoptose ou par nécrose.



**Figure 13 : Représentation schématique de la réponse au stress par HSF1 chez les vertébrés.** Le stress cellulaire induit la trimérisation de HSF1 puis sa relocalisation dans le noyau cellulaire. La phosphorylation stimule son activité transcriptionnelle, permettant ainsi la synthèse des gènes des HSPs. D'après la thèse de Margaux Sevin, *Rôle des protéines de choc thermique dans les néoplasies myéloprolifératives : implication de HSP27 dans la myélofibrose*, 2017.

## 7.2. Classification des HSPs :

Les HSPs sont classées en fonction de leur poids moléculaires. On distingue ainsi 6 grandes familles de HSPs chez les mammifères : HSP110, HSP90, HSP70, HSP60, HSP47 et les petites HSPs ou small heat shock proteins (sHSP) (Tableau 1)<sup>286</sup>. Bien que les HSPs partagent des propriétés communes, chaque classe possède des caractéristiques particulières du fait de leur localisation cellulaire, leur dépendance ou non à l'ATP ou encore leur mécanisme d'action. Les HSPs peuvent être exprimé de façon constitutionnelle ou induite, et sont retrouvées dans différents compartiments cellulaires : le cytoplasme, le noyau, la mitochondrie, le réticulum endoplasmique ou encore dans les membranes. Il existe une liste non exhaustive des HSPs, certaines étant plus étudiées que d'autres. Quatre familles nous intéressent particulièrement ici.

**Tableau 1 : Nomenclature des principales familles des HSPs chez l'Homme. D'après Kampinga et al, Cell stress and chaperones, 2009.**

	Gene name	Protein name	Old names	Human gene ID	Mouse ortholog ID
<b>HSP A</b>					
1	<i>HSPA1A</i>	HSPA1A	HSP70-1; HSP72; HSPA1	3303	193740
2	<i>HSPA1B</i>	HSPA1B	HSP70-2	3304	15511
3	<i>HSPA1L</i>	HSPA1L	hum70t; hum70t; Hsp-hom	3305	15482
4	<i>HSPA2</i>	HSPA2	Heat-shock 70kD protein-2	3306	15512
5	<i>HSPA5</i>	HSPA5	BIP; GRP78; MIF2	3309	14828
6	<i>HSPA6</i>	HSPA6	Heat shock 70kD protein 6 (HSP70B')	3310	X
7	<i>HSPA7<sup>m</sup></i>	HSPA7	Heat shock 70kD protein 7	3311	X
8	<i>HSPA8</i>	HSPA8	HSC70; HSC71; HSP71; HSP73	3312	15481
9	<i>HSPA9</i>	HSPA9	GRP75; HSPA9B; MOT; MOT2; PBP74; mot-2	3313	15526
10	<i>HSPA12A</i>	HSPA12A	FLJ13874; KIAA0417	259217	73442
11	<i>HSPA12B</i>	HSPA12B	RP23-32L15.1; 2700081N06Rik	116835	72630
12	<i>HSPA13<sup>b</sup></i>	HSPA13	Sich	6782	110920
13	<i>HSPA14</i>	HSPA14	HSP70-4; HSP70L1; MGC131990	51182	50497
<b>HSP H</b>					
1	<i>HSPH1</i>	HSPH1	HSP105	10808	15505
2	<i>HSPH2<sup>b</sup></i>	HSPH2	HSPA4; APG-2; HSP110	3308	15525
3	<i>HSPH3<sup>b</sup></i>	HSPH3	HSPA4L; APG-1	22824	18415
4	<i>HSPH4<sup>b</sup></i>	HSPH4	HYOU1/Grp170; ORP150; HSP12A	10525	12282
<b>The HSP90/HSPC family</b>					
	Gene name	Protein name	Old names	Human gene ID	Mouse ortholog ID
1	<i>HSPC1<sup>a</sup></i>	HSPC1	HSP90AA1; HSPN; LAP2; HSP86; HSPC1; HSPCA; HSP89; HSP90; HSP90A; HSP90N; HSPCAL1; HSPCAL4; FLJ31884	3320	15519
2	<i>HSPC2<sup>a</sup></i>	HSPC2	HSP90AA2; HSPCA; HSPCAL3; HSP90ALPHA;	3324	X
3	<i>HSPC3<sup>a</sup></i>	HSPC3	HSP90AB1; HSPC2; HSPCB; D6S182; HSP90B; FLJ26984; HSP90-BETA	3326	15516
4	<i>HSPC4<sup>a</sup></i>	HSPC4	HSP90B1; ECGP; GP96; TRA1; GRP94; endoplasmic	7184	22027
5	<i>HSPC5<sup>a</sup></i>	HSPC5	TRAP1; HSP75; HSP90L	10131	68015
<b>The HSPB family (small heat shock proteins)</b>					
	Gene name	Protein name	Old names	Human gene ID	Mouse ortholog ID
1	<i>HSPB1</i>	HSPB1	CMT2F; HMN2B; HSP27; HSP28; HSP25; HS.76067; DKFZp586P1322	3315	15507
2	<i>HSPB2</i>	HSPB2	MKBP; HSP27; Hs.78846; LOH11CR1K; MGC133245	3316	69253
3	<i>HSPB3</i>	HSPB3	HSPL27	8988	56534
4	<i>HSPB4<sup>a</sup></i>	HSPB4	crystallin alpha A; CRYAA; CRYA1	1409	12954
5	<i>HSPB5<sup>a</sup></i>	HSPB5	crystallin alpha B; CRYAB; CRYA2	1410	12955
6	<i>HSPB6</i>	HSPB6	HSP20; FLJ32389	126393	243912
7	<i>HSPB7</i>	HSPB7	cvHSP; FLJ32733; DKFZp779D0968	27129	29818
8	<i>HSPB8</i>	HSPB8	H11; HMN2; CMT2L; DHMN2; E2IG1; HMN2A; HSP22	26353	80888
9	<i>HSPB9</i>	HSPB9	FLJ27437	94086	75482
10	<i>HSPB10<sup>a</sup></i>	HSPB10	ODF1; ODF; RT7; ODF2; ODFP; SODF; ODF27; ODFPG; ODFPGA; ODFPGB; MGC129928; MGC129929	4956	18285
11	<i>HSPB11</i>	HSPB11	HSP16.2; C1orf41; PP25	51668	72938

### 7.3. Structure des principales HSPs :

#### 7.3.1. HSP27 :

La famille des petites HSPs est composée de 10 membres partageant tous un domaine commun appelé  $\alpha$ -crystallin et diffèrent par leurs région N-terminale et C-terminale (Tableau 1, Figure 14). Le membre le plus étudié des petites HSPs est HSP27. HSP27 une protéine chaperon de 27 kDa exprimée dans tous les tissus humains. Elle possède des sites de phosphorylation en N-terminal qui vont réguler sa forme tridimensionnelle : à l'état phosphorylé, HSP27 se trouve sous forme de dimère tandis que sous une forme non phosphorylée, HSP27 est capable de former des oligomères allant jusqu'à 800 kDa<sup>287</sup> (Figure 14). Ainsi, HSP27 agit tel un senseur cellulaire qui modifie son activité via des interactions moléculaires en fonction de l'environnement physiologique<sup>287,288</sup>.



### 7.3.2. HSP90 :

La famille HSP90 est fortement conservée au cours de l'évolution. On distingue 5 sous-familles classées en fonction de leur localisation subcellulaire (Tableau 1)<sup>286</sup>. Ce sont également des chaperons moléculaires dépendants de l'ATP qui sont exprimés à des niveaux très élevés dans la cellule.

Les formes les plus étudiées sont HSP90 $\alpha$ , dont l'expression dans le cytosol et le noyau est inductible, et HSP90 $\beta$  qui, elle, est constitutivement exprimée dans le cytoplasme. Tous les membres de la famille possèdent une structure conservée, divisée en 3 parties : un domaine C-terminal responsable de la dimérisation, un domaine médian qui constitue le PBD, et un domaine N-terminal contenant un site de liaison à l'ATP (ABD)<sup>289,290</sup> (Figure 14). HSP90 agit le plus souvent sous forme d'homodimère mais peut, dans certains cas, agir sous forme d'hétérodimère ou de monomère.

### 7.3.3. HSP110 :

La famille HSP110 est constituée de 4 membres, chacun étant encore mal connu<sup>286</sup>. La plus étudiée dans la littérature est HSP105. C'est aussi un chaperon moléculaire de 105 kDa qui existe sous 2 isoformes : HSP105 $\alpha$ , constitutivement exprimée dans le cytoplasme et le noyau des cellules, et HSP105 $\beta$ , exprimée de façon inductible suite à un épissage alternatif de la forme  $\alpha$ , dans le noyau exclusivement. Leur structure sont également très proches et sont constituées de 4 principaux domaines : un domaine N-terminal qui forme l'ABD, un domaine qui forme le PBD, un domaine « Loop » qui contient signal de localisation nucléaire (NLS, *Nuclear Localization Signal*) et un domaine C-terminal qui contient un signal d'export nucléaire (NES, *Nuclear Export Signal*)<sup>291,292</sup> (Figure 14).


### 7.3.4. HSP70 :

La famille HSP70 est la plus conservée au cours de l'évolution. C'est également la plus connue et la plus étudiée. Cette famille est constituée de 13 isoformes qui diffèrent par leur séquence en acide-aminés, leur niveau d'expression et leur localisation subcellulaire (Tableau 1)<sup>286</sup>. Certaines sont exprimés constitutionnellement comme HSC70, tandis que d'autres sont inductibles telle que HSP70-1 (HSPA1)<sup>293</sup>.


Néanmoins, la structure des isoformes de HSP70 est très conservée. HSP70-1 (HSPA1) est le membre le mieux décrit dans la littérature. C'est un chaperon moléculaire de 70 kDa, dépendant de l'ATP<sup>294</sup>. Sa structure se divise en deux domaines principaux : un domaine N-terminal qui forme l'« *ATP Binding Domain* » (ABD), capable de fixer l'ATP et de l'hydrolyser, et un domaine C-terminal qui forme le « *Peptide Binding Domain* » (PBD) permettant d'interagir avec ses partenaires<sup>295</sup>. Ce dernier inclue notamment un motif EEVD, nécessaire à la liaison et au repliement du substrat, ainsi qu'à la fixation d'autres HSPs ou co-chaperons (Figure 14). Contrairement à HSP27, HSP70 est présent sous forme de

monomère dans la cellule, et peut être localisée dans la cellule, à la membrane, ou dans le milieu extracellulaire. Dans ce travail, nous nous intéresserons plus particulièrement à HSP70.

### A) HSP110




### B) HSP90



### C) HSP70



### D) HSP27



**Figure 14 : Structure des principales HSPs.** A) Structure de HSP110 qui est composée de 4 domaines distincts. B) Structure d'un monomère de HSP90 : N représentant le domaine amino-terminal capable de lier l'ATP, M représentant le domaine médian, C représentant le domaine c-terminal responsable de la dimérisation de HSP90 et qui contient le motif MEEVD nécessaire à la fixation de co-chaperons. C) Structure de HSP70. D) Structure et organisation de HSP27 selon son statut de phosphorylation. Adaptée de la thèse de Margaux Sevin, *Rôle des protéines de choc thermique dans les néoplasies myéloprolifératives : implication de HSP27 dans la myélofibrose*, 2017.


## 7.4. Fonctions de HSP70 :

### 7.4.1. Rôle de chaperon moléculaire :


Les protéines HSP70 sont des composants essentiels du réseau cellulaire des chaperons moléculaires. Elles participent à une large diversité de processus de repliement de protéines dans la cellule par leur association transitoire avec leur substrat. Les HSP70 participent à de nombreuses fonctions cellulaires en condition normales incluant le repliement des protéines néosynthétisées, la translocation des polypeptides dans les mitochondries et le réticulum endoplasmique, à l'assemblage et désassemblage de complexes protéiques, à la régulation de l'activité de certaines protéines ou encore en assistant le cycle d'autres HSPs ou co-chaperons (Figure 15)<sup>296,297</sup>.

En réponse à un stress cellulaire, la cellule va rapidement synthétiser les formes inductibles de HSP70, notamment HSPA1, afin de permettre de maintenir l'homéostasie et la survie cellulaire. HSP70 va ainsi empêcher l'agrégation des protéines, solubiliser les agrégats protéiques, promouvoir le repliement des protéines incorrectement repliées ou non repliées ou encore favoriser la dégradation des protéines aberrantes ou des agrégats via des systèmes de dégradation tels que le protéasome ou l'autophagie médiée par les chaperonnes<sup>294,296,297</sup> (Figure 15).

Ces activités sont rendues possibles par l'intermédiaire de son cycle allostérique chaperon qui a lieu en trois étapes : (i) HSP40 prend en charge la protéine cliente dénaturée et viens la fixer à l'ABD de HSP70. A cette étape, l'ATP est déjà fixée à l'ABD de HSP70 et lui permet d'avoir une conformation dite « ouverte ». (ii) L'hydrolyse de l'ATP en ADP entraîne le transfert du substrat, en l'occurrence la protéine dénaturée, dans le PBD de HSP70 qui se referme. HSP40 quitte alors le complexe. (iii) Des facteurs d'échanges nucléotidiques (NEF) comme HSP110 viennent s'associer au complexe afin de stimuler l'échange de l'ADP par l'ATP, ce qui provoque le relargage de la protéine renaturée. Une fois le cycle terminé, si la protéine cliente relarguée est toujours défectueuse, elle est soit dirigée vers le protéasome ou l'autophagie médiée par les chaperonnes, soit dirigée vers HSP90 pour un repliement plus complexe<sup>294,296-298</sup> (Figure 16).



**Figure 15 : Rôles de HSP70 dans la cellule.** HSP70 joue un rôle en conditions normales (housekeeping activities) et en condition de stress (stress-related activities). En conditions de stress, HSP70 est capable d'empêcher l'agrégation des protéines (protein aggregation prevention) ou de les désagréger (protein disaggregation), de replier correctement les protéines (protein folding) ou de favoriser leur dégradation (protein degradation). D'après Rosenzweig et al, Nature Reviews Molecular Cell Biology, 2019.



**Figure 16 : Cycle allostérique chaperon de HSP70.** HSP40 vient fixer la protéine cliente dénaturée sur HSP70 déjà liée à l'ATP. L'hydrolyse de l'ATP entraîne un changement de conformation de HSP70 qui se « referme » sur son substrat pour le stabiliser. Des facteurs d'échanges nucléotidiques (NEF) viennent ensuite catalyser le remplacement de l'ADP par l'ATP menant ainsi au relargage du substrat. D'après la thèse Margaux Sevin, Rôle des protéines de choc thermique dans les néoplasies myéloprolifératives : implication de HSP27 dans la myélofibrose, 2017.


#### 7.4.2. Rôle anti-apoptotique :

HSP70 est une protéine hautement conservée dont l'expression augmente les capacités de la cellule à survivre en conditions de stress intense. Plusieurs études ont montré qu'une modification de l'expression de HSP70 jouait sur la mort cellulaire à différents niveaux<sup>299-301</sup>.

Comme son nom l'indique, la voie extrinsèque de l'apoptose est déclenchée par un signal extérieur à la cellule. Cette voie est activée par liaison des ligands des récepteurs à domaines de mort tels que TNF (*Tumor Necrosis Factor*), FAS et TRAIL (*Tumor necrosis factor-Related Apoptosis-Inducing Ligand*). Cette fixation entraîne la formation à la membrane d'un complexe protéique appelé DISC (*Death-Inducing Signaling Complex*), qui est composé des molécules adaptatrices FADD (*Fas Associated Death Domain*) et de la procaspase 8, et déclenche ensuite la cascade des caspases. HSP70 est capable d'interagir avec différentes protéines de cette voie afin d'empêcher la cascade de signalisation aboutissant à l'apoptose. Ainsi, HSP70 se lie à JNK (*c-Jun N-terminal Kinase*) inhibant ainsi la mort cellulaire<sup>302,303</sup>. Ceci a également pour effet de bloquer l'activation de la protéine Bid<sup>302</sup>. Par ailleurs, HSP70 est également capable d'empêcher la formation du complexe DISC et la signalisation qui en découle<sup>304</sup>. Enfin, HSP70 chaperonne la protéine Akt, ce qui la stabilise, et promeut la voie de signalisation qui favorise la survie cellulaire<sup>305</sup> (Figure 17).

Contrairement à la voie extrinsèque, la voie intrinsèque de l'apoptose est déclenchée par des signaux internes à la cellule. En effet, elle repose principalement sur la rupture ou l'ouverture de la mitochondrie, ce qui permet la libération dans le cytosol de molécules pro-apoptotiques telles que le cytochrome c, SMAC/DIABLO, ou encore l'AIF (*Apoptosis Inducing Factor*). Ces molécules vont ensuite chacune induire l'apoptose via différentes voies ; Le cytochrome c s'associe à APAF1 et la procaspase-9 pour former un complexe nommé apoptosome, qui est capable de déclencher la voie des caspases. SMAC/DIABLO inhibe les protéines de la famille des IAP (*Inhibitor of apoptosis*) et lève ainsi l'inhibition de l'activité des caspases tandis que AIF est capable d'induire à lui seul l'apoptose. Ici aussi, HSP70 est capable de prévenir la mort cellulaire via des interactions avec de nombreux membres de cette voie de signalisation. Par exemple, HSP70, couplé à HSP40, bloque la translocation de Bax, empêchant ainsi la perméabilisation de la membrane mitochondriale et donc la libération du cytochrome c et de l'AIF<sup>299,306</sup>. De plus, HSP70 est capable de se fixer directement à AIF et d'inhiber ainsi l'apoptose<sup>307</sup>. D'autre part, il a été démontré que HSP70 peut se lier à Apaf-1 et empêcher le recrutement de la procaspase-9 pour former l'apoptosome<sup>308,309</sup>. Enfin, HSP70 est capable d'inhiber des cibles de la caspase-3 telles que GATA-1 (*GATA binding protein 1*)<sup>310</sup>, CAD (*Caspases-Activated DNase*)<sup>311</sup> et la protéine de réparation de l'ADN, PARP (*Poly ADP-ribose Polymerase*)<sup>312</sup> (Figure 17).

En agissant ainsi à différents niveaux de l'apoptose, HSP70 est un puissant agent cytoprotecteur qui protège efficacement les cellules de la mort cellulaire.



**Figure 17 : Rôle anti-apoptotique de HSP70.** HSP70 agit sur de nombreux effecteurs de la voie apoptotique extrinsèque (à gauche) et intrinsèque (à droite) constituant ainsi une des protéines les plus importantes dans la survie cellulaire.

## 8. HSP70 et cancer :

En conditions normales, HSP70 est faiblement exprimé. Cette expression peut augmenter fortement mais de façon transitoire en réponse à un stress. Au contraire, les cellules cancéreuses ont la propriété de surexprimer continuellement HSP70, qui est essentielle à la survie de nombreux cancers<sup>299</sup>.

### 8.1. HSP70 : tumorigénicité et résistance des cellules cancéreuses :

Dans une grande majorité de tumeurs solides, HSP70 est surexprimé afin de promouvoir la survie des cellules cancéreuses, la tumorigénicité et la résistance à l'apoptose. Des expériences menées sur des modèles *in vivo* ont indiqué que la surexpression de HSP70 entraînait une augmentation de la capacité des cellules cancéreuses à former une tumeur<sup>313</sup>, tandis que la diminution de son expression la réduisait fortement<sup>314</sup>. Ainsi, la forte expression de HSP70 a été corrélée avec une prolifération cellulaire élevée, le stade clinique et le mauvais pronostic de patients atteints de cancer du poumon non à petites cellules<sup>315</sup>, de cancer du sein, de l'endomètre, de l'utérus<sup>316</sup>, ou encore de leucémie<sup>317</sup>, de cancer colorectal<sup>318</sup>, de la prostate<sup>319</sup> ou du foie<sup>320</sup>.

L'expression de HSP70 a également été associée à la réponse au traitement. Ainsi, il a été démontré que la surexpression de HSP70 dans la leucémie chronique myéloïde BCR-ABL était associée à la résistance à l'imatinib, une chimiothérapie efficace utilisée pour bloquer l'activité tyrosine kinase de ce récepteur<sup>321,322</sup>. De la même façon, Vargas-Roig et ses collègues ont observé que la surexpression de HSP70 était corrélée à la résistance à la chimiothérapie du cancer du sein<sup>323</sup>. Enfin, Une étude a montré que la résistance à la radiothérapie était liée à une augmentation de HSP70 dans des cellules humaines de glioblastome<sup>324</sup>.

Outre ses rôles cytoprotecteurs dans le cytoplasme des cellules, HSP70 a été retrouvé dans le milieu extracellulaire, sous une forme libre (soluble), ou associée aux membranes, en particulier à la surface des exosomes<sup>325,326</sup>. Hightower and Guidon ont démontré que cette sécrétion était indépendante des mécanismes de mort cellulaire<sup>327</sup>. Il a été supposé que la surexpression de HSP70 dans les cellules cancéreuses entraînait une partie de ces protéines à être exposée à la surface (10 à 15%)<sup>328</sup>, laissant seulement un petit fragment de 14 acides aminés exposé à l'extérieur de la cellule, que l'on appelle le « TKD »<sup>329</sup>. Cependant, les HSPs cytosoliques ne contiennent pas de peptide leader leur permettant d'être transportés à la membrane. Plusieurs mécanismes d'externalisation ont ainsi été suggérés tels que le chaperonnage de protéines transmembranaires ou encore via l'association avec la phosphatidylsérine<sup>330,331</sup>. Cependant ces mécanismes sont encore mal connus<sup>330</sup>.

## 8.2. Rôle de HSP70 extracellulaire soluble :

Tandis que HSP70 intracellulaire est considéré comme un acteur majeur du maintien de l'homéostasie cellulaire, sa forme extracellulaire est décrite pour ses fonctions immunomodulatrices<sup>332,333</sup>. Il a été démontré que HSP70 est capable d'induire une réponse immunitaire anti-tumorale via le chaperonnage de peptides antigéniques. En effet, HSP70 a été décrit comme ayant un rôle important dans la cross-présentation de peptides antigéniques dérivés de tumeur qui sont internalisés par les cellules présentatrices d'antigènes (CPA)<sup>334</sup>. Cette captation par les CPA est suivie d'un « processing » de l'antigène, puis de sa présentation sur les molécules de CMH I, qui va induire une réponse T CD8 cytotoxique dirigée contre les cellules cancéreuses<sup>332,333,335</sup>. Les complexes peptide-HSP70 ont également été décrits comme améliorant l'activation des cellules T CD4 via la présentation sur le CMH II des CPA<sup>336</sup>. Ces données ont poussé les chercheurs à utiliser HSP70 en tant que vaccin dans de nombreuses études<sup>337-342</sup>.

Cependant, HSP70 est aussi capable d'induire des réponses anti-inflammatoires qui vont favoriser la croissance tumorale<sup>343</sup>. Ainsi, Stocki et ses collègues ont révélé que HSP70 induisait un phénotype tolérogène dans les cellules dendritiques monocytaires, et contribue donc à la formation d'un microenvironnement immunosuppresseur<sup>344</sup>. De la même manière, des chercheurs ont montré que

HSP70 augmentait l'activité des cellules T régulatrices et donc leur capacité à neutraliser le système immunitaire<sup>345</sup>.

Plus récemment, Fong et ses collègues ont mené une série d'expériences qui ont abouti à la découverte de nouveaux récepteurs de HSP70 extracellulaire : les SIGLECs (*sialic acid-binding immunoglobulin-like lectin*)<sup>346</sup>. Les SIGLECs sont des immunoglobulines qui bloquent l'inflammation via leur interaction avec les TLRs. Ainsi, les chercheurs ont montré qu'une liaison de HSP70 avec les différents SIGLECs induisait des réponses immunitaires opposées, ce qui pourrait expliquer les effets contradictoires décrits dans la littérature<sup>346,347</sup>.

Ainsi, de nombreuses études se sont intéressées à la présence de HSP70 soluble dans le sang des patients atteints de cancer<sup>348</sup>. Plusieurs publications relatent d'une corrélation du taux de HSP70 circulant avec la présence d'un cancer du foie ou du pancréas<sup>349,350</sup>, ou avec le volume tumoral du cancer du poumon<sup>348,351</sup>. Enfin, l'équipe de Gabriele Multhoff a également lié la quantité de HSP70 circulant avec la réponse à la radiothérapie<sup>349,349,352</sup>.

### 8.3. Rôle de HSP70 extracellulaire lié aux membranes :


En 1995, Multhoff et ses collègues ont démontré que les cellules tumorales humaines différaient des cellules normales de par leur capacité à exprimer HSP70 à leur surface<sup>353</sup>. En effet, une large proportion de cellules cancéreuses possède une forme membranaire de HSP70, dont seuls 14 acides aminés sont exposés au niveau extracellulaire ; ce domaine est appelé le « TKD »<sup>329</sup>. Cette découverte a mené à l'étude du rôle de HSP70 membranaire dans le cancer. Ainsi, Multhoff et son équipe ont montré que HSP70 membranaire est capable d'activer les cellules NK et d'induire une lyse tumorale<sup>354,355</sup>. Par la suite, l'équipe a montré que les cellules NK pré-stimulées avec HSP70 ou un dérivé peptidique en présence d'IL-2 ou d'autres cytokines induisait une réponse anti-tumorale conséquente, allant jusqu'à une étude clinique de phase II dans le cancer du poumon non à petites cellules<sup>356-359</sup>.

L'équipe de Multhoff a ainsi réalisé une étude qui a permis de révéler qu'environ 50% des tumeurs présentent HSP70 à la membrane<sup>360</sup>. De plus, la densité membranaire de HSP70 sur les cellules cancéreuses est sélectivement augmentée en réponse à un traitement tel que la chimiothérapie ou la radiothérapie<sup>361</sup>. Elle est également augmentée considérablement dans les métastases<sup>362</sup>, ce qui suggère un rôle de HSP70 membranaire dans leur formation. Ainsi, l'expression de HSP70 membranaire a été associée avec un pronostic défavorable et une survie globale diminuée chez les patients atteints d'un cancer rectal et du poumon<sup>363</sup>. Sur la base des résultats obtenus, la présence de HSP70 à la membrane peut donc être considérée comme un marqueur spécifique des tumeurs agressives.



Mais plusieurs études indiquent également que HSP70 est présent sous une forme membranaire dans la circulation, soit à la membrane des CTCs<sup>364</sup>, soit des vésicules extracellulaires et notamment des exosomes<sup>215,357,365,366</sup>. Différentes recherches ont indiqué un rôle immunomodulateur des exosomes présentant HSP70 à la membrane. Ainsi, les « HSP70-exosomes » exercent des fonctions immunostimulantes via l'activation des cellules NK<sup>357,366</sup>, la maturation des cellules dendritiques<sup>365</sup>, et la surexpression du CMHII sur les CPA<sup>367</sup>, ce qui aboutit à l'amélioration de la réponse anti-tumorale (Figure 18).

Cependant, d'autres études dont plusieurs de notre équipe, ont également démontré un rôle immunosuppresseur des HSP70-exosomes via l'activation des MDSCs<sup>215,368,369</sup>. Plus précisément, notre équipe a révélé que le domaine extracellulaire de HSP70 membranaire (TKD) est capable de se lier au récepteur TLR-2 à la surface des MDSCs, et d'activer la voie de signalisation NF- $\kappa$ B. Cette signalisation déclenche l'expression de la cytokine inflammatoire IL-6, qui se lie à son récepteur, l'IL-6R, de manière autocrine et conduit à la phosphorylation de STAT3 par la voie JAK2<sup>215,368</sup>. Une fois activées, les MDSCs vont inhiber l'activité d'autres effecteurs du système immunitaire et promouvoir la progression tumorale (Figure 18).




**Figure 18 : Rôle des HSP70-exosomes sur le système immunitaire.** La présence de HSP70 à la membrane des exosomes dérivés de tumeur peut engendrer une réponse immunitaire anti-cancéreuse via l'activation des cellules NK, la cytotoxicité des cellule T médiée via la maturation des cellules dendritiques, et la surexpression du CMHII à la surface des CPA. Les HSP70-exosomes peuvent également favoriser la croissance tumorale via l'activation des MDSCs. D'après Elmallah et al, Cancer letters, 2020.

# PROJET DE RECHERCHE

Les exosomes concentrent énormément d'espoir dans le domaine de la biopsie liquide. Ces nanovésicules sont sécrétées par toutes les cellules et sont présentes dans tous les fluides biologiques, ce qui les rends très attractif en vue d'un prélèvement peu voire pas invasif, avec le potentiel de pouvoir suivre la maladie. La voie de formation des exosomes entraîne le chargement spécifique de molécules qui peut permettre une analyse multiparamétrique, dans l'optique d'une utilisation en clinique. Néanmoins, l'hétérogénéité des exosomes aussi bien au niveau de leur contenu que de leur fonction, est un frein à son utilisation en clinique. Un des défis actuels du domaine des VEs réside dans la possibilité d'identifier et d'analyser une sous-population particulière d'exosomes.


Notre équipe travaille depuis de nombreuses années sur les HSPs et notamment HSP70 qui a un rôle majeur dans le cancer. HSP70, une des HSPs les étudiées, est un chaperon moléculaire aux rôles divers dans le cancer. Son expression, notamment à la membrane des cellules cancéreuses, a été corrélée avec le diagnostic, le pronostic et/ou la réponse au traitement<sup>329-331</sup>. Notre équipe a démontré que les exosomes possédant HSP70 à la membrane étaient capables d'activer les MDSCs via son interaction avec le TLR2, et ainsi d'inhiber la réponse immunitaire antitumorale<sup>215,368</sup>. Nous les avons appelés les « HSP70-exosomes ». Par la suite, notre équipe a mis au point une technologie basée sur l'interférométrie optique capable de capturer les HSP70-exosomes grâce à un aptamère peptidique qui cible spécifiquement la partie extracellulaire de HSP70. Ceci a permis de révéler qu'une large partie des exosomes dérivés de cellules cancéreuses présentaient HSP70 à la membrane, comparé aux cellules normales, suggérant que ce phénomène est universel dans le cancer (Figure 19)<sup>368</sup>.

Mon projet de thèse s'inscrit dans le cadre d'une étude clinique pilote appelée ExoDiag, qui vise à déterminer si les HSP70-exosomes dérivés de tumeurs peuvent être utilisés dans le diagnostic et le suivi du cancer. Pour cela, nous avons isolé et analysé les exosomes dérivés de plasma de 20 patients atteints d'un cancer du sein et 20 atteints d'un cancer du poumon non à petites cellules, deux des cancers dont l'incidence est la plus importante en France et dans le monde. Nous les avons également suivis tout au long de leur ligne de traitement, pendant 1 an.



**Figure 19 : Les HSP70-exosomes sont universel au cancer.** A. Liaison des exosomes dérivés de MEF, NCM, B16F10, CT26, HCT116 et SW480 immobilisés sur un biocapteur fonctionnalisé avec l'aptamère peptidique A8, déterminé par BLI. B. Analyse de l'expression de HSP70 à la membrane des exosomes dérivés de surnageant cellulaire, déterminé par cytométrie en flux. C. Courbes d'association des HSP70-exosomes circulants de patients atteints d'un cancer du sein (n=3) et du poumon (n=3), ou de contrôles (n=3). Mann-Whitney,  $p < 0,001$ . D'après Gobbo et al, JNCI, 2016.

# RESULTATS



## Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study

Gaëtan Chanteloup, Marine Cordonnier, Nicolas Isambert, Aurélie Bertaut, Alice Hervieu, Audrey Hennequin, Maxime Luu, Sylvie Zanetta, Bruno Coudert, Leila Bengrine, Isabelle Desmoulins, Laure Favier, Aurélie Lagrange, Pierre-Benoit Pages, Ivan Gutierrez, Jeanine Lherminier, Laure Avoscan, Clémentine Jankowski, Cédric Rébé, Angélique Chevriaux, Marie-Martine Padeano, Charles Coutant, Sylvain Ladoire, Sylvain Causeret, Laurent Arnould, Céline Charon-Barra, Vanessa Cottet, Julie Blanc, Christine Binquet, Marc Bardou, Carmen Garrido & Jessica Gobbo

To cite this article: Gaëtan Chanteloup, Marine Cordonnier, Nicolas Isambert, Aurélie Bertaut, Alice Hervieu, Audrey Hennequin, Maxime Luu, Sylvie Zanetta, Bruno Coudert, Leila Bengrine, Isabelle Desmoulins, Laure Favier, Aurélie Lagrange, Pierre-Benoit Pages, Ivan Gutierrez, Jeanine Lherminier, Laure Avoscan, Clémentine Jankowski, Cédric Rébé, Angélique Chevriaux, Marie-Martine Padeano, Charles Coutant, Sylvain Ladoire, Sylvain Causeret, Laurent Arnould, Céline Charon-Barra, Vanessa Cottet, Julie Blanc, Christine Binquet, Marc Bardou, Carmen Garrido & Jessica Gobbo (2020) Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study, *Journal of Extracellular Vesicles*, 9:1, 1766192, DOI: [10.1080/20013078.2020.1766192](https://doi.org/10.1080/20013078.2020.1766192)

To link to this article: <https://doi.org/10.1080/20013078.2020.1766192>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.



[View supplementary material](#)



Published online: 20 May 2020.



[Submit your article to this journal](#)



Article views: 62



[View related articles](#)



View Crossmark data [↗](#)

---

Full Terms & Conditions of access and use can be found at  
<https://www.tandfonline.com/action/journalInformation?journalCode=zjev20>

## Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study

Gaëtan Chanteloup<sup>a,b</sup>, Marine Cordonnier<sup>a,b</sup>, Nicolas Isambert<sup>c</sup>, Aurélie Bertaut<sup>d</sup>, Alice Hervieu<sup>d</sup>, Audrey Hennequin<sup>d</sup>, Maxime Luu<sup>e</sup>, Sylvie Zanetta<sup>d</sup>, Bruno Coudert<sup>d</sup>, Leila Bengrine<sup>d</sup>, Isabelle Desmoulin<sup>d</sup>, Laure Favier<sup>d</sup>, Aurélie Lagrange<sup>d</sup>, Pierre-Benoit Pages<sup>f</sup>, Ivan Gutierrez<sup>f</sup>, Jeanine Lherminier<sup>g</sup>, Laure Avoscan<sup>g</sup>, Clémentine Jankowski<sup>d</sup>, Cédric Rébé<sup>d</sup>, Angélique Chevriaux<sup>d</sup>, Marie-Martine Padeano<sup>d</sup>, Charles Coutant<sup>d</sup>, Sylvain Ladoire<sup>d</sup>, Sylvain Causeret<sup>d</sup>, Laurent Arnould<sup>d</sup>, Céline Charon-Barra<sup>d</sup>, Vanessa Cottet<sup>e</sup>, Julie Blanc<sup>d</sup>, Christine Binquet<sup>e</sup>, Marc Bardou<sup>e</sup>, Carmen Garrido<sup>a,b,d,\*</sup> and Jessica Gobbo<sup>a,b,d,e,\*</sup>

<sup>a</sup>Inserm, UMR 1231, label d'Excellence Ligue Nationale contre le Cancer and Laboratoire d'Excellence LipSTIC, Dijon, France; <sup>b</sup>Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France; <sup>c</sup>Inserm U-1084, Pôle Régional de Cancérologie, CHU de Poitiers Poitiers Cedex – France, Université de Poitiers, Poitiers, France; <sup>d</sup>CHU Dijon-Bourgogne, Georges-François Lederc Centre, CGFL, Dijon, France; <sup>e</sup>Centre d'Investigation Clinique INSERM 1432, CHU Dijon-Bourgogne, Dijon, France; <sup>f</sup>Department of Thoracic Surgery, Dijon University Hospital, Dijon, France; <sup>g</sup>INRA, UMR1347 Agroécologie, ERL CNRS 6300, Plateforme DimaCell, Centre de Microscopie INRA/Université de Bourgogne, Dijon, France

### ABSTRACT

Exosomes are nanovesicles released by all cells that can be found in the blood. A key point for their use as potential biomarkers in cancer is to differentiate tumour-derived exosomes from other circulating nanovesicles. Heat shock protein-70 (HSP70) has been shown to be abundantly expressed by cancer cells and to be associated with bad prognosis. We previously showed that exosomes derived from cancer cells carried HSP70 in the membrane while those from non-cancerous cells did not. In this work, we opened a prospective clinical pilot study including breast and lung cancer patients to determine whether it was possible to detect and quantify HSP70 exosomes in the blood of patients with solid cancers. We found that circulating exosomal HSP70 levels, but not soluble HSP70, reflected HSP70 content within the tumour biopsies. Circulating HSP70 exosomes increased in metastatic patients compared to non-metastatic patients or healthy volunteers. Further, we demonstrated that HSP70-exosome levels correlated with the disease status and, when compared with circulating tumour cells, were more sensitive tumour dissemination predictors. Finally, our case studies indicated that HSP70-exosome levels inversely correlated with response to the therapy and that, therefore, monitoring changes in circulating exosomal HSP70 might be useful to predict tumour response and clinical outcome.

### ARTICLE HISTORY

Received 23 January 2020  
Revised 26 March 2020  
Accepted 21 April 2020

### KEYWORDS

Exosomes; HSP70; diagnosis; liquid biopsy; cancer

## Introduction

A key issue to improve cancer patients' outcome relies on earlier cancer diagnosis. Metastases, as opposed to primary tumours, are responsible for most cancer deaths and patients' prognosis is closely linked to early cancer management. Today, cancer patient follow-up care relies mainly on imagery techniques that unfortunately are not sensitive enough to detect metastasis at an early stage. Thus, it is essential to develop new strategies for the early detection of recurrent or metastatic disease.


Although different circulating tumour markers have been characterised, only a few have demonstrated to be clinically useful for monitoring response to therapy and detecting early relapse. Therefore, there is an urgent need for development of biomarkers for the prediction of the

effectiveness of the treatment or the chance of cancer recurrence. A major advance for metastasis diagnosis and monitoring has been the detection of circulating tumour cells (CTCs) in the blood. Current detection of CTCs from circulating blood is based on the epithelial cell adhesion molecule (EpCAM), frequently over-expressed in many cancers and seems to allow earlier detection of recurrence [1]. However, this approach suffers from important limitations, the main being that CTCs are rare events: only one single circulating tumour cell in a background of as many as  $10^9$  blood cells [2].

Exosomes constitute a heterogeneous population of small extracellular vesicles from 50 to 150 nm, present in all body fluids and involved in cell-cell communication [3]. Indeed, exosomes can be bioactive cargos of

**CONTACT** Carmen Garrido  [cgarrido@u-bourgogne.fr](mailto:cgarrido@u-bourgogne.fr)  7 Bd Jeanne d'Arc, Dijon 21000

<sup>\*</sup>Co-direction of the work

 Supplemental data for this article can be accessed here.

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

proteins, lipids and nucleotides that will be introduced into the receptor cells and thereby modify their physiology [4]. A broad range of cells secrete exosomes, including tumour cells, which have specific biological functions as they are able to promote cancer growth, metastasis formation and modulation of the immune system [5–8]. These properties have promoted exosomes as new potential biomarkers for the diagnosis and monitoring of cancer. However, since most cells can secrete exosomes that will be found circulating in the blood, a key issue is to differentiate those coming from cancer cells.

We and others have recently shown that whereas exosomes released by tumour cells express in their membrane the stress protein HSP70 (heat shock protein-70), exosomes released by normal cells do not [7,9–11]. We have called this sub-population of tumour-derived nanovesicles “HSP70-exosomes” [11]. Among the different HSPs, HSP70 is the most strongly and widely induced by different stresses. HSP70 is over-expressed in many cancer types, about 70% of solid tumours, and HSP70 expression level has been shown to be useful for the diagnosis, monitoring and response to treatment [12]. Taking into consideration these results and knowing that compelling recent literature supports that exosome-based diagnostics provide higher sensitivity and specificity over conventional biopsy or liquid biomarkers due to their stability in biofluids, we hypothesise that HSP70 exosomes might be used as biomarkers in the monitoring of cancer. To this end, we opened a prospective clinical pilot study called ExoDiag that aimed at quantifying HSP70 exosomes in the blood of cancer patients for the monitoring of malignant solid tumours.

## Patients and methods

### Study population and specimen collection

40 adult patients with either non-metastatic or metastatic solid tumours were included in the study (NCT02662621). Briefly, 20 women with breast cancer, 10 men and 10 women with non-small cell lung cancer were included (Table 1). Eligibility criteria for cancer patients are listed in Table 1. Additionally, 14 healthy volunteers with no previous cancer history, negative serology for HIV, HCV and HBC and aged 50–70 years old were also included. Age group of healthy volunteers is in agreement with the average age of occurrence of the different solid tumours studied. Upon patient

**Table 1.** Patient’s characteristics.

	Patient
	N = 40
Age	
N	40
Mean (Std)	62.5 (10.2)
Median [min–max]	57.0 [36.0–83.0]
Sex	
Women	26 (65.0%)
Men	14 (35.0%)
OMS	
0	18 (45.0%)
1	17 (42.5%)
2	2 (5.0%)
3	2 (5.0%)
Missing	1 (2.5%)
Localisation	
Breast	17 (42.5%)
Lung	20 (50.0%)
Missing	3 (7.5%)
Breast histologic type	
Lobular	4 (23.5%)
Ductal	13 (76.5%)
Lung histologic type	
Adenocarcinoma	16 (80.0%)
Squamous cell carcinoma	4 (20%)
Stage M	
M0	20 (50.0%)
M1	14 (35.0%)
Mx	2 (5.0%)
Missing	4 (1.0%)
	Controls
	N = 14
Age	
N	14
Mean (Std)	55.0 (5.7)
Median [min–max]	53.0 [50.0–69.0]
Sex	
Women	7 (50.0%)
Men	7 (50.0%)
OMS	
0	14 (100.0%)

written consent, serology to HIV, HCV and HBV was tested. Only patients with negative serology for these infectious agents were included. During the study, 10 ml of blood, collected in an EDTA tube were necessary for each exosomal HSP70 analysis and additional 10 ml of blood, collected with preservative cell save (Cell Search<sup>®</sup>) were required for each CTCs analysis. *Initial sampling.* Blood were collected prior to any treatment (radiotherapy, hormone therapy, surgery or chemotherapy). *Follow-up.* Sample collection schedule were dependent from the standard treatment line. (i) Follow-up D1 C (x)-Day1CureX: upon a surgical treatment, initial follow-up blood samples for HSP70 analysis were collected during the first visit after surgery; (ii) upon hormone therapy, blood samples were collected at each follow-up oncology visit, in average every 6 months; (iii) upon chemotherapy samples



were collected every two cures. *Disease progression.* If disease progression was observed, blood was collected and the study was stopped.

### **Isolation, characterisation and quantification of exosomes**

Exosomes were isolated from fresh plasma samples using an optimised protocol derived from Théry et al [13]. Briefly, plasma samples were differentially centrifuged  $300 \times g$  for 5 min at  $4^{\circ}\text{C}$  and then  $17,000 \times g$  for 10 min at  $4^{\circ}\text{C}$ . Next, supernatant obtained from the previous step were ultracentrifuged at  $2,00,000 \times g$  for 1 h at  $4^{\circ}\text{C}$  (Beckman Coulter, Optima XPN-100, Brea, California, the USA). The supernatants were carefully removed and the exosome pellets re-suspended in  $100 \mu\text{l}$  of 1% RIPA lysis buffer or PBS and frozen at  $-80^{\circ}\text{C}$  until further use.

Exosome presence was verified by transmission electron microscopy (TEM). The samples dissolved in PBS buffer were dropped into a carbon-coated copper grid and then were stained with 3% uranyl acetate. Images of the sample were captured using a Hitachi 7500 electron microscope (Hitachi high technologies, Tokyo, Japan).

Exosomes were evaluated for their size and concentration by nanoparticle tracking analysis (NTA) using a NS300 Instrument (Malvern Instruments, Malvern, the UK). Briefly, exosome preparations were homogenised by vortexing followed by dilution of 1:500 in filtered phosphate saline buffer and analysed by NanoSight NS300. Each sample analysis was conducted for 60 s. Data were analysed by Nanosight NTA 3.2 Analytical Software (Malvern Instruments, Malvern, the UK) with the detection threshold optimised for each sample and screen gain at 10 to track as many particles as possible with minimal background. A blank  $0.1 \mu\text{m}$ -filtered  $1 \times$  PBS was also run as a negative control. At least three analyses were done for each individual sample.

### **Immunohistochemistry**

Formalin-fixed paraffin-embedded tumour tissue samples were also obtained for correlation analysis of HSP70 (ADI-SPA-810, Enzo Life science) expression between tissue and circulating exosomes. All IHC procedures were performed using a Benchmark apparatus (Ventana).

### **Statistical analysis**


Statistical analysis was performed using the Graphpad Prism 8 software. Data presented are from at least three independent experiments. Error bars shown in graphical

data represent mean  $\pm$  SEM. When data are presented as box plots, the bar indicates the median, the box shows the interquartile range (25–75%) and the whiskers extend to 1.5 the interquartile range. For normally distributed data, significance of mean differences was determined using two-tailed paired or unpaired student t-test or ANOVA. For data that were not normally distributed, non-parametric Wilcoxon tests were used for paired analysis. A Firth logistic regression was used to determine the association between HSP70-exosomes concentration and the presence of metastasis. Odds ratio was given with its 95% confidence interval. For information, the best cut-off maximising both sensitivity and specificity was determined using ROC curves and the Youden index. Tests were two sided and a *p* value less than 0.05 was considered significant. All analyses were performed using SAS version 9.4.

### **Results and discussion**

The ExoDiag prospective clinical study includes 40 cancer patients suffering from a lung cancer ( $n = 20$ ) or a breast cancer ( $n = 20$ ). Inclusion of patients started in 2016 and ended in March 2019. Patients were followed for 1 year (Table 1). Three patients with breast cancer had to be removed from the study because no follow up was possible (pre-mature death). Samples were taken at diagnosis, after surgery and before and after each cure. In addition, baseline assays of the patients were compared with 14 healthy volunteers (with bilateral alpha of 5% and 40 patients, we will have a power of more than 95% to compare exosome HSP70 concentrations between cases and controls).

Exosomes were isolated from plasma samples and characterised by the nanovesicle size (50–150 nm), by the expression of the exosomal markers such as TSG101, CD9, CD63, by the absence of the endoplasmic reticulum marker Grp94, and by their typical cup-shaped appearance as observed by TEM (Supplementary Figure 1). When comparing HSP70 in lysates of circulating exosomes versus soluble in the plasma by ELISA, we found that whereas HSP70 within exosomes was detected in all patients, soluble HSP70 level was in most patients undetectable (Figure 1(a)). This could be explained by the fact that HSP70 is stabilised by the cholesterol-rich membrane of the exosome [2]. We used an already validated biolayer interferometry (BLI) protocol using a peptide aptamer that binds to the extracellular part of membrane-bound HSP70, to capture exosomes expressing HSP70 in their membrane (HSP70-exosomes) from total blood exosomes [11,14]. We found that the number of HSP70-exosomes in the plasma samples from patients was significant higher than in those from healthy volunteers, in which the level of HSP70 exosomes was barely detectable (Figure 1), thus confirming our previous reports [11].



**Figure 1.** Exosomal HSP70 as a potential cancer biomarker. (a) Expression of circulating HSP70 within exosomes or soluble in paired samples at different time points ( $n = 68$ ), Wilcoxon's test,  $p < 0.0001$ . (b) Capture of tumour-derived exosomes by BLI using the peptide aptamer A8 from metastatic (M,  $n = 18$ ), non-metastatic patients (NM,  $n = 19$ ) and healthy volunteers (HC,  $n = 14$ ), one way ANOVA,  $p < 0.0001$ . Recombinant human HSP70 (rhHSP70) and PBS are used as controls. (c) Expression of HSP70 within HSP70 exosomes either in all cancer patients ( $n = 37$ ) or in lung cancer ( $n = 20$ ) or breast cancer patients ( $n = 17$ ) and healthy volunteers ( $n = 14$ ), student t-test and ANOVA,  $p < 0.05$ , mean  $\pm$  SEM. (d) Immunohistochemical HSP70 staining within tumour biopsy slides. A semi-quantitative evaluation was performed by counting positive cells in 100 cells, from three randomly selected fields. A representative immunohistochemistry picture of HSP70 expression is shown. NM = Non-metastatic, M = Metastatic.


This result is all the more interesting given that in our cohort the total number of exosomes did not differ between patients and healthy volunteers (Supplementary Figure 2). HSP70-exosomes levels were increased in metastatic patients compared to non-metastatic patients and healthy volunteers, as quantified by BLI (Figure 1(b)) and ELISA (Figure 1(c,d)). Therefore, as happens in cells where the amount of HSP70 in the membrane is in general proportional to the intracellular expression of HSP70 [15], exosomes expressing HSP70 in the membrane also contained high amounts of this stress protein inside the vesicle.

As in plasma samples, the number of total exosomes in urine samples was measured by NTA and that of HSP70 exosomes by BLI (Supplementary Figure 3). In contrast to plasma samples, no differences were found in the number of HSP70 exosomes between metastatic and non-

metastatic patients (Supplementary Figure 3). It should be mentioned that the cellular origin of the exosomes found in the blood and in the urines must be different.

Interestingly, when analysing HSP70 in tumour biopsies, we found that blood HSP70 exosomes matched HSP70 expression within the tumour (Figure 1(d)). This result suggests that circulating exosomes reproduce features within the tumour, particularly HSP70 status.

Next, we compared circulating HSP70 exosomes with CTCs quantified by Cell-Search (a current FDA-approved approach), as predictors of tumour progression. We performed receiver operating characteristic (ROC) curve analysis to discriminate metastatic from non-metastatic patients. As shown in Figure 2, HSP70 exosomes showed a better discrimination since the area under the curve (AUC) was higher when quantifying HSP70 exosomes in the blood than CTCs (AUC =




**Figure 2.** HSP70 exosomes compared to CTCs to discriminate metastatic from non-metastatic patients. ROC curve analysis for the detection level of HSP70 exosomes (left panel) or circulating tumour cells (CTCs, right panel), AUC = 0.8968, CI95% = [0.7387–1],  $p < 0.0001$  compared to 0.7857, CI95% = [0.5873–0.9842],  $p = 0.0048$ .

0.8968, CI95% = [0.7387–1],  $p < 0.0001$  for HSP70 exosomes compared with 0.7857, CI95% = [0.5873–0.9842],  $p = 0.0048$ , for CTCs). Based on curve ROC analysis, we calculated a preliminary HSP70-exosome optimal cut off of 1.92 ng/ml ( $p = 0.0288$ , 95% Wald confidence limits < 0.001, 0.674). Due to the size of this pilot cohort ( $n = 40$ ), the reliability of this HSP70-exosome cut-off value needs confirmation in larger cohorts. That HSP70 exosomes may be more reliable predictors of cancer dissemination than CTCs is not surprising since CTCs are rare events, less than 10 cells/ml of blood, whereas exosomes are found in large amounts in body fluids. To our knowledge, this is the first study comparing in a clinical cohort tumour-derived exosome with CTCs as biomarkers.

To determine whether HSP70 exosomes could be used as predictors of response to the therapy, we compared

HSP70-exosome levels at diagnosis and after treatment, at the same time as the first tumour evaluation by imagery. We found that patients in clinical response had a mean decrease of 77%, whereas patients in clinical progression had a mean increase of 92% (Figure 3(a)). For longer-term follow up, we demonstrated that variation in the level of HSP70 exosomes was associated with the disease status, as determined by scanner imagery. For instance, the level of exosomal HSP70 for patient 1, diagnosed with a metastatic HER2+ breast cancer, T4N1M1, varied according to treatments until the stabilisation after the 12th cure. Between the diagnosis and the second cure, the concentration of HSP70 decreased from 2.62 to 0.835 ng/ml corresponding to the start of the treatment (trastuzumab, pertuzumab and paclitaxel). At the fourth cure, we observed an increase from 0.835 to 3.931 ng/ml corresponding to the replacement of paclitaxel (taxol) by docetaxel (taxotere), due to excessive toxicity. At the sixth cure, we detected a decrease to 1.529 ng/ml that kept stable until the eighth cure. At the 10th cure, the level of HSP70 increased up to 2.874 ng/ml corresponding to a decrease in the dosage of taxotere. Finally, at the 12th cure, the concentration of HSP70 decreased to 0.938 ng/ml and then stabilised until the end of follow up. This stabilisation correlated with clinical stable disease, diagnosed by scanner imagery (Figure 3(b)). Interestingly, when compared HSP70 exosomes with that of the CA-15-3 breast cancer clinical marker, we observed that both reached a sustained low level when the disease stabilised.

Patient 2 was diagnosed with a metastatic NSCLC, T3N2M1. The levels of HSP70 and CEA (a gold standard lung cancer marker) followed the same variations during the different treatments until the disease clinical



**Figure 3.** Exosome HSP70 levels correlates with the response to treatment. (a) Exosomal HSP70 variation ratio between diagnosis and the first tumour evaluation according to the clinical status. CR/PR = Complete/Partial response ( $n = 6$ ), SD = Stable disease ( $n = 3$ ), PD = Progression disease ( $n = 11$ ),  $p = 0.0043$ . (b)–(d): Case study of the correlation between HSP70 levels in exosomes (blue lines) and their response to the different cures (C2, C4, etc.). CA-15-3 and CEA clinical tumour marker measurements, when available, are indicated by a red line. EOR = End of radiotherapy, EOS = End of study, SD = Stable Disease, PD = Progression disease, PR = Partial response. Panels below show the respective scan imagery. Metastasis is visualised by black spots (patient 1) and red arrows (patients 2 and 3).

progression. Indeed, this patient had brain metastases as revealed by scanner imagery. Interestingly, this progression correlated with an important increase in exosomal HSP70 levels (from 0.466 to 1.461 ng/ml) (Figure 3(c)).

Patient 3 was also diagnosed with a metastatic NSCLC, T3N2M1. Exosomal HSP70 level varied depending on the treatment, especially between second and fourth cures where the concentration of HSP70 increased from 0.071 to 1.719 ng/ml, which corresponded to a change in platinum salts due to bad tolerance. Then, after eighth cure, exosomal HSP70 level progressively increased from 1.468 to 2.72 ng/ml, increase that associated with ganglionic cerebral and peritoneal cancer progression, as observed by imagery (Figure 3(d)). Altogether, these results are consistent with data in the literature, since several studies have reported that the expression of HSP70 within the tumour biopsies correlated with tumour volume [16,17]. We hypothesise that the treatments which lead to a reduction in the size of the tumour, consequently lead also to a decrease in the amount of HSP70 exosomes released. Conversely, non-responder patients might have a tumour growth that translates to a higher release of HSP70 exosomes. Although these case reports suggest a correlation between HSP70 exosomes and conventional tumour markers, the curve of HSP70 exosomes have several peaks compared to that of conventional tumoural markers (Figure 3(b,c)). Further studies are needed to determine whether these peaks reflect a higher sensitivity to detect changes in the physiological state of the tumour [18].

High expression of HSPs, particularly HSP70 and HSP90, has been shown to correlate with clinical parameters such as diagnosis, prognosis and/or response to therapy in a wide variety of cancers, both at the intracellular [15,19–25] and extracellular levels [2,11,16,24,26–30]. Our findings here provide for the first time in a prospective cohort an overview of HSP70 expression (circulating, both in exosomes and soluble, and within the tumour) and indicate that exosomal HSP70 hold promises as a potential predictor of tumour growth/spread for the monitoring of cancer patients bearing HSP70-expressing tumours. Further, towards a more personalised patient care, our follow-up studies point out the interest of measuring for each patient the difference between exosomal HSP70 level at baseline and the value after a cure. We intend to perform a multi-centre study that will include larger homogeneous cohorts to refine cut-off values and to confirm whether monitoring variations in circulating exosomal HSP70 levels could be used to detect responders to the therapy.

From a functional point of view, we previously showed that HSP70-exosomes restrain tumour immune surveillance by promoting myeloid-derived suppressor cells' (MDSCs) functions [7,11]. Thus, the abundant HSP70 exosomes found in metastatic patients may lead to a pro-tumoural environment. Since HSP70-targeting therapies are being developed in cancer, quantifying HSP70 exosomes from a simple blood sample might be a strategy to select the patients likely to benefit from these innovative therapies [11,14,31,32].

The main advantage of the HSP70 exosomes is that these tumour-specific nanovesicles are found in large amounts in the peripheral blood, providing a minimally invasive method for serial assessment of predictive and prognostic markers during multi-stage cancer progression. Further progress is needed to bring the exosomes to clinical practice, especially concerning the isolation technique. We are currently pursuing this issue through the development of a nanovesicle isolation technic based on a microfluidic system-on-chip approach.

### Acknowledgments

We would like to thank all members of the early phase unit from the Cancer Center Georges-François Leclerc.

### Funding

This project was supported a French Government grant managed by the French National Research Agency (ANR) under the program "Investissements d'Avenir" with reference ANR-11-LABX-0021-01-LipSTIC Labex, "Ligue Nationale Contre le Cancer", "Institut National du Cancer", Centre Georges-François Leclerc, Canceropole Est, Fondation Silab Jean Paufique, Regional Council Burgundy/Franche-Comté et FEDER, Fondation pour la Recherche Médicale [FRM grant number ECO2016073609].

### Competing interest

The authors declare that they have no competing interests.

### ORCID

Audrey Hennequin  <http://orcid.org/0000-0001-8043-1836>

### References

- [1] Gold B, Cankovic M, Furtado LV, et al. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. *J Mol Diagn.* 2015 May;17(3):209–224.

- [2] Cordonnier M, Chanteloup G, Isambert N, et al. Exosomes in cancer theranostic: diamonds in the rough. *Cell Adhes Migr*. 2017 Feb 6;1–13.
- [3] Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol*. 2009 Aug;9(8):581–593.
- [4] Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007 Jun;9(6):654–659.
- [5] Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat Med*. 2012 Jun;18(6):883–891. .
- [6] Hoshino A, Costa-Silva B, Shen T-L, et al. Tumour exosome integrins determine organotropic metastasis. *Nature*. 2015 Nov 19;527(7578):329–335.
- [7] Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. *J Clin Invest*. 2010 Feb;120(2):457–471. .
- [8] Li L, Cao B, Liang X, et al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral  $\gamma\delta$  T cell equilibrium via tumor-derived exosomes. *Oncogene*. 2018 Dec 13.
- [9] Multhoff G, Botzler C, Wiesnet M, et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. *Int J Cancer*. 1995 Apr 10;61(2):272–279.
- [10] Multhoff G. Heat shock protein 70 (Hsp70): membrane location, export and immunological relevance. *Methods San Diego Calif*. 2007 Nov;43(3):229–237.
- [11] Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. *J Natl Cancer Inst*. 2016 Mar;108(3):dju330.
- [12] Murphy ME. The HSP70 family and cancer. *Carcinogenesis*. 2013 Jun;34(6):1181–1188.
- [13] Théry C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. In: *Current Protocols in Cell Biology* [Internet]. John Wiley & Sons, Inc.; 2001. Available from: <http://onlinelibrary.wiley.com/gate2.inist.fr/doi/10.1002/0471143030.cb0322s30/abstract>
- [14] Rérole A-L, Gobbo J, Thonel AD, et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. *Cancer Res*. 2011 Jan 15;71(2):484–495.
- [15] Seigneuric R, Mjahed H, Gobbo J, et al. Heat shock proteins as danger signals for cancer detection. *Front Oncol* [Internet]. 2011 Nov 10;1. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355996/>
- [16] Gunther S, Ostheimer C, Stangl S, et al. Correlation of HSP70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer. *Front Immunol*. 2015;6:556.
- [17] Gehrman MK, Kimm MA, Stangl S, et al. Imaging of HSP70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles. *Int J Nanomedicine*. 2015 Sep 8;10:5687–5700.
- [18] Kulasingam V, Prassas I, Diamandis EP. Towards personalized tumor markers. *Npj Precis Oncol*. 2017 May 25;1(1):1–4.
- [19] Lee HW, Lee EH, Kim S-H, et al. Heat shock protein 70 (HSP70) expression is associated with poor prognosis in intestinal type gastric cancer. *Virchows Arch Int J Pathol*. 2013 Oct;463(4):489–495.
- [20] Stangl S, Tontcheva N, Sievert W, et al. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multi-centre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Int J Cancer*. 2017 Dec 13.
- [21] Mano R, Zilber S, Di Natale RG, et al. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy. *Urol Oncol*. 2018;36(12):531.e9–531.e17. .
- [22] Gehrman M, Specht HM, Bayer C, et al. Hsp70—a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. *Radiat Oncol Lond Engl*. 2014 Jun 9;9(1):131.
- [23] Tavassol F, Starke OF, Kokemüller H, et al. Prognostic significance of heat shock protein 70 (HSP70) in patients with oral cancer. *Head Neck Oncol*. 2011 Feb 23;3(1):10.
- [24] Liu W, Li J, Zhang P, et al. A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. *Cancer Sci*. 2019 Sep;110(9):2941–2959. .
- [25] Ono K, Eguchi T, Sogawa C, et al. HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. *J Cell Biochem*. 2018;119(9):7350–7362. .
- [26] Ostheimer C, Gunther S, Bache M, et al. Dynamics of heat shock protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin. *Front Immunol*. 2017;8:1305.
- [27] Gráf L, Barabás L, Madaras B, et al. High serum Hsp70 level predicts poor survival in colorectal cancer: results obtained in an independent validation cohort. *Cancer Biomark Sect Dis Markers*. 2018;23(4):539–547.
- [28] Tang T, Yang C, Brown HE, et al. Circulating heat shock protein 70 is a novel biomarker for early diagnosis of lung cancer. *Dis Markers*. 2018;2018:6184162.
- [29] Saini J, Sharma PK. Clinical, prognostic and therapeutic significance of heat shock proteins in cancer. *Curr Drug Targets*. 2018;19(13):1478–1490.

- [30] Breuninger S, Erl J. Quantitative analysis of liposomal heat shock protein 70 (Hsp70) in the blood of tumor patients using a novel LipHsp70 ELISA. *J Clin Cell Immunol* [Internet]. 2014 [cited 2020 Mar 17];5(5). Available from: <https://www.omicsonline.org/open-access/quantitative-analysis-of-liposomal-heat-shock-protein-hsp-in-the-blood-of-tumor-patients-2155-9899-5-264.php?aid=38483>
- [31] Shevtsov M, Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for the treatment of cancer. *Front Immunol* [Internet]. 2016 Apr 29 [cited 2017 May 18];7. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850156/>
- [32] Boudesco C, Cause S, Jego G, et al. Hsp70: a cancer target inside and outside the cell. *Methods Mol Biol Clifton NJ*. 2018;1709:371–396.

## Supplementary material

### Materials and methods

#### *Western blotting*

Isolated exosomes were tested for the expression of exosomes markers such as TSG101. Nanovesicles were lysed with Laemmli buffer and separated on SDS/PAGE gels. Then, proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (Amersham GE Healthcare Life Sciences) for western-blotting analysis. After transferring, the membranes were blocked with 5% bovine serum albumin for 1 hour and incubated overnight at 4°C with antibodies specific for HSP72 (ADI-SPA-810-F, EnzoLife), TSG101 (sc-7964, Santacruz), CD9 (ab92726, Abcam), CD63 (NBP2-4225, BioTechne), GRP94 (ab2791, Abcam),  $\beta$ -actin (A3854, Sigma Aldrich). Then, the horseradish peroxidase (HRP)-conjugated secondary antibody (Jackson ImmunoResearch) was added for 1 h 30 at room temperature (RT). The immunoreactive proteins were revealed using ECL detection reagents (34095, ThermoFisher Scientific). Band intensities on membrane were captured using Chemidoc XRS+ system and image were analyzed using Image Lab software (Bio-Rad Laboratories).

#### *Dosage of HSP70*

The dosage of HSP70 has been performed by HSP70 High Sensitivity ELISA kit (Enzo Life science) according to the manufacturer protocol.

#### **CTC detection**

Whole blood (7.5mL) was collected in CellSave® preservative tubes. Within 96 h, CTCs were enriched using the CellSearch® CTC Kit (Silicon Biosystems, Menarini), with the automated CellTracks® Autoprep® system according to manufacturer's instructions. Isolated cells were collected in a cartridge and scanned with the CellTracks analyzer II® System. CTCs were blinded counted by experienced investigators. EpCAM- and Cytokeratin-positive and CD45 (common leukocyte antigen)-negative cells are identified as CTCs. We used the established cutoff of  $\geq 5$  CTCs to define CTC-positive patients.

### ***Tumor response evaluation***

Tumor response was determined as best response-based response evaluation criteria in solid tumors (RECIST) version 1.0 measurable disease.

### ***Biolayer Interferometry***

Capture of tumor-derived exosomes have been performed as previously described<sup>9</sup>. HSP70 exosomes capture experiments were conducted with an Octet Red instrument (FortéBio, Menlo Park, CA). The ligand (A8 aptamer) was biotinylated using EZ-Link NHS-PEG4-biotin (2 nM, 30 min, RT, Thermo Fisher Scientific, Germany) and immobilized on streptavidin sensors (black 96-well plate, FortéBio). Functionalized sensors were incubated in PBS (10 min) then incubated with exosomes, recombinant human HSP70 (100nM, ADI-ESP, EnzoLife Sciences) or PBS (for 600 seconds). All sensorgrams were corrected for baseline drift by subtracting a control sensor exposed to running buffer only (FortéBio, Data analysis software version 7.1.0.89).




## Supplementary legends


**Supplementary Figure 1: Characterization of tumor-derived exosomes.** A. Representative western-blot analysis of exosomes isolated from breast (BrCa) and lung cancer (NSCLC) patients, and healthy controls (HC). Cell lysate is used as a control. B. TEM images suggesting the presence of exosomes. C. Representative size/distribution profile determined by NTA.

**Supplementary Fig 2: Exosomes concentration does not differ between patients and healthy volunteers.** A-C. Exosome concentration in the plasma of breast and lung cancer patients (A, n=31, NM: Non-metastatic n=21, M: Metastatic, n=10) or just in lung cancer (B, n=15, NM: Non-metastatic n=10, M: Metastatic, n=5) or in breast cancer patients (C, n=16, NM: Non-metastatic n=11, M: Metastatic, n=5), versus healthy controls (n=7), Student t test, ns.


**Supplementary figure 3: Analysis of exosomes in urine samples.** A. NTA quantification of exosomes in healthy volunteers (controls) and cancer patients. B. Capture of exosomes presenting HSP70 in their membrane by BLI, using the peptide aptamer A8, from urine samples of metastatic (M, n=18), non-metastatic patients (NM, n=19) and healthy volunteers (HC, n=14). Recombinant human HSP70 and PBS were used as controls, 1way ANOVA,  $p < 0.001$ . C-D. Expression of HSP70 within urinary exosomes in all cancer patients (n=27), metastatic (M, n=17), non-metastatic patients (NM, n=10) and healthy volunteers (n=14), Mean +/- SEM. (1way ANOVA, ns).



**Supplementary Figure 1: Characterization of tumor-derived exosomes.**



**Supplementary Fig 2: Exosomes concentration does not differ between patients and healthy volunteers.**



**Supplementary figure 3: Analysis of exosomes in urine samples.**

## DISCUSSION ET PERSPECTIVES

Le travail décrit dans ce manuscrit a pour but d'émettre la preuve de concept de l'utilisation des HSP70-exosomes en tant que biomarqueur de tumeurs solides. Pour cela, nous avons ouvert une étude clinique pilote qui inclue 20 patients des deux cancers les plus fréquents en France : le cancer du sein et le cancer du poumon.

Différentes études indépendantes s'intéressant à HSP70 ont démontré sa surexpression dans les tumeurs, à la fois au niveau intracellulaire et membranaire, ainsi que sa sécrétion dans le milieu extracellulaire<sup>325,329,370,371</sup>. Les différents groupes de chercheurs ont également indiqué que l'expression de HSP70, qu'elle soit intracellulaire, membranaire ou soluble dans la circulation, corrélait avec différents paramètres cliniques importants pour le diagnostic, le pronostic ou le suivi des tumeurs<sup>331,348,350,363,371</sup>. Cependant, aucune étude ne s'est appliquée à étudier l'ensemble de ces paramètres dans un même projet. Au cours de ce travail, nous avons pu mettre en évidence que HSP70 extracellulaire était majoritairement dans les exosomes et que la forme soluble était faiblement exprimée dans le plasma des patients. Ceci peut s'expliquer par le fait que la membrane des exosomes est enrichie en cholestérol et en certains lipides qui rendent la double membrane plus rigide et stabilise HSP70, contrairement à la forme soluble qui est exposée à la dégradation<sup>330,370</sup>. Ces résultats indiquent que la sécrétion de HSP70 se fait préférentiellement via les exosomes, ce qui implique certainement un tri spécifique, qui reste néanmoins à démontrer.

De plus, nous avons montré que l'expression de HSP70 dans les exosomes semblait correspondre à celle dans la biopsie tumorale ce qui laisse à penser que les exosomes reproduisent les caractéristiques de la tumeur. Enfin, nos résultats indiquent que les patients atteints d'un cancer à un stade métastatique possèdent plus de HSP70-exosomes que les non métastatiques, et encore plus que les sujets témoins, tandis que le nombre total d'exosomes ne diffère pas. Nous n'avons pas non plus observé de différences dans l'urine des patients ; cette analyse semble être plus pertinente pour les cancers uro-génitaux<sup>264,265,267,372</sup>. Il a été décrit que HSP70 à la membrane des cellules cancéreuses est une caractéristique propre au cancer, et que ce phénomène semble être présent dans une grande majorité des tumeurs solides, faisant de HSP70 membranaire un marqueur tumoral<sup>329,330,353,363,373</sup>. Nos résultats indiquent donc que la quantité de HSP70-exosomes (*ie* dérivés de tumeur) est d'autant plus importante que la maladie est avancée. D'autres recherches sont nécessaires afin de déterminer si la quantité de HSP70-exosomes est corrélée au volume tumoral.

Notre équipe a démontré, en collaboration avec l'équipe du Pr François Ghiringhelli, que les HSP70-exosomes sont capables d'activer les MDSCs et d'induire un environnement immunosuppresseur qui favorise la croissance tumorale. Depuis, cette même équipe a observé que les patients atteints d'un cancer du côlon à un stade métastatique présentaient significativement plus de MDSCs circulantes que

les sujets témoins<sup>374</sup>. De notre côté, nous avons démontré que les HSP70-exosomes semblent être universels au cancer<sup>368</sup>. Ainsi, ces données semblent converger vers le fait que plus la maladie progresse, plus le nombre de HSP70-exosomes sécrété augmente et plus le nombre de MDSCs est important, formant ainsi un mécanisme qui permet à la tumeur de croître. Il est cependant nécessaire de confirmer cette hypothèse via une étude portant sur le même type de tumeur, et qui inclue ces deux paramètres.


Ensuite, nous avons montré via nos courbes ROC que la détection des HSP70-exosomes est plus sensible et plus spécifique que la détection des CTCs, avec une aire sous la courbe bien plus élevée (AUC=0,8968, CI95% = [0,7387-1],  $p < 0,0001$  pour les HSP70-exosomes comparé à 0,7857, CI95% = [0,5873-0,9842],  $p = 0,0048$ , pour les CTCs). C'est à notre connaissance la première étude comparant la détection de ces deux marqueurs circulants. Nos résultats semblent logiques puisqu'une cellule libère des milliers d'exosomes tandis que les CTCs restent un événement rare et difficile à détecter techniquement<sup>9,126,375</sup>. De plus, les technologies actuelles de détection des CTCs ne permettent pas d'identifier totalement toute l'hétérogénéité de ces cellules, ce qui entraîne un certain nombre de faux positifs et faux négatifs<sup>88,376</sup>. Au contraire, dans l'optique d'une analyse combinatoire multiparamétrique, les exosomes, dont les HSP70-exosomes, sont présents en grand nombre dans la circulation sanguine ce qui permet d'envisager moins de contraintes techniques ; je pense notamment à la quantité de matériel à disposition pour réaliser des analyses. Nous avons déterminé un seuil (préliminaire au vu de la taille de la cohorte), au-delà duquel les patients auraient un risque de présenter des métastases : 1,92ng/mL. Ce seuil est bien évidemment à affiner via un jeu de données plus important.

Nous avons également démontré que les HSP70-exosomes semblent être utiles dans le suivi des patients comme marqueurs de réponse au traitement. En effet, nos résultats indiquent que la variation du taux de HSP70-exosomes entre le diagnostic et la première évaluation tumorale par imagerie est corrélée à la réponse à la thérapie. Ainsi, nous avons observé que les patients en réponse clinique avaient une diminution moyenne de HSP70-exosomes de 77% tandis que les patients progressifs avaient une augmentation moyenne de 92%. Les patients stables avaient quant à eux une variation minimale, de l'ordre de 1% en moyenne. Ensuite, nous avons également montré que le taux de HSP70-exosomes pouvait être utilisé pour le suivi à long terme puisqu'il est associé au statut de la maladie déterminé par imagerie médicale, chez trois patients que nous avons pu suivre ; au cours du suivi, le patient 1 a été diagnostiqué comme répondeur partiel à deux cures différentes, à chaque fois traduites par une chute du taux de HSP70, puis comme étant stable pendant plusieurs cures, correspondant à une variation quasi nulle du taux de HSP70. Les patients 2 et 3 ont, eux, été diagnostiqués comme progressifs au cours de leur ligne de traitement, phénomène associé à une augmentation importante

du taux de HSP70. Ces données sont en adéquation avec la littérature qui indique que l'expression de HSP70 dans les biopsies tumorales sont corrélées avec le volume de la tumeur<sup>348,373,377</sup>. L'hypothèse est que le traitement aboutit à une réduction de la taille de la tumeur et donc de la quantité de HSP70-exosomes libérés. Au contraire, les patients non répondeurs ont très certainement une croissance tumorale qui se traduit par une augmentation de cette sécrétion de HSP70-exosomes.

De plus, nous avons pu observer pour les patients 1 et 2 que le taux de HSP70-exosomes suivait l'évolution de la courbe du taux des marqueurs tumoraux conventionnels que sont le CA-15-3 pour le cancer du sein et l'ACE pour le cancer du poumon. Cependant, la courbe des HSP70-exosomes contient plusieurs pics qui sont absents des courbes des marqueurs tumoraux. Nous avons noté une variation à la suite d'une intolérance ou une toxicité excessive de la molécule chimiothérapeutique. Des études complémentaires sont nécessaires afin de déterminer si la détection des HSP70-exosomes est une méthode plus sensible, qui pourrait notamment refléter plus précisément les changements physiologiques.

De fortes concentrations de HSPs ont été corrélées au diagnostic, au pronostic et la réponse au traitement de différents cancers, à la fois au niveau intracellulaire<sup>328,349,356,378-380</sup> et extracellulaire<sup>126,351,351,352,368,381</sup>. Cette étude pilote a permis pour la première fois dans une cohorte prospective de fournir une vue d'ensemble de l'expression de HSP70 dans le cancer du sein et du poumon. Elle a également permis de démontrer l'intérêt des HSP70-exosomes en tant que potentiel biomarqueurs de la croissance tumorale des patients porteurs de tumeurs surexprimant HSP70. Il est important de noter que cette étude est une étude pilote, qui vise uniquement à émettre la preuve de concept de l'intérêt de cette sous-population d'exosomes dérivés de tumeurs en tant que biomarqueurs de tumeurs solides malignes. Afin de démontrer son utilité clinique, il est nécessaire de monter des études plus grandes, avec des cohortes plus homogènes. Nous avons d'ores et déjà commencé l'extension de cette étude sur une cohorte plus importante de patients atteint du cancer colorectal, avec des résultats préliminaires encourageants (Figure 19).



**Figure 20 : Résultats préliminaires de l'étude des HSP70-exosomes dans le cancer colorectal.** A. Analyse par western-blot d'exosomes isolés du plasma de patients atteints d'un cancer colorectal. Un lysat cellulaire a été utilisé comme contrôle. B. Capture des HSP70-exosomes des patients métastatiques (M), non-métastatiques (NM) et des sujets sains (HC) par BLI. C. Quantification de HSP70 exosomal par ELISA. Student t test,  $p < 0,005$ .

L'identification d'une sous-population d'exosome dérivée de tumeur constitue une première étape dans la perspective de l'utilisation des exosomes en tant que biomarqueur. L'apparition d'un anticorps commercial dirigé contre la partie extracellulaire de HSP70, couplé à l'émergence de technologies innovantes qui permettent l'analyse des VEs, offre la possibilité de déterminer avec précision la proportion de HSP70-exosomes dans le plasma de patients atteints d'un cancer. Il pourrait donc être possible très prochainement de déterminer si le pourcentage d'exosomes dérivés de tumeurs, mesuré de façon quantitative et directe, a une valeur clinique. Cela pourrait également permettre d'isoler spécifiquement cette sous-population, par FACS ou via des billes magnétiques par exemple, de façon à analyser son contenu. En effet, les exosomes possèdent la capacité de refléter toute la complexité tumorale au travers de leur contenu en protéines, en lipides et en matériel génétique. La capacité éventuelle d'analyser le contenu biologique des HSP70-exosomes uniquement, et donc des exosomes dérivés de tumeurs, offre la possibilité d'une analyse combinatoire puissante en vue d'une utilisation diagnostique, pronostique ou de suivi des patients. Le fait de coupler des marqueurs de nature différente au sein des exosomes, comme l'expression d'une protéine couplée à celle d'un micro-ARN particulier, pourrait permettre d'augmenter la sensibilité et la spécificité d'un test diagnostique basé sur les exosomes.

Enfin, un des défis majeurs de la recherche sur les exosomes consiste à mettre au point une technologie permettant une isolation et une analyse plus automatisée, afin de pouvoir envisager son utilisation en clinique. En effet, les techniques actuelles d'isolation des exosomes ne sont que très peu compatibles avec une routine hospitalière. Ainsi, de nombreuses équipes travaillent sur le développement de technologies innovantes, capables d'isoler et d'analyser les exosomes à partir d'un faible volume<sup>252,382-384</sup>. Nous nous penchons également sur le sujet puisque nous travaillons en collaboration avec l'équipe du Dr Wilfried Boireau de l'institut Femto de Besançon qui a mis au point une plateforme NanoBioAnalytique (NBA) combinant trois techniques : l'imagerie par Résonance des Plasmons de Surface (SPRi), la Microscopie à Force Atomique (AFM) et la Spectrométrie de Masse (MS)<sup>385,386</sup>. L'enjeu ici est de coupler leur technologie avec notre aptamère peptidique ou l'anticorps spécifique de la partie extracellulaire de HSP70, afin d'analyser le contenu protéique des HSP70-exosomes.

A ce jour, les exosomes présentent donc un fort potentiel dans le diagnostic du cancer. Cependant, le besoin d'une meilleure connaissance de l'hétérogénéité de ces nanovésicules, le manque de standardisation des protocoles, et le manque d'études réalisées à grande échelle retardent son apparition en clinique. Actuellement, une seule entreprise, appelée ExosomeDx™, possède une technologie sur le marché. Elle est incluse dans les « *National Comprehensive Cancer Center Network Guidelines* » (NCCN) aux Etats-Unis et consiste en la détection de plusieurs mutations dans les



transcrits d'exosomes dérivés d'urine de patients atteints d'un cancer de la prostate avec un taux de PSA compris entre 2 et 10 ng/mL<sup>264,265</sup>. Les chercheurs ont établi un score qui permet d'indiquer au clinicien si les patients au risque élevé de cancer de la prostate doivent subir une biopsie ou non. Cet exemple unique d'application médicale, à la valeur clinique clairement établie, illustre parfaitement le potentiel des exosomes dans le diagnostic du cancer.

## CONCLUSION GENERALE

Ce travail a donc permis d'émettre la preuve de concept de l'utilisation des HSP70-exosomes dérivés de tumeurs, dans le diagnostic et le suivi de patients atteints d'un cancer du sein et du poumon. Il analyse pour la première fois l'expression de HSP70 sous toutes ses formes chez les patients atteints de ces cancers, et suggère que l'utilisation des HSP70-exosomes est plus sensible et plus spécifique que celle des CTCs. Enfin, ce travail montre l'intérêt d'analyser les HSP70-exosomes lors du suivi des patients puisque leur taux est corrélé à la réponse à la thérapie. Enfin, cette étude pilote ouvre la voie à une étude plus approfondie et plus généralisée de l'utilité des HSP70-exosomes dans cancer.

## BIBLIOGRAPHIE

1. Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* **68**, 394–424 (2018).
2. Cancers. /maladies-et-traumatismes/cancers.
3. Données globales d'épidémiologie des cancers - Epidémiologie des cancers. <https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Donnees-globales>.
4. Oliveira, K. C. S. *et al.* Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer. *Mol. Cancer Res.* (2020) doi:10.1158/1541-7786.MCR-19-0768.
5. Cohen, J. D. *et al.* Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 10202–10207 (2017).
6. Cohen, J. D. *et al.* Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science* **359**, 926–930 (2018).
7. Chan, K. C. A. *et al.* Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. *N. Engl. J. Med.* **377**, 513–522 (2017).
8. Pantel, K. & Alix-Panabières, C. Circulating tumour cells in cancer patients: challenges and perspectives. *Trends Mol Med* **16**, 398–406 (2010).
9. Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. *Nat Rev Clin Oncol* (2017) doi:10.1038/nrclinonc.2017.14.
10. Wan, J. C. M. *et al.* Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nature Reviews Cancer* **17**, 223–238 (2017).
11. Alix-Panabières, C. & Pantel, K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer Discov* **6**, 479–491 (2016).
12. Hofman, P., Heeke, S., Alix-Panabières, C. & Pantel, K. Liquid biopsy in the era of immunoncology: is it ready for prime-time use for cancer patients? *Ann. Oncol.* **30**, 1448–1459 (2019).
13. Pantel, K. & Alix-Panabières, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. *Nat Rev Clin Oncol* **16**, 409–424 (2019).
14. Amorim, M. G. *et al.* A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. *Sci Rep* **7**, 14395 (2017).
15. Chan, K. C. A. *et al.* Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 18761–18768 (2013).
16. Kim, Y. *et al.* Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. *Nat Commun* **7**, 11906 (2016).
17. Mayers, J. R. *et al.* Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. *Nat. Med.* **20**, 1193–1198 (2014).
18. Ulz, P. *et al.* Inferring expressed genes by whole-genome sequencing of plasma DNA. *Nat. Genet.* **48**, 1273–1278 (2016).
19. Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. *Cell* **164**, 57–68 (2016).

20. Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P. & Stroun, M. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev.* **35**, 347–376 (2016).
21. Anker, P., Stroun, M. & Maurice, P. A. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. *Cancer Res.* **35**, 2375–2382 (1975).
22. Kahlert, C. *et al.* Identification of Double-stranded Genomic DNA Spanning All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic Cancer. *J. Biol. Chem.* **289**, 3869–3875 (2014).
23. Thakur, B. K. *et al.* Double-stranded DNA in exosomes: a novel biomarker in cancer detection. *Cell Res.* **24**, 766–769 (2014).
24. Corcoran, R. B. & Chabner, B. A. Application of Cell-free DNA Analysis to Cancer Treatment. *New England Journal of Medicine* (2018).
25. Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. *Nat. Rev. Genet.* **20**, 71–88 (2019).
26. Uchôa Guimarães, C. T. *et al.* Liquid biopsy provides new insights into gastric cancer. *Oncotarget* **9**, 15144–15156 (2018).
27. De Mattos-Arruda, L. *et al.* Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nat Commun* **6**, 8839 (2015).
28. De Mattos-Arruda, L. *et al.* Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. *Ann. Oncol.* **25**, 1729–1735 (2014).
29. Jamal-Hanjani, M. *et al.* Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. *Ann. Oncol.* **27**, 862–867 (2016).
30. Murtaza, M. *et al.* Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. *Nat Commun* **6**, 1–6 (2015).
31. Ulz, P. *et al.* Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer. *Nat Commun* **7**, 12008 (2016).
32. Siravegna, G. *et al.* Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nat. Med.* **21**, 795–801 (2015).
33. Bettgowda, C. *et al.* Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. *Sci Transl Med* **6**, 224ra24 (2014).
34. Carreira, S. *et al.* Tumor clone dynamics in lethal prostate cancer. *Sci Transl Med* **6**, 254ra125 (2014).
35. Newman, A. M. *et al.* An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nat. Med.* **20**, 548–554 (2014).
36. Scherer, F. *et al.* Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. *Sci Transl Med* **8**, 364ra155 (2016).
37. Yu, M. *et al.* Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. *Science* **345**, 216–220 (2014).
38. Yi, X. *et al.* The feasibility of using mutation detection in ctDNA to assess tumor dynamics. *Int. J. Cancer* **140**, 2642–2647 (2017).
39. Abbosh, C. *et al.* Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature* **545**, 446–451 (2017).
40. Heidary, M. *et al.* The dynamic range of circulating tumor DNA in metastatic breast cancer. *Breast Cancer Res.* **16**, 421 (2014).

41. Campos-Carrillo, A. *et al.* Circulating tumor DNA as an early cancer detection tool. *Pharmacol. Ther.* **207**, 107458 (2020).
42. Diehl, F. *et al.* BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. *Nat. Methods* **3**, 551–559 (2006).
43. Hindson, B. J. *et al.* High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. *Anal. Chem.* **83**, 8604–8610 (2011).
44. Adalsteinsson, V. A. *et al.* Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. *Nat Commun* **8**, 1324 (2017).
45. Forshew, T. *et al.* Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Sci Transl Med* **4**, 136ra68 (2012).
46. Leary, R. J. *et al.* Development of personalized tumor biomarkers using massively parallel sequencing. *Sci Transl Med* **2**, 20ra14 (2010).
47. Murtaza, M. *et al.* Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* **497**, 108–112 (2013).
48. Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. Detection and quantification of rare mutations with massively parallel sequencing. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 9530–9535 (2011).
49. Newman, A. M. *et al.* Integrated digital error suppression for improved detection of circulating tumor DNA. *Nat. Biotechnol.* **34**, 547–555 (2016).
50. Torga, G. & Pienta, K. J. Patient-Paired Sample Congruence Between 2 Commercial Liquid Biopsy Tests. *JAMA Oncol* **4**, 868–870 (2018).
51. Zill, O. A. *et al.* Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. *Cancer Discov* **5**, 1040–1048 (2015).
52. Strickler, J. H. *et al.* Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. *Cancer Discov* **8**, 164–173 (2018).
53. Meric-Bernstam, F. *et al.* Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. *J. Clin. Oncol.* **33**, 2753–2762 (2015).
54. Goyal, L. *et al.* Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. *Cancer Discov* **7**, 252–263 (2017).
55. Schiavon, G. *et al.* Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. *Sci Transl Med* **7**, 313ra182 (2015).
56. Russo, M. *et al.* Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. *Cancer Discov* **6**, 147–153 (2016).
57. Dawson, S.-J. *et al.* Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. <http://dx.doi.org.proxy.insermbiblio.inist.fr/10.1056/NEJMoa1213261>  
<http://www.nejm.org/doi/10.1056/NEJMoa1213261> (2013) doi:10.1056/NEJMoa1213261.
58. Misale, S. *et al.* Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature* **486**, 532–536 (2012).
59. Diaz, L. A. *et al.* The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature* **486**, 537–540 (2012).
60. Hazar-Rethinam, M. *et al.* Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. *Cancer Discov* **8**, 417–427 (2018).

61. Oxnard, G. R. *et al.* Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. *J. Clin. Oncol.* **34**, 3375–3382 (2016).
62. Chabon, J. J. *et al.* Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun* **7**, 11815 (2016).
63. Malapelle, U. *et al.* Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. *Expert Rev. Mol. Diagn.* **17**, 209–215 (2017).
64. Corcoran, R. B. *et al.* Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. *Cancer Discov* **8**, 428–443 (2018).
65. Piotrowska, Z. *et al.* Heterogeneity Underlies the Emergence of EGFR T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. *Cancer Discov* **5**, 713–722 (2015).
66. Blakely, C. M. *et al.* Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. *Nat. Genet.* **49**, 1693–1704 (2017).
67. Joseph, J. D. *et al.* A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509. *Cancer Discov* **3**, 1020–1029 (2013).
68. Heitzer, E. *et al.* Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. *Cancer Res.* **73**, 2965–2975 (2013).
69. Diehl, F. *et al.* Circulating mutant DNA to assess tumor dynamics. *Nat. Med.* **14**, 985–990 (2008).
70. Tie, J. *et al.* Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. *Sci Transl Med* **8**, 346ra92 (2016).
71. Garcia-Murillas, I. *et al.* Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. *Sci Transl Med* **7**, 302ra133 (2015).
72. McDonald, B. R. *et al.* Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. *Sci Transl Med* **11**, (2019).
73. Chaudhuri, A. A. *et al.* Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. *Cancer Discov* **7**, 1394–1403 (2017).
74. Sausen, M. *et al.* Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. *Nat Commun* **6**, 7686 (2015).
75. Racila, E. *et al.* Detection and characterization of carcinoma cells in the blood. *Proc Natl Acad Sci U S A* **95**, 4589–4594 (1998).
76. Meng, S. *et al.* Circulating Tumor Cells in Patients with Breast Cancer Dormancy. *Clin Cancer Res* **10**, 8152–8162 (2004).
77. Larson, C. J. *et al.* Apoptosis of circulating tumor cells in prostate cancer patients. *Cytometry A* **62**, 46–53 (2004).
78. Tanaka, F. *et al.* Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer. *Clin Cancer Res* **15**, 6980–6986 (2009).
79. Danila, D. C., Fleisher, M. & Scher, H. I. Circulating Tumor Cells as Biomarkers in Prostate Cancer. *Clin Cancer Res* **17**, 3903–3912 (2011).
80. Cristofanilli, M. *et al.* Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. *New England Journal of Medicine* **351**, 781–791 (2004).

81. Ross, A. A. *et al.* Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. *Blood* **82**, 2605–2610 (1993).
82. Miller, M. C., Doyle, G. V. & Terstappen, L. W. M. M. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. *J Oncol* **2010**, 617421 (2010).
83. Pantel, K. & Alix-Panabières, C. Tumour microenvironment: informing on minimal residual disease in solid tumours. *Nat Rev Clin Oncol* **14**, 325–326 (2017).
84. Alix-Panabières, C. & Pantel, K. Challenges in circulating tumour cell research. *Nat. Rev. Cancer* **14**, 623–631 (2014).
85. Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell* **133**, 704–715 (2008).
86. Aceto, N. *et al.* Circulating Tumor Cell Clusters are Oligoclonal Precursors of Breast Cancer Metastasis. *Cell* **158**, 1110–1122 (2014).
87. Bailey, P. C. & Martin, S. S. Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology. *Cells* **8**, (2019).
88. Tayoun, T. *et al.* CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs). *Cells* **8**, (2019).
89. Grover, P. K., Cummins, A. G., Price, T. J., Roberts-Thomson, I. C. & Hardingham, J. E. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. *Ann. Oncol.* **25**, 1506–1516 (2014).
90. Zhang, L. *et al.* Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer. *Clin Cancer Res* **18**, 5701–5710 (2012).
91. Rack, B. *et al.* Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. *J Natl Cancer Inst* **106**, (2014).
92. Stott, S. L. *et al.* Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. *Sci Transl Med* **2**, 25ra23 (2010).
93. Lohr, J. G. *et al.* Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. *Nat. Biotechnol.* **32**, 479–484 (2014).
94. Bono, J. S. de *et al.* Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* **14**, 6302–6309 (2008).
95. Cohen, S. J. *et al.* Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer. *JCO* **26**, 3213–3221 (2008).
96. Rink, M. *et al.* Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *Eur. Urol.* **61**, 810–817 (2012).
97. Schulze, K. *et al.* Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. *Int. J. Cancer* **133**, 2165–2171 (2013).
98. Vashist, Y. K. *et al.* Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. *Ann. Surg.* **255**, 1105–1112 (2012).
99. Strati, A. *et al.* Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Ann. Oncol.* **28**, 1923–1933 (2017).
100. Mostert, B. *et al.* KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. *Int. J. Cancer* **133**, 130–141 (2013).

101. Gasch, C. *et al.* Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. *Clin. Chem.* **59**, 252–260 (2013).
102. Jiang, Y., Palma, J. F., Agus, D. B., Wang, Y. & Gross, M. E. Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer. *Clinical Chemistry* **56**, 1492–1495 (2010).
103. Sakaizawa, K. *et al.* Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. *Br. J. Cancer* **106**, 939–946 (2012).
104. Schneck, H. *et al.* Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. *Mol Oncol* **7**, 976–986 (2013).
105. Antonarakis, E. S. *et al.* AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N. Engl. J. Med.* **371**, 1028–1038 (2014).
106. Babayan, A. *et al.* Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. *PLoS ONE* **8**, e75038 (2013).
107. Paoletti, C. *et al.* Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor-Positive Breast Cancer. *Clin Cancer Res* **21**, 2487–2498 (2015).
108. Riethdorf, S. *et al.* Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. *Clin Cancer Res* **16**, 2634–2645 (2010).
109. M, I. *et al.* HER2-positive Circulating Tumor Cells in Breast Cancer. *PloS one* <https://pubmed.ncbi.nlm.nih.gov/21264346/?dopt=Abstract> (2011) doi:10.1371/journal.pone.0015624.
110. Mazel, M. *et al.* Frequent expression of PD-L1 on circulating breast cancer cells. *Molecular Oncology* **9**, 1773–1782 (2015).
111. David, R. PD-L1 expression by circulating breast cancer cells. *The Lancet Oncology* **16**, e321 (2015).
112. Janning, M. *et al.* Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. *Cancers (Basel)* **11**, (2019).
113. Miyamoto, D. T. *et al.* Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer. *Cancer Discov* **2**, 995–1003 (2012).
114. Théry, C. *et al.* Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles* **7**, 1535750 (2018).
115. Harding, C., Heuser, J. & Stahl, P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. *J Cell Biol* **97**, 329–339 (1983).
116. Pan, B. T., Teng, K., Wu, C., Adam, M. & Johnstone, R. M. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. *J Cell Biol* **101**, 942–948 (1985).
117. Théry, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. *Nat. Rev. Immunol.* **9**, 581–593 (2009).
118. Colombo, M., Raposo, G. & Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu. Rev. Cell Dev. Biol.* **30**, 255–289 (2014).
119. Cocucci, E. & Meldolesi, J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends in Cell Biology* **25**, 364–372 (2015).

120. Trams, E. G., Lauter, C. J., Salem, N. & Heine, U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. *Biochim. Biophys. Acta* **645**, 63–70 (1981).
121. Pan, B. T. & Johnstone, R. M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. *Cell* **33**, 967–978 (1983).
122. Raposo, G. *et al.* B lymphocytes secrete antigen-presenting vesicles. *J. Exp. Med.* **183**, 1161–1172 (1996).
123. Zitvogel, L. *et al.* Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat. Med.* **4**, 594–600 (1998).
124. Wolfers, J. *et al.* Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. *Nat. Med.* **7**, 297–303 (2001).
125. Bastos, N., Ruivo, C. F., da Silva, S. & Melo, S. A. Exosomes in cancer: Use them or target them? *Semin. Cell Dev. Biol.* **78**, 13–21 (2018).
126. Cordonnier, M. *et al.* Exosomes in cancer theranostic: Diamonds in the rough. *Cell Adh Migr* **11**, 151–163 (2017).
127. van Niel, G. *et al.* Intestinal epithelial cells secrete exosome-like vesicles. *Gastroenterology* **121**, 337–349 (2001).
128. Fauré, J. *et al.* Exosomes are released by cultured cortical neurones. *Mol. Cell. Neurosci.* **31**, 642–648 (2006).
129. Whiteside, T. L. The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. *Future Oncology* (2017) doi:10.2217/fon-2017-0343.
130. Caby, M.-P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G. & Bonnerot, C. Exosomal-like vesicles are present in human blood plasma. *Int. Immunol.* **17**, 879–887 (2005).
131. Pisitkun, T., Shen, R.-F. & Knepper, M. A. Identification and proteomic profiling of exosomes in human urine. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 13368–13373 (2004).
132. Ogawa, Y., Kanai-Azuma, M., Akimoto, Y., Kawakami, H. & Yanoshita, R. Exosome-like vesicles with dipeptidyl peptidase IV in human saliva. *Biol. Pharm. Bull.* **31**, 1059–1062 (2008).
133. Admyre, C. *et al.* Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. *Eur. Respir. J.* **22**, 578–583 (2003).
134. Street, J. M. *et al.* Identification and proteomic profiling of exosomes in human cerebrospinal fluid. *J Transl Med* **10**, 5 (2012).
135. Kalluri, R. The biology and function of exosomes in cancer. *J Clin Invest* **126**, 1208–1215.
136. McAndrews, K. M. & Kalluri, R. Mechanisms associated with biogenesis of exosomes in cancer. *Molecular Cancer* **18**, 52 (2019).
137. Mathieu, M., Martin-Jaular, L., Lavieu, G. & Théry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. *Nature Cell Biology* **21**, 9 (2019).
138. Niel, G. van, D'Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol* **19**, 213–228 (2018).
139. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. *Science* **367**, (2020).
140. Bebelman, M. P., Smit, M. J., Pegtel, D. M. & Baglio, S. R. Biogenesis and function of extracellular vesicles in cancer. *Pharmacol. Ther.* **188**, 1–11 (2018).
141. Hurley, J. H. ESCRTs are everywhere. *EMBO J.* **34**, 2398–2407 (2015).
142. Tamai, K. *et al.* Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. *Biochem. Biophys. Res. Commun.* **399**, 384–390 (2010).



143. Colombo, M. *et al.* Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. *J. Cell. Sci.* **126**, 5553–5565 (2013).
144. Willms, E. *et al.* Cells release subpopulations of exosomes with distinct molecular and biological properties. *Sci Rep* **6**, 22519 (2016).
145. Stuffers, S., Sem Wegner, C., Stenmark, H. & Brech, A. Multivesicular endosome biogenesis in the absence of ESCRTs. *Traffic* **10**, 925–937 (2009).
146. Trajkovic, K. *et al.* Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science* **319**, 1244–1247 (2008).
147. Kajimoto, T., Okada, T., Miya, S., Zhang, L. & Nakamura, S. Ongoing activation of sphingosine 1-phosphate receptors mediates maturation of exosomal multivesicular endosomes. *Nat Commun* **4**, 2712 (2013).
148. Baietti, M. F. *et al.* Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. *Nat. Cell Biol.* **14**, 677–685 (2012).
149. Imjeti, N. S. *et al.* Syntenin mediates SRC function in exosomal cell-to-cell communication. *Proc. Natl. Acad. Sci. U.S.A.* (2017) doi:10.1073/pnas.1713433114.
150. Hikita, T., Kuwahara, A., Watanabe, R., Miyata, M. & Oneyama, C. Src in endosomal membranes promotes exosome secretion and tumor progression. *Sci Rep* **9**, 3265 (2019).
151. Ghossoub, R. *et al.* Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. *Nat Commun* **5**, 3477 (2014).
152. Zimmerman, B. *et al.* Crystal Structure of a Full-Length Human Tetraspanin Reveals a Cholesterol-Binding Pocket. *Cell* **167**, 1041-1051.e11 (2016).
153. Yáñez-Mó, M., Barreiro, O., Gordon-Alonso, M., Sala-Valdés, M. & Sánchez-Madrid, F. Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. *Trends Cell Biol.* **19**, 434–446 (2009).
154. van Niel, G. *et al.* The tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal sorting during melanogenesis. *Dev. Cell* **21**, 708–721 (2011).
155. van Niel, G. *et al.* Apolipoprotein E Regulates Amyloid Formation within Endosomes of Pigment Cells. *Cell Rep* **13**, 43–51 (2015).
156. Gauthier, S. A. *et al.* Enhanced exosome secretion in Down syndrome brain - a protective mechanism to alleviate neuronal endosomal abnormalities. *Acta Neuropathol Commun* **5**, 65 (2017).
157. Buschow, S. I. *et al.* MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. *Traffic* **10**, 1528–1542 (2009).
158. Chairoungdua, A., Smith, D. L., Pochard, P., Hull, M. & Caplan, M. J. Exosome release of  $\beta$ -catenin: a novel mechanism that antagonizes Wnt signaling. *J. Cell Biol.* **190**, 1079–1091 (2010).
159. Zhen, Y. & Stenmark, H. Cellular functions of Rab GTPases at a glance. *J. Cell. Sci.* **128**, 3171–3176 (2015).
160. Ostrowski, M. *et al.* Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat. Cell Biol.* **12**, 19–30; sup pp 1-13 (2010).
161. Hsu, C. *et al.* Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. *J. Cell Biol.* **189**, 223–232 (2010).
162. Ostenfeld, M. S. *et al.* Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. *Cancer Res.* **74**, 5758–5771 (2014).

163. Webber, J. P. *et al.* Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. *Oncogene* **34**, 290–302 (2015).
164. Gross, J. C., Chaudhary, V., Bartscherer, K. & Boutros, M. Active Wnt proteins are secreted on exosomes. *Nat. Cell Biol.* **14**, 1036–1045 (2012).
165. Fader, C. M., Sánchez, D. G., Mestre, M. B. & Colombo, M. I. TI-VAMP/VAMP7 and VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the autophagy/multivesicular body pathways. *Biochim. Biophys. Acta* **1793**, 1901–1916 (2009).
166. Wei, Y. *et al.* Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. *Nat Commun* **8**, 14041 (2017).
167. Koles, K. & Budnik, V. Exosomes go with the Wnt. *Cell Logist* **2**, 169–173 (2012).
168. Hoshino, D. *et al.* Exosome Secretion Is Enhanced by Invadopodia and Drives Invasive Behavior. *Cell Reports* **5**, 1159–1168 (2013).
169. Snyder, D. A., Kelly, M. L. & Woodbury, D. J. SNARE complex regulation by phosphorylation. *Cell Biochem Biophys* **45**, 111–123 (2006).
170. Verweij, F. J. *et al.* Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling. *J Cell Biol* **217**, 1129–1142 (2018).
171. Crescitelli, R. *et al.* Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. *J Extracell Vesicles* **2**, (2013).
172. Kowal, J. *et al.* Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc. Natl. Acad. Sci. U.S.A.* **113**, E968-977 (2016).
173. Skotland, T., Sandvig, K. & Llorente, A. Lipids in exosomes: Current knowledge and the way forward. *Prog. Lipid Res.* **66**, 30–41 (2017).
174. Valadi, H. *et al.* Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* **9**, 654–659 (2007).
175. Balkom, B. W. M. van, Eisele, A. S., Pegtel, D. M., Bervoets, S. & Verhaar, M. C. Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting. *Journal of Extracellular Vesicles* **4**, 26760 (2015).
176. Jeppesen, D. K. *et al.* Reassessment of Exosome Composition. *Cell* **177**, 428-445.e18 (2019).
177. Wu, Y. *et al.* Advances in the study of exosomal lncRNAs in tumors and the selection of research methods. *Biomed. Pharmacother.* **123**, 109716 (2020).
178. Guria, A., Sharma, P., Natesan, S. & Pandi, G. Circular RNAs-The Road Less Traveled. *Front Mol Biosci* **6**, 146 (2019).
179. Cheng, L., Sharples, R. A., Scicluna, B. J. & Hill, A. F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. *J Extracell Vesicles* **3**, (2014).
180. Kahlert, C. Liquid Biopsy: Is There an Advantage to Analyzing Circulating Exosomal DNA Compared to cfDNA or Are They the Same? *Cancer Res.* **79**, 2462–2465 (2019).
181. Zhang, H. *et al.* Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. *Nat Cell Biol* **20**, 332–343 (2018).
182. Wen, S. W. *et al.* Breast Cancer-Derived Exosomes Reflect the Cell-of-Origin Phenotype. *PROTEOMICS* **19**, 1800180 (2019).
183. Morelli, M. P. *et al.* Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. *Ann Oncol* **26**, 731–736 (2015).

184. Sung, B. H., Ketova, T., Hoshino, D., Zijlstra, A. & Weaver, A. M. Directional cell movement through tissues is controlled by exosome secretion. *Nat Commun* **6**, 7164 (2015).
185. Hoshino, A. *et al.* Tumour exosome integrins determine organotropic metastasis. *Nature* **527**, 329–335 (2015).
186. Nazarenko, I. *et al.* Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. *Cancer Res.* **70**, 1668–1678 (2010).
187. Rana, S., Yue, S., Stadel, D. & Zöller, M. Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. *Int. J. Biochem. Cell Biol.* **44**, 1574–1584 (2012).
188. Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J.-P. & Belting, M. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 17380–17385 (2013).
189. Morelli, A. E. *et al.* Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. *Blood* **104**, 3257–3266 (2004).
190. Nakase, I., Kobayashi, N. B., Takatani-Nakase, T. & Yoshida, T. Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes. *Sci Rep* **5**, 10300 (2015).
191. Feng, D. *et al.* Cellular internalization of exosomes occurs through phagocytosis. *Traffic* **11**, 675–687 (2010).
192. Kamerkar, S. *et al.* Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. *Nature advance online publication*, (2017).
193. Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles* **3**, (2014).
194. Tian, T., Wang, Y., Wang, H., Zhu, Z. & Xiao, Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. *J. Cell. Biochem.* **111**, 488–496 (2010).
195. Bissig, C. & Gruenberg, J. ALIX and the multivesicular endosome: ALIX in Wonderland. *Trends Cell Biol.* **24**, 19–25 (2014).
196. Heusermann, W. *et al.* Exosomes surf on filopodia to enter cells at endocytic hot spots, traffic within endosomes, and are targeted to the ER. *J. Cell Biol.* **213**, 173–184 (2016).
197. King, H. W., Michael, M. Z. & Gleadle, J. M. Hypoxic enhancement of exosome release by breast cancer cells. *BMC Cancer* **12**, 421 (2012).
198. Stefanius, K. *et al.* Human pancreatic cancer cell exosomes, but not human normal cell exosomes, act as an initiator in cell transformation. *eLife* **8**, e40226 (2019).
199. Melo, S. A. *et al.* Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. *Cancer Cell* **26**, 707–721 (2014).
200. Elmageed, Z. Y. A. *et al.* Neoplastic Reprogramming of Patient-Derived Adipose Stem Cells by Prostate Cancer Cell-Associated Exosomes. *STEM CELLS* **32**, 983–997 (2014).
201. Liu, C. *et al.* Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function. *The Journal of Immunology* **176**, 1375–1385 (2006).
202. Mu, W., Rana, S. & Zöller, M. Host Matrix Modulation by Tumor Exosomes Promotes Motility and Invasiveness. *Neoplasia* **15**, 875–887 (2013).
203. Webber, J., Steadman, R., Mason, M. D., Tabi, Z. & Clayton, A. Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation. *Cancer Res* **70**, 9621–9630 (2010).
204. Kriebel, P. W. *et al.* Extracellular vesicles direct migration by synthesizing and releasing chemotactic signals. *J Cell Biol* **217**, 2891–2910 (2018).

205. Théry, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. *Nat. Rev. Immunol.* **2**, 569–579 (2002).
206. Théry, C. *et al.* Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. *Nat. Immunol.* **3**, 1156–1162 (2002).
207. Cordonnier, M. *et al.* Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. *J Extracell Vesicles* **9**, 1710899 (2020).
208. Kim, D. H. *et al.* Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. *Exp. Mol. Med.* **51**, 1–13 (2019).
209. Theodoraki, M.-N., Yerneni, S. S., Hoffmann, T. K., Gooding, W. E. & Whiteside, T. L. Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients. *Clin. Cancer Res.* **24**, 896–905 (2018).
210. Poggio, M. *et al.* Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. *Cell* **177**, 414-427.e13 (2019).
211. Abusamra, A. J. *et al.* Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. *Blood Cells Mol. Dis.* **35**, 169–173 (2005).
212. Kim, J. W. *et al.* Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. *Clin. Cancer Res.* **11**, 1010–1020 (2005).
213. Zhou, J. *et al.* Melanoma-released exosomes directly activate the mitochondrial apoptotic pathway of CD4+ T cells through their microRNA cargo. *Exp. Cell Res.* **371**, 364–371 (2018).
214. Mrizak, D. *et al.* Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. *J. Natl. Cancer Inst.* **107**, 363 (2015).
215. Chalmin, F. *et al.* Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. *J. Clin. Invest.* **120**, 457–471 (2010).
216. Clayton, A. *et al.* Human tumor-derived exosomes down-modulate NKG2D expression. *J. Immunol.* **180**, 7249–7258 (2008).
217. Lundholm, M. *et al.* Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. *PLoS ONE* **9**, e108925 (2014).
218. Wang, T. *et al.* Functions of Exosomes in the Triangular Relationship between the Tumor, Inflammation, and Immunity in the Tumor Microenvironment. *J Immunol Res* **2019**, (2019).
219. Ekström, E. J. *et al.* WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. *Mol Cancer* **13**, 88 (2014).
220. Sato, S. *et al.* EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. *JCI Insight* **4**, (2019).
221. Kucharzewska, P. *et al.* Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. *PNAS* **110**, 7312–7317 (2013).
222. Hsu, Y.-L. *et al.* Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. *Oncogene* (2017) doi:10.1038/onc.2017.105.
223. Tominaga, N. *et al.* Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier. *Nat Commun* **6**, 1–12 (2015).

224. Zhou, W. *et al.* Cancer-Secreted miR-105 Destroys Vascular Endothelial Barriers to Promote Metastasis. *Cancer Cell* **25**, 501–515 (2014).
225. Adachi, E. *et al.* Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma. *Oncotarget* **7**, 70779–70793 (2016).
226. Peinado, H. *et al.* Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat. Med.* **18**, 883–891 (2012).
227. Costa-Silva, B. *et al.* Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nat Cell Biol* **17**, 816–826 (2015).
228. Zomer, A. *et al.* In Vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. *Cell* **161**, 1046–1057 (2015).
229. Suetsugu, A. *et al.* Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. *Adv. Drug Deliv. Rev.* **65**, 383–390 (2013).
230. Safaei, R. *et al.* Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. *Mol Cancer Ther* **4**, 1595–1604 (2005).
231. Ma, X. *et al.* Essential role for TrpC5-containing extracellular vesicles in breast cancer with chemotherapeutic resistance. *PNAS* **111**, 6389–6394 (2014).
232. Qin, X. *et al.* Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. *Int J Nanomedicine* **12**, 3721–3733 (2017).
233. Qu, L. *et al.* Exosome-Transmitted IncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. *Cancer Cell* **29**, 653–668 (2016).
234. Qu, Z. *et al.* Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. *J. Exp. Clin. Cancer Res.* **35**, 159 (2016).
235. Ciravolo, V. *et al.* Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. *Journal of Cellular Physiology* **227**, 658–667 (2012).
236. Aung, T. *et al.* Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. *PNAS* **108**, 15336–15341 (2011).
237. Gold, B., Cankovic, M., Furtado, L. V., Meier, F. & Gocke, C. D. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. *J Mol Diagn* **17**, 209–224 (2015).
238. Fitts, C. A., Ji, N., Li, Y. & Tan, C. Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery. *Adv Healthc Mater* **8**, e1801268 (2019).
239. Xu, R. *et al.* Extracellular vesicles in cancer — implications for future improvements in cancer care. *Nat Rev Clin Oncol* **15**, 617–638 (2018).
240. Alegre, E. *et al.* Circulating melanoma exosomes as diagnostic and prognosis biomarkers. *Clin. Chim. Acta* **454**, 28–32 (2016).
241. Moon, P.-G. *et al.* Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection. *Clin Cancer Res* **22**, 1757–1766 (2016).
242. Moon, P.-G. *et al.* Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer. *Oncotarget* **7**, 40189–40199 (2016).
243. Arbelaiz, A. *et al.* Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. *Hepatology* **66**, 1125–1143 (2017).
244. Chen, I.-H. *et al.* Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. *PNAS* **114**, 3175–3180 (2017).

245. Tang, M. K. S. *et al.* Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface. *Nat Commun* **9**, 2270 (2018).
246. Chen, G. *et al.* Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature* **560**, 382–386 (2018).
247. Fan, Y. *et al.* Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis. *Ann. Surg. Oncol.* **26**, 3745–3755 (2019).
248. Melo, S. A. *et al.* Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* **523**, 177–182 (2015).
249. Frampton, A. E. *et al.* Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden. *Oncotarget* **9**, 19006–19013 (2018).
250. Qian, J.-Y., Tan, Y.-L., Zhang, Y., Yang, Y.-F. & Li, X.-Q. Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy. *Oncology Letters* **16**, 1253–1258 (2018).
251. Li, J. *et al.* The clinical significance of circulating GPC1 positive exosomes and its regulative miRNAs in colon cancer patients. *Oncotarget* **8**, 101189–101202 (2017).
252. Yoshioka, Y. *et al.* Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. *Nat Commun* **5**, 3591 (2014).
253. Yuan, T. *et al.* Plasma extracellular RNA profiles in healthy and cancer patients. *Sci Rep* **6**, 1–11 (2016).
254. Li, S. *et al.* exoRBase: a database of circRNA, lncRNA and mRNA in human blood exosomes. *Nucleic Acids Res.* **46**, D106–D112 (2018).
255. Thind, A. & Wilson, C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. *Journal of Extracellular Vesicles* **5**, 31292 (2016).
256. Salehi, M. & Sharifi, M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. *Journal of Cellular Physiology* **233**, 6370–6380 (2018).
257. Krutovskikh, V. A. & Herceg, Z. Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers. *Bioessays* **32**, 894–904 (2010).
258. Bhagirath, D. *et al.* MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer. *Cancer Res.* (2018) doi:10.1158/0008-5472.CAN-17-2069.
259. Li, X. J., Ren, Z. J., Tang, J. H. & Yu, Q. Exosomal MicroRNA MiR-1246 Promotes Cell Proliferation, Invasion and Drug Resistance by Targeting CCNG2 in Breast Cancer. *CPB* **44**, 1741–1748 (2017).
260. Sakha, S., Muramatsu, T., Ueda, K. & Inazawa, J. Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma. *Sci Rep* **6**, 38750 (2016).
261. Alhasan, A. H. *et al.* Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. *PNAS* **113**, 10655–10660 (2016).
262. Zhou, X. *et al.* Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. *Sci Rep* **5**, 1–13 (2015).
263. Ebrahimkhani, S. *et al.* Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. *npj Precision Onc* **2**, 1–9 (2018).
264. McKiernan, J. *et al.* A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. *JAMA Oncol* **2**, 882–889 (2016).

265. McKiernan, J. *et al.* A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy. *European Urology* **74**, 731–738 (2018).
266. Donovan, M. J. *et al.* A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. *Prostate Cancer Prostatic Dis* **18**, 370–375 (2015).
267. Zhan, Y. *et al.* Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. *Mol. Cancer* **17**, 142 (2018).
268. Zhao, R. *et al.* Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. *Mol. Cancer* **17**, 68 (2018).
269. Fanale, D., Taverna, S., Russo, A. & Bazan, V. Circular RNA in Exosomes. *Adv. Exp. Med. Biol.* **1087**, 109–117 (2018).
270. Wang, M. *et al.* The functional roles of exosomal long non-coding RNAs in cancer. *Cell. Mol. Life Sci.* **76**, 2059–2076 (2019).
271. Kalluri, R. & LeBleu, V. S. Discovery of Double-Stranded Genomic DNA in Circulating Exosomes. *Cold Spring Harb Symp Quant Biol* **81**, 275–280 (2016).
272. Allenson, K. *et al.* High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. *Ann Oncol* **28**, 741–747 (2017).
273. Bernard, V. *et al.* Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. *Gastroenterology* **156**, 108-118.e4 (2019).
274. Yang, S. *et al.* Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. *Cancer Biology & Therapy* **18**, 158–165 (2017).
275. Krug, A. K. *et al.* Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. *Ann. Oncol.* **29**, 700–706 (2018).
276. Ritossa, F. A new puffing pattern induced by temperature shock and DNP in drosophila. *Experientia* **18**, 571–573 (1962).
277. Ritossa, F. Discovery of the heat shock response. *Cell Stress Chaperones* **1**, 97–98 (1996).
278. Tissières, A., Mitchell, H. K. & Tracy, U. M. Protein synthesis in salivary glands of *Drosophila melanogaster*: Relation to chromosome puffs. *Journal of Molecular Biology* **84**, 389–398 (1974).
279. Pirkkala, L., Nykänen, P. & Sistonen, L. Roles of the heat shock transcription factors in regulation of the heat shock response and beyond. *The FASEB Journal* **15**, 1118–1131 (2001).
280. Morimoto, R. I. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. *Genes Dev.* **12**, 3788–3796 (1998).
281. Kallio, M. *et al.* Brain abnormalities, defective meiotic chromosome synapsis and female subfertility in HSF2 null mice. *EMBO J.* **21**, 2591–2601 (2002).
282. Ostling, P., Björk, J. K., Roos-Mattjus, P., Mezger, V. & Sistonen, L. Heat shock factor 2 (HSF2) contributes to inducible expression of hsp genes through interplay with HSF1. *J. Biol. Chem.* **282**, 7077–7086 (2007).
283. Fujimoto, M. *et al.* Analysis of HSF4 Binding Regions Reveals Its Necessity for Gene Regulation during Development and Heat Shock Response in Mouse Lenses. *J Biol Chem* **283**, 29961–29970 (2008).
284. Fujimoto, M. *et al.* HSF4 is required for normal cell growth and differentiation during mouse lens development. *EMBO J* **23**, 4297–4306 (2004).

285. Trinklein, N. D., Murray, J. I., Hartman, S. J., Botstein, D. & Myers, R. M. The Role of Heat Shock Transcription Factor 1 in the Genome-wide Regulation of the Mammalian Heat Shock Response. *Mol Biol Cell* **15**, 1254–1261 (2004).
286. Kampinga, H. H. *et al.* Guidelines for the nomenclature of the human heat shock proteins. *Cell Stress Chaperones* **14**, 105–111 (2009).
287. Arrigo, A.-P. & Gibert, B. HspB1 dynamic phospho-oligomeric structure dependent interactome as cancer therapeutic target. *Curr. Mol. Med.* **12**, 1151–1163 (2012).
288. Arrigo, A.-P. Mammalian HspB1 (Hsp27) is a molecular sensor linked to the physiology and environment of the cell. *Cell Stress Chaperones* **22**, 517–529 (2017).
289. Pearl, L. H., Prodromou, C. & Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. *Biochem. J.* **410**, 439–453 (2008).
290. Hoter, A., El-Sabban, M. E. & Naim, H. Y. The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease. *Int J Mol Sci* **19**, (2018).
291. Yasuda, K., Nakai, A., Hatayama, T. & Nagata, K. Cloning and expression of murine high molecular mass heat shock proteins, HSP105. *J. Biol. Chem.* **270**, 29718–29723 (1995).
292. Oh, H. J., Easton, D., Murawski, M., Kaneko, Y. & Subject, J. R. The chaperoning activity of hsp110. Identification of functional domains by use of targeted deletions. *J. Biol. Chem.* **274**, 15712–15718 (1999).
293. Dugaard, M., Rohde, M. & Jäättelä, M. The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. *FEBS Letters* **581**, 3702–3710 (2007).
294. Hartl, F. U. Molecular chaperones in cellular protein folding. *Nature* **381**, 571–579 (1996).
295. Flaherty, K. M., DeLuca-Flaherty, C. & McKay, D. B. Three-dimensional structure of the ATPase fragment of a 70K heat-shock cognate protein. *Nature* **346**, 623–628 (1990).
296. Rosenzweig, R., Nillegoda, N. B., Mayer, M. P. & Bukau, B. The Hsp70 chaperone network. *Nat Rev Mol Cell Biol* **20**, 665–680 (2019).
297. Mayer, M. P. & Bukau, B. Hsp70 chaperones: cellular functions and molecular mechanism. *Cell. Mol. Life Sci.* **62**, 670–684 (2005).
298. Yakubu, U. M. & Morano, K. A. Roles of the nucleotide exchange factor and chaperone Hsp110 in cellular proteostasis and diseases of protein misfolding. *Biol Chem* **399**, 1215–1221 (2018).
299. Garrido, C. *et al.* Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. *Cell Cycle* **5**, 2592–2601 (2006).
300. Mosser, D. D. & Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. *Oncogene* **23**, 2907–2918 (2004).
301. Mosser, D. D. *et al.* The chaperone function of hsp70 is required for protection against stress-induced apoptosis. *Mol. Cell. Biol.* **20**, 7146–7159 (2000).
302. Gabai, V. L., Mabuchi, K., Mosser, D. D. & Sherman, M. Y. Hsp72 and stress kinase c-jun N-terminal kinase regulate the bid-dependent pathway in tumor necrosis factor-induced apoptosis. *Mol. Cell. Biol.* **22**, 3415–3424 (2002).
303. Park, H. S., Lee, J. S., Huh, S. H., Seo, J. S. & Choi, E. J. Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. *EMBO J.* **20**, 446–456 (2001).
304. Guo, F. *et al.* Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. *Blood* **105**, 1246–1255 (2005).
305. Gao, T. & Newton, A. C. The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. *J. Biol. Chem.* **277**, 31585–31592 (2002).



306. Kondrikov, D., Fulton, D., Dong, Z. & Su, Y. Heat Shock Protein 70 Prevents Hyperoxia-Induced Disruption of Lung Endothelial Barrier via Caspase-Dependent and AIF-Dependent Pathways. *PLoS ONE* **10**, e0129343 (2015).
307. Ravagnan, L. *et al.* Heat-shock protein 70 antagonizes apoptosis-inducing factor. *Nat Cell Biol* **3**, 839–843 (2001).
308. Beere, H. M. *et al.* Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. *Nat. Cell Biol.* **2**, 469–475 (2000).
309. Saleh, A., Srinivasula, S. M., Balkir, L., Robbins, P. D. & Alnemri, E. S. Negative regulation of the Apaf-1 apoptosome by Hsp70. *Nat. Cell Biol.* **2**, 476–483 (2000).
310. Ribeil, J.-A. *et al.* Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. *Nature* **445**, 102–105 (2007).
311. Sakahira, H. & Nagata, S. Co-translational folding of caspase-activated DNase with Hsp70, Hsp40, and inhibitor of caspase-activated DNase. *J. Biol. Chem.* **277**, 3364–3370 (2002).
312. Kotoglou, P. *et al.* Hsp70 translocates to the nuclei and nucleoli, binds to XRCC1 and PARP-1, and protects HeLa cells from single-strand DNA breaks. *Cell Stress Chaperones* **14**, 391–406 (2009).
313. Jäättelä, M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. *Int. J. Cancer* **60**, 689–693 (1995).
314. Nylandsted, J. *et al.* Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 7871–7876 (2000).
315. Małusecka, E., Zborek, A., Krzyzowska-Gruca, S. & Krawczyk, Z. Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study. *Anticancer Res.* **21**, 1015–1021 (2001).
316. Ciocca, D. R. & Calderwood, S. K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. *Cell Stress Chaperones* **10**, 86–103 (2005).
317. Thomas, X. *et al.* Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. *Leuk. Res.* **29**, 1049–1058 (2005).
318. Hwang, T. S. *et al.* Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer. *J. Gastroenterol. Hepatol.* **18**, 690–700 (2003).
319. Abe, M. *et al.* Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. *Clin Prostate Cancer* **3**, 49–53 (2004).
320. Chuma, M. *et al.* Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. *Hepatology* **37**, 198–207 (2003).
321. Pocaly, M. *et al.* Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. *Leukemia* **21**, 93–101 (2007).
322. Ray, S. *et al.* Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. *J. Biol. Chem.* **279**, 35604–35615 (2004).
323. Vargas-Roig, L. M., Gago, F. E., Tello, O., Aznar, J. C. & Ciocca, D. R. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. *Int. J. Cancer* **79**, 468–475 (1998).
324. Brondani Da Rocha, A. *et al.* Radioresistance is associated to increased Hsp70 content in human glioblastoma cell lines. *Int. J. Oncol.* **25**, 777–785 (2004).

325. Asea, A. Mechanisms of HSP72 release. *J. Biosci.* **32**, 579–584 (2007).
326. Mambula, S. S. & Calderwood, S. K. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. *J. Immunol.* **177**, 7849–7857 (2006).
327. Hightower, L. E. & Guidon, P. T. Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. *J. Cell. Physiol.* **138**, 257–266 (1989).
328. Seigneuric, R. *et al.* Heat Shock Proteins as Danger Signals for Cancer Detection. *Front Oncol* **1**, (2011).
329. Multhoff, G. Heat shock protein 70 (Hsp70): membrane location, export and immunological relevance. *Methods* **43**, 229–237 (2007).
330. Elmallah, M. I. Y. *et al.* Membrane-anchored heat-shock protein 70 (Hsp70) in cancer. *Cancer Lett.* **469**, 134–141 (2020).
331. Boudesco, C., Cause, S., Jegu, G. & Garrido, C. Hsp70: A Cancer Target Inside and Outside the Cell. *Methods Mol. Biol.* **1709**, 371–396 (2018).
332. Multhoff, G., Pockley, A. G., Streffer, C. & Gaip, U. S. Dual role of heat shock proteins (HSPs) in anti-tumor immunity. *Curr. Mol. Med.* **12**, 1174–1182 (2012).
333. Pockley, A. G., Muthana, M. & Calderwood, S. K. The dual immunoregulatory roles of stress proteins. *Trends Biochem. Sci.* **33**, 71–79 (2008).
334. Bendz, H. *et al.* Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. *J. Biol. Chem.* **282**, 31688–31702 (2007).
335. Flechtner, J. B. *et al.* High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses. *J. Immunol.* **177**, 1017–1027 (2006).
336. Haug, M., Schepp, C. P., Kalbacher, H., Dannecker, G. E. & Holzer, U. 70-kDa heat shock proteins: specific interactions with HLA-DR molecules and their peptide fragments. *Eur. J. Immunol.* **37**, 1053–1063 (2007).
337. Toomey, D. *et al.* Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. *Vaccine* **26**, 3540–3549 (2008).
338. Mizukami, S. *et al.* Both CD4+ and CD8+ T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. *Cancer Sci.* **99**, 1008–1015 (2008).
339. Enomoto, Y. *et al.* Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. *J. Immunol.* **177**, 5946–5955 (2006).
340. Jimbo, J. *et al.* Induction of leukemia-specific antibodies by immunotherapy with leukemia-cell-derived heat shock protein 70. *Cancer Sci.* **99**, 1427–1434 (2008).
341. Kottke, T. *et al.* Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. *Cancer Res.* **67**, 11970–11979 (2007).
342. Shevtsov, M. & Multhoff, G. Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer. *Front Immunol* **7**, (2016).
343. Borges, T. J. *et al.* The anti-inflammatory mechanisms of Hsp70. *Front Immunol* **3**, 95 (2012).
344. Stocki, P., Wang, X. N. & Dickinson, A. M. Inducible heat shock protein 70 reduces T cell responses and stimulatory capacity of monocyte-derived dendritic cells. *J. Biol. Chem.* **287**, 12387–12394 (2012).
345. Wachstein, J. *et al.* HSP70 enhances immunosuppressive function of CD4(+)CD25(+)FoxP3(+) T regulatory cells and cytotoxicity in CD4(+)CD25(-) T cells. *PLoS ONE* **7**, e51747 (2012).

346. Fong, J. J. *et al.* Immunomodulatory activity of extracellular Hsp70 mediated via paired receptors Siglec-5 and Siglec-14. *EMBO J* **34**, 2775–2788 (2015).
347. Calderwood, S. K. & Murshid, A. Siglecs take a TOLL on inflammation: deciphering the Hsp70 riddle. *EMBO J.* **34**, 2733–2734 (2015).
348. Breuninger, S. & Erl, J. Quantitative Analysis of Liposomal Heat Shock Protein 70 (Hsp70) in the Blood of Tumor Patients Using a Novel LipHsp70 ELISA. *J Clin Cell Immunol* **05**, (2014).
349. Gehrmann, M. *et al.* Hsp70—a biomarker for tumor detection and monitoring of outcome of radiation therapy in patients with squamous cell carcinoma of the head and neck. *Radiat Oncol* **9**, 131 (2014).
350. Dutta, S. K. *et al.* Serum HSP70: a novel biomarker for early detection of pancreatic cancer. *Pancreas* **41**, 530–534 (2012).
351. Gunther, S. *et al.* Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. *Front Immunol* **6**, 556 (2015).
352. Ostheimer, C., Gunther, S., Bache, M., Vordermark, D. & Multhoff, G. Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin. *Front Immunol* **8**, 1305 (2017).
353. Multhoff, G. *et al.* A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. *Int. J. Cancer* **61**, 272–279 (1995).
354. Multhoff, G. *et al.* Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. *Exp. Hematol.* **27**, 1627–1636 (1999).
355. Multhoff, G. *et al.* Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. *The Journal of Immunology* **158**, 4341–4350 (1997).
356. Stangl, S. *et al.* Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). *Int. J. Cancer* (2017) doi:10.1002/ijc.31213.
357. Gastpar, R. *et al.* Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. *Cancer Res.* **65**, 5238–5247 (2005).
358. Multhoff, G. *et al.* A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. *Cell Stress Chaperones* **6**, 337–344 (2001).
359. Specht, H. M. *et al.* Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial. *Front Immunol* **6**, 162 (2015).
360. Radons, J. The human HSP70 family of chaperones: where do we stand? *Cell Stress Chaperones* **21**, 379–404 (2016).
361. Gehrmann, M. *et al.* Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels. *Biol. Chem.* **383**, 1715–1725 (2002).
362. Gehrmann, M. *et al.* Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B. *PLoS ONE* **7**, e41341 (2012).
363. Pfister, K. *et al.* Patient survival by Hsp70 membrane phenotype. *Cancer* **110**, 926–935 (2007).
364. Breuninger, S. *et al.* Membrane Hsp70-A Novel Target for the Isolation of Circulating Tumor Cells After Epithelial-to-Mesenchymal Transition. *Front Oncol* **8**, 497 (2018).

365. Vega, V. L. *et al.* Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. *J. Immunol.* **180**, 4299–4307 (2008).
366. Lv, L.-H. *et al.* Anticancer Drugs Cause Release of Exosomes with Heat Shock Proteins from Human Hepatocellular Carcinoma Cells That Elicit Effective Natural Killer Cell Antitumor Responses in Vitro. *J. Biol. Chem.* **287**, 15874–15885 (2012).
367. Cho, J., Lee, Y.-S., Kim, S.-H., Ko, J.-K. & Kim, C.-W. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models. *Cancer Letters* **275**, 256–265 (2009).
368. Gobbo, J. *et al.* Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. *J. Natl. Cancer Inst.* **108**, (2016).
369. Diao, J. *et al.* Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3. *Med Oncol* **32**, 35 (2015).
370. De Maio, A. Extracellular Hsp70: export and function. *Curr. Protein Pept. Sci.* **15**, 225–231 (2014).
371. Albakova, Z., Armeev, G. A., Kanevskiy, L. M., Kovalenko, E. I. & Sapozhnikov, A. M. HSP70 Multi-Functionality in Cancer. *Cells* **9**, (2020).
372. Dhondt, B. *et al.* Unravelling the proteomic landscape of extracellular vesicles in prostate cancer by density-based fractionation of urine. *J Extracell Vesicles* **9**, 1736935 (2020).
373. Gehrman, M. K. *et al.* Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles. *Int J Nanomedicine* **10**, 5687–5700 (2015).
374. Limagne, E. *et al.* Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen. *Cancer Res* **76**, 5241–5252 (2016).
375. Bardelli, A. & Pantel, K. Liquid Biopsies, What We Do Not Know (Yet). *Cancer Cell* **31**, 172–179 (2017).
376. Bailey, P. C. & Martin, S. S. Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology. *Cells* **8**, (2019).
377. Boudesco, C., Cause, S., Jago, G. & Garrido, C. Hsp70: A Cancer Target Inside and Outside the Cell. *Methods Mol. Biol.* **1709**, 371–396 (2018).
378. Lee, H. W. *et al.* Heat shock protein 70 (HSP70) expression is associated with poor prognosis in intestinal type gastric cancer. *Virchows Arch.* **463**, 489–495 (2013).
379. Mano, R. *et al.* Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy. *Urol. Oncol.* **36**, 531.e9-531.e17 (2018).
380. Tavassol, F. *et al.* Prognostic significance of heat shock protein 70 (HSP70) in patients with oral cancer. *Head Neck Oncol* **3**, 10 (2011).
381. Ono, K. *et al.* HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. *J. Cell. Biochem.* **119**, 7350–7362 (2018).
382. Nazarenko, I. Extracellular Vesicles: Recent Developments in Technology and Perspectives for Cancer Liquid Biopsy. *Recent Results Cancer Res.* **215**, 319–344 (2020).
383. Blanco-Formoso, M. & Alvarez-Puebla, R. A. Cancer Diagnosis through SERS and Other Related Techniques. *Int J Mol Sci* **21**, (2020).
384. Guo, S.-C., Tao, S.-C. & Dawn, H. Microfluidics-based on-a-chip systems for isolating and analysing extracellular vesicles. *J Extracell Vesicles* **7**, 1508271 (2018).


385. Obeid, S. *et al.* NanoBioAnalytical characterization of extracellular vesicles in 75-nm nanofiltered human plasma for transfusion: A tool to improve transfusion safety. *Nanomedicine* **20**, 101977 (2019).
386. Obeid, S. *et al.* Development of a NanoBioAnalytical platform for 'on-chip' qualification and quantification of platelet-derived microparticles. *Biosens Bioelectron* **93**, 250–259 (2017).

# ANNEXES

## **ANNEXE 1**

*Tracking the evolution of circulating exosomal-PDL1 to  
monitor melanoma patients*

Marine Cordonnier, Charlée Nardin, Gaëtan Chanteloup, Valentin  
Derangere, Marie-Paule Algros, Laurent Arnould, Carmen Garrido, François  
Aubin & Jessica Gobbo



## Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients

Marine Cordonnier, Charlée Nardin, Gaëtan Chanteloup, Valentin Derangere, Marie-Paule Algros, Laurent Arnould, Carmen Garrido, François Aubin & Jessica Gobbo

To cite this article: Marine Cordonnier, Charlée Nardin, Gaëtan Chanteloup, Valentin Derangere, Marie-Paule Algros, Laurent Arnould, Carmen Garrido, François Aubin & Jessica Gobbo (2020) Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients, Journal of Extracellular Vesicles, 9:1, 1710899, DOI: [10.1080/20013078.2019.1710899](https://doi.org/10.1080/20013078.2019.1710899)

To link to this article: <https://doi.org/10.1080/20013078.2019.1710899>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



[View supplementary material](#)



Published online: 07 Jan 2020.



[Submit your article to this journal](#)



Article views: 2627



[View related articles](#)



[View Crossmark data](#)



Citing articles: 5 [View citing articles](#)

Full Terms & Conditions of access and use can be found at <https://www.tandfonline.com/action/journalInformation?journalCode=zjev20>



## Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients

Marine Cordonnier<sup>a,b\*</sup>, Charlée Nardin<sup>c,d\*</sup>, Gaëtan Chanteloup<sup>a,b</sup>, Valentin Derangere<sup>a,e</sup>, Marie-Paule Algros<sup>d</sup>, Laurent Arnould<sup>e</sup>, Carmen Garrido<sup>a,b,e,f,g\*</sup>, François Aubin<sup>c,d,g\*</sup> and Jessica Gobbo<sup>a,b,e,f,g\*</sup>

<sup>a</sup>INSERM 1231, Label "Ligue National contre le Cancer" and Label d'Excellence LipSTIC, Dijon, France; <sup>b</sup>Faculty of Medicine, University of Burgundy-Franche-Comté, Dijon, France; <sup>c</sup>University of Burgundy-Franche-Comté, Besançon, France; <sup>d</sup>Department of Dermatology, University Hospital Center, Besançon, France; <sup>e</sup>Department of Medical Oncology, Center Georges-François Leclerc, Dijon, France; <sup>f</sup>Inserm, CIC1432, Module plurithématique, U2P, Dijon, France

### ABSTRACT

In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal-PD-L1 in melanoma patients' follow-up. We studied the dynamics of exosomal-PD-L1 from 100 melanoma patients by using an enzyme-linked immunosorbent assay. We found that PD-L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD-L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T-cell activation. In plasma from melanoma patients, the level of PD-L1 (n=30, median 64.26 pg/mL) was significantly higher in exosomes compared to soluble PD-L1 (n=30, 0.1 pg/mL). Furthermore, exosomal-PD-L1 was detected in all patients whereas only 67% of tumour biopsies were PD-L1 positive. Although baseline exosomal-PD-L1 levels were not associated with clinic-pathologic characteristics, their variations after the cures ( $\Delta$ ExoPD-L1) correlated with the tumour response to treatment. A  $\Delta$ ExoPD-L1 cut-off of > 100 was defined, yielding an 83% sensitivity, a 70% specificity, a 91% positive predictive value and 54% negative predictive values for disease progression. The use of the cut-off allowed stratification in two groups of patients statistically different concerning overall survival and progression-free survival. PD-L1 levels in circulating exosomes seem to be a more reliable marker than PD-L1 expression in tumour biopsies. Monitoring of circulating exosomal-PD-L1 may be useful to predict the tumour response to treatment and clinical outcome.

### ARTICLE HISTORY

Received 18 September 2019  
Revised 12 December 2019  
Accepted 25 December 2019

### KEYWORDS

Melanoma; exosome; PD-L1/PD-1; immune checkpoint; follow-up

## Introduction

Immune checkpoint inhibitors such as antibodies targeting PD-L1 (programmed death-ligand) are revolutionizing cancer patients' management, particularly in melanoma and non-small cell lung cancer (NSCLC) treatment. Two monoclonal antibodies have already been approved by the FDA (Nivolumab and Pembrolizumab) in both indications [1–3]. In advanced melanoma patients, around 40% of objective response rate is observed whereas in NSCLC patients, Nivolumab response rate is approximately 20%. Therefore, there is an urgent need to validate a biomarker allowing selection of patients who might benefit from an immunotherapeutic approach. With this goal, the first studies aimed to identify PD-L1 expression in patients' biopsies but this test has proven to be unreliable due to the heterogeneity of PD-L1 expression within the tumour [4,5].

Additionally, different studies attempted to measure PD-L1 level in blood samples. However, this protein is very unstable and not easy to detect. Recent studies report the interest of using circulating nanovesicles, such as exosomes, as a diagnostic tool.

Exosomes are 40–150 nm lipid bilayer membrane-bound particles generated and released by most kinds of cells through a defined intracellular trafficking route [6,7]. Exosomes carry nucleic acids, lipids and proteins, potential biomarkers that are protected by an exosome's cholesterol-rich membrane. Among the proteins, exosomes contain membrane proteins (flotillin-1, tetraspanins, annexinV, ICAM-1), immunostimulatory molecules (MHC I/II) and ESCRT proteins (Alix, TSG101) [8–10]. In the setting of cancer, exosomes are released by all tumour cells and they can be isolated from circulating peripheral blood [6,11,12]. Exosome-based diagnostics provide higher sensitivity and

**CONTACT** Jessica Gobbo  [jgobbo@cgfl.fr](mailto:jgobbo@cgfl.fr); Carmen Garrido  [cgarrido@u-bourgogne.fr](mailto:cgarrido@u-bourgogne.fr)  Center Georges-François Leclerc, 1 rue du Professeur Marion, Dijon 21000, France

\*These authors contributed equally to this work.

<sup>†</sup>Co-direction of the work.

 Supplemental data for this article can be accessed here.

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

specificity over conventional biopsies or liquid biomarkers due to their stability in biofluids. In addition, exosomal markers are readily available from most biofluids and recent isolation technologic advances make exosome-based diagnostics cost and labour effective [13]. Recent studies indicate that PD-L1 expression in extracellular vesicles isolated from cancer patients' blood samples can correlate with tumour features [14–18]. Additionally, studies of tumour-derived exosomes, performed in cultured cells, have demonstrated that these exosomes represent an effective mechanism of immunosuppression [17,19–21].

In this work, we have performed a prospective clinical study to investigate whether PD-L1 levels in exosomes isolated from melanoma patients' plasma could predict a patient's response to immunotherapy.

## Material and methods

### Cell culture

Non-cancerous human lung cells (MRC-5) human lung fibroblasts, A549 human lung cancer cells, B16F10 mouse melanoma cells and SK-MEL-2 human melanoma cells were purchased from the ATCC. All cell lines were cultured at 37°C, 5% CO<sub>2</sub> in RPMI 1640 medium (Dutscher) supplemented with 10% foetal bovine serum (Dutscher) depleted in exosomes and were tested weekly for mycoplasma contamination.

### Exosomes purification from the cell's supernatants

Cells were cultured in medium depleted from serum-derived exosomes. Supernatants were collected from cell lines and sequentially centrifuged at 300g for 10 min (4°C), at 2000g for 20 min and at 10,000g for 40 min. Then, exosomes were ultracentrifugated at 100,000g for 70 min and washed in PBS (Beckman Coulter, Optima XPN-100). Supernatants were carefully removed and exosome pellets were suspended either in 50 µl of 1% RIPA lysis buffer or in 50 µl of PBS.

### Lymphocyte isolation and co-culture experiment

PBMC were isolated from buffy coats (EFS, Besançon) by centrifugation using a density gradient (Lymphocytes separation medium, Eurobio). Red blood cells were lysed and T cells were enriched (RosetteSep, Stem Cell). Then, purified T cells (10<sup>5</sup>) were activated with CD2/CD3/CD28 beads (Miltenyi Biotec) and incubated with either human melanoma cells (10<sup>5</sup>) (SK-MEL-2) or human lung cancer cells (A549) or exosomes derived from these cell lines (10<sup>6</sup>).

After 48 h of culture, T cells were collected and analysed by flow cytometry for the expression of membrane-bound PD-1 (46-1799-42, eBioscience), and intracellular Ki67 (48-5699-42, eBioscience), IFN $\gamma$  (506516, Biolegend) after fixation and permeabilization (BD Perm/Wash Buffer, Biosciences).

### EXOMEL clinical study

This prospective study was conducted between January 2016 and December 2018 in the Department of Dermatology, University Hospital of Besançon, France. The study design was approved by the local research ethics committee and a written informed consent was provided before enrolment. Study adhered to the Declaration of Helsinki Principles. Patients with melanoma were included at different clinical stages graded according to the latest American Joint Committee on Cancer staging classification (8<sup>th</sup> edition, Balch 2018).

### Study objectives and endpoints

The primary objective of this study was to quantify exosomal PD-L1 in the blood of melanoma patients. The secondary objectives were to determine whether the amount of ExoPD-L1 could be associated to: (i) stages diseases, (ii) response to treatment, (iii) overall survival (OS) and progression-free survival (PFS), (iv) clinical variable and (v) PD-L1 expression in tumours or soluble in the plasma. The primary endpoint of the study was the blood concentration of PD-L1-exosomes at different time points using ELISA. The secondary endpoints were to compare: (i) the baseline concentration of ExoPD-L1 with clinic/pathologic features (age, gender, primary melanoma histology subtype and location, tumour burden, prior therapy and disease status, biologic data-lactate dehydrogenase, lymphopenia, soluble PD-L1 using ELISA dosage and tumour PD-L1 using immunohistochemistry staining, (ii) the concentration of ExoPD-L1 and their variation of in patients having a complete response (CR), partial response (PR), progressive disease (PD) (based on immune-related irRECIST).

### Blood collection and storage

Peripheral blood was drawn into sodium heparin tubes. First sampling at inclusion was labelled S1. Second sampling was labelled S2. Change in ExoPD-L1 from S1 to S2 was labelled  $\Delta$ ExoPD-L1. To ensure exosomes integrity, blood was centrifuged at 2400g for 15 min to remove cell debris and dead cells. Plasma samples were stored in 1 mL aliquots at -18°C.

### Exosomes isolation from plasma samples

Thawed plasma samples of 5 mL were differentially centrifuged 300g for 5 min at 4°C and then 17,000g for 10 min at 4°C. Next, supernatants obtained in the previous step were ultra-centrifuged at 200,000g for 1 h at 4°C (Beckman Coulter, Optima XPN-100). Supernatants were carefully removed and exosome pellets suspended either in 50 µl of 1% RIPA lysis buffer or in 50 µl of PBS.

### Exosomes characterization

Exosomes size and concentration were determined by nanoparticle tracking analysis using a NS300 Instrument (Nanosight, Amesbury, UK).

To determine PD-L1 expression at the exosome's surface, protein-protein interaction experiments were conducted with an Octet Red instrument FortéBio, Menlo Park, CA). The ligand (PD-1) was biotinylated using EZ-Link NHS-PEG<sub>4</sub>-biotin (2 nM, 30 min, RT, Thermo Fisher Scientific, Germany) and immobilized on streptavidin sensors (black 96-well plate, FortéBio, USA). Functionalized sensors were incubated in PBS (10 min) then incubated with exosomes (10<sup>6</sup>, isolated from either the supernatant of cancer cell lines, normal cells, melanoma patients' plasma, lung cancer patients' plasma or healthy donors' plasma). All sensorgrams were corrected for baseline drift by subtracting a control sensor exposed to running buffer only (FortéBio, Data analysis software version 7.1.0.89).

Isolated exosomes were tested for the expression of exosomal markers. Nanovesicles were lysed and separated on SDS/PAGE gels. Proteins were transferred onto a polyvinylidene fluoride membrane (Amersham GE Healthcare Life Sciences) for western-blotting analysis. After transferring, membranes were blocked with 5% bovine serum albumin for 1 h and incubated overnight at 4°C with antibodies specific for Alix (2171s, Cell Signalling), TSG101 (sc-7964, Santacruz), PD-L1 (sc-50298), CD9 (ab92726, Abcam), CD63 (NBP2-4225, BioTechne), GRP94 (ab2791, Abcam), β-actin (A3854, Sigma Aldrich). Horse radish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch) was added and immunoreactive proteins revealed using ECL detection reagents (34095, ThermoFisher Scientific). Band intensities were captured using Chemidoc XRS+ system and images were analysed using Image Lab software (Bio-Rad Laboratories).

### Determination of PD-L1 concentration in plasma and circulating exosomes

Soluble PD-L1 and PD-L1 in exosomes levels were measured using an enzyme-linked immunosorbent assay (PD-L1 Human ELISA Kit, Invitrogen),

according to the manufacturer's instructions. Protein concentrations were determined according to standard curves.

### Immunohistochemistry of PD-L1 in tumour tissue samples

Formalin-fixed paraffin-embedded tumour tissue samples were obtained for correlation analysis of PD-L1 expression between tissue and circulating exosomes. All IHC procedures were performed using Benchmark apparatus (Ventana). PD-L1 expression was evaluated with 22C3 clone (Dako). PD-L1 immunostaining on tumour tissue samples (blind coded) was assessed by a dedicated pathologist.

### Tumour response evaluation

Tumour response was based on immune-related irRECIST using unidimensional measurements on contrast-enhanced computed tomography scan or PET-CT (Positron Emission Tomography) [19]. CR, complete response; PR, partial response. Stable disease (SD) was labelled SD. High tumour burden was defined as 10 lesions or more, or only 1 lesion bigger than 3 cm. Imaging re-evaluation was performed in blind-coded samples.

### Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics v24.0 and the Graphpad Prism 6 program. Data presented are from at least three independent experiments. Error bars shown in graphical data represent mean ± SEM. When data are presented as box plots, the bar indicates the median, the box shows the interquartile range (25–75%) and the whiskers extend to 1.5 the interquartile range. For normally distributed data, significance of mean differences was determined using two-tailed paired or unpaired Student *t*-test. For data not normally distributed, non-parametric Kruskal–Wallis and Wilcoxon tests were used for unpaired and paired analysis, respectively. To test the relationship between variables, Spearman correlation coefficients were calculated. Dependence was ruled out with a correlation coefficient (absolute *q*-value) of <0.7. Kaplan–Meier survival curve, Log-rank test and Cox proportional hazards model were used to analyse survival data. Results from Cox proportional hazards models were reported as hazard ratios (HRs) with 95% confidence interval (CIs). A two-tailed value of *p* < 0.05 was considered statistically significant. Quantitative data are expressed as mean ± SEM from at least three independent experiments. Quantitative results were compared using the Mann–Whitney test according to their distribution. The

cut-off value for the change in PD-L1-Exo was calculated by the Receiver Operating Characteristic (ROC) curve analysis to identify melanoma patients with high probability to display disease control.

## Results

### *Cancer cells release exosomes expressing membrane PD-L1*

We first studied whether PD-L1 could be secreted through exosomes. We purified exosomes from different cell lines such as human and murine melanoma (SK-MEL-2, B16F10), human lung cancer (A549) and MRC-5. TSG101, Alix, CD9 and CD63 were used as markers of exosomes and Grp94 served as a negative control. As shown in Figure 1(a), PD-L1 was expressed in exosomes from the three cancer cell lines analysed but not in the non-cancerous cell line. We then analysed PD-L1 expression in exosomes (ExoPD-L1) isolated from pooled blood samples of melanoma patients ( $n = 6$ ) or lung cancer patients ( $n = 6$ ) or exosomes isolated from healthy donors ( $n = 5$ ). As previously observed for cell lines, we only detected PD-L1 in the exosomes isolated from cancer patients (Figure 1(b)). While there was a difference between cancer patients and healthy donors in the detection of PD-L1 expressing exosomes, no difference was found in the total number and size of the exosomes (Supplementary Figure 1A-B).

To determine whether PD-L1 was expressed at the membrane of the vesicles, we used an interference biolayer approach to capture exosomes with a PD-1 recombinant protein. As shown in Figure 1(c-d), exosomes could be captured both from cancer cell lines and cancer patients' blood samples (melanoma, lung cancer), indicating the presence of PD-L1 in their membrane. In contrast, no ExoPD-L1 (or negligible amounts) could be captured from the non-cancerous cells' supernatant or from the blood of healthy donors. These results indicate that PD-L1 is present at the membrane of tumour-derived exosomes.

Next, we determined whether isolated PD-L1-exosomes were functional. Primary T cells were activated (CD3, CD28) and then co-cultured for 24 h with either human melanoma SK-MEL-2 cells (positive control) or with exosomes purified from those cells' supernatant (ExoPD-L1). As shown in Figure 1(e), the exosomes were as efficient as cancer cells in inhibiting T-cell activation, as determined by the expression of PD-1, Ki67 and IFN $\gamma$ . Indeed, we observed an almost two-fold decrease in the percentage of PD-1, Ki67 and IFN $\gamma$  in the T cells cultured in the presence of SK-

MEL-2 cells and SK-MEL-2-derived exosomes (respective comparisons: PD-1:  $52.43\% \pm 7.56$  and  $54.84\% \pm 7.60$  vs 100%;  $57.54\% \pm 5.95$ , Ki67:  $67.51\% \pm 6.20$  vs 100%;  $43.71\% \pm 3.45$  and IFN $\gamma$ :  $68.01\% \pm 3.44$  vs 100%) (Figure 1(e)). Similar results were observed with lung cancer cells (Supplementary Figure 1C).

Altogether, these results show that PD-L1 is secreted in exosomes derived from cancer cells and that this molecule is functional since it is able to mediate T-cell immunosuppression.

### *Patient characteristics: the EXOMEL cohort*


To study ExoPD-L1 as potential biomarkers, we opened a prospective clinical study. Over the study period, 100 melanoma patients were included. Among these patients, 43% received anti-PD-1 antibodies, 10% ipilimumab and 18% BRAF and MEK inhibitors. Treatment information and clinical outcomes are detailed in Supplemental Table 1. Overall, 12 had a CR, 28 had a PR, 10 had SD, and 46 had PD). In the cohort, 46 patients were evaluated after a median follow-up of 16 months. Among them 5 had a CR, 23 had a PR, 8 had SD, and 10 had PD, giving an overall risk ratio of 60.8%. Mean age was 64 years old (SD, 13.7) and 39% of patients were female. Most primary melanomas were cutaneous (84%) and carried a BRAF mutation (51%). At the time of inclusion, most patients were AJCC stage IV (74%) with M1c and M1d disease (80%) (Table 1).

### *Expression of PD-L1 in plasma or in circulating exosomes versus tumour biopsies*

First, we compared the expression of PD-L1 within exosomes in blood samples versus PD-L1 tumour expression in biopsies by IHC. Then, in plasma samples, we compared by ELISA the levels of soluble PD-L1 with PD-L1 in exosomes (Figure 2(a)). As expected, the level of ExoPD-L1 ( $n = 30$ , median 64.26 pg/mL) was significantly higher compared with soluble PD-L1 in the plasma, which was barely detectable ( $n = 30$ , 0.1 pg/mL). Interestingly, ExoPD-L1 was detected in all patients (100%) (Figure 2(b)) whereas, only 67% were PD-L1 positive in tumour biopsies (Figure 2(c-d)). We conclude that PD-L1 was much easier to detect and quantify in circulating exosomes rather than in biopsies or when soluble in plasma.

### *Association between baseline ExoPD-L1 expression and clinical variables*

Baseline ExoPD-L1 levels (S1) were not associated with clinical/pathologic characteristics such as age, gender, primary melanoma histology subtype and location,



**Figure 1.** PD-L1 expression in tumour-derived exosomes. (A/B) Representative immunoblots showing expression of Alix, CD63, TSG101, PD-L1 and CD9 in exosomes derived from cell lines (a) MRC-5 (normal human lung cells), A549 (human lung cancer), B16F10 (mouse melanoma) or SK-MEL-2 (human melanoma) or (b) plasma-derived exosomes from melanoma patients, lung cancer patients and healthy donors. Grp94 is used here as an exosomal negative control and actin as a loading control. Cell lysates are also included. (C/D) Binding of exosomes (nm) derived from cell lines (MRC-5, A549, SK-MEL-2, B16F10) or from plasma samples of melanoma patients ( $n = 6$ ) or lung cancer patients ( $n = 6$ ) and healthy donors ( $n = 5$ ) to immobilized biotinylated PD-1 determined by biolayer interferometry. Binding curves represent mean signal of triplicate measurements for each sample. Mann–Whitney. (c),  $***p < 0.001$ ,  $**p = 0.0081$ ,  $*p = 0.0041$ . (d)  $*p = 0.0039$  melanoma,  $*p = 0.0031$  lung cancer). (e) Percentage of PD-1, Ki67 and IFN $\gamma$  mean fluorescence intensity in lymphocytes cultured 24 h in the presence or absence of SK-MEL-2 or SK-MEL-2-derived exosomes, determined by flow cytometry ( $***p = 0.0006$ ,  $****p < 0.0001$ ).

tumour burden, prior therapy, or disease status, with the exception of lymphopenia that associated with a significantly higher ExoPD-L1 level ( $p = 0.048$ ) (Supplementary Table 2).

**Association between changes in exosomal-PD-L1 expression and tumour response**

We evaluated whether a variation in ExoPD-L1 expression could be predictive of tumour response to therapy. Two blood samples, before and after treatment (S1+ S2), were obtained from 46 patients. Median interval between S1 and S2 was 4.5 months. Reasons for S2 sample unavailability were either patient death ( $n = 23$ ) or the patient was lost to follow-up ( $n = 31$ ). Among these 46 patients, 36 patients received anti-PD-1 therapy. The other patients received Ipilimumab ( $n = 2$ , including 1 in association with anti-PD

-1 therapy), anti-BRAF and anti-MEK targeted therapies ( $n = 8$ , including 4 in association with anti-PD-1 therapy). The mean change in exosomal-PD-L1 ( $\Delta$ ExoPD-L1) between S1–S2 was 43.4 pg/mL. Association between  $\Delta$ ExoPD-L1 and disease status is shown in Figure 3(a–b). In patients experiencing complete and PR ( $n = 27$ ),  $\Delta$ ExoPD-L1 decreased without statistical significance (mean S1:  $121.06 \pm 26.65$  vs mean S2:  $104.78 \pm 17.11$ ,  $p = 0.8607$ ). In patients experiencing progression ( $n = 9$ ),  $\Delta$ ExoPD-L1 increased significantly (mean S1  $85.90 \pm 24.46$  vs mean S2  $344.20 \pm 70.30$   $p = 0.0002$ ), (Figure 3(a)). Furthermore,  $\Delta$ ExoPD-L1 was significantly associated with disease status, i.e. responders (CR+PR+SD) vs non-responders ( $p = 0.001$ ) (Figure 3(b–e)).

Using ROC curve analysis,  $\Delta$ ExoPD-L1 showed good discrimination between patients experiencing disease response ( $n = 36$ ) and those experiencing disease

**Table 1.** Clinical characteristics of melanoma patients with available  $\Delta$ ExoPD-L1 ( $n = 46$ ).

		Patients <i>N</i> = 46
Age, years	<70	28 (60.9%)
	≥70	18 (39.1%)
Gender	Male	28 (60.9%)
	Female	18 (39.1%)
ECOG performance status	0	36 (78.3%)
	≥1	10 (21.7%)
Anatomic location of primary melanoma	Cutaneous	36 (78.3%)
	Head and neck	7
	Lower limb	8
	Upper limb	6
	Trunk	14
	Hand and foot	1
	Mucosal	4 (8.7%)
	Uveal	3 (6.5%)
	Unknown	3 (6.5%)
	Histological subtype*	SSM
NM		8 (17.4%)
LMN		-
ALM		1 (2.2%)
Desmoplastic		1 (2.2%)
Unknown		12 (26.1%)
NA		10 (21.7%)
-		-
Breslow, mm*	0–1 mm	7 (15.2%)
	1.01–2 mm	7 (15.2%)
	2.01–4 mm	12 (26.1%)
	≥4 mm	9 (19.6%)
	Unknown	1 (2.2%)
	NA	10 (21.7%)
	-	-

progression ( $n = 10$ ) (AUC = 0.867, SE: 0.057, CI): 95% = 0.755–0.978;  $p < 0.001$ ) (Figure 3(d)). Based on ROC curve analysis, we calculated an optimal cut-off. The  $\Delta$ ExoPD-L1 cut-off >100 pg/mL demonstrated an 83% sensitivity, a 70% specificity, a 91% positive predictive value and a 54% negative predictive value for disease progression.

#### Association between changes in ExoPD-L1 expression and clinical outcome

The median follow-up was at 9.9 months. No significant difference was found between the two groups of patients for either the total number of circulating exosomes or exosome size (Supplementary Figure 2A–B). In univariate analysis, ExoPD-L1 blood levels at S1 were not associated with OS and PFS. The small number of events regarding OS and PFS (5 events for OS and 15 events for PFS) precluded multivariable analysis. However,  $\Delta$ ExoPD-L1 was associated with PFS (HR: 1.003, CI 95% = 1.001 – 1.006;  $p = 0.006$ ) and OS (HR: 1.004, CI: 95% = 1.001–1.008,  $p = 0.034$ ) (Supplemental Table 3). The use of a  $\Delta$ ExoPD-L1 cut-


off allowed stratification in two groups of patients statistically different in terms of OS (median not reached,  $p = 0.048$ ) and PFS ( $\Delta$ ExoPD-L1 < 100, median PFS not reached vs.  $\Delta$ ExoPD-L1 > 100, median PFS = 9 months, CI: 95% = 4–14.2,  $p = 0.011$ ) (Figure 4(a–b)). Altogether, these results suggest that monitoring changes in circulating ExoPD-L1 might be used to predict tumour response and clinical outcome.

#### ExoPD-L1 as a biomarker to detect early responders

Finally, we explored the possibility of following the evolution of the disease by measuring changes in ExoPD-L1 levels. For eight patients, we studied in detail whether PD-L1 levels in circulating exosomes could be used as a potential marker of response to therapy. At key points during different therapies, tumour progression/response was evaluated by medical imagery scanning and, in parallel, we quantified ExoPD-L1 in blood samples. As shown in Figure 5(a–d), tumour response detected in the scan was associated with a decrease in the level of circulating ExoPD-L1 and, inversely, tumour progression in the scan associated with an increase in circulating ExoPD-L1. Interestingly, this inverse association between ExoPD-L1 level and response to the treatment was observed independently of the therapy used (anti-PD-1 or targeted therapies). These encouraging results open the possibility of using exosomes expressing PD-L1, which can be easily isolated from blood samples during cancer patients' follow-up assessments, as predictors of response to the treatment.

#### Discussion

In this study aiming to explore ExoPD-L1 as a potential tumour biomarker in melanoma cells and patients, we first confirmed previous reports showing that PD-L1 was found in exosomes including on their surface [14]. However, in contrast to what was reported by Liao X et al [23], we found that PD-L1 within the exosomes was detectable and measurable in all patients examined in our EXOMEL cohort but soluble PD-L1 could not be detected (or at very low levels). Soluble PD-L1 is probably not a reliable marker as compared with ExoPD-L1 and the most likely explanation is that in exosomes, PD-L1 is stabilized by the cholesterol-rich membrane [10]. We demonstrate that while PD-L1 within the circulating exosomes was detected in all 100 patients of the cohort (although at different levels, providing a rationale for a cut-off value), only 67% of tumour biopsies were positive for PD-L1. This lack of




**Figure 2.** PD-L1 is easily detected in exosomes, when compared with soluble PD-L1 in plasma or in tumour biopsies. (a) Levels of PD-L1 in exosomes isolated from the plasma of melanoma patients compared with PD-L1 levels free in the plasma ( $n = 30$ ) (\*\*\*\* $p < 0.0001$ ), determined by ELISA. (b) Levels of ExoPD-L1 isolated from the 100 patient plasma samples of the EXOMEL cohort. (c) Representative IHC image of PD-L1 negative (PD-L1<sup>-</sup>) or positive (PD-L1<sup>+</sup>) tumours (22C3 antibody). Scale bars indicated 100  $\mu\text{m}$ . (d) Percentage of patients positive for PD-L1 when measured in circulating exosomes versus tumour biopsies.

reliability on tumour biopsies can be explained by heterogeneity and dynamic PD-L1 expression changes within the tumour. Moreover, not only do circulating exosomes provide a reliable way to quantify PD-L1 levels, but also they allow for a non-invasive procedure with a blood sample. This is a clear advantage considering that biopsies have inherent risks. The abundance of circulating ExoPD-L1 can be explained by the fact that a single cancer cell can release thousands of exosomes, thereby resulting in a signal amplification [24]. In addition, other cells such as myeloid-derived suppressive cells, macrophages, or dendritic cells can also release exosomes with PD-L1 [22,25–29,30], thereby contributing to the overall number of circulating exosomes expressing PD-L1 observed in patients' blood. The identification of each subpopulation of circulating exosomes expressing PD-L1 with cell-specific markers

may help to improve the use of PD-L1 as a circulating predictor of tumour growth.

We also demonstrate here that PD-L1 is present at the exosome membrane in the supernatant of cancer cells (but at very low levels in normal cells) and in the blood of cancer patients (but not in healthy donors). The exosomes expressing PD-L1 are as efficient as the cancer cells from which they derive to render T-cells anergic, thereby blocking immune surveillance. These observations are consistent with the work of Chen et al [17]. We can hypothesize that, through exosomes, PD-L1 not only acts on tumours and close tumour microenvironments but also at distal sites. ExoPD-L1 can, therefore, play a key role in immunosuppression involving PD-1/PD-L1 by targeting T lymphocytes in secondary lymphoid organs. Although there are no data concerning the circulating ExoPD-L1 threshold beyond which immunosuppression is induced,



**Figure 3.** Changes in the level of ExoPD-L1 stratify melanoma patients according to disease status. (a) Mean value of circulating ExoPD-L1 evaluated at S1 and S2 in patients grouped according to disease status (response,  $n = 36$ ) or progression,  $n = 10$ ). Mann-Whitney ( $***p = 0.0002$ ). (b) Comparison of changes in level of ExoPD-L1 in melanoma patients between S1/S2, according to disease status. Mann-Whitney ( $***p = 0.0002$ ). (c) Waterfall plots showing changes in level of ExoPD-L1 between S1/S2, according to disease status. Black bars represent responder patients ( $n = 36$ ) and grey bars represent progressive patients ( $n = 10$ ). (d) ROC curve analysis of changes in level of ExoPD-L1 (S1/S2) in responder patients compared with non-responders (AUC = 0.867, SE 0.057, CI95% 0.755–0.978;  $p < 0.001$ ). (e) An increase in ExoPD-L1 is associated with disease progression  $p < 0.009$ . A decrease in ExoPD-L1 is associated with response  $p < 0.009$ . All patients with a decrease in level of ExoPD-L1 experienced a tumour response and all patients with an increase in level of ExoPD-L1 experienced progression.

this observation provides a rationale to combine PD-1/PD-L1 inhibitors with a targeted therapy.

In agreement with these results, analysis of the EXOMEL cohort indicates that the level of ExoPD-L1 inversely correlates with the response to the therapy: A high increase in ExoPD-L1 is associated with tumour

progression while a decrease is associated with tumour regression, as determined by imaging scan analysis. The rate of circulating PD-L1 might reflect anti-tumour immunity involving CD8 + T-cells elicited by different therapies including, but not exclusively, checkpoint inhibitors. Since it has been reported that the tumour mutation burden






Figure 4. Melanoma-derived ExoPD-L1 can be used as a marker of survival. Kaplan–Meier estimates of (a) progression-free survival ( $p = 0.011$ ) and (b) overall survival ( $p = 0.048$ ) in patients according to  $\Delta$ ExoPD-L1 ( $n = 46$ ).




Figure 5. ExoPD-L1 can be used as follow-up markers in melanoma patients. Case study of the correlation between ExoPD-L1 levels in plasma samples from melanoma patients and response to PD-L1-based therapy. Concomitant imaging and ExoPD-L1 sampling in four patients experiencing (a) response as observed in the parotid gland and cervical lymph nodes on CT scan; (b) complete response in the subcutaneous tissue, popliteal and ilioinguinal lymph nodes on PET-CT; (c) disease response in the muscle and infraclavicular lymph nodes on CT scan; (d) initial response (at cure 1) then disease progression as detected in the brain on MRI. R: response, PD: progression of the disease. Tumour metastases in the scans are indicated by an arrow.

(TMB) is positively associated with the response to therapy [31,32], it will be interesting to correlate ExoPD-L1 levels with patient TMB.

### Conclusions

The present study offers the rationale for using ExoPD-L1 as a predictor of treatment response in melanoma patients, with the advantages of its non-invasive collection and real-time monitoring. It has already been suggested as a marker of PD-1/PD-L1 response [14,17]. In this work, we go further and demonstrate in a larger and prospective cohort that ExoPD-L1 may be a marker of different therapies (immuno- or targeted-therapy). We are currently conducting a multicenter clinical study with melanoma patients to establish precise cut-off values. The interest in ExoPD-L1 as a marker of patients' response to therapy undoubtedly goes beyond melanoma and might be useful in other cancer types in which tumour evasion from T-cell surveillance plays a crucial role in patients' survival and response to therapy, such as with lung cancer. The ability to capture Exo-PD-L1 directly from blood using a microchip requiring only a few microlitres of blood demands urgent investigation.

### Acknowledgments

We would like to thank Isabel Grégoire and Kathryn Nason for editing and reviewing this manuscript for English language.

### Disclosure statement

No potential conflict of interest was reported by the authors.

### Funding

This project was supported by a French Government grant managed by the French National Research Agency (ANR) under the programme "Investissements d'Avenir" with reference ANR-11-LABX-0021-01-LipSTIC Labex, "Ligue Nationale Contre le Cancer", "Institut National du Cancer", Centre Georges-Francois Leclerc, Canceropole Est, Fondation Silab Jean Paufigue, Regional Council Burgundy/Franche-Comté, FEDER and Fondation pour la Recherche Médicale (FRM grant number ECO2016073609).

### Trial registration

AC-2015-2496/DC-2014-2086

### References

- [1] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443–2454.
- [2] Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. *JAMA*. 2016 Apr 19;315(15):1600–1609.
- [3] Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015 Jan 22;372(4):320–330.
- [4] Kaunitz GJ, Cottrell TR, Lilo M, et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. *Lab Investig J Tech Methods Pathol*. 2017 Sep;97(9):1063–1071.
- [5] Madore J, Vilain RE, Menzies AM, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. *Pigment Cell Melanoma Res*. 2015 May;28(3):245–253.
- [6] Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol*. 2014;30:255–289.
- [7] Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. *Cell Mol Life Sci CMLS*. 2018;75(2):193–208.
- [8] Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. *Nat Rev Immunol*. 2002;2(8):569–579.
- [9] Kowal J, Arras G, Colombo M, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci U S A*. 2016 Feb 23;113(8):E968–977.
- [10] Cordonnier M, Chanteloup G, Isambert N, et al. Exosomes in cancer theranostic: diamonds in the rough. *Cell Adhes Migr*. 2017 Mar 4;11(2):151–163.
- [11] Kalluri R. The biology and function of exosomes in cancer. *J Clin Invest*. 2016 Apr 1;126(4):1208–1215.
- [12] Théry C, Amigorena S, Raposo G, et al. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol*. 2006 Apr;Chapter 3:Unit 3.22.
- [13] Sheridan C. Exosome cancer diagnostic reaches market. *Nat Biotechnol*. 2016 Apr;34(4):359–360.
- [14] Theodoraki M-N, Yerneni SS, Hoffmann TK, et al. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2018 Feb 15;24(4):896–905.
- [15] Ludwig S, Floros T, Theodoraki M-N, et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. *Clin Cancer Res*. 2017 Aug 15;23(16):4843–4854.
- [16] Ricklefs FL, Alayo Q, Krenzlin H, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. *Sci Adv*. 2018 Mar;4(3):eaar2766.
- [17] Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*. 2018;560(7718):382–386.
- [18] Poggio M, Hu T, Pai -C-C, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. *Cell*. 2019 Apr 4;177(2):414–427.e13.

- [19] Nishino M, Giobbie-Hurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2013 Jul 15;19(14):3936–3943.
- [20] Soluble PD-L1 as a biomarker in malignant melanoma and checkpoint blockade | Cancer immunology research [Internet]. [cited 2019 Feb 12]. Available from: <http://cancerimmunolres.aacrjournals.org/content/early/2017/05/18/2326-6066.CIR-16-0329>
- [21] Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. *J Natl Cancer Inst*. 2016 Mar;108(3), djv330.
- [22] Sage PT, Schildberg FA, Sobel RA, et al. Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function. *J Immunol*. 2018 Apr 15;200(8):2592–2602.
- [23] Gibbons Johnson RM, Dong H. Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. *Front Immunol* [Internet]. 2017 Aug 10;8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC554355/>
- [24] Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front Pharmacol* [Internet]. 2017 Aug 23;8. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572324/>
- [25] Lu C, Redd PS, Lee JR, et al. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. *Oncoimmunology*. 2016;5(12):e1247135.
- [26] Hartley GP, Chow L, Ammons DT, et al. Programmed cell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation. *Cancer Immunol Res*. 2018 Oct;6(10):1260–1273.
- [27] Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) | PNAS [Internet]. [cited 2019 Feb 12]. Available from: <https://www.pnas.org/content/115/43/E10119>
- [28] PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers | Annals of oncology | Oxford academic [Internet]. [cited 2019 Feb 12]. Available from: <https://academic.oup.com/annonc/article-abstract/29/10/2085/5079837>
- [29] Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther*. 2017;16(11):2598–2608.
- [30] Kowanetz M et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). *Proc Natl Acad Sci U S A*. 2018;23;115(43):E10119–E10126.
- [31] Sabari JK, Leonardi GCShu CA, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. *Ann Oncol*. 2018;1;29(10):2085–2091.
- [32] Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in Diverse Cancers. *Mol Cancer Ther*. 2017;16(11):25-98-2608.

## **ANNEXE 2**

### *Membrane-anchored heat-shock protein 70 (Hsp70) in cancer*

Mohammed I.Y. Elmallah, Marine Cordonnier, Valentin Vautrot,

Gaëtan Chanteloup, Carmen Garrido, Jessica Gobbo

*review*



## Mini-review

## Membrane-anchored heat-shock protein 70 (Hsp70) in cancer

Mohammed I.Y. Elmallah<sup>a,b,c,\*</sup>, Marine Cordonnier<sup>a,d</sup>, Valentin Vautrot<sup>a,b,e</sup>,  
Gaëtan Chanteloup<sup>a,d</sup>, Carmen Garrido<sup>a,b,d,\*\*</sup>, Jessica Gobbo<sup>a,b</sup>

<sup>a</sup>INSERM 1231, Label Ligue Nationale contre le Cancer and Label d'excellence LipSTIC, 7 Bd Jeanne d'Arc, 21000, Dijon, France

<sup>b</sup>Anti-cancer Center Georges-François Leclerc, Dijon, France

<sup>c</sup>Chemistry Department, Faculty of Science, Helwan University, 11795, Ain Helwan, Cairo, Egypt

<sup>d</sup>Faculty of Medicine, University of Burgundy-Franche-Comté, France

<sup>e</sup>University of Bourgogne Franche-Comté, EA 3181, France



## ARTICLE INFO

## Keywords:

Membrane Hsp70  
Exosomal Hsp70  
Hsp70 translocation  
Targeting Hsp70

## ABSTRACT

Hsp70 is a highly conserved and inducible heat shock protein that belongs to the *HSP70* family of molecular chaperones and plays a central role in protein homeostasis. The main function of Hsp70 is to protect cells from physiological, pathological and environmental insults, as it assists an ATP-dependent manner the process of protein folding. Since Hsp70 provides critical cell survival functions, cancer cells are assumed to rely on this chaperone. Strong evidence suggests that Hsp70 is upregulated in different type of cancers and is involved in tumor growth, invasion, migration and resistance to anti-cancer therapy. Interestingly, this Hsp70 upregulation induces Hsp70 re-location into plasma membrane. In this review, the role of Hsp70 in cancer will be discussed focusing particularly on the extracellular membrane-bound Hsp70. The mechanism by which Hsp70 is translocated to plasma membrane of tumor cells and the recent discoveries of drugs targeting this Hsp70 in cancer therapy will be also highlighted.

## 1. Introduction

Heat shock protein-70 (Hsp70 also called Hsp72 or HSPA1) is a stress-inducible 70-kDa molecular chaperone of the highly conserved *HSP70* family [1]. The main physiological functions of Hsp70 within the cell are: (1) folding of both nascent and denatured proteins to native state, (2) refolding of intracellular aggregated proteins, and (3) degradation of aggregated proteins by ubiquitin proteasome system or via the process of molecular chaperones-mediated lysosomal autophagy [2]. It can also contribute to several cellular homeostatic events including the transportation of macromolecules like proteins and RNA, secretion, stimulation of signal transduction, regulation of transcription factors, cell division, migration, and differentiation (Fig. 1A) [3]. Structurally, Hsp70 has two distinct domains: a nucleotide-binding domain (NBD) and a substrate binding domain (SBD), where the unfolded peptide binds. Although the molecular mechanism by which Hsp70 assists the folding of denatured proteins into their native state still remains enigmatic, the common suggested mechanism is mainly assigned to the binding of the chaperone to hydrophobic residues of client proteins thereby preventing intermolecular interactions in an ATP-dependent manner [4,5]. In normal unstressed cells, Hsp70 is

expressed at low or undetectable levels. However, its expression is upregulated in response to different types of cellular stress particularly protein damaging conditions like heat shock, oxidative stress, hypoxia, altered pH, and heavy metals [6,7]. A large number of studies including from us describe a cytoprotective role of Hsp70 toward different types of cell death like caspase-dependent/-independent apoptosis, necrosis or autophagic programmed cell death [8–15]. In addition, Hsp70 can be localized on the endolysosomal membrane of transformed cells and plays a major role in the resistance of the cancer cells to lysosomal cathepsine-induced cell death (Fig. 2B) [16]. In cells overexpressing Hsp70 such as cancer cells, Hsp70 can translocate to plasma membrane or can be extracellularly secreted. Although the function of membrane Hsp70 is still largely unknown, it may provide an additional stress inducible role for Hsp70 such as stimulation of antitumor immune responses [10]. Extracellular Hsp70 has been shown to have a protective role against injury in different tissues such as liver and spleen since it stimulates the immune system to remove the unwanted cells from circulation [17]. As Hsp70 may confer survival advantage to tumor cells, several studies revealed Hsp70 major contribution to cancer cell resistant to chemotherapy. This includes *in vitro* resistance to cisplatin in prostate cancer [18], imatinib in chronic myeloid leukemia [19],

\* Corresponding author. INSERM UMR1231 and Center Georges-François Leclerc, 7 Boulevard Jeanne D'ARC, 21000, Dijon, France.

\*\* Corresponding author. INSERM UMR1231 and Center Georges-François Leclerc, 7 Boulevard Jeanne D'ARC, 21000, Dijon, France.

E-mail addresses: [melmallah77@gmail.com](mailto:melmallah77@gmail.com) (M.I.Y. Elmallah), [cgarrido@u-bourgogne.fr](mailto:cgarrido@u-bourgogne.fr) (C. Garrido).

<https://doi.org/10.1016/j.canlet.2019.10.037>

Received 16 August 2019; Received in revised form 18 October 2019; Accepted 22 October 2019  
0304-3835/ © 2019 Elsevier B.V. All rights reserved.





Fig. 1. (A) Illustrating the physiological functions of Hsp70: assists protein folding into its native form, proteasomal degradation of aggregated proteins, transport of client proteins across the cellular membrane, and some other homeostatic events. (B) The suggested role of Hsp70 in different type of cancers. Overexpression of Hsp70 in cancer cells can mediate several oncogenic events like anti-apoptotic response, antitumor immune response, tumor growth, and cell migration.

topotecan and gemcitabine in fibrosarcoma [20], and oxaliplatin and 5-fluorouracil in colon cancer [21,22]. Therefore, Hsp70 inhibition can provide a novel therapeutic strategy to treat different types of cancers by targeting several oncoproteins and signaling pathways required for cancer initiation and progression. In this review, the role of membrane-anchored Hsp70, particularly in cancer, the mechanism by which Hsp70 translocated to plasma membrane and its pharmaceutical targeting in cancer therapy will be discussed.

## 2. Overexpression of Hsp70 in tumor cells

Tumor cells because they have to re-wire their metabolism have a strong need of chaperones for their survival particularly Hsp70. Besides, tumor micro environment (TME) is considered to be a setting where cells are subjected to various types of environmental, physiological and pathophysiological stress including elevated level of oxidative stress, lack of nutrients, hypoxia and increased expression of mutant proteins. These factors are believed to play a central role in cancer initiation and progression [23] and contribute to the overexpression of Hsp70 in different types of cancer cells including hepatocellular



**Fig. 2.** Illustrating the suggested mechanism by which Hsp70 is translocated to plasma membrane. As Hsp70 lacks a consensual sequence necessary for its transportation across plasma membrane through the canonical secretory pathway, it is believed that Hsp70 can be transported within detergent-resistant lipid rich microdomains (DRM). Methyl-β-cyclodextrin can inhibit Hsp70 release, but not classical secretory pathway inhibitor like brefeldin A (BFA).

carcinoma [24], cervical cancers [25], and acute myeloid leukemia [26].

Several *in vivo* and *in vitro* studies revealed that increased expression level of Hsp70 significantly stimulates both tumor growth [27–33] and cell migration [34–39] of different tumor cells (Fig. 2B). Correlation linking Hsp70 increased expression level to cancer development and progression prompted several research scientists to consider Hsp70 as a putative diagnostic biomarker for poor prognosis in cancer. For instance, Hsp70 was reported to be a potential diagnostic marker in hepatocellular carcinoma [40], prostate cancer [41], esophageal adenocarcinoma [42], lymph node metastasis in colorectal carcinoma [34], lung [43], ovarian [44] and breast cancers [45]. Hsp70 expression level has been associated to the clinical stage in melanoma [46], oral cancer [47], and to overall survival in bladder cancer [48]. Moreover, poor survival and prognosis in several tumors like acute myeloid leukemia, breast, and cervical cancers is greatly linked to high staining of Hsp70 in biopsies [49–51].

### 3. Membrane Hsp70

#### 3.1. Mechanism of Hsp70 translocation to the cytoplasmic membrane

The expression of inducible Hsp70 in the membrane of various tumor cells, but not normal cells, was reported by several studies in response to the aforementioned stressful conditions [52–54]. The molecular mechanism by which Hsp70 is translocated to plasma membrane still remains under investigation. However, it is well reported that when anchored, the chaperone only leaves extracellular a 14-amino acid loop (aa 450–463) located in its C-terminal domain (TKD-DNNLLGRFELSG, termed TKD) [55]. Hsp70 protein lacks a consensual

sequence/signal peptide for the canonical (ER/Golgi) secretory pathway. Moreover, the translocation of Hsp70 across the plasma membrane of tumor cell is unaffected by the common inhibitor of the canonical secretory pathway such as brefeldin A (BFA) [56,57]. Here we summarize the suggested mechanisms for Hsp70 translocation to cancer cells plasma membrane (Fig. 2).

The influence of lipid rafts as an alternative molecular transport system on the delivery of Hsp70 to the cell membrane was studied. The isolated soluble and detergent-resistant microdomain (DRM) fractions from colon cancer Caco-2 cell line revealed the localization of Hsp70 in the DRM fraction. Exposure of cells to heat shock treatment obviously increased the Hsp70 expression and its efficient translocation to DRM. It has been also revealed that Caco-2 cells are able to release Hsp70 into culture medium under heat stress conditions. Treating with classical secretory pathway inhibitors did not affect this result. Interestingly, Hsp70 release was disrupted by treating cells with the cholesterol sequestering agent methyl-β-cyclodextrin (MβCD). This result supports the significant impact of DRM on Hsp70 membrane association and release [57]. Similarly, Hunter-Lavin and colleagues [58], also confirmed the Hsp70 release in PBMCs under normal culture conditions. Viable cell count and lactate dehydrogenase enzyme assay indicated that Hsp70 release occurs in the absence of cell damage. Indeed, Hsp70 release was inhibited by treating the cells with MβCD, but not the classical secretory pathway inhibitor BFA. The interaction of Hsp70 with an artificial membrane bilayer mainly consisting of 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS) was investigated. The results displayed a rapid interaction of liposome-incorporated recombinant Hsp70 with the artificial membrane, accompanied by an opening of ion channel conductance. In addition, Hsp70 was detected on the surface of the plasma

membrane of heat-stressed HepG2 using immunostaining with FITC conjugated cmHsp70 monoclonal antibody that targets the TKD peptide of Hsp70. These results indicate that Hsp70 might translocate to the plasma membrane within DRM [59,60]. It has been reported that both Hsp70 proteins, i.e. the stress inducible (Hsp70) and the constitutively expressed (Hsc70), have the ability to interact and to aggregate in an artificial liposome, mainly consisting of phosphatidylserine (PS) in a time and a protein concentration-dependent manners. These results suggested a role for the heat shock proteins in the proper folding of membrane proteins and in client proteins translocation across the membrane [61]. Liposome insertion assay detected the interaction of Hsp70 with liposomes enriched in PS. The authors also reported high molecular weight Hsp70 oligomers following insertion into the lipid bilayer. Moreover, Hsp70 accumulation on the liposomal surface was increased in the presence of PS-enriched saturated fatty acids. The results of this study suggested that Hsp70 interaction with the plasma membrane may favor a rigid membrane structure [62]. Hsp70 can specifically interact with PS moieties on the membrane of pheochromocytoma PC12 cells in the early apoptotic phase. This was accompanied by rapid Hsp70 integration into the cell membrane. Addition of Hsp70 to the medium resulted in a significant reduction of PC12 cell viability. Hsp70 binding to PS was disrupted following cell treatment with annexinV. This suggested a role for Hsp70 in the phospholipid flip flop during early apoptotic cell death [55]. It has been reported that the interaction of Hsp70 with liposomes depends on their lipid compositions. A weak binding of Hsp70 to the liposomal surface that mainly consisting of phosphatidylcholine (PC), was reported. Fluorescence microscopic analysis revealed the insertion of both tryptophan residues W90 and W580 of Hsp70 in the liposome bilayer hydrocarbon region. In contrast, Hsp70 was found to peripherally bind to a liposomal surface mainly consisting of phosphatidylserine, cardiolipin, or bis-monoacylglycerol phosphate [63]. In heat-stressed primary and differentiated adipocytes, Hsp70 was found to be localized within a lipid droplet enriched in a triacylglycerol, cholesterol ester, and surrounded by a monolayer of phospholipids. Alkaline treatment of adipocyte revealed that Hsp70 may bind to droplet surface monolayer through noncovalent interactions. Results suggested the essential role of Hsp70 stabilizing the droplet monolayer, protein transport to lipid droplet, and proper folding of denatured protein on the surface of lipid monolayer [64].

### 3.2. Membrane-anchored Hsp70 in tumor cells

Membrane Hsp70 in cancer cells was reported to have additional stress-inducible roles such as induction of cell survival and contribution to antitumor immune response. These properties are often associated to the membrane Hsp70 extracellular 14 amino acids TKD sequence [55,65,66]. In this context, the role of membrane-associated Hsp70 in the pathogenesis of cancer was investigated. Flow cytometry analysis revealed a significant increase of Hsp70 surface expression level on both dysplasia and carcinoma cells via *in vitro* enhancement of the cytolytic activity of NK cells in oral [67], colon cancer [68] and fibrosarcoma MethA tumors [69]. Increased expression level of another Hsp, Hsp90, was also observed in the membrane of poorly differentiated tumor cells as well as in advanced clinical stage of tumors (T3/T4). *In vitro* activation of NK cells by both Hsp70 peptide (TKD) and interleukin-2 (IL-2) followed by reinfusion of activated cells, greatly enhanced NK cells cytolytic activity against Hsp70 membrane-positive colon carcinoma cells [67]. Activation and maturation of dendritic cells were also found to be mediated by Hsp70 via the TLR4 pathway [70,71]. Elevated Hsp70 level enhances the proliferative responsiveness of T-lymphocytes toward Hsp70 positive in osteosarcoma cell lines [72]. It has also been reported that Hsp70 is localized on the endolysosomal membrane of CX2 human colon carcinoma cells and plays a major role in the resistance of cancer cells to lysosomal cathepsine-induced cell death. Depletion of Hsp70 significantly enhanced lysosomal membrane permeability and subsequent release of hydrolyzing

enzymes to the cytosol, suggesting a pro-survival function of Hsp70 in colon cancer [16].

### 3.3. Membrane Hsp70 in tumor-derived exosomes

Accumulating evidence suggests that Hsp70 can be secreted through extracellular vesicles (EVs), particularly exosomes. These are nanovesicles (50–200 nm) generated within the endosomal compartment by most eukaryotic cells [73,74]. It is well known that tumor cells produce larger number of exosomes when compared to normal cells and the content of the tumor-derived exosomes (TDEs) is quite different from normal cells-derived exosomes. One of the specific surface biomarkers associated with TDEs is the stress protein Hsp70 [75].

It has been reported that Hsp70 interacts with death silencing domain (Bag4) on the surface of colon (CX+) cancer cells-derived exosomes. Localization of Hsp70/Bag4 on the exosomal surface significantly stimulated NK cells migration and cytolytic activity against a Hsp70-positive tumor [76]. Considering possible vaccination strategies against hepatocellular carcinoma, it has been reported that exosomes derived from the chemotherapeutic resistant cell line HepG2 possessed high amounts of Hsp70 both within exosomes and on exosomal membrane. Moreover, exosomes bearing Hsp70 showed immunoregulatory properties by stimulating NK antitumor response and production of granzyme B. Since expression of the inhibitory receptor CD94 was up-regulated, the expression level of activating receptors CD69, NKG2D, and Nkp44 was decreased [77]. The ability of TDEs to stimulate anti-tumor immune response was analyzed in an engineered myeloma (J558HSP) cell line. Cells were manipulated to express the endogenous P1A tumor antigen and membrane-bound Hsp70. It was revealed that exosomal Hsp70 derived from such tumor cell line stimulated the maturation of dendritic cells accompanied by an upregulation of CD40 and CD80 (Fig. 3). Furthermore, immunization of BALB/c inbred mice with TDEs enriched with Hsp70 leads to stimulation of T-helper cells and CD8<sup>+</sup> cytotoxic T-lymphocytes suggesting exosomal Hsp70 antitumor activity [78].

Hsp70-enriched exosomes derived from heat-treated CT26 mouse colon carcinoma cells significantly enhanced antitumor effect of TDEs via the expression of MHC II in an *in vitro* antigen presenting cell model. Investigating the antitumor effect in an allogenic mouse model, authors found a stimulation of Th1-polarization followed by an increased production of IgG2a and Interferon gamma (IFN- $\gamma$ ) [79]. A study was conducted to test the immunomodulatory effect of tumor-derived




Fig. 3. Illustrating the suggested role of tumor-derived exosomal Hsp70 in cancer. The presence of Hsp70 on the membrane of TDEs may exert an anti-tumor immune response via NK cells activation, maturation of DCs-mediated T-cell cytotoxicity, and overexpression of MCHII on the surface of APCs. It can also enhance tumor growth via stimulation of the immune suppressive activity of MDSC and overexpression of phosphorylated STAT3.



exosomal Hsp70 on the suppressive activity of myeloid-derived suppressor cells (MDSCs). It was shown that TDEs enriched in membrane-bound Hsp70 triggered MDSCs activation. This occurred via association of Hsp70 to the toll like receptor 2 (TLR2) on MDSCs, resulting in up-regulation of phosphorylated signal transducer and activator of transcription 3 (STAT3) and autocrine secretion of IL-6 (Fig. 3). These effects were no longer observed if exosomes previously treated with a Hsp70 specific antibody or peptide aptamer binding to the extracellular domain (TKD) of membrane-bound Hsp70. Moreover, treatment of tumor cells with amiloride decreased exosomes production led to the enhancement of the antitumor effect of the chemotherapeutic drug cyclophosphamide [75]. TDEs from the supernatants of Renca cell cultures were found to exhibit more Hsp70 on the membrane. In accord with the previous reports, addition of these Hsp70-exosomes to MDSCs stimulated proinflammatory cytokines activation, tumor growth factors production, and tumor progression. However, this observation was totally reversed when exosomes were preincubated with an anti-Hsp70 antibody. The effect of exosomal Hsp70 on the stimulation of MDSCs suppressive activity via STAT3 phosphorylation was confirmed in renal carcinoma. This mechanism might provide a future therapeutic approach [80]. Our previous results indicated that several cancer cell lines including breast, lung, and ovarian cancer were able to produce high amount of exosomes when compared to their normal counterparts. Moreover, interferometric analysis of exosomes using the Hsp70 aptamer A8 indicated a significant Hsp70 expression on the surface of TDEs from a wide panoply of cancer cell lines, compared to their normal counterparts where membrane Hsp70 remained undetected. Combined treatment of tumor-bearing mice with cisplatin/A8 or 5-fluorouracil/A8, but not single treatments, induced a complete regression of tumor that was linked to the inhibition of Hsp70 immunosuppressive activity, suggesting that Hsp70 role in MDSCs activation may contribute to its overall effect on tumor growth [22].

#### 4. Membrane Hsp70 as a promising target in cancer therapy

The higher metabolic activity of tumor cells associated to the overexpression of oncogenes, mutated proteins and down regulation of tumor suppressor genes explains the essential role of chaperones like Hsp70 in tumor cells survival [81]. Targeting membrane Hsp70 can provide a novel strategy in cancer immunotherapy. Since it is well reported that the amount of Hsp70 in the membrane is dependent on the total cellular amount of Hsp70 (approximately 10% of cytosolic Hsp70 is anchored to plasma membrane [10,22]), here, we will discuss both direct inhibitors, which target the extracellular Hsp70 TKD domain, and indirect inhibitors that target intracellular Hsp70.

The first molecule described targeting specifically inducible Hsp70 was a neutralizing peptide, which contained the apoptosis inducing factor (AIF) domain that interacts with Hsp70. This peptide, known as ADD70 for AIF-derived decoy for Hsp70, was found to sensitize rat colon cancer cells (PROb) and mouse melanoma cells (B16F10) toward apoptosis-induced by cisplatin (see Fig. 4). ADD70 had the ability to bind the substrate binding domain (SBD) of Hsp70 blocking Hsp70-AIF association and subsequent cytoprotective activity [84,85]. 2-Phenylethanesulfonamide (PES), also known as Pifithrin- $\mu$ , is a chemical molecule that blocks Hsp70 by binding to its SBD thereby preventing Hsp70 association with several client proteins like APAF-1 and p53 and its co-chaperone Hsp40 [16]. The molecular mechanism by which PES triggers tumor cell death was mainly attributed to induction of apoptosis, degradation of the misfolded proteins and destabilization of lysosomal membrane [86]. The combined treatment between Pifithrin- $\mu$  and oxaliplatin greatly enhanced the cytotoxic effect of oxaliplatin against both colon (HCT116 and LoVo) and prostate (LNCaP, PC-3, and DU145) cancer cell lines [87]. In addition, PES displayed an obvious cytotoxic effect in several leukemia cell lines in combination with the histone deacetylase inhibitor vorinostat (SAHA) or with the Hsp90 inhibitor, geldanamycin analog (17-AAG) [88]. A similar interesting




Fig. 4. Compounds targeting Hsp70 in cancer therapy. Most of the inhibitors bind to the nucleotide binding domain (NBD) blocking ATPase activity like MAL3-101, A17 aptamer, MKT-088, and VER-155008. The extracellular motif of membrane Hsp70 (TKD) is recognized by the monoclonal antibody cmHsp70 and the aptamer A8. Finally, Pifithrin (PES) and ADD70 target the substrate binding domain (SBD) of Hsp70.

combinational effect was obtained when PES was associated to the proteasome inhibitor bortezomib [89] or MG-132 to treat primary multiple myeloma cells [90]. MAL3-101 is an allosteric Hsp70 inhibitor targeting the nucleotide binding domain (NBD) by inhibiting its ATPase activity. It showed an anti-proliferative effect against breast (SK-BR-3) cancer [91], multiple myeloma [89], and Merkel cell carcinoma [92] cell lines. The adenosine-derived compound VER-155008, a specific Hsp70 inhibitor that blocks NBD, was found to induce apoptotic cell death in colon carcinoma cells [93], and to exert a significant reduction of cell viability in both melanoma [94] and colon cancer [93] cell lines, when combined with the Hsp90 inhibitor tanespimycin. The rhodocyanine dye analog of MKT-077 is also an allosteric Hsp70 inhibitor that binds the NBD. This compound revealed a marked cytotoxic effect in breast cancer MDA-MB-231 and MCF-7 cell lines via destabilization of the chaperone client proteins Akt1 and Raf1 and subsequent apoptosis induction [95].

In a more targeted approach, the monoclonal antibody cmHsp70 was designed to specifically bind the extracellular TKD domain of membrane Hsp70. This antibody showed an antitumor effect in colon tumor bearing BALB/c mice resulting in a significant reduction of tumor growth and an enhancement of overall survival. Moreover, these effects were associated to an increase of NK cells, macrophages, and granulocytes tumor infiltration. The cmHsp70 has also shown efficacy in combination with radiotherapy in NSCLC patients [10]. Concerning Hsp70-peptides-based vaccines, several studies reported the immunogenic potential of oncogenic peptides chaperoned by Hsp70. These peptides showed specific immune response against cancer indicating their broad application in clinical trials. For instance, a Hsp70-peptide complex purified from cell lysates of autologous tumors were evaluated in clinical trials (phase I and II) against different cancer types including malignant melanoma, chronic lymphatic leukemia, glioblastoma, colon carcinoma, NSCLC and HCC. The results revealed a significant immune response in a large number of patients treated either with the Hsp70-peptide complex alone or in combination with certain agents like GM-CSF and IFN- $\gamma$  [97]. Peptide aptamers were also developed to inhibit Hsp70 as novel lead compounds in cancer therapy. For example, A8 is a peptide aptamer that binds to the extracellular TKD domain of membrane Hsp70. As a result, A8 blocks MDSCs activation by TDEs expressing Hsp70 on the surface. Treatment of tumor-bearing mice with A8 has been shown to induce a marked decrease of tumor growth by decreasing number and the activation of splenic MDSCs. Furthermore, this treatment has also been reported to improve

the development of an antitumor immune response via enhancement of the number of anti-tumor macrophages (M1-like) and CD8<sup>+</sup> T cells. When combining with chemotherapeutic treatments such as cisplatin or 5-fluorouracil, the antitumor effect of A8 was further improved [22]. A17 is another peptide aptamer that binds Hsp70 ATP-binding domain, has been shown to exert cytotoxic effects when combined to chemotherapeutic drugs cisplatin in different cancer cell lines and to induce cell death and tumor regression in B16F10 tumor bearing mice [96]. Studies combining A8, to develop an efficient anticancer immune response, and A17 to induce cancer cell death, are currently under investigation. Another phase I clinical trial investigated the stimulatory effect of Hsp70 peptide TKD along with interleukin-2 (IL-2) on NK cells in patients with advanced colorectal and non-small cell lung cancer (NSCLC). Results evidenced that NK cells killed Hsp70-positive tumor cells after activation with TKD and low doses of IL-2 [67]. Recently, targeting membrane-anchored Hsp70 in glioma malignant cells by magnetic nanoparticles (MNPs), such as the biocompatible superparamagnetic iron oxide nanoparticles (SPIONs) loaded with cmHsp70, was found to increase the retention of the nanoparticles within the tumor cells [98,99]. Another *in vitro* study indicated that conjugation of cmHsp70 to gold nanoparticles (AuNPs-Hsp70) enhanced both targeting and uptake of AuNPs-Hsp70 within the membrane Hsp70-positive mouse colon carcinoma (CT26) cells [59,100].

### 5. Concluding remarks

The stress inducible molecular chaperone Hsp70 shows a high level of expression in a great variety of cancers, explaining why TDEs express Hsp70 in their membrane. The process by which a part of cytosolic Hsp70 re-locates to the plasma membrane is still a matter of debated issue, as the protein is deprived of a signal peptide enabling transport via the canonical secretory pathway. Several studies suggested Hsp70 transportation within lipid rich microdomains. Hsp70 can therefore be used as a diagnostic marker for cancers. Clinical results so far indicate that Hsp70 is present in tumor liquid biopsies, notably in circulating TDEs, and is associated with a poor prognosis. From a functional point of view Hsp70 has been involved in cancer initiation and progression. The signaling pathway induced by Hsp70 seems to depend on the type of cancer cells and stress conditions. This include uncontrolled cell proliferation, cytoprotective effect, enhanced cell survival and cell migration. The expression of Hsp70 on the surface of cancer cells was also reported to have additional roles in cancer development. Pharmaceutical targeting of Hsp70 has become an interesting trend towards the development of a novel therapeutic strategies against different types of cancer. Several compounds are now under preclinical evaluation. Molecules specifically targeting membrane Hsp70 (antibodies and peptide aptamers) might have particular interest. Those molecules block Hsp70 activation of MDSCs thereby inducing an efficient anti-cancer immune response. They could be used in combination with any anti-cancer therapy inducing Hsp70 (most chemotherapeutic drugs or Hsp90 inhibitors). Those peptides or antibodies could be used both for therapeutic and diagnosis purposes (to detect circulating Hsp70, particularly nanovesicles expressing Hsp70 on the membrane). These molecules may open new avenues for the use of Hsp70 as a target in cancer theranostics.

### Author contributions

ME, JG, and CG conceived the idea for the review. ME and MC searched the literature and wrote the manuscript. ME and MC generated the figure panels. GC and VV edited the final version of the manuscript.

### Declaration of competing interest

The authors declare no financial conflict.

### Acknowledgments

We thank Isabel Gregoire for carefully reading the manuscript. ME and VV have grants from the Conseil Régional de Bourgogne and a French Government grant managed by the French National Research Agency under the program "Investissements d'Avenir" with reference ANR-11-LABX-0021 (LabEX LipSTIC). MC has a fellowship from La Ligue Contre le Cancer and GC from the Fondation pour la Recherche Médicale. CG's team has the Label Excellence from La Ligue National Contre le Cancer.

### References

- [1] M.P. Mayer, B. Bukau, Hsp70 chaperones: cellular functions and molecular mechanism, *Cell. Mol. Life Sci.* 62 (2005) 670–684, <https://doi.org/10.1007/s0018-004-4464-6>.
- [2] K. Rokutan, Role of heat shock proteins in gastric mucosal protection, *J. Gastroenterol. Hepatol.* 15 (2000) 12–19, <https://doi.org/10.1046/j.1440-1746.2000.02144.x>.
- [3] C. Săfti, C. Pál, B. Papp, P. Csérmely, Molecular chaperones as regulatory elements of cellular networks, *Curr. Opin. Cell Biol.* 17 (2005) 210–215, <https://doi.org/10.1016/j.ccb.2005.02.012>.
- [4] A.P. Ben-Zvi, P. Goloubinoff, Review: mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones, *J. Struct. Biol.* 135 (2001) 84–93, <https://doi.org/10.1006/j.sbi.2001.4352>.
- [5] M.P. Mayer, S. Rüdiger, B. Bukau, Molecular basis for interactions of the DnaK chaperone with substrates, *Biol. Chem.* 381 (2000), <https://doi.org/10.1515/BC.2000.199>.
- [6] K. Juhász, A.-M. Lipp, B. Nimmervoll, A. Sonnleitner, J. Hesse, T. Haselgrueber, Z. Balog, The complex function of Hsp70 in metastatic cancer, *Cancers* 6 (2013) 42–66, <https://doi.org/10.3390/cancers6010042>.
- [7] R.I. Morimoto, Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators, *Genes Dev.* 12 (1998) 3788–3796, <https://doi.org/10.1101/gad.12.24.3788>.
- [8] D.D. Mosser, A.W. Caron, L. Bourget, A.B. Meriin, M.Y. Sherman, R.I. Morimoto, B. Massie, The chaperone function of hsp70 is required for protection against stress-induced apoptosis, *Mol. Cell. Biol.* 20 (2000) 7146–7159, <https://doi.org/10.1128/MCB.20.19.7146-7159.2000>.
- [9] S. Gurbuxani, J.-M. Bruey, A. Fromentin, N. Larmonier, A. Parcellier, M. Jäättelä, F. Martin, E. Solary, C. Garrido, Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells, *Oncogene* 20 (2001) 7478–7485, <https://doi.org/10.1038/sj.onc.1204948>.
- [10] G. Jego, A. Hazoum, R. Seigneuric, C. Garrido, Targeting heat shock proteins in cancer, *Cancer Lett.* 332 (2013) 275–285, <https://doi.org/10.1016/j.canlet.2010.10.014>.
- [11] A.R. Goloudina, O.N. Demidov, C. Garrido, Inhibition of HSP70: a challenging anti-cancer strategy, *Cancer Lett.* 325 (2012) 117–124, <https://doi.org/10.1016/j.canlet.2012.06.003>.
- [12] S. Kumar, J. Stokes, U.P. Singh, K. Scissum Gunn, A. Acharya, U. Manne, M. Mishra, Targeting Hsp70: a possible therapy for cancer, *Cancer Lett.* 374 (2016) 156–166, <https://doi.org/10.1016/j.canlet.2016.01.056>.
- [13] Y.H. Park, J.H. Seo, J.-H. Park, H.S. Lee, K.-W. Kim, Hsp70 acetylation prevents caspase-dependent/independent apoptosis and autophagic cell death in cancer cells, *Int. J. Oncol.* 51 (2017) 573–578, <https://doi.org/10.3892/ijo.2017.4039>.
- [14] S.R. Srinivasan, L.C. Cesa, X. Li, O. Julien, M. Zhuang, H. Shao, J. Chung, I. Maillard, J.A. Wells, C.S. Duckett, J.E. Gestwicki, Heat shock protein 70 (Hsp70) suppresses RIP1-dependent apoptotic and necroptotic cascades, *Mol. Cancer Res.* 16 (2018) 58–68, <https://doi.org/10.1158/1541-7786.MCR-17-0408>.
- [15] K. Nanbu, I. Konishi, M. Mandai, H. Kuroda, A.A. Hamid, T. Komatsu, T. Mori, Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas, *Cancer Detect. Prev.* 22 (1998) 549–555.
- [16] M. Gyrd-Hansen, J. Nylandsted, M. Jäättelä, Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity, *Cell Cycle* 3 (2004) 1484–1485, <https://doi.org/10.4161/cc.3.12.1287>.
- [17] S. Merchant, M. Korbelik, Heat shock protein 70 is acute phase reactant: response elicited by tumor treatment with photodynamic therapy, *Cell Stress Chaperones* 16 (2011) 153–162, <https://doi.org/10.1007/s12192-010-0227-5>.
- [18] A. Ren, G. Yan, B. You, J. Sun, Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells, *Cancer Res.* 68 (2008) 2266–2274, <https://doi.org/10.1158/0008-5472.CCR-07-6248>.
- [19] M. Pocaly, V. Lagarde, G. Etienne, J.-A. Ribeil, S. Claverol, M. Bonneu, F. Moreau-Gaudry, V. Guyonnet-Duperat, O. Hermine, J.V. Melo, M. Dupouy, B. Turcq, F.-X. Mahon, J.-M. Pasquet, Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia, *Leukemia* 21 (2007) 93–101, <https://doi.org/10.1038/sj.leu.2404463>.
- [20] G. Sliutz, J. Karlseder, C. Tempfer, L. Orel, G. Holzer, M.M. Simon, Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitizer in chemotherapy, *Br. J. Canc.* 74 (1996) 172–177, <https://doi.org/10.1038/bjc.1996.334>.
- [21] I. Grivicich, A. Regner, C. Zanoni, L.P. Correa, G.P. Jotz, J.A.P. Henriques,

- G. Schwartzmann, A.B. da Rocha, Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines, *Int. J. Colorectal Dis.* 22 (2007) 1201–1208, <https://doi.org/10.1007/s00384-007-0307-x>.
- [22] J. Gobbo, G. Marcion, M. Cordonnier, A.M.M. Dias, N. Pernet, A. Hammann, S. Richaud, H. Mjahed, N. Isambert, V. Clause, C. Rébé, A. Bertaut, V. Goussot, F. Lirussi, F. Ghiringhelli, A. de Thonel, P. Fumoleau, R. Seignuric, C. Garrido, Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer, *J. Natl. Cancer Inst.* 108 (2016) djv330, <https://doi.org/10.1093/jnci/djv330>.
- [23] K. Xie, S. Huang, Regulation of cancer metastasis by stress pathways, *Clin. Exp. Metastasis* 20 (2003) 31–43.
- [24] M. Chuma, N. Sasaki, Y. Yamamoto, T. Ohta, M. Asaka, S. Hirohashi, M. Sakamoto, Expression profiling in the hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis, *Keio J. Med.* 53 (2004) 90–97, <https://doi.org/10.2302/kjm.53.90>.
- [25] M. Garg, D. Kanojia, S. Saini, S. Suri, A. Gupta, A. Suroliya, A. Suri, Germ cell-specific heat shock protein 70-2 is expressed in cervical carcinoma and is involved in the growth, migration, and invasion of cervical cells, *Cancer* 116 (2010) 3785–3796, <https://doi.org/10.1002/ncr.25218>.
- [26] I.D. Chant, P.E. Rose, A.G. Morris, Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry, *Br. J. Haematol.* 90 (1995) 163–168, <https://doi.org/10.1111/j.1365-2141.1995.tb03395.x>.
- [27] Y. Tao, J.S. Messer, K.H. Goss, J. Hart, M. Bissonnette, E.B. Chang, Hsp70 exerts oncogenic activity in the Apc mutant Min mouse model, *Carcinogenesis* 37 (2016) 731–739, <https://doi.org/10.1093/carcin/bgw056>.
- [28] M. Rohde, Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms, *Genes Dev.* 19 (2005) 570–582, <https://doi.org/10.1101/gad.305405>.
- [29] M. Joo, J.G. Chi, H. Lee, Expressions of HSP70 and HSP27 in hepatocellular carcinoma, *J. Korean Med. Sci.* 20 (2005) 829–834, <https://doi.org/10.3346/jkms.2005.20.5.529>.
- [30] J. Xiong, X.-M. Jiang, S.-S. Mao, X.-N. Yu, X.-X. Huang, Heat shock protein 70 downregulation inhibits proliferation, migration and tumorigenicity in hepatocellular carcinoma cells, *Oncol. Lett.* 14 (2017) 2703–2708, <https://doi.org/10.3892/ol.2017.6531>.
- [31] Z.-G. Zhao, Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901, *World J. Gastroenterol.* 11 (2005) 73, <https://doi.org/10.3748/wjg.v11.i1.73>.
- [32] J. Xu, K. Wang, X. Zhang, Y. Qiu, D. Huang, W. Li, X. Xiao, Y. Tian, HSP70: a promising target for laryngeal carcinoma radiotherapy by inhibiting cleavage and degradation of nucleolin, *J. Exp. Clin. Cancer Res.* 29 (2010) 106, <https://doi.org/10.1186/1756-9966-29-106>.
- [33] J. Jang, M.R. Kim, T.-K. Kim, W.R. Lee, J.H. Kim, K. Heo, S. Lee, CLEC14a-HSP70-1A interaction regulates HSP70-1A-induced angiogenesis, *Sci. Rep.* 7 (2017), <https://doi.org/10.1038/s41598-017-11118-y>.
- [34] T.S. Hwang, H.S. Han, H.K. Choi, Y.J. Lee, Y.-J. Kim, M.-Y. Han, Y.-M. Park, Differential, stage-dependent expression of Hsp70, Hsp110 and Bcl-2 in colorectal cancer, *J. Gastroenterol. Hepatol.* 18 (2003) 690–700, <https://doi.org/10.1046/j.1440-1746.2003.03011.x>.
- [35] L.K. Borroughs, M.A. Antonyak, J.L. Johnson, R.A. Cerione, A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration, *J. Biol. Chem.* 286 (2011) 37094–37107, <https://doi.org/10.1074/jbc.M111.242438>.
- [36] H. Li, Y. Li, D. Liu, H. Sun, D. Su, F. Yang, J. Liu, Extracellular HSP70/HSP70-PCs promote epithelial-mesenchymal transition of hepatocarcinoma cells, *PLoS One* 8 (2013) e84759, <https://doi.org/10.1371/journal.pone.0084759>.
- [37] W. Wen, W. Liu, Y. Shao, L. Chen, VER-155008, a small molecule inhibitor of HSP70 with potent anti-cancer activity on lung cancer cell lines, *Exp. Biol. Med.* 239 (2014) 638–645, <https://doi.org/10.1177/1535370214527899>.
- [38] H. Jin, Q. Xie, X. Guo, J. Xu, A. Wang, J. Li, J. Zhu, X.-R. Wu, H. Huang, C. Huang, p63 $\alpha$  protein up-regulates heat shock protein 70 expression via E2F1 transcription factor 1, promoting Wnt3/Wave3/MMP9 signaling and bladder cancer invasion, *J. Biol. Chem.* 292 (2017) 15952–15963, <https://doi.org/10.1074/jbc.M117.792010>.
- [39] P. Kasioumi, P. Vrazelli, P. Vezyraki, S. Zerikiotis, C. Katsouras, A. Damalas, C. Angelidis, Hsp70 (HSP70A1A) downregulation enhances the metastatic ability of cancer cells, *Int. J. Oncol.* (2018), <https://doi.org/10.3892/ijo.2018.4666>.
- [40] M. Sakamoto, Early HCC: diagnosis and molecular markers, *J. Gastroenterol.* 44 (2009) 108–111, <https://doi.org/10.1007/s00535-008-2245-y>.
- [41] Alan So, Boris Hadaschik, Richard Sowery, Martin Gleave, The role of stress proteins in prostate cancer, *Curr. Genom.* 8 (2007) 252–261, <https://doi.org/10.2174/138920207781386951>.
- [42] H.K. Söderström, J.T. Kauppi, N. Oksala, T. Paavonen, L. Krogerus, J. Räsänen, T. Rantanen, Overexpression of HSP27 and HSP70 is associated with decreased survival among patients with esophageal adenocarcinoma, *World J. Clin. Cases.* 7 (2019) 260–269, <https://doi.org/10.12998/wjcc.v7.i3.260>.
- [43] E. Maluscka, S. Krzyzowska-Gruca, J. Gawrychowski, A. Fiszer-Kierzkowska, Z. Kozloska, Z. Krawczyk, Stress proteins HSP27 and HSP70 predict survival in non-small cell lung carcinoma, *Anticancer Res.* (2008) 6.
- [44] P. Athanassiadou, E. Petrakakou, V. Sakelariou, C. Zerva, A. Liossi, S. Michalakis, P. Athanassiadis, Expression of p53, bcl-2 and heat shock protein (hsp72) in malignant and benign ovarian tumours, *Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ. ECP.* 7 (1998) 225–231.
- [45] N. Gupta, N. Jagadish, A. Suroliya, A. Suri, Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer, *Am. J. Cancer Res.* 7 (2017) 1252–1269.
- [46] A.C. Lazaris, G.E. Theodoropoulos, K. Aroni, A. Saetta, P.S. Davaris, Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma, *Virchows Arch.* 426 (1995), <https://doi.org/10.1007/BF00193169>.
- [47] J. Kaur, A. Srivastava, R. Ralhan, Expression of 70-kDa heat shock protein in oral lesions: marker of biological stress or pathogenicity, *Oral Oncol.* 34 (1998) 496–501, [https://doi.org/10.1016/S1368-8375\(98\)00064-5](https://doi.org/10.1016/S1368-8375(98)00064-5).
- [48] K.N. Syrigos, K.J. Harrington, A.J. Karayiannakis, E. Sekara, E. Chatzivianni, E.I. Syrigou, J. Waxman, Clinical significance of heat shock protein-70 expression in bladder cancer, *Urology* 61 (2003) 677–680, [https://doi.org/10.1016/S0090-4295\(02\)2289-6](https://doi.org/10.1016/S0090-4295(02)2289-6).
- [49] T.F. pubmeddeval et, Heat-shock protein 70 as a prognostic marker in node-negative breast cancer. - PubMed - NCBI, n.d. <http://www.ncbi.nlm.nih.gov/pubmed/12820347>, Accessed date: 20 July 2019.
- [50] K. Kawanishi, H. Shiozaki, Y. Doki, I. Sakita, M. Inoue, M. Yano, T. Tsujinaka, A. Shamma, M. Monden, Prognostic significance of heat shock proteins 27 and 70 in patients with squamous cell carcinoma of the esophagus, *Cancer* 85 (1999) 1649–1657, [https://doi.org/10.1002/\(SICI\)1097-0142\(19990415\)85:8<1649::AID-CNCR2>3.0.CO;2-V](https://doi.org/10.1002/(SICI)1097-0142(19990415)85:8<1649::AID-CNCR2>3.0.CO;2-V).
- [51] X. Thomas, L. Campos, C. Mounier, J. Cornillon, Q.-H. Le, S. Piselli, D. Guyot, Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia, *Leuk. Res.* 29 (2005) 1049–1058, <https://doi.org/10.1016/j.leukres.2005.02.010>.
- [52] I. Guzhova, K. Kislyakova, O. Moskaliova, I. Fridlanskaya, M. Tytell, M. Cheetham, B. Margulis, In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance, *Brain Res.* 914 (2001) 66–73, [https://doi.org/10.1016/S0006-8993\(01\)02774-3](https://doi.org/10.1016/S0006-8993(01)02774-3).
- [53] M.A. Febbraio, P. Ott, H.B. Nielsen, A. Steensberg, C. Keller, P. Krustrup, N.H. Secher, B.K. Pedersen, Exercise induces hepatoplanchnic release of heat shock protein 72 in humans, *J. Physiol.* 544 (2002) 957–962, <https://doi.org/10.1113/jphysiol.2002.025148>.
- [54] M. Fleshner, J. Campisi, L. Amiri, D.M. Diamond, Cat exposure induces both intracellular and extracellular Hsp72: the role of adrenal hormones, *Psychoneuroendocrinology* 29 (2004) 1142–1152, <https://doi.org/10.1016/j.psyneuen.2004.01.007>.
- [55] N. Arispe, M. Doh, O. Simakova, B. Kurganov, A. De Maio, Hsc70 and Hsp70 interact with phosphatidyserine on the surface of PC12 cells resulting in a decrease of viability, *FASEB J.* 18 (2004) 1636–1645, <https://doi.org/10.1096/fj.04-2088.com>.
- [56] L.E. Hightower, P.T. Guidon, Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins, *J. Cell. Physiol.* 138 (1989) 257–266, <https://doi.org/10.1002/jcp.1041380206>.
- [57] A.H. Broquet, G. Thomas, J. Masliyah, G. Trugman, M. Bachellet, Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release, *J. Biol. Chem.* 278 (2003) 21601–21606, <https://doi.org/10.1074/jbc.M302326200>.
- [58] C. Hunter-Lavin, E.L. Davies, M.M.F.V.G. Bacelar, M.J. Marshall, S.M. Andrew, J.H.H. Williams, Hsp70 release from peripheral blood mononuclear cells, *Biochem. Biophys. Res. Commun.* 324 (2004) 511–517, <https://doi.org/10.1016/j.bbrc.2004.09.075>.
- [59] M. Gehrman, M. Kimm, S. Stangl, T. Schmid, P. Noël, E. Rummeny, G. Multhoff, Imaging of Hsp70-positive tumors with cmHsp70.1 antibody-conjugated gold nanoparticles, *Int. J. Nanomed.* (2015) 5687, <https://doi.org/10.2147/IJN.S87174>.
- [60] V.L. Vega, M. Rodriguez-Silva, T. Frey, M. Gehrman, J.C. Diaz, C. Steinem, G. Multhoff, N. Arispe, A. De Maio, Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages, *J. Immunol.* 180 (2008) 4299–4307, <https://doi.org/10.4049/jimmunol.180.6.4299>.
- [61] N. Arispe, M. Doh, A. De Maio, Lipid interaction differentiates the constitutive and stress-induced heat shock proteins Hsc70 and Hsp70, *Cell Stress Chaperones* 7 (2002) 330, [https://doi.org/10.1379/1466-1268\(2002\)007<0330:LIIDTCA>2.0.CO;2](https://doi.org/10.1379/1466-1268(2002)007<0330:LIIDTCA>2.0.CO;2).
- [62] G. Armijo, J. Okerblom, D.M. Cauvi, V. Lopez, D.E. Schlamadinger, J. Kim, N. Arispe, A. De Maio, Interaction of heat shock protein 70 with membranes depends on the lipid environment, *Cell Stress Chaperones* 19 (2014) 877–886, <https://doi.org/10.1007/s12192-014-0511-x>.
- [63] A.K. Mahalka, T. Kirkegaard, L.T.I. Jukola, M. Jäättelä, P.K.J. Kinnunen, Human heat shock protein 70 (Hsp70) as a peripheral membrane protein, *Biochim. Biophys. Acta BBA - Biomembr.* 1838 (2014) 1344–1361, <https://doi.org/10.1016/j.bbmem.2014.01.022>.
- [64] H. Jiang, J. He, S. Pu, C. Tang, G. Xu, Heat shock protein 70 is translocated to lipid droplets in rat adipocytes upon heat stimulation, *Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids.* 1771 (2007) 66–74, <https://doi.org/10.1016/j.bbalip.2006.10.004>.
- [65] G. Multhoff, C. Botzler, M. Wiesner, G. Eissner, R. Issels, CD3<sup>+</sup> large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells, *Blood* 86 (1995) 1374–1382.
- [66] G. Multhoff, K. Pfister, M. Gehrman, M. Hantschel, C. Gross, M. Hafner, W. Hiddemann, A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity, *Cell Stress Chaperones* 6 (2001) 337, [https://doi.org/10.1379/1466-1268\(2001\)006<0337:AMHPSN>2.0.CO;2](https://doi.org/10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2).
- [67] S.W. Krause, Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial, *Clin. Cancer Res.* 10 (2004) 3699–3707, <https://doi.org/10.1158/1078-0432.CCR-03-0683>.
- [68] L. Taglia, D. Matusiak, R.V. Benya, GRP-induced up-regulation of Hsp72 promotes CD16<sup>+</sup>/94<sup>+</sup> natural killer cell binding to colon cancer cells causing tumor cell cytotoxicity, *Clin. Exp. Metastasis* 25 (2008) 451–463, <https://doi.org/10.1007/>

- s10585-008-9151-9.
- [69] P.R. Clark, A. Ménotet, The inducible Hsp70 as a marker of tumor immunogenicity, *Cell Stress Chaperones* 6 (2001) 121, [https://doi.org/10.1379/1466-1268\(2001\)006<0121:TIHAAM>2.0.CO;2](https://doi.org/10.1379/1466-1268(2001)006<0121:TIHAAM>2.0.CO;2).
- [70] M.-F. Tsan, B. Gao, Heat shock proteins and immune system, *J. Leukoc. Biol.* 85 (2009) 905–910, <https://doi.org/10.1189/jlb.0109005>.
- [71] T. Chen, J. Guo, C. Han, M. Yang, X. Cao, Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway, *J. Immunol.* 182 (2009) 1449–1459, <https://doi.org/10.4049/jimmunol.182.3.1449>.
- [72] K. Trieb, S. Lang, R. Kotz, Heat-shock protein 72 IN human osteosarcoma: T-lymphocyte reactivity and cytotoxicity, *Pediatr. Hematol. Oncol.* 17 (2000) 355–364, <https://doi.org/10.1080/08880010050034283>.
- [73] M.P. Bebelman, M.J. Smit, D.M. Pegtel, S.R. Baglio, Biogenesis and function of extracellular vesicles in cancer, *Pharmacol. Ther.* 188 (2018) 1–11, <https://doi.org/10.1016/j.pharmthera.2018.02.013>.
- [74] M. Colombo, G. Raposo, C. Théry, Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles, *Annu. Rev. Cell Dev. Biol.* 30 (2014) 255–289, <https://doi.org/10.1146/annurev-cellbio-101512-122326>.
- [75] F. Chalmin, S. Ladoire, G. Mignot, J. Vincent, M. Bruchard, J.-P. Remy-Martin, W. Boireau, A. Rouleau, B. Simon, D. Lanneau, A. De Thonel, G. Multhoff, A. Hamman, F. Martin, B. Chauffert, E. Solary, L. Zitvogel, C. Garrido, B. Ryffel, C. Borg, L. Apetoh, C. Rébé, F. Ghiringhelli, Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells, *J. Clin. Investig.* (2010), <https://doi.org/10.1172/JCI40483>.
- [76] R. Gastpar, M. Gehrmann, M.A. Bausero, A. Asea, C. Gross, J.A. Schroeder, G. Multhoff, Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells, *Cancer Res.* 65 (2005) 5238–5247, <https://doi.org/10.1158/0008-5472.CAN-04-3804>.
- [77] L.-H. Lv, Y.-L. Wan, Y. Lin, W. Zhang, M. Yang, G.-L. Li, H.-M. Lin, C.-Z. Shang, Y.-J. Chen, J. Min, Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses *in vitro*, *J. Biol. Chem.* 287 (2012) 15874–15885, <https://doi.org/10.1074/jbc.M112.340588>.
- [78] Y. Xie, O. Bai, H. Zhang, J. Yuan, S. Zong, R. Chibbar, K. Slattery, M. Qureshi, Y. Wei, Y. Deng, J. Xiang, Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumor immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70, *J. Cell Mol. Med.* 14 (2010) 2655–2666, <https://doi.org/10.1111/j.1582-4934.2009.00851.x>.
- [79] J. Cho, Y.-S. Lee, S.-H. Kim, J.-K. Ko, C.-W. Kim, MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models, *Cancer Lett.* 275 (2009) 256–265, <https://doi.org/10.1016/j.canlet.2008.10.021>.
- [80] J. Diao, X. Yang, X. Song, S. Chen, Y. He, Q. Wang, G. Chen, C. Luo, X. Wu, Y. Zhang, Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3, *Med. Oncol.* 32 (2015), <https://doi.org/10.1007/s12032-014-0453-2>.
- [81] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, *Cell* 144 (2011) 646–674, <https://doi.org/10.1016/j.cell.2011.02.013>.
- [82] S. Gurbuxani, E. Schmitt, C. Cande, A. Parcellier, A. Hammann, E. Daugas, I. Kouranti, C. Spahr, A. Pance, G. Kroemer, C. Garrido, Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor, *Oncogene* 22 (2003) 6669–6678, <https://doi.org/10.1038/sj.onc.1206794>.
- [83] E. Schmitt, L. Maingret, P.-E. Puig, A.-L. Rerole, F. Ghiringhelli, A. Hammann, E. Solary, G. Kroemer, C. Garrido, Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma, *Cancer Res.* 66 (2006) 4191–4197, <https://doi.org/10.1158/0008-5472.CAN-05-3778>.
- [84] J.L.-J. Leu, J. Pimkina, A. Frank, M.E. Murphy, D.L. George, A small molecule inhibitor of inducible heat shock protein 70, *Mol. Cell* 36 (2009) 15–27, <https://doi.org/10.1016/j.molcel.2009.09.023>.
- [85] A. McKeon, A. Egan, J. Chandanshive, H. McMahon, D. Griffith, Novel improved synthesis of HSP70 inhibitor, pifithrin- $\mu$ . In vitro synergy quantification of pifithrin- $\mu$  combined with Pt drugs in prostate and colorectal cancer cells, *Molecules* 21 (2016) 949, <https://doi.org/10.3390/molecules21070949>.
- [86] M. Kaiser, A. Kühnl, J. Reins, S. Fischer, J. Ortiz-Tanchez, C. Schlee, L.H. Mochmann, S. Heesch, O. Benlasfer, W.-K. Hofmann, E. Thiel, C.D. Baldus, Antileukemic activity of the HSP70 inhibitor pifithrin- $\mu$  in acute leukemia, *Blood Canc. J.* 1 (2011), <https://doi.org/10.1038/bcj.2011.28.e28-e28>.
- [87] M.J. Braunstein, S.S. Scott, C.M. Scott, S. Behrman, P. Walter, P. Wipf, J.D. Coplan, W. Chrico, D. Joseph, J.L. Brodsky, O. Batuman, Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101, *J. Oncol.* 2011 (2011) 1–11, <https://doi.org/10.1155/2011/232037>.
- [88] H. Whetstone, C. Lingwood, 3'Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity *in vitro*, *Biochemistry* 42 (2003) 1611–1617, <https://doi.org/10.1021/bi026735t>.
- [89] A. Rodina, M. Vilenchik, K. Moulick, J. Aguirre, J. Kim, A. Chiang, J. Litz, C.C. Clement, Y. Kang, Y. She, N. Wu, S. Felts, P. Wipf, J. Massague, X. Jiang, J.L. Brodsky, G.W. Krystal, G. Chiosis, Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer, *Nat. Chem. Biol.* 3 (2007) 498–507, <https://doi.org/10.1038/nchembio.2007.10>.
- [90] C. Adam, A. Baeurle, J.L. Brodsky, P. Wipf, D. Schrama, J.C. Becker, R. Houben, The HSP70 modulator MAL3-101 inhibits Merkel cell carcinoma, *PLoS One* 9 (2014) e92041, <https://doi.org/10.1371/journal.pone.0092041>.
- [91] A.J. Massey, D.S. Williamson, H. Browne, J.B. Murray, P. Dokurno, T. Shaw, A.T. Macias, Z. Daniels, S. Geoffroy, M. Denson, P. Lavan, N. Matassova, G.L. Francis, C.J. Graham, R. Parsons, Y. Wang, A. Padfield, M. Comer, M.J. Drysdale, M. Wood, A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells, *Cancer Chemother. Pharmacol.* 66 (2010) 535–545, <https://doi.org/10.1007/s00280-009-1194-3>.
- [92] M. Chatterjee, M. Andrusis, T. Stuhmer, E. Müller, C. Hofmann, T. Steinbrunn, T. Heimerger, H. Schraud, S. Kressmann, H. Einsle, R.C. Bargou, The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma, *Haematologica* 98 (2013) 1132–1141, <https://doi.org/10.3324/haematol.2012.066175>.
- [93] X. Li, S.R. Srinivasan, J. Connarn, A. Ahmad, Z.T. Young, A.M. Kabza, Erik R.P. Zuderweg, D. Sun, J.E. Gestwicki, Analogues of the allosteric heat shock protein 70 (Hsp70) inhibitor, MKT-077, as anti-cancer agents, *ACS Med. Chem. Lett.* 4 (2013) 1042–1047, <https://doi.org/10.1021/ml400204n>.
- [94] Correction, Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy, *Cancer Res.* 75 (2015), <https://doi.org/10.1158/0008-5472.CAN-15-0042> 902–902.
- [95] S. M. M. G. Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer, *Front. Immunol* 7 (2016), <https://doi.org/10.3389/fimmu.2016.00171>.
- [96] S. MA, N. BP, et al., Recombinant Interleukin-1 Receptor Antagonist Conjugated to Superparamagnetic Iron Oxide Nanoparticles for Theranostic Targeting of Experimental Glioblastoma, *Neoplasia* (2015) 32–42, <https://doi.org/10.1016/j.neo.2014.11.001>.
- [97] S. MA, Y. LY, N. BP, et al., Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma, *Neuro-Oncol* 16 (2014) 38–49, <https://doi.org/10.1093/neuonc/not141>.
- [98] S. M. H. G. M. G. Membrane heat shock protein 70: a theranostic target for cancer therapy, *Philos. Trans. R. Soc. B Biol. Sci* 373 (2018), <https://doi.org/10.1098/rstb.2016.0526>.

## **ANNEXE 3**

### *Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer*

*Valentin Vautrot, Gaëtan Chanteloup, Mohammed Elmallah,  
Marine Cordonnier, François Aubin, Carmen Garrido,  
and Jessica Gobbo  
review*

## Review Article

# Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer

Valentin Vautrot <sup>1,2,3</sup> Gaëtan Chanteloup <sup>1,4</sup> Mohammed Elmallah <sup>1,3,5</sup>  
Marine Cordonnier <sup>1,4</sup> François Aubin <sup>2,6</sup> Carmen Garrido <sup>1,3,4</sup>  
and Jessica Gobbo <sup>1,3</sup>

<sup>1</sup>INSERM 1231, Label Ligue Nationale Contre le Cancer and Label d'excellence LipSTIC, Dijon, France

<sup>2</sup>University of Bourgogne Franche-Comté, EA 318, Besançon, France

<sup>3</sup>Anti-cancer Center Georges-François Leclerc, Dijon, France

<sup>4</sup>Faculty of Medicine, University of Burgundy-Franche-Comté, France

<sup>5</sup>Chemistry Department, Faculty of Science, Helwan University, 11795 Ain Helwan, Cairo, Egypt

<sup>6</sup>Centre Hospitalier Universitaire, Besançon, France

Correspondence should be addressed to Jessica Gobbo; [jgobbo@cgfl.fr](mailto:jgobbo@cgfl.fr)

Received 24 May 2019; Accepted 10 August 2019; Published 13 October 2019

Guest Editor: Nathaniel Weygant

Copyright © 2019 Valentin Vautrot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colorectal cancer (CRC) is one of the major causes of cancer-related deaths worldwide. Tumor microenvironment (TME) contains many cell types including stromal cells, immune cells, and endothelial cells. The TME modulation explains the heterogeneity of response to therapy observed in patients. In this context, exosomes are emerging as major contributors in cancer biology. Indeed, exosomes are implicated in tumor proliferation, angiogenesis, invasion, and premetastatic niche formation. They contain bioactive molecules such as proteins, lipids, and RNAs. More recently, many studies on exosomes have focused on miRNAs, small noncoding RNA molecules able to influence protein expression. In this review, we describe miRNAs transported by exosomes in the context of CRC and discuss their influence on TME and their potential as circulating biomarkers. This overview underlines emerging roles for exosomal miRNAs in cancer research for the near future.

## 1. Introduction

Colorectal cancer (CRC) is the second leading cause of cancer death in men and the third in women in Europe [1]. 772,000 newly diagnosed cases were registered in 2018, and the estimated number of CRC-related deaths is 242,000. Recently, despite the development of therapies revolutionizing cancer treatment like immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies), clinical prognosis in CRC remains unsatisfactory, with a 5-year survival rate neighboring 13% at the metastatic stage IV of the disease [2]. An area of study carrying hope for future therapies is the understanding of the relationship between patient prognosis and tumor landscape in primary colorectal tumors. Genetic and epigenetic background of the tumor, as well as tumor microenvironment (TME) composition, are

the main factors explaining heterogeneity of response to therapy observed in patients. The TME contains many cell types including stromal cells, immune cells, and endothelial cells. The resulting intra- or intertumoral heterogeneity is of prime importance for all aspects of tumor metabolism and explains the differences in tumor abilities to proliferate, invade, and escape therapy [3–6].

In this context, exosomes are emerging as major contributors in cancer biology. Exosomes are lipid-bilayer, cup-shaped nanovesicles (diameter: ~50–150 nm) secreted by cells and originating from the endosomal pathway. Exosome release is a common mechanism, and a broad range of cells secrete exosomes, including tumor cells. As a result, exosomes have been detected in a wide variety of biological fluids (e.g., blood, urine, saliva, malignant ascites, and breast milk) [7, 8]. Cumulative evidence suggests that exosomes

can establish a fertile environment to support tumor proliferation, angiogenesis, invasion, and premetastatic niche formation. Moreover, they may also facilitate tumor growth and metastasis by inhibiting immune surveillance and by increasing chemoresistance via removal of chemotherapeutic drugs. It has been often reported that tumor cells generate more exosomes than normal cells and that circulating exosome levels are increased in the blood of cancer patients when compared to healthy individuals [9–11]. These features make exosomes interesting reservoirs of potential cancer biomarkers such as proteins, lipids, and RNAs. Although there are some CRC tumor markers used worldwide, there is a particular need for new biomarkers due to technical constraints concerning their detection [12]. In this context, exosomes have become in the last few years an important area of research.

Given their role in TME, exosomes have an essential function in cell-to-cell communication, but they also have specific biological functions. The bioactive cargos received by a recipient cell can modify its physiology by tempering with a vast range of processes [13–17]. Exosomes are implicated in tumor cell proliferation [18], increased migration and invasive properties [19–21], resistance to chemotherapy [22], angiogenesis [23], and escape from the immune system [24]. Although miRNA proportion in exosomes may drastically change depending on the physiological context, tissue, or cell type, they often represent one of the predominant RNAs contained in exosomes [25–27]. Exosomes protect miRNAs from degradation, enabling them to be stably expressed in the extracellular space and to be efficiently integrated by specific recipient cells [28]. Consequently, exosomal miRNAs are also deeply implicated in cancer progression. Therefore, modification or inhibition of exosomal miRNAs might be a potential therapeutic strategy in cancer. In this review, we focus on the impact of miRNA on TME in CRC. First, a description of miRNAs and their biogenesis will be presented, followed by a description of exosome biogenesis and composition. We will conclude by a description of the action of exosomal miRNAs in CRC.

## 2. miRNAs

miRNAs are short single-stranded noncoding RNAs, with a size varying generally between 18 nt and 25 nt (usually 22 nt), that possess the ability to bind complementary target messenger RNAs (mRNAs). miRNAs can induce either translational repression or sometimes degradation of their mRNA targets, thereby constituting a crucial part of post-transcriptional regulation of mRNA expression. Several studies reported the importance of miRNAs in cancer progression, including tumor proliferation, invasion, migration, cell survival, regulation of the immune response, angiogenesis, epithelial-mesenchymal transition (EMT), and cellular stemness [29–35].

In the canonical pathway, miRNAs are at first expressed by the RNA polymerase II as immature stem-loop structure-containing precursors, known as pri-miRNA, of a few hundred to several thousand nucleotides long [36]. However, some pri-miRNAs can be transcribed by RNA

polymerase III and some, like miRtrons, are not issued from dedicated transcriptional units but are matured from mRNA introns. A whole cellular machinery is devoted to their processing and nucleocytoplasmic export into functional cytoplasmic miRNAs. First, pri-miRNA precursors are processed into smaller stem-loop pre-miRNAs (approx. 70 nt) by the Microprocessor complex [37]. This complex consists of the Drosha protein, carrying the RNase activity and DGCR8, that helps determining the proper endonucleolytic cleavage site [38, 39]. Pre-miRNAs are then recognized and exported to the cytoplasm by Exportin-5, where they undergo further endonucleolytic cleavage at the extremities of the stem structure by the RNase Dicer [40]. The resulting product corresponds to a duplex of 2 complementary miRNAs, the leading strand miRNA or 5p miRNA (formerly at the 5' extremity of the pre-miRNA) and the passenger strand or 3p or star (\*) miRNA (formerly at the 3' extremity of the pre-miRNA). This duplex is loaded into a protein complex containing notably Argonaute protein (Ago2), which retains only one of the 2 miRNA strands to form the functionally active RISC complex [41]. The miRNA within RISC complex can recognize and bind to a crucial guide sequence in the target mRNA, located in the vast majority of cases in the 3'-untranslated region (3'-UTR). This sequence, called "seed," corresponds typically to the position 2 to 8 at the 5' extremity of the miRNA [42]. Mostly, miRNA pairing with its target is rather imperfect and leads to translational repression or destabilization of the mRNA target [43, 44]. Occasionally, complementarity with the mRNA target is almost total, leading to mRNA cleavage and degradation [45]. As of today, there are around 2,000 entries for human miRNAs in the miRBase database (v22.1) (<http://www.mirbase.org/index.shtml>). Even if the function of most of them is still unknown, miRNAs are predicted to target most existing mRNAs. Over the years, evidence for their involvement in almost all biological processes accumulated, especially concerning their ability to target oncogenic or tumor suppressor genes in multiple cancer-related cellular pathways [46, 47]. miRNAs are present in significant proportions in blood (and several biological fluids such as saliva, urine, and semen), either incorporated in nucleoprotein complexes with Ago2 protein, nucleophosmin1 protein, within high-density lipoproteins (HDL) particles, or finally encapsulated within exosomes or other extracellular vesicles (EVs) [48–50].

## 3. Exosome Biogenesis and Composition

Exosome biogenesis is initiated by inward membrane invagination of early endosomes to form intracellular multivesicular bodies (MVBs) and then released into the extracellular environment by MVB fusion with the plasma membrane (Figure 1). They differ from other EVs, like ectosomes, which are created by outward budding of the plasma membrane, and apoptotic bodies created during the apoptosis process [51]. Using complex signaling and molecular machineries, like the Endosomal Sorting Complex Required for Transport (ESCRT), newly forming exosomes can incorporate various biologically active molecules. These




FIGURE 1: Scheme of exosome biogenesis, composition, and major role in TME modification, in the context of CRC. The biogenesis of exosomes involves 4 different steps: (1) the membrane invagination; (2) endosome formation; (3) generation of the exosome precursors, called intraluminal vesicles (ILVs), by inward budding of endosomes (these accumulations of ILVs are termed as multivesicular bodies (MVBs)); and (4) the fusion of MVBs with the plasma membrane release the ILVs in the extracellular space by exocytosis and become exosomes. Composition: exosomes are composed of different types of enzymes and proteins involved in adhesion, intracellular signaling, immunostimulatory molecules, multivesicular body (MVB) formation, and heat shock proteins (HSPs). Exosomes contain nucleic acids, including miRNA, mRNA, DNA, and small noncoding RNA (snRNA and tRNA). In addition to direct interactions between CRC cells and TME, exosomes, especially exosomal miRNAs, play a key role in the cross talk between cells in TME. CRC cells can release exosomes that will modify TME cells and promote tumor growth, metastasis formation, and chemoresistance. Inversely, stromal cells can also release exosomes that influence tumor cell metabolism. Differential expression of miRNAs within exosomes could also be useful in CRC as biomarker for diagnosis and monitoring.

include different types of nucleic acids and soluble and transmembrane proteins [52, 53]. Among the proteins present in secreted exosomes, some are involved in its biogenesis, like tetraspanins (CD9, CD63, and CD81), Tsg101, and Alix (Figure 1). These proteins are often used as markers, validating exosome enrichment during exosome isolation. Coupled to exosome physical-chemical characteristics (size, density, and buoyancy), they can help discriminating exosomes from other EVs and extracellular particles [54, 55]. Besides, exosome membranes are enriched in lipids (e.g., ceramide, cholesterol, phosphatidylserine, and sphingolipids) and lipid rafts, also playing an important role in their biogenesis and conferring exosomes reinforced rigidity compared to plasma membrane [53]. In particular, ceramide accumulation resulting from conversion of sphingomyelin by sphingomyelinases participates in the formation MVBs [56]. Exosomes also contain proteins that

play a functional role in cellular communication, like in antigen presentation. Proteins of the molecular histocompatibility complex (MHC) and various heat shock proteins (Hsp60, Hsp70, and Hsp90) are present in exosomes [57–62]. The incorporation of secreted exosomes into the recipient cell takes place by several mechanisms including macropinocytosis, phagocytosis, endocytosis, or interaction through surface receptors [63, 64].

During their formation, exosomes naturally incorporate cytoplasmic medium. Initially, it was hypothesized to be a nonselective process, resulting in a similar miRNA concentration both in exosomes and parenting cells. Some studies using miRNA for cancer diagnosis or prognosis purposes were implicitly based on the fact that circulating exosomal miRNA levels, especially in body fluids, should reflect accurately the miRNA content of their cells of origin. However, it was rapidly shown in several contexts that the



most expressed endogenous miRNAs in tumor or normal cells were not necessarily the ones predominantly secreted into the extracellular environment [65–67]. It is to note, however, that while some miRNA proportions are very different between the cell and the released EVs, this is not always the case. For example, some miRNAs among the most commonly present in both parent cells and exosomes, and that may be potential CRC diagnostic biomarkers present in tissue, plasma, and serum, are miR-192-5p, miR-10a-5p, and miR-191-5p [68, 69].

#### 4. Exosomal miRNAs in CRC

The way miRNAs are selectively transported into exosomes for secretion (exosomal sorting) is still not completely clear, although several mechanisms have been proposed [70]. In this section, we will address those hypotheses and the role of different types of biomolecules in miRNAs selective transport into exosomes in the context of CRC.

**4.1. Role of miRNA Putative Sequence Signals.** Several studies suggest the requirement of intrinsic sorting signal sequences in miRNAs, needed for their incorporation into exosomes [71, 72]. One of those sorting mechanisms was described in exosomes from peripheral blood mononuclear cells. It involves recognition of 4-bp RNA motifs, GGAG, by the RNA-binding hnRNP A2B1 protein, provided that it is sufficiently sumoylated [72]. hnRNPC and hnRNP A1, members of the same family of protein, can also bind exosomal miRNAs. Nevertheless, no associated motif has been identified. Another RNA motif, GUUG, was found to be enriched in miRNAs present in exosomes derived from a CRC cell line (SW620) and resembles the GGAG motif recognized by hnRNP A2B1 [73]. This motif was also suggested to be involved in miRNA loading, but it is not known whether it constitutes a specificity of cancer cells or if some RNA-binding proteins, like hnRNP A2B1, intervene in the recognition of this motif.

**4.2. Role of Exosome Membrane Lipid Composition.** It has been reported that the lipid composition of exosome membranes directly influences exosome biogenesis and composition [53, 56, 74]. This also affects miRNA sorting into exosomes. For instance, the level of neutral sphingomyelinase 2 (nSMase2), regulating ceramide synthesis, can influence the quantity of miRNA exported through exosomes [70, 75]. In CRC and hepatocellular carcinoma cell lines, it has been shown that sphingomyelin phosphodiesterase 3 (SMPD3), which also generates ceramide from sphingomyelin, is also involved in miRNA encapsulation [76]. SMPD3 inhibition leads to a decrease in exosomal miRNA levels, while the intracellular miRNA level in CRC cells increases. This influence of SMPD3 was, for example, reported for mir-638, a miRNA also downregulated in exosomes of CRC patients which has been proposed as a biomarker [77, 78].

**4.3. Role of Proteins Involved in miRNA Biogenesis and Functions.** The miRNA maturation process is connected with miRNA export in exosomes and endosomal trafficking. Knockout of Ago2 leads to the selective decrease of certain miRNA populations in exosomes from several cell lines [79]. In addition, components of the RISC complex can colocalize with MVBs, when MVBs turnover into lysosomes is blocked [80]. In exosomes derived from different cancer cell types, all the essential elements required for pre-miRNAs processing into mature miRNAs, including Dicer and Ago2, are available [10, 81]. When transfected with *C. elegans* pre-miRNA, those exosomes were able to process this pre-miRNA into mature miRNA. This was confirmed to be a Dicer-dependent process. In contrast, miRNA maturation machinery was not detected in exosomes from nontumorigenic cancer cells. CD43, a suspected mediator of active protein transported into exosomes, is enriched in those exosomes. This protein is responsible for the increased level of Dicer, further linking exosome processing with miRNA biogenesis [82, 83]. Probably also related to miRNA biogenesis, it was observed that passenger-strand (3p) miRNAs seem predominant in CRC cell-derived EVs compared to their 5p counterparts [84].

One mechanism highlighted in CRC cells underlines a possible role of the small GTPase KRAS in miRNA sorting. KRAS mutations occur in more than a third of sporadic colorectal cancers, and it has been associated with several other cancers, in particular, regarding tumor aggressiveness [85–87]. Exosomes secreted by KRAS mutant CRC cells can induce growth and migration of wild type (WT) cells [88, 89]. KRAS mutations can influence the recruitment of Ago2, involved in miRNA maturation and secretion, into the nascent exosome [90, 91]. In particular, KRAS mutations affect exosomal encapsulation of several miRNAs implicated in CRC, such as the oncogenic miR-10b, which is selectively retained in WT KRAS-cell exosomes [90]. A higher rate of tumor-suppressor miRNA sequestration and decreased level of oncomiRs were observed in exosomes compared to their parent CRC cells [92]. This process seems to depend on the major vault protein (MVP), a proposed miRNA-binding protein responsible for sorting miRNA to exosomes that is overexpressed in multidrug-resistant cancer cells [93, 94]. Since tumor cells can selectively retain oncomiRs, it was suggested as a phenomenon favoring tumor growth and progression [90, 92]. Moreover, exosome secretion could be used as a way to discard tumor-suppressor miRNAs or other molecules that promote apoptosis, cell cycle arrest, or differentiation, thus also enhancing tumor cell growth and metastasis. This selective secretion was, for example, observed for several tumor-suppressor miRNAs, like miR-23b, miR-224, and miR-921 [95]. In that study, it was shown to be dependent on an important exosome transporter, Rab27, and to significantly affect metastasis and angiogenesis potential of bladder carcinoma cell lines. Because most studies rather focused on how the miRNAs secreted from tumor cells influence their environment, these interesting data need further investigation.

As we will see in the following sections, there are hints that these mechanisms can be disturbed during the tumorigenic process in CRC, explaining the differences systematically observed in miRNA content between exosomes from healthy individuals and CRC patients.

## 5. Exosomal miRNAs Influence CRC Tumor Microenvironment

Exosomal miRNAs in the tumor microenvironment (TME) have a significant influence on tumor development and progression but are also able to transfer the ability to resist to the anticancer therapy [96–98]. The following section will present the main exosomal miRNAs (exomiRs) proven to be functionally implicated in CRC tumor metabolism. These include miR-21, the miR-200 family, the miR 17~92 cluster, and miR-1246 alongside other relevant miRNAs. Information on expression, role as a biomarker, and function of each miRNA in CRC will be further detailed in the following sections. Available data are summarized in Table 1.

### 5.1. Exosomal miR-21 and miR-155

**5.1.1. Expression and Role as Biomarker.** miR-21 was the first shown to be expressed at high levels in the exosomes of 3 different CRC cell lines (HCT-15, SW480, and WiDr) [99]. Interestingly, these tumor-derived exosomes were found to be transferred to normal hepatic and lung cell types, preferred metastasis targets for colon tumors. Later, it was confirmed that miR-21 was overexpressed not only in colon tumor tissue and in liver metastases tissue, but also in plasma exosomes of CRC patients [11, 100]. Exosomal miR-21 expression in plasma has been significantly correlated to its expression on tumor tissue, but also to disease stage, occurrence of liver metastasis, and prognosis. Other studies have reported that this exomiR can be used as a biomarker in CRC [101] but also as a general biomarker of gastrointestinal cancers including esophagus, rectum, and pancreas [102].

miR-21 was systematically found in miRNA populations characterizing circulating exosomes from plasma, feces, and serum in the context of colorectal cancer, as well as in exosomes from different CRC cell lines [84]. It is thereby possible that the circulating biomarker value of miR-21 comes mostly from its presence in exosomes. Nevertheless, it was recently shown that nonvesicular Ago2-associated miR-21 was actively released from HT29 CRC cell lines and that its levels could surpass those of EV-encapsulated miRNA in the absence of chemical lysis [120].

**5.1.2. Function in CRC.** Exosomal signal of stromal origin, such as exosomes produced by normal fibroblasts (NOFs), can be transferred to CRC cell lines (DLD1 or SW40) and lead to an increased expression of miR-21-5p. This transfer also leads to increased phosphorylation of cell-signaling factors Erk, Akt, and Bad, resulting in an increased resistance to the anticancer drug oxaliplatin (Figure 2(a)).

Overexpression of miR-21 observed in exosomes from CRC tissues leads to a drastic reduction of endothelial progenitors cell (EPC) migration, proliferation, and invasion properties [121]. EPCs are circulating progenitor cells of different types, able to differentiate into functional endothelial cells and to participate in new vessel formation and blood vessel regeneration. This effect on EPCs occurs most likely through direct targeting of interleukin 6 receptor

(IL6R) (Figure 2(b)). Since EPCs promote thrombus repair and resolution, it was hypothesized that it led to a higher incidence of deep-vein thrombosis, a prognostic factor in cancer patients.

In the context of CRC, stromal cells themselves can also release miR-21 into the TME, in agreement with previous observations based on stromal microdissections [122]. The altered cancer-associated fibroblasts (CAFs) produce miR-21 rich exosomes, both in regards to intracellular levels but also to the exosome content of NOFs. This increased expression in exosomes is associated with an increase in liver metastasis. These data were confirmed *in vivo* in mouse orthotopic xenografts (Figure 2(c)) [103].

miR-21 is enriched in exosomes produced by M2 macrophages, as is the oncomiR miR-155 [104]. M2 macrophages serves as *in cellulo* model for tumor-associated macrophages (TAMs) present in the TME. These macrophages promote proliferation, invasion, and metastasis of cancer cells, angiogenesis, and immune escape [123]. In CRC cells, both miR-21 and miR-155 are able to target the transcriptional regulator BRG1, resulting in increased migration and invasive behavior (Figure 2(d)). Exosomal miR-21 and miR-155 were thus suggested to be partly responsible for TAM's effects on CRC cells.

### 5.2. Exosomal miR 17~92 and 25~106b Clusters

**5.2.1. Expression and Role as Biomarker.** Members of the 17~92 miRNA cluster (miR-17, -18a, -19a, -19b-1, -20a, and -92a-1) were detected in high proportions in exosomes from the LIM1863 CRC cell line, alongside the members of its paralog cluster miR 106b~25 (miR-25b, -93, and -106b) [84]. Interestingly, miR-17, -19a, -20, and -92a are specifically enriched in exosomes as compared to several of their parent CRC cell lines, indicating their potential importance in exosomal communication [106]. miR-19a, -19b, and -92a are also upregulated in serum exosomes of CRC patients compared to those of healthy individuals, which has been linked to liver metastasis recurrence [9]. miR-19a-5p, in particular, was also suggested as a convincing biomarker for CRC severity and lymph node metastasis appearance and prognosis. The upregulation and biomarker value for disease stage of miR-19a-5p, as well as miR-19a-3p and miR-17-5p, were confirmed in serum exosomes of CRC patients [101, 106]. Moreover, miR-17-5p, -18a-5p, -19a/b-3p, -20a-5p, and -92a-1-5p expression is significantly upregulated in exosomes derived from metastatic CRC cell line SW620 compared to exosomes derived from the nonmetastatic SW480 cell line [107].

**5.2.2. Function in CRC (miR-25-3p).** Concerning the precise role of those two miRNA clusters in exosomal regulation, the main set of evidence comes from miR-25-3p and its action on the formation of premetastatic niche. Serum-derived exosomal miR-25-3p expression has been associated with higher rate of metastases in CRC patients [23]. *In vitro* data suggest that CRC cell-derived exosomes containing miR-25-3p can enter endothelial cells and induce migration, angiogenesis, and vascular permeability. This was confirmed *in*

TABLE 1: Summary of exosomal miRNA with known functions in CRC. The main source of exosomes in the publications is indicated. Exosome isolation techniques employed in the literature are indicated with their respective exosome enrichment validation procedures. Without any other mentions, plasma and serum are to be considered from human origin.

miRNA	Exosome source	Isolation technique	Exosome validation technique	Associated function	References
miR-21	(i) Cell supernatant (a) HCT-15, SW480, WIDR (b) CAFs, NOFs (c) Macrophages (ii) Serum (iii) Plasma (whole/mesenteric vs peripheral)	(i) UC (ii) UC/ExoQuick (iii) UC	(i) (a) WB: CsD81, (b) NTA/TEM/WB, (c) TEM/WB (ii) WB: CD81/none (iii) TEM/TEM + WB: Tsg101	Diagnosis biomarker, migration, invasion, liver metastasis, chemoresistance	[11, 99-105]
miR-155	(i) Plasma (whole/mesenteric vs peripheral) (ii) Cell supernatant (macrophages)	UC	(i) TEM/TEM + WB: Tsg101 (ii) NTA + TEM + WB	Migration, invasion	[104, 105]
miR-17~92 and 25~106b clusters	(i) Cell supernatant (SW480, SW620) (ii) Serum (i) Cell supernatant (SW480, HCT116) (ii) Serum	(i) UC + OptiPrep (ii) qEV SEC/ExoQuick/UC	(i) TEM + WB (ii) EM + WB/-TEM/TEM + WB	Diagnosis biomarker	[9, 23, 101, 106, 107]
miR-25-3p	(i) Cell supernatant (SW480, HCT116) (ii) Serum	UC	TEM + WB	Migration, angiogenesis, vascular permeability, pre-metastatic niches	[23]
miR-200 family	(i) Cell supernatant (a) SW640, SW480 (b) CCL27 (spheroid cultures) (ii) Plasma (mesenteric vs peripheral)	(i) (a) UC, (b) ExoQuick-TC (ii) UC	(i) (a) TEM, (b) None (ii) TEM, WB: Tsg101	EMT reversion marker, preventing permeation, associated with lower survival in exosomes	[98, 108-110]
miR-200b	Cell supernatant (SW480, HCT116)	UC	TEM + NTA	Proliferative activity	[98]
miR-1246	(i) Cell supernatant (HCT116, HT29, SW480, Colo201, WIDR) (ii) Serum (iii) Plasma	UC	(i) WB: CD81/NTA/TEM (ii) WB: CD81 (iii) NTA + TEM + WB	Diagnosis biomarker, proliferation, migration, angiogenesis, pre-metastatic niches induction, TAM reprogramming	[11, 23, 102, 111]
miR-96 and miR-149	(i) Tissue (ii) Plasma	ExoCapTM + SG + FACS	TEM + WB: CD63	Tumor suppressor	[112, 113]
miR-486-5p	Plasma	Total exosome isolation kit	None	Tumor suppressor	[78, 114]
miR-6869-5p	Serum	Total exosome isolation kit	None	Prognostic biomarker, tumor suppressor	[78, 115]
miR-8073	Cell supernatant-HCT116	UC	None	Tumor suppressor	[116]
miR-193a	(i) Modified CT26 cells xenograft (ii) Serum	(i) UC + SG, pulldown (ii) exoEasy	NTA	Tumor suppressor	[92]
miR-10b	(i) Tissue (ii) Cell supernatant (HCT116)	UC + ExoQuick + exosomes precipitation solution	TEM-IG + WB	Oncogenic, CAF transformation	[117]
miR-142-3p	Cell supernatant (HCT-116, HT-29, SW480, MSCs)	UC	NTA + TEM-IG + WB	Induces stemness	[118]
miR-196b-5p	Serum	—	—	Induces stemness prognostic biomarker	[119]
miR-210	Cell supernatant (HCT-8)	Exosome precipitation solution	TEM	Induces EMT transition	[19]

EMT: epithelial-mesenchymal transition; FACS: fluorescence-activated cell sorting; MSCs: mesenchymal stem cells; OptiPrep: commercial density gradient medium; SG: sucrose gradient; TAM: tumor-associated macrophages; TEM/TEM-IG: electron microscopy (transmission/transmission coupled with immunogold labelling); UC: ultracentrifugation (may include differential centrifugation steps and eventual additional filtering); WB: western blot. Total exosome isolation kit (Invitrogen), ExoQuick (System Biosciences), exoEasy or exoRNeasy (Qiagen), qEV SEC (120m), ExoCapTM (JSR), and exosome precipitation solution (Machery-Nagel): commercial exosome purification solution or kits.




FIGURE 2: Proposed models for the role of exosomal miR-21 in CRC development. (a) Fibroblast-derived exosomes have an effect on CRC cells. The internalization of normal fibroblast- (NOF-) derived exosomes into CRC cells leads to an increase of cellular miR-21 and to the activation of phospho-Erk/Akt pathway, leading to oxaliplatin resistance. (b) CRC cells release miR-21-containing exosomes that are able to inhibit endothelial progenitor cell (EPC) IL6R mRNA transcription, leading to a reduced migration, proliferation, and invasion and favoring thrombosis in CRC. (c) Cancer-associated fibroblasts (CAFs) secrete miR-21-overexpressing exosomes which increase liver metastases. Tumor-associated macrophages (TAMs) also release miR-21-containing exosomes that can negatively regulate BRG1 mRNA in CRC cells and lead to an increased migration and proliferation.

*vivo* by tail vein injection of exosomes in mice, leading to a higher rate of metastases formation in liver and lungs, in a miR-25-3p-dependent manner. It was suggested to result from miR-25-3p targeting of the transcription factor KLF2. KLF2 negatively regulates expression of angiogenesis factor VEGFR2 and of KLF4, a transcription factor regulating the integrity of endothelial barrier and tight junctions.

### 5.3. Exosomal miR-200 Family

**5.3.1. Expression and Role as Biomarker.** Another important family of exosomal miRNAs in CRC is the miR-200 family, which encompasses two miRNA clusters. The first regroups miR-200a, -200b, and miR-429, and the second regroups miR-141 and 200c. Lower expression levels of miR-200c and miR-141 were significantly associated with better survival, in both the tumor draining vein (mesenteric) plasma and the corresponding exosomal fraction [124].

**5.3.2. Function in CRC.** On one hand, miR-141, -200c, and -429 have a protective effect against tumor progression, but only seemingly active in absence of the epithelial-mesenchymal transition (EMT), a crucial feature of cancer cells acquiring metastatic properties. Indeed, CRC metastatic cells (SW640) treated with the anticancer drug decitabine (DAC) reacquire epithelial characteristics by undergoing EMT reversal (MET). This includes inhibition of their

migration and invasion properties. During this phenomenon, exosomal miR-141 and -200c expression increases, while remaining unaffected when DAC has no effect on EMT, like in the corresponding primary tumor cell line (SW480) [108]. This suggests that miR-141 and -200c expression in exosomes is negatively impacted by EMT and positively impacted by the mesenchymal-epithelial transition (MET) (Figure 3(a)).

miR-200c and also miR-141 and miR-429 are expressed in exosomes of naive CCL27 CRC cell spheroids in 3D culture models [109, 110]. In cells surrounding the tumor, they directly target several members of the ZEB family, which are transcription factors involved in EMT (Figure 3(b)). As a result, miR-200c inhibits EMT in the lymphatic endothelial cells (LECs) co-cultured with CRC spheroids [110], and miR-200c, -141, and -429 inhibit EMT in co-cultured blood endothelial cells (BECs) [109]. Since exosomal expression of those miRNAs is lost in 5-FU (5-fluorouracil) chemoresistant spheroid cultures, surrounding cells engage in EMT transition, visibly weakening the lymphatic (LEC) and blood (BEC) endothelial barriers. By facilitating the crossing of those barriers by CRC cells, this phenomenon could explain increased metastasis occurrence in chemoresistant CRC. Thus, the data suggest that transfer of those miRNAs through exosomes contribute to preventing cell permeation into epithelia and maintaining tissue and organ integrity in normal physiological cell conditions (Figure 3(c)).




FIGURE 3: Proposed models for the dual roles of exosomal miR-200 family members on TME in CRC. (a) Upon decitabine (DAC) treatment, CRC cells enter a MET process that stimulates the release of miR-141/miR-200c enriched exosomes. (b) In endothelial cells, exosomal miR-200c, -141, and -429 can also inhibit the expression of transcription factors belonging to the ZEB family, activators of EMT. (c) On the contrary, 5-FU-resistant CRC cells release exosomes without miR-200 family members, favoring EMT. (d) CRC cells exposed to TGF- $\beta$ 1 release miR-200b-enriched exosomes that inhibit p27/kip mRNA, leading to an increased proliferation.

On the other hand, an oncogenic effect of exosomal miR-200b derived from CRC cells (HCT-116 and SW480) was also reported [98]. Exosomal miR-200b level is increased in cells treated with TGF- $\beta$ 1 in a dose-dependent manner and is responsible for the proliferative properties of the resulting exosomes, observed on another CRC cell line. These results were assigned to direct targeting of the antiproliferative cyclin-dependent kinase inhibitor 1B (p27/kip) by miR-200b (Figure 3(d)). The decrease of p27/kip expression was confirmed *in vivo* following miR-200b injection in xenograft of tumor cells. This also led to an increase in tumor size, as expected.

#### 5.4. Exosomal miR-1246

**5.4.1. Expression and Role as Biomarker.** It was reported that miR-1246 is specifically upregulated in exosomes derived from several CRC cell lines and carcinoma cell lines from the cervix (HeLa), bladder (T24), prostate (PC-3), and liver (HepG2) [11, 23]. In a meta-analysis encompassing literature data from blood, urine, and other bodily fluids, it was the best performing miRNA biomarker for gastrointestinal cancers in terms of specificity and sensitivity [102]. This was in agreement with a previous high-throughput experimental study in serum exosomes, concluding that miR-1246 was the best potential miRNA biomarker for CRC diagnosis in serum together with miR-23a [11].

**5.4.2. Function in CRC.** Through its action on inflammation, exosomal miR-1246 holds an important role in TME. It was

shown that this action was linked to the presence of p53 (*TP53*) mutations in CRC cells. These alterations are one of the most frequent genetic traits of human cancers [111, 125]. The experimental proofs obtained both *in vitro* and *in vivo* allowed to establish a model, in which the presence of *TP53* mutations in CRC cells, specifically resulting in a gain of function (mutp53), led to an increase of miR-1246 levels in exosomes [111]. Exosomal miR-1246 can induce reprogramming of macrophages towards a TAM phenotype, a hallmark of solid tumors associated with poor prognosis (Figure 4). Indeed, those mutp53-reprogrammed TAMs possess an anti-inflammatory cytokine secretion signature (e.g., IL-10, TGF- $\beta$ , or VEGF). Moreover, their proinflammatory cytokine secretion (e.g., IL-8, IFN- $\gamma$ , and ICAM-1) is decreased. Mutp53-reprogrammed macrophages also revealed a marked stimulation of extracellular matrix (ECM) degradation activity and enhanced migration and invasion properties. As a consequence, the anti-inflammatory, immunosuppressive, promigration, and proinvasion properties obtained by such macrophages promote tumor growth and metastatic burden to liver and lungs, as confirmed in mice hetero- and orthotopic xenograft models.

Interestingly, a pull-down experiment revealed an association of miR-1246 with hnRNPA2B1, which is suggested to be responsible for miRNA sorting in exosomes in its sumoylated form [72, 111]. The motif recognized by hnRNPA2B1 (GGAG) is carried by miR-1246, and hnRNPA2B1 sumoylation is 3 times higher in mutp53 CRC cells than in the WT CRC cells, suggesting that changes in this mechanism are involved in exosomal miR-1246 oncogenic properties.




FIGURE 4: Proposed models for the effects of exosomal miR-1246 on the TME. p53 mutations resulting in gain of function (GOF) in CRC cells induce the release miR-1246-overexpressing exosomes. Exosomal miR-1246 can induce a switch of macrophage phenotype towards a tumor-associated phenotype (TAM), modifying tumor inflammatory state. It leads to a decreased secretion of proinflammatory and increased secretion of anti-inflammatory cytokines. TAMs also present enhanced ECM degradation, migration, and invasion properties. Exosomes are represented as small orange circles.

5.5. *miR-149 and miR-96-5p, -486-5p, -6869-5p, -8073, and -193a: Tumor Suppressors.* GPC1 (glypican-1) is a member of the heparan sulphate proteo-glycan family and is an important biomarker, found in several types of cancer (breast, pancreatic, and glioma) and involved in angiogenesis and tumor growth [126–129]. It was shown that GPC1 overexpression in CRC cells induces EMT and promotes cell invasion and migration [112]. The miR-149 gene is located within an intron in the *GPC1* gene. miR-149 and miR-96-5p are both able to directly target GPC1 mRNA, resulting in proapoptotic and antiproliferative effects in CRC cells *in vitro* and *in vivo*. Both miRNAs are downregulated in exosomes from CRC tissues or in plasma when compared to those of healthy individuals, while the exosomal GPC1 level is increased [113].

It was shown that exosomal miR-486 was upregulated within plasma exosomes and whole plasma of CRC patients. Therefore, it was suggested as a CRC diagnosis biomarker [114]. However, miR-486-5p possesses a tumor suppressor

activity via inhibition of cell proliferation. Indeed, it targets directly *PLAGL2*, a transcription factor for  $\beta$ -catenin and IGF2 that promotes both proliferation and metastasis and inhibits apoptosis. Nevertheless, in CRC tissues, it has been shown that miR-486-5p expression is inhibited due to a high rate of DNA methylation of its promoter region. The consequent upregulation of *PLAGL2*/ $\beta$ -catenin/IGF2 pathway leading to proliferation and migration was confirmed in CRC cells.

miR-6869-5p downregulation was also observed in tumor tissues and serum exosomal fractions from CRC patients, and it was proposed as a potential biomarker of CRC prognosis [115]. The tumor-suppressor activity of miR-6869-5p was supported by direct targeting of TLR4, subsequently inhibiting TNF- $\alpha$  and IL-6 production in CRC cells via the TLR4/NF- $\kappa$ B signaling pathway, leading to a decrease in cellular proliferation.

While there is no difference between intra- or extracellular miR-8073 in normal colorectal cells, it is at least 60 times more

expressed in exosomes from CRC cells than in the intracellular extracts. Mizoguchi et al. demonstrated that it can directly target several factors involved in survival, proliferation, and antiapoptosis (FOXO1, MBD3, CCND1, KLK10, and CASP2), resulting in its antiproliferative properties *in vitro* and its effect on tumor growth *in vivo* [116].

Finally, miR-193a was shown to have a tumor-suppressor activity by targeting Caprin1, an upstream activator of the G1/S-specific cyclin-D2 (Ccn2) and the proto-oncogene transcription factor c-Myc [92]. This causes G1 cell cycle arrest, leading to inhibition of cell proliferation. miR-193a is present at high levels in the exosomal fraction of CRC patients' serum, particularly in advanced stages, with high risks of metastasis. It was also demonstrated that miR-193a sorting into exosomes, which is increased in CRC, was caused by the MVP transporter [92].

**5.6. miR-10b: Indirect Oncogenic Activity via CAF Transformation.** miR-10b was detected in exosomes derived from multiple types of cancer cells and was particularly enriched in exosomes from CRC cells [90], but also breast cancer [130] and non-small cell lung cancer [131]. It can target directly PIK3CA, thus inhibiting PI3K/Akt/mTor pathway activity, closely associated with the inhibition of cell migration and invasion [117, 132]. Moreover, exosomes derived from CRC cells that contain miR-10b can be transferred to fibroblasts. In the target cells, this results in increased expression of TGF- $\beta$  and SM  $\alpha$ -actin. Expression of those genes are characteristics of myofibroblast-like CAF phenotype [103], and should stimulate tumor cells proliferation. miR-10b was shown to be particularly sensitive to mutation in the exosomal sorting protein KRAS, as KRAS mutations lead to a decreased incorporation of miR-10b in secreted exosomes [90].

**5.7. miR-142-3p and 196b-5p: Stemness-Inducing miRNAs.** Bone marrow-derived progenitors are an additional important type of stromal cells present in tumors, which are able to release cytokines and exosomes and influence TME. Bone marrow mesenchymal stem cells (BM-MSCs) are indeed able to release exosomes that increase markers of stemness (Oct4, lin28, KLF, Bmi-1, CD44, and SOX2) in CRC cells and their subsequent invasion, adhesion, and drug resistance properties [118]. It has been shown that this effect relies on the influence of miR-142-3p, present in exosomes, which can directly target Numb, an inhibitor of the Notch stem cells pathway [133]. Consequently, exposure to miR-142-3p-containing BM-MSC exosomes results in a boost of tumorigenesis and tumor metastasis, but not tumor weight and size, as shown in orthotopic grafts in mice [118].

miR-196b-5p influences stemness by targeting directly SOCS1 and SOCS3, modulators of stemness pathways, resulting notably in increased STAT3 transcription factor activity in CRC cells and tissues. It increases the production of antiapoptotic factors, like Bcl-2, Bcl-xL, and BIRC, and stem cell factor markers, like NANOG, Bmi-1, OCT4, and SOX2, and increases resistance to the drug 5-fluorouracil [119]. miR-

196b-5p was confirmed to be dramatically upregulated in serum exosomes of CRC patients, in a much more distinct manner than in the whole serum, and associated with poor prognosis.

**5.8. Lead on miR-210 Importance in EMT.** It has been observed that a subpopulation of HCT-8 CRC cells became nonadherent after a few days of culture. Additionally, their proportion increased with culture time, and they developed chemoresistance properties by undergoing EMT [19, 134]. This metastatic-like phenotype can be spontaneously reverted in new cell-free cultures, but not in the presence of other HCT-8 cultured cells. Indeed, the reverse MET phenomenon was inhibited by exosomes produced by cultured cells. As miR-210 is significantly upregulated in HCT-8 exosomes, the authors suggested that it may play a role in MET inhibition [19].

**5.9. Other miRNAs.** Finally, additional miRNAs found in exosomes were also identified as potential biomarkers in CRC patients. Even if they are not described to play a role in exosomes mode of action, we tried to make a list as exhaustive as possible of the main reported ones in the current state of the art. Data are outlined in Table 2 [105, 135–139].

## 6. Concluding Remarks

Cell-to-cell transfer of miRNAs by means of exosomes, released by both stromal and tumor cells, plays an important role in tumor progression and metastasis. Several technical obstacles should be overcome to allow improved exosome characterization and further research in particular subjects that remain less covered. Study of miRNA targets and role in CRC provides great hopes for better understanding and characterization of tumor properties, diagnosis and personalized medicine, and innovative therapeutic approaches. These aspects will be briefly discussed in the following sections.

**6.1. Limitations regarding Exosome Isolation Methods and Exosome Purity.** Exosomes constitute great reservoir of biomarkers since they preserve miRNAs from extracellular environment and have dedicated roles and a specific biology. For example, in one of the first high-throughput characterization of exosomal miRNAs in CRC cells by Ji et al., almost a third of miRNAs from a subpopulation of exosomes were not reported as implicated in colon cancer before [84]. However, exosomal miRNA studies are limited due to a few technical issues. It is currently almost impossible to achieve a very high degree of purity without sacrificing yield when isolating exosomes. There are many approaches to isolate exosomes from the same medium, which are fundamentally different in their principles, resulting in different yields and degree of purity and often used according to the objectives of downstream applications [140].

Unfortunately, it has been shown that the purification method has a great impact on the exosome population

TABLE 2: Summary of exosomal miRNAs with a potential biomarker role in CRC or whose expression is associated with CRC diagnosis and progression. The main source of exosomes referred in the literature is indicated. Exosome isolation techniques employed in the diverse references are indicated with their respective exosome enrichment validation procedures. Without any other mentions, plasma and serum are to be considered from human origin.

miRNA	Exosome source	Isolation technique	Validation	Associated effect	References
mir-221	Cell supernatant (HT-15, SW480, WiDR)	UC	WB; CD81	Biomarker for tumor size, TNM stage, Dukes stage, lymph node metastasis, recurrence	[99, 135]
mir-215	(i) Cell supernatant (a) HT-15, SW480, WiDR (b) CAFs, NOFs	(i) UC (ii) UC	(i) WB; CD81/ NTA + TEM + WB (ii) NTA + TEM + WB	Upregulation in CAF exosomes	[99, 103]
mir-23a	(i) Serum (ii) Cell supernatant (SW48, SW480, SW620, HCT116, HT29, RKO)	(i) UC (ii) UC	(i) TEM/WB (ii) TEM/WB	Diagnosis biomarker associated with liver metastasis recurrence	[9, 11]
mir-320a, -4476	(i) Tissue (ii) Serum	UC	TEM	Associated with liver metastasis recurrence	[9]
mir-125a	Plasma	ExoQuick	SEM/none	Early tumor stage biomarker	[27, 136]
mir-320c	Plasma	ExoQuick	SEM	Higher levels in CRC patients	[136]
mir-328	Plasma (mesenteric vs. peripheral)	UC	TEM + WB; Tsg101	Liver metastasis biomarker (better performing in mesenteric vein)	[105]
mir-4472-3p	Serum	ExoQuick	TEM + WB	Diagnosis and tumor recurrence biomarker	[137]
mir-6803-5p	Serum	Total exosome isolation kit	None	Diagnosis and prognostic biomarker, associated with stage and lymph node metastasis	[138]
mir-4644	Meta-analysis	—	—	GI cancer diagnosis biomarker	[102]
mir-7641	Cell supernatant (HT-15, SW480, WiDR)	UC + OptiPrep	TEM + WB; Alix, Tsg101	Diagnosis biomarker	[107]
mir-638	Serum	Total exosome isolation kit	None	Biomarker for TNM stages III-IV and liver metastasis	[77, 78]
mir-548c	(i) Serum (ii) Plasma (mesenteric vs peripheral)	(i) Total exosome isolation kit (ii) UC	(i) None (ii) TEM + WB; Tsg101	Diagnosis and prognostic biomarker, associated with faster relapse	[78, 105, 139]
mir-let-7a, -1229, -150, -223	(i) Cell supernatant (HCT116, HT29, RKO, SW48, SW480) (ii) Serum	UC	WB	Potential diagnosis biomarkers	[11]

GI cancers: gastrointestinal cancers; OptiPrep: commercial density gradient medium; TEM/SEM: electron microscopy (transmission/scanning); UC: ultracentrifugation (may include differential centrifugation steps and eventual additional filtering); WB: western blot. Total exosome isolation kit (Invitrogen), ExoQuick (System Biosciences), and qEV SEC (Zon): commercial exosome purification solution or kits.



obtained, including on miRNA content [141, 142]. To help ensure that the obtained isolates are enriched in exosomes, several validation tests also have been proposed. These tests typically include nanoparticle tracking analysis (NTA), exosomes markers detection by western blot, or examination of exosomes by electron microscopy. Studies on the research of biomarkers, mentioned along this review, used different methods of purification, as summarized briefly in Tables 1 and 2. Both the purification method and validation of exosomal enrichment experiments have to be taken into account during result interpretation.

**6.2. Nonexosomal vs. Exosomal Extracellular RNAs.** Concerning the vesicle-free part of circulating miRNAs secreted by cells by other means, the involved mechanisms are still unclear. Their release could also largely result from cellular lysis. Compared to miRNAs contained in EVs, it is not clear if their role in tumor transformation and progression is negligible or not. To elucidate these roles entirely will remain difficult due to current technical impediments limiting the purity of isolated exosomes and EVs in general [53, 140]. This state of the art was recently backed up by a study in rat serum and plasma, showing that vesicle-free miRNAs are also present in EV fractions after isolation. Moreover, even Ago2-associated part of vesicle-free circulating miRNAs could result from either cellular or exosomal lysis [10, 143].

If the proportion of circulating miRNAs present in exosomes compared to free circulating miRNAs remains elusive, it seems that only a small fraction (down to 10%) of plasma miRNAs are vesicular, whereas in serum or saliva, the majority of miRNA are concentrated in exosomes [48, 49, 144, 145]. In plasma, the fraction of miRNAs present in the vesicle fraction is strongly dependent on the identity of the miRNA considered. Some, like *let-7a*, were found predominantly enriched in vesicle fractions compared to vesicle-free fractions, while others like miR-16 and miR-92a are preferably associated with circulating Ago2 and seemingly absent from vesicles under physiological conditions [48]. However, it is worth noting that at least in one report (in high-risk colorectal adenomas), 2 serum exosomal miRNAs were considered less efficient biomarkers than their whole serum miRNA counterparts despite their correlated expressions [146]. Although it seems that isolated vesicle-incorporated miRNAs are more stably expressed and constitute more reliable cancer biomarkers than their vesicle-free counterparts [28, 147].

**6.3. Exosome Subpopulations in CRC and Their Advantages.** Different CRC cell types produce different populations of exosomes. For example, it was shown that CRC cell line exosomes do not contain the same combination of tetraspanin proteins, exosomal markers involved in exosome biogenesis [99]. On the same note, Chen et al. showed that miRNA composition of SW480- and SW620-derived exosomes is significantly different, with more than a third of the miRNAs detected being differentially expressed between the 2 types of exosomes [107]. Moreover, while miRNAs are

sorted into exosomes in a differentiation state and cell-type dependent fashion, several types of exosome populations with diverse morphologies have been reported to be secreted by the same cells, in particular in colorectal cancer [148, 149]. The LIM1863 CRC cell line can produce two mutually distinct populations of exosomes, one presenting A33 and the other EpCAM surface proteins, an important cancer-initiating marker in CRC and pancreatic cancer [150, 151]. Their protein and miRNA populations vary significantly between each exosome type and previously determined proteomes of other exosomes, suggesting different effects and/or target recipient cells [84, 150]. Indeed, it was shown that exosomes are tailored to target specific types of recipient cells [152, 153]. This could provide an explanation for the site-specific formation of metastases in colorectal cancer, e.g., the liver, lungs, and lymph nodes. Moreover, their compositions reflect not only this tailoring, but also regulatory events arising in the secreting cell [80]. Exosomes could thus give great advantages for both study of TME and discovery of biomarkers. Indeed, a given exosome population could thereby directly inform us about particular cell types and events they were exposed to, with great specificity. These subpopulations may contain multiple determinants of tumor metastatic potential. The complex interplay between exosome subpopulations, their specific contents, and their potential target cells needs further investigation.

**6.4. A Word on Therapeutic Perspectives.** Studies on exosomal miRNAs may soon be applied to the clinical setting, as new therapeutic approaches using delivery of miRNA mimics or miRNA antagonist on tumor sites are in development. Several clinical trials concerning the use of miRNAs in the treatment of CRC are currently ongoing and gain more and more interest from biopharmaceutical companies [154]. Furthermore, exosomes themselves constitute a great strategy for the delivery of those new therapeutic actors. Freely circulating miRNAs are rather instable in blood [48] and are also negatively charged, rendering delivery through cell membranes difficult even *in vitro*. Exosomes, on top of their low immunogenicity and cytotoxicity, may enhance therapy deliverability and protect molecules from RNase activity, making them suitable therapeutic vectors for CRC treatment [155, 156]. Treatment of cells with FF/CAP18 (analog of cathelicidin LL-37), a peptide limiting cancer cell proliferation, induces production of exosomes with antiproliferative properties [157]. This effect is suspected to come from the expression of exosomal miRNAs miR-584-5p, -1202, and -3162-5p. Kyuno et al., have also shown that it is possible to tailor exosomes for therapeutic purposes by transfection with tumor-suppressor miRNAs [158]. The miRNAs in question were miR-342 and -498, which target Claudin7 (*cld7*) and EpCAM, respectively. Coupled with exosomal expression of ectopic Tspan8, shown to enhance internalization by cancer cells [152], it was sufficient to inhibit tumor growth, motility, and invasion, especially by affecting stemness traits.

To conclude, exosome-carrying miRNAs originating both from the stromal and the tumor cells have a major role in CRC TME. Exosome encapsulation enables miRNA expression in extracellular space and involvement in cell-to-cell communication. Therefore, miRNAs can influence cell inflammatory environment, differentiation status, proliferation, survival, migration, invasion, and angiogenesis properties. Being stably released in the circulatory system, it has been shown at least through venal injection that they can influence distant cell barrier permeability, underlining the role they play in premetastatic niche formation. The delivery of exosome cargo into specific types of target cells may also be one of the mechanisms explaining organ preference of cancer metastasis. For all those reasons, exomiRs constitute a key target for the discovery of biomarkers and new therapeutic approaches in CRC, and an important axis of research in the near future.

### Abbreviations

CRC:	Colorectal cancer
TME:	Tumor microenvironment
mRNA:	Messenger RNA
EV:	Extracellular vesicle
MVB:	Multivesicular body
MVP:	Major vault protein
exomiR:	Exosomal miRNA
NOF:	Normal fibroblast
EPC:	Endothelial progenitor cell
CAF:	Cancer-associated fibroblast
TAM:	Tumor-associated macrophage
EMT:	Epithelial-mesenchymal transition
DAC:	Dacitabine
MET:	Mesenchymal-epithelial transition
LEC:	Lympho-endothelial cell
BEC:	Blood endothelial cell
5-FU:	5-Fluorouracil
BM-MSC:	Bone marrow mesenchymal stem cell
MHC:	Molecular histocompatibility complex
HSP:	Heat shock protein.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Acknowledgments

The authors would like to thank Isabel Grégoire for editing and reviewing this manuscript for English language. This project was supported by a French Government grant managed by the French National Research Agency (ANR) under the program "Investissements d'Avenir" with reference ANR-11-LABX-0021-01-LipSTIC Labex, "Ligue Nationale Contre le Cancer," "Institut National du Cancer," Centre Georges-Francois Leclerc, Canceropole Est, Regional Council Burgundy/Franche-Comté et FEDER. This study was supported by the Fondation pour la Recherche Médicale (FRM grant no. ECO20160736090 (to GC)).

### References

- [1] J. Ferlay, M. Colombet, I. Soerjomataram et al., "Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018," *European Journal of Cancer*, vol. 103, pp. 356–387, 2018.
- [2] R. Siegel, C. Desantis, and A. Jemal, "Colorectal cancer statistics, 2014," *CA: A Cancer Journal for Clinicians*, vol. 64, no. 2, pp. 104–117, 2014.
- [3] E. Becht, A. de Reyniès, N. A. Giraldo et al., "Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy," *Clinical Cancer Research*, vol. 22, no. 16, pp. 4057–4066, 2016.
- [4] M. Castells, B. Thibault, J.-P. Delord, and B. Couderc, "Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death," *International Journal of Molecular Sciences*, vol. 13, no. 8, pp. 9545–9571, 2012.
- [5] M. Koi and J. M. Carethers, "The colorectal cancer immune microenvironment and approach to immunotherapies," *Future Oncology*, vol. 13, no. 18, pp. 1633–1647, 2017.
- [6] Z. Zhai, X. Yu, B. Yang et al., "Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges and solutions for treatment resistance," *Seminars in Cell and Developmental Biology*, vol. 64, pp. 107–115, 2017.
- [7] G. Raposo and W. Stoorvogel, "Extracellular vesicles: exosomes, microvesicles, and friends," *The Journal of Cell Biology*, vol. 200, no. 4, pp. 373–383, 2013.
- [8] T. Liu, Q. Zhang, J. Zhang et al., "EVmiRNA: a database of miRNA profiling in extracellular vesicles," *Nucleic Acids Research*, vol. 47, no. D1, pp. D89–D93, 2019.
- [9] T. Matsumura, K. Sugimachi, H. Iinuma et al., "Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer," *British Journal of Cancer*, vol. 113, no. 2, pp. 275–281, 2015.
- [10] S. A. Melo, H. Sugimoto, J. T. O'Connell et al., "Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis," *Cancer Cell*, vol. 26, no. 5, pp. 707–721, 2014.
- [11] H. Ogata-Kawata, M. Izumiya, D. Kurioka et al., "Circulating exosomal microRNAs as biomarkers of colon cancer," *PLoS One*, vol. 9, no. 4, Article ID e92921, 2014.
- [12] M. Carpelan-Holmström, J. Louhimo, U. H. Stenman, H. Alftan, C. Haglund, and CEA, "CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers," *Anticancer Research*, vol. 22, pp. 2311–2316, 2002.
- [13] M. Cordonnier, G. Chanteloup, N. Isambert et al., "Exosomes in cancer theranostic: diamonds in the rough," *Cell Adhesion and Migration*, vol. 11, no. 2, pp. 151–163, 2017.
- [14] N. Iraci, T. Leonardi, F. Gessler, B. Vega, and S. Pluchino, "Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles," *International Journal of Molecular Sciences*, vol. 17, no. 2, p. 171, 2016.
- [15] C. Théry, M. Ostrowski, and E. Segura, "Membrane vesicles as conveyors of immune responses," *Nature Reviews Immunology*, vol. 9, no. 8, pp. 581–593, 2009.
- [16] M. Tkach and C. Théry, "Communication by extracellular vesicles: where we are and where we need to go," *Cell*, vol. 164, no. 6, pp. 1226–1232, 2016.
- [17] M. Yáñez-Mó, P. R.-M. Siljander, Z. Andreu et al., "Biological properties of extracellular vesicles and their physiological functions," *Journal of Extracellular Vesicles*, vol. 4, p. 27066, 2015.

- [18] H. Ji, D. W. Greening, T. W. Barnes et al., "Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components," *Proteomics*, vol. 13, no. 10-11, pp. 1672-1686, 2013.
- [19] E. Bigagli, C. Luceri, D. Guasti, and L. Cinci, "Exosomes secreted from human colon cancer cells influence the adhesion of neighboring metastatic cells: role of microRNA-210," *Cancer Biology and Therapy*, vol. 17, no. 10, pp. 1062-1069, 2016.
- [20] L. Lugini, M. Valtieri, C. Federici et al., "Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells," *Oncotarget*, vol. 7, no. 31, pp. 50086-50098, 2016.
- [21] B. Costa-Silva, N. M. Aiello, A. J. Ocean et al., "Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver," *Nature Cell Biology*, vol. 17, no. 6, pp. 816-826, 2015.
- [22] M. Ragusa, L. Statello, M. Maugeri et al., "Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomolecular, genetic and translational implications," *Oncoscience*, vol. 1, pp. 132-157, 2014.
- [23] Z. Zeng, Y. Li, Y. Pan et al., "Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis," *Nature Communications*, vol. 9, no. 1, 2018.
- [24] J. Gobbo, G. Marcion, M. Cordonnier et al., "Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer," *Journal of the National Cancer Institute*, vol. 108, no. 3, 2016.
- [25] X. Huang, T. Yuan, M. Tschannen et al., "Characterization of human plasma-derived exosomal RNAs by deep sequencing," *BMC Genomics*, vol. 14, no. 1, p. 319, 2013.
- [26] C. Lässer, M. Eldh, and J. Lötvall, "Isolation and characterization of RNA-containing exosomes," *Journal of Visualized Experiments*, vol. 59, p. e3037, 2012.
- [27] T. Yuan, X. Huang, M. Woodcock et al., "Plasma extracellular RNA profiles in healthy and cancer patients," *Scientific Reports*, vol. 6, no. 1, p. 19413, 2016.
- [28] L. Cheng, R. A. Sharples, B. J. Scicluna, and A. F. Hill, "Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood," *Journal of Extracellular Vesicles*, vol. 3, 2014.
- [29] M. Arenas-Padilla and V. Mata-Haro, "Regulation of TLR signaling pathways by microRNAs: implications in inflammatory diseases," *Central European Journal of Immunology*, vol. 43, no. 4, pp. 482-489, 2018.
- [30] J. Chen, J. Yin, J. Liu, R.-X. Zhu, Y. Zheng, and X.-L. Wang, "MiR-202-3p functions as a tumor suppressor and reduces cell migration and invasion in papillary thyroid carcinoma," *European Review for Medical and Pharmacological Sciences*, vol. 23, pp. 1145-1150, 2019.
- [31] M. Fabbri, A. Paone, F. Calore et al., "MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response," *Proceedings of the National Academy of Sciences*, vol. 109, no. 31, pp. E2110-E2116, 2012.
- [32] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," *Cell*, vol. 144, no. 5, pp. 646-674, 2011.
- [33] G. Mao, Y. Liu, X. Fang et al., "Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer," *Angiogenesis*, vol. 18, no. 3, pp. 373-382, 2015.
- [34] D. Nie, J. Fu, H. Chen, J. Cheng, and J. Fu, "Roles of microRNA-34a in epithelial to mesenchymal transition, competing endogenous RNA sponging and its therapeutic potential," *International Journal of Molecular Sciences*, vol. 20, 2019.
- [35] Z.-Y. Shen, Z.-Z. Zhang, H. Liu, E.-H. Zhao, and H. Cao, "miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression," *Experimental and Therapeutic Medicine*, vol. 7, no. 6, pp. 1757-1761, 2014.
- [36] S. Lin and R. I. Gregory, "MicroRNA biogenesis pathways in cancer," *Nature Reviews Cancer*, vol. 15, no. 6, pp. 321-333, 2015.
- [37] A. M. Denli, B. B. J. Tops, R. H. A. Plasterk, R. F. Ketting, and G. J. Hannon, "Processing of primary microRNAs by the Microprocessor complex," *Nature*, vol. 432, no. 7014, pp. 231-235, 2004.
- [38] W.-T. Guo and Y. Wang, "Dgcr8 knockout approaches to understand microRNA functions in vitro and in vivo," *Cellular and Molecular Life Sciences*, vol. 76, no. 9, pp. 1697-1711, 2019.
- [39] Y. Lee, C. Ahn, J. Han et al., "The nuclear RNase III Drosha initiates microRNA processing," *Nature*, vol. 425, no. 6956, pp. 415-419, 2003.
- [40] J.-E. Park, I. Heo, Y. Tian et al., "Dicer recognizes the 5' end of RNA for efficient and accurate processing," *Nature*, vol. 475, no. 7355, pp. 201-205, 2011.
- [41] T. Kawamata and Y. Tomari, "Making RISC," *Trends in Biochemical Sciences*, vol. 35, no. 7, pp. 368-376, 2010.
- [42] D. P. Bartel, "Metazoan MicroRNAs," *Cell*, vol. 173, no. 1, pp. 20-51, 2018.
- [43] D. P. Bartel, "MicroRNAs," *Cell*, vol. 116, no. 2, pp. 281-297, 2004.
- [44] E. Huntzinger and E. Izaurralde, "Gene silencing by microRNAs: contributions of translational repression and mRNA decay," *Nature Reviews Genetics*, vol. 12, pp. 99-110, 2011.
- [45] F. V. Karginov, S. Cheloufi, M. M. W. Chong, A. Stark, A. D. Smith, and G. J. Hannon, "Diverse endonucleolytic cleavage sites in the mammalian transcriptome depend upon microRNAs, Drosha, and additional nucleases," *Molecular Cell*, vol. 38, no. 6, pp. 781-788, 2010.
- [46] V. A. Krutovskikh and Z. Herceg, "Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers," *BioEssays*, vol. 32, no. 10, pp. 894-904, 2010.
- [47] R. Rupaimoole and F. J. Slack, "MicroRNA therapeutics: towards a new era for the management of cancer and other diseases," *Nature Reviews Drug Discovery*, vol. 16, no. 3, pp. 203-222, 2017.
- [48] J. D. Arroyo, J. R. Chevillet, E. M. Kroh et al., "Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma," *Proceedings of the National Academy of Sciences*, vol. 108, no. 12, pp. 5003-5008, 2011.
- [49] A. Turchinovich, L. Weiz, A. Langheinz, and B. Burwinkel, "Characterization of extracellular circulating microRNA," *Nucleic Acids Research*, vol. 39, no. 16, pp. 7223-7233, 2011.
- [50] K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins," *Nature Cell Biology*, vol. 13, no. 4, pp. 423-433, 2011.
- [51] E. Cocucci and J. Meldolesi, "Exosomes and exosomes: shedding the confusion between extracellular vesicles," *Trends in Cell Biology*, vol. 25, no. 6, pp. 364-372, 2015.

- [52] D. K. Jeppesen, A. M. Fenix, J. L. Franklin et al., "Reassessment of exosome composition," *Cell*, vol. 177, no. 2, pp. 428–445, 2019.
- [53] H. Kalra, G. Drummen, and S. Mathivanan, "Focus on extracellular vesicles: introducing the next small big thing," *International Journal of Molecular Sciences*, vol. 17, no. 2, p. 170, 2016.
- [54] S. Keerthikumar, L. Gangoda, M. Liem et al., "Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes," *Oncotarget*, vol. 6, no. 17, pp. 15375–15396, 2015.
- [55] J. Lötvall, A. F. Hill, F. Hochberg et al., "Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles," *Journal of Extracellular Vesicles*, vol. 3, no. 1, p. 26913, 2014.
- [56] K. Trajkovic, C. Hsu, S. Chiantia et al., "Ceramide triggers budding of exosome vesicles into multivesicular endosomes," *Science*, vol. 319, no. 5867, pp. 1244–1247, 2008.
- [57] L.-H. Lv, Y.-L. Wan, Y. Lin et al., "Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro," *Journal of Biological Chemistry*, vol. 287, no. 19, pp. 15874–15885, 2012.
- [58] A. Lo Cicero, G. Schiera, P. Proia et al., "Oligodendrogloma cells shed microvesicles which contain TRAIL as well as molecular chaperones and induce cell death in astrocytes," *International Journal of Oncology*, vol. 39, pp. 1353–1357, 2011.
- [59] G. Raposo, H. W. Nijman, W. Stoorvogel et al., "B lymphocytes secrete antigen-presenting vesicles," *Journal of Experimental Medicine*, vol. 183, no. 3, pp. 1161–1172, 1996.
- [60] L. Zitvogel, A. Regnault, A. Lozier et al., "Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes," *Nature Medicine*, vol. 4, no. 5, pp. 594–600, 1998.
- [61] A. Montecalvo, W. J. Shufesky, D. Beer Stolz et al., "Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition," *The Journal of Immunology*, vol. 180, no. 5, pp. 3081–3090, 2008.
- [62] V. R. Simhadri, K. S. Reiners, H. P. Hansen et al., "Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function," *PLoS One*, vol. 3, no. 10, p. e3377, 2008.
- [63] N. P. Hessvik and A. Llorente, "Current knowledge on exosome biogenesis and release," *Cellular and Molecular Life Sciences*, vol. 75, no. 2, pp. 193–208, 2018.
- [64] K. J. McKelvey, K. L. Powell, A. W. Ashton, J. M. Morris, and S. A. McCracken, "Exosomes: mechanisms of uptake," *Journal of Circulating Biomarkers*, vol. 4, no. 7, 2015.
- [65] B. W. M. van Balkom, A. S. Eisele, D. M. Pegtel, S. Bervoets, and M. C. Verhaar, "Quantitative and qualitative analysis of small RNAs in human endothelial cells and exosomes provides insights into localized RNA processing, degradation and sorting," *Journal of Extracellular Vesicles*, vol. 4, no. 1, p. 26760, 2015.
- [66] A. Eirin, S. M. Riester, X.-Y. Zhu et al., "MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells," *Gene*, vol. 551, no. 1, pp. 55–64, 2014.
- [67] L. Pigati, S. C. S. Yaddanapudi, R. Iyengar et al., "Selective release of microRNA species from normal and malignant mammary epithelial cells," *PLoS One*, vol. 5, no. 10, Article ID e13515, 2010.
- [68] Q. Wang, Z. Huang, S. Ni et al., "Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer," *PLoS One*, vol. 7, no. 9, Article ID e44398, 2012.
- [69] Y. Xi, A. Formentini, M. Chien et al., "Prognostic values of microRNAs in colorectal cancer," *Biomark Insights*, vol. 2, pp. 113–121, 2006.
- [70] J. Zhang, S. Li, L. Li et al., "Exosome and exosomal microRNA: trafficking, sorting, and function," *Genomics, Proteomics and Bioinformatics*, vol. 13, no. 1, pp. 17–24, 2015.
- [71] D. Koppers-Lalic, M. Hackenberg, I. V. Bijnisdorp et al., "Nontemplated nucleotide additions distinguish the small RNA composition in cells from exosomes," *Cell Reports*, vol. 8, no. 6, pp. 1649–1658, 2014.
- [72] C. Villarroya-Beltri, C. Gutiérrez-Vázquez, F. Sánchez-Cabo et al., "Sumoylated hnRNP2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs," *Nature Communications*, vol. 4, no. 1, p. 2980, 2013.
- [73] T. Gao, J. Shu, and J. Cui, "A systematic approach to RNA-associated motif discovery," *BMC Genomics*, vol. 19, no. 1, p. 146, 2018.
- [74] S. Stuffers, C. Sem Wegner, H. Stenmark, and A. Brech, "Multivesicular endosome biogenesis in the absence of ESCRTs," *Traffic*, vol. 10, no. 7, pp. 925–937, 2009.
- [75] N. Kosaka, H. Iguchi, K. Hagiwara, Y. Yoshioka, F. Takeshita, and T. Ochiya, "Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis," *Journal of Biological Chemistry*, vol. 288, no. 15, pp. 10849–10859, 2013.
- [76] S. Kubota, M. Chiba, M. Watanabe, M. Sakamoto, and N. Watanabe, "Secretion of small/microRNAs including miR-638 into extracellular spaces by sphingomyelin phosphodiesterase 3," *Oncology Reports*, vol. 33, no. 1, pp. 67–73, 2015.
- [77] S. Yan, G. Dang, X. Zhang et al., "Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients," *Oncotarget*, vol. 8, no. 42, pp. 72220–72226, 2017.
- [78] S. Yan, B. Han, S. Gao et al., "Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer," *Oncotarget*, vol. 8, no. 36, pp. 60149–60158, 2017.
- [79] J. Guduric-Fuchs, A. O'Connor, B. Camp, C. L. O'Neill, R. J. Medina, and D. A. Simpson, "Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types," *BMC Genomics*, vol. 13, no. 1, p. 357, 2012.
- [80] Y. S. Lee, S. Pressman, A. P. Andress et al., "Silencing by small RNAs is linked to endosomal trafficking," *Nature Cell Biology*, vol. 11, no. 9, pp. 1150–1156, 2009.
- [81] G. van Niel, G. D'Angelo, and G. Raposo, "Shedding light on the cell biology of extracellular vesicles," *Nature Reviews Molecular Cell Biology*, vol. 19, no. 4, pp. 213–228, 2018.
- [82] B. Shen, N. Wu, J.-M. Yang, and S. J. Gould, "Protein targeting to exosomes/microvesicles by plasma membrane anchors," *Journal of Biological Chemistry*, vol. 286, no. 16, pp. 14383–14395, 2011.
- [83] F. M. Tuccillo, A. de Laurentis, C. Palmieri et al., "Aberrant glycosylation as biomarker for cancer: focus on CD43," *BioMed Research International*, vol. 2014, Article ID 742831, 13 pages, 2014.
- [84] H. Ji, M. Chen, D. W. Greening et al., "Deep sequencing of RNA from three different extracellular vesicle (EV) subtypes released from the human LIM1863 colon cancer cell line uncovers distinct miRNA-enrichment signatures," *PLoS One*, vol. 9, no. 10, Article ID e110314, 2014.

- [85] T. Akman, I. Oztop, Y. Baskin et al., "The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status," *Journal of Cancer Research and Therapeutics*, vol. 12, no. 1, pp. 96–102, 2016.
- [86] S. Perincheri and P. Hui, "KRAS mutation testing in clinical practice," *Expert Review of Molecular Diagnostics*, vol. 15, no. 3, pp. 375–384, 2015.
- [87] R. Wong and D. Cunningham, "Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies," *Journal of Clinical Oncology*, vol. 26, no. 35, pp. 5668–5670, 2008.
- [88] M. Demory Beckler, J. N. Higginbotham, J. L. Franklin et al., "Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS," *Molecular and Cellular Proteomics*, vol. 12, no. 2, pp. 343–355, 2013.
- [89] J. N. Higginbotham, M. Demory Beckler, J. D. Gephart et al., "Amphiregulin exosomes increase cancer cell invasion," *Current Biology*, vol. 21, no. 9, pp. 779–786, 2011.
- [90] D. J. Cha, J. L. Franklin, Y. Dou et al., "KRAS-dependent sorting of miRNA to exosomes," *eLife*, vol. 4, article e07197, 2015.
- [91] A. J. McKenzie, D. Hoshino, N. H. Hong et al., "KRAS-MEK signaling controls Ago2 sorting into exosomes," *Cell Reports*, vol. 15, no. 5, pp. 978–987, 2016.
- [92] Y. Teng, Y. Ren, X. Hu et al., "MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression," *Nature Communications*, vol. 8, no. 1, p. 14448, 2017.
- [93] S. M. Sisodiya, L. Martinian, G. L. Scheffer et al., "Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies," *Neuropathology and Applied Neurobiology*, vol. 32, no. 1, pp. 51–63, 2006.
- [94] Y.-N. Zhao, D.-N. He, Y.-D. Wang, J.-J. Li, and M.-W. Ha, "Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer," *Oncology Letters*, vol. 11, no. 4, pp. 2925–2933, 2016.
- [95] M. S. Ostenfeld, D. K. Jeppesen, J. R. Laurberg et al., "Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties," *Cancer Research*, vol. 74, no. 20, pp. 5758–5771, 2014.
- [96] W.-X. Chen, X.-M. Liu, M.-M. Lv et al., "Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs," *PLoS One*, vol. 9, no. 4, Article ID e95240, 2014.
- [97] K. Valencia, D. Luis-Ravelo, N. Bovy et al., "miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization," *Molecular Oncology*, vol. 8, no. 3, pp. 689–703, 2014.
- [98] Z. Zhang, T. Xing, Y. Chen, and J. Xiao, "Exosome-mediated miR-200b promotes colorectal cancer proliferation upon TGF- $\beta$ 1 exposure," *Biomedicine and Pharmacotherapy*, vol. 106, pp. 1135–1143, 2018.
- [99] M. Chiba, M. Kimura, and S. Asari, "Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines," *Oncology Reports*, vol. 28, no. 5, pp. 1551–1558, 2012.
- [100] M. Tsukamoto, H. Iinuma, T. Yagi, K. Matsuda, and Y. Hashiguchi, "Circulating exosomal microRNA-21 as a biomarker in each tumor stage of colorectal cancer," *Oncology*, vol. 92, no. 6, pp. 360–370, 2017.
- [101] M. Zhu, Z. Huang, D. Zhu et al., "A panel of microRNA signature in serum for colorectal cancer diagnosis," *Oncotarget*, vol. 8, pp. 17081–17091, 2017.
- [102] C. Wei, Y. Li, K. Huang, G. Li, and M. He, "Exosomal miR-1246 in body fluids is a potential biomarker for gastrointestinal cancer," *Biomarkers in Medicine*, vol. 12, no. 10, pp. 1185–1196, 2018.
- [103] R. Bhome, R. W. Goh, M. D. Bullock et al., "Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression," *Aging*, vol. 9, no. 12, pp. 2666–2694, 2017.
- [104] J. Lan, L. Sun, F. Xu et al., "M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer," *Cancer Research*, vol. 79, no. 1, pp. 146–158, 2019.
- [105] M. Monzo, S. Santasusagna, I. Moreno et al., "Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer," *Oncotarget*, vol. 8, pp. 30859–30869, 2017.
- [106] F. Fu, W. Jiang, L. Zhou, and Z. Chen, "Circulating exosomal miR-17-5p and miR-92a-3p predict pathologic stage and grade of colorectal cancer," *Translational Oncology*, vol. 11, no. 2, pp. 221–232, 2018.
- [107] M. Chen, R. Xu, A. Rai et al., "Distinct shed microvesicle and exosome microRNA signatures reveal diagnostic markers for colorectal cancer," *PLoS One*, vol. 14, no. 1, Article ID e0210003, 2019.
- [108] S. Tanaka, M. Hosokawa, K. Ueda, and S. Iwakawa, "Effects of decitabine on invasion and exosomal expression of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells," *Biological and Pharmaceutical Bulletin*, vol. 38, no. 9, pp. 1272–1279, 2015.
- [109] S. Holzner, D. Senfter, S. Stadler et al., "Colorectal cancer cell-derived microRNA200 modulates the resistance of adjacent blood endothelial barriers in vitro," *Oncology Reports*, vol. 36, no. 5, pp. 3065–3071, 2016.
- [110] D. Senfter, S. Holzner, M. Kalipciyan et al., "Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro," *Human Molecular Genetics*, vol. 24, pp. 3689–3698, 2015.
- [111] T. Cooks, I. S. Pateras, L. M. Jenkins et al., "Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246," *Nature Communications*, vol. 9, no. 1, p. 771, 2018.
- [112] J. Li, B. Li, C. Ren et al., "The clinical significance of circulating GPC1 positive exosomes and its regulative miRNAs in colon cancer patients," *Oncotarget*, vol. 8, pp. 101189–101202, 2017.
- [113] J. Li, Y. Chen, X. Guo et al., "GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer," *Journal of Cellular and Molecular Medicine*, vol. 21, no. 5, pp. 838–847, 2017.
- [114] X. Liu, X. Chen, K. Zeng et al., "DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/ $\beta$ -catenin signal pathways," *Cell Death and Disease*, vol. 9, p. 1037, 2018.
- [115] S. Yan, G. Liu, C. Jin et al., "MicroRNA-6869-5p acts as a tumor suppressor via targeting TLR4/NF- $\kappa$ B signaling pathway in colorectal cancer," *Journal of Cellular Physiology*, vol. 233, no. 9, pp. 6660–6668, 2018.
- [116] A. Mizoguchi, A. Takayama, T. Arai, J. Kawachi, and H. Sudo, "MicroRNA-8073: tumor suppressor and potential

- therapeutic treatment," *PLoS One*, vol. 13, no. 12, Article ID e0209750, 2018.
- [117] G. Dai, X. Yao, Y. Zhang et al., "Colorectal cancer cell-derived exosomes containing miR-10b regulate fibroblast cells via the PI3K/Akt pathway," *Bulletin du Cancer*, vol. 105, no. 4, pp. 336–349, 2018.
- [118] H. Li and F. Li, "Exosomes from BM-MSCs increase the population of CSCs via transfer of miR-142-3p," *British Journal of Cancer*, vol. 119, no. 6, pp. 744–755, 2018.
- [119] D. Ren, B. Lin, X. Zhang et al., "Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway," *Oncotarget*, vol. 8, no. 30, pp. 49807–49823, 2017.
- [120] T. Fuji, Y. Umeda, A. Nyuya et al., "Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy," *International Journal of Cancer*, vol. 144, no. 9, pp. 2169–2180, 2019.
- [121] W. Wang, X. Yuan, A. Xu et al., "Human cancer cells suppress behaviors of endothelial progenitor cells through miR-21 targeting IL6R," *Microvascular Research*, vol. 120, pp. 21–28, 2018.
- [122] M. D. Bullock, K. Pickard, R. Mitter et al., "Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs," *Oncotarget*, vol. 6, no. 9, pp. 7262–7279, 2015.
- [123] M. R. Riih a and P. A. Puolakkainen, "Tumor-associated macrophages (TAMs) as biomarkers for gastric cancer: a review," *Chronic Diseases and Translational Medicine*, vol. 4, no. 3, pp. 156–163, 2018.
- [124] S. Santasusagna, I. Moreno, A. Navarro et al., "Prognostic impact of mir-200 family members in plasma and exosomes from tumor-draining versus peripheral veins of colon cancer patients," *Oncology*, vol. 95, no. 5, pp. 309–318, 2018.
- [125] A. I. Robles, J. Jen, and C. C. Harris, "Clinical outcomes of TP53 mutations in cancers," *Cold Spring Harbor Perspectives in Medicine*, vol. 6, no. 9, 2016.
- [126] T. Aikawa, C. A. Whipple, M. E. Lopez et al., "Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells," *Journal of Clinical Investigation*, vol. 118, no. 1, pp. 89–99, 2008.
- [127] K. Matsuda, H. Maruyama, F. Guo et al., "Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells," *Cancer Research*, vol. 61, pp. 5562–5569, 2001.
- [128] G. Su, K. Meyer, C. D. Nandini, D. Qiao, S. Salamat, and A. Friedl, "Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells," *The American Journal of Pathology*, vol. 168, no. 6, pp. 2014–2026, 2006.
- [129] S. A. Melo, L. B. Luecke, C. Kahlert et al., "Glypican-1 identifies cancer exosomes and detects early pancreatic cancer," *Nature*, vol. 523, no. 7559, pp. 177–182, 2015.
- [130] R. Singh, R. Pochampally, K. Watabe, Z. Lu, and Y.-Y. Mo, "Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer," *Molecular Cancer*, vol. 13, no. 1, p. 256, 2014.
- [131] Q. Liu, Z. Yu, S. Yuan et al., "Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer," *Oncotarget*, vol. 8, pp. 13048–13058, 2016.
- [132] Y. Wang, Z. Li, X. Zhao, X. Zuo, and Z. Peng, "miR-10b promotes invasion by targeting HOXD10 in colorectal cancer," *Oncology Letters*, vol. 12, no. 1, pp. 488–494, 2016.
- [133] Y. Guo, K. Zhang, C. Cheng et al., "Numb–flowEnriches a castration-resistant prostate cancer cell subpopulation associated with enhanced Notch and hedgehog signaling," *Clinical Cancer Research*, vol. 23, no. 21, pp. 6744–6756, 2017.
- [134] X. Tang, T. B. Kuhlenschmidt, Q. Li et al., "A mechanically-induced colon cancer cell population shows increased metastatic potential," *Molecular Cancer*, vol. 13, no. 1, p. 131, 2014.
- [135] L. Liu, T. Meng, X.-H. Yang et al., "Prognostic and predictive value of long non-coding RNA GAS5 and microRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion," *Cancer Biomarkers*, vol. 22, no. 2, pp. 283–299, 2018.
- [136] J. Wang, F. Yan, Q. Zhao et al., "Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer," *Scientific Reports*, vol. 7, no. 1, p. 4150, 2017.
- [137] C. Liu, C. Eng, J. Shen et al., "Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer," *Oncotarget*, vol. 7, no. 46, pp. 76250–76260, 2016.
- [138] S. Yan, Y. Jiang, C. Liang et al., "Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer," *Journal of Cellular Biochemistry*, vol. 119, no. 5, pp. 4113–4119, 2018.
- [139] Z.-Y. Peng, R.-H. Gu, and B. Yan, "Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer," *Journal of Extracellular Vesicles*, vol. 4, no. 1, p. 27031, 2018.
- [140] C. Th ery, K. W. Witwer, E. Aikawa et al., "Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines," *Journal of Extracellular Vesicles*, vol. 7, Article ID 1535750, 2018.
- [141] R. J. Lobb, M. Becker, S. Wen Wen et al., "Optimized exosome isolation protocol for cell culture supernatant and human plasma," *Journal of Extracellular Vesicles*, vol. 4, no. 1, p. 27031, 2015.
- [142] J. Van Deun, P. Mestdagh, R. Sormunen et al., "The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling," *Journal of Extracellular Vesicles*, vol. 3, no. 1, p. 24858, 2014.
- [143] J. Karttunen, M. Heiskanen, V. Navarro-Ferrandis et al., "Precipitation-based extracellular vesicle isolation from rat plasma co-precipitate vesicle-free microRNAs," *Journal of Extracellular Vesicles*, vol. 8, no. 1, Article ID 1555410, 2019.
- [144] A. Gallo, M. Tandon, I. Alevizos, and G. G. Illei, "The majority of microRNAs detectable in serum and saliva is concentrated in exosomes," *PLoS One*, vol. 7, Article ID e30679, 2012.
- [145] K. Kai, R. L. Dittmar, and S. Sen, "Secretory microRNAs as biomarkers of cancer," *Seminars in Cell and Developmental Biology*, vol. 78, pp. 22–36, 2018.
- [146] R. Uratani, Y. Toyama, T. Kitajima et al., "Diagnostic potential of cell-free and exosomal MicroRNAs in the identification of patients with high-risk colorectal adenomas," *PLoS One*, vol. 11, Article ID e0160722, 2016.
- [147] E. Endzeliņš, A. Berger, V. Melne et al., "Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients," *BMC Cancer*, vol. 17, p. 730, 2017.
- [148] D. Lucchetti, F. Calap a, V. Palmieri et al., "Differentiation affects the release of exosomes from colon cancer cells and their ability to modulate the behavior of recipient cells." *The*

- American Journal of Pathology*, vol. 187, no. 7, pp. 1633–1647, 2017.
- [149] D. Zabeo, A. Cvjetkovic, C. Lässer, M. Schorb, J. Lötval, and J. L. Höög, “Exosomes purified from a single cell type have diverse morphology,” *Journal of Extracellular Vesicles*, vol. 6, no. 1, p. 1329476, 2017.
- [150] B. J. Tauro, D. W. Greening, R. A. Mathias, S. Mathivanan, H. Ji, and R. J. Simpson, “Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids,” *Molecular and Cellular Proteomics*, vol. 12, no. 3, pp. 587–598, 2013.
- [151] B. J. Tauro, D. W. Greening, R. A. Mathias et al., “Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes,” *Methods*, vol. 56, no. 2, pp. 293–304, 2012.
- [152] S. Rana, S. Yue, D. Stadel, and M. Zöller, “Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection,” *The International Journal of Biochemistry and Cell Biology*, vol. 44, no. 9, pp. 1574–1584, 2012.
- [153] A. Hoshino, B. Costa-Silva, T.-L. Shen et al., “Tumour exosome integrins determine organotropic metastasis,” *Nature*, vol. 527, no. 7578, pp. 329–335, 2015.
- [154] C. Chakraborty, A. R. Sharma, G. Sharma, C. G. P. Doss, and S.-S. Lee, “Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine,” *Molecular Therapy-Nucleic Acids*, vol. 8, pp. 132–143, 2017.
- [155] S. Lakhil and M. J. A. Wood, “Exosome nanotechnology: an emerging paradigm shift in drug delivery,” *BioEssays*, vol. 33, no. 10, pp. 737–741, 2011.
- [156] Z. Naseri, R. Kazemi Oskuee, M. R. Jaafari, and M. Forouzandeh, “Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo,” *International Journal of Nanomedicine*, vol. 13, pp. 7727–7747, 2018.
- [157] M. Hayashi, K. Kuroda, K. Ihara, T. Iwaya, and E. Isogai, “Suppressive effect of an analog of the antimicrobial peptide of LL-37 on colon cancer cells via exosome-encapsulated miRNAs,” *International Journal of Molecular Medicine*, vol. 42, pp. 3009–3016, 2018.
- [158] D. Kyuno, K. Zhao, N. Bauer, E. Ryschich, and M. Zöller, “Therapeutic targeting cancer-initiating cell markers by exosome miRNA: efficacy and functional consequences exemplified for claudin7 and EpCAM,” *Translational Oncology*, vol. 12, no. 2, pp. 191–199, 2019.

## ANNEXE 4

*The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7*

Dominique Thuringer, Gaëtan Chanteloup, Pascale Winckler and Carmen Garrido



## The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7

Dominique Thuringer<sup>1,2</sup>, Gaetan Chanteloup<sup>1,2</sup>, Pascale Winckler<sup>3</sup> and Carmen Garrido<sup>1,2,4</sup>

<sup>1</sup>INSERM U1231, Laboratory of Excellence Ligue Nationale contre le Cancer, 21000 Dijon, France

<sup>2</sup>Université de Bourgogne Franche Comté, 21000 Dijon, France

<sup>3</sup>AgroSup Dijon, PAM UMR, DIMaCell Imaging Facility, Université de Bourgogne Franche Comté, 21000 Dijon, France

<sup>4</sup>Centre Georges François Lederer (CGFL), 21000 Dijon, France

**Correspondence to:** Dominique Thuringer, **email:** dominique.thuringer@u-bourgogne.fr

**Keywords:** chloride intracellular channel; microRNA; exosome; transient receptor potential melastatin; glioblastoma

**Received:** April 23, 2018

**Accepted:** August 16, 2018

**Published:** September 07, 2018

**Copyright:** Thuringer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### ABSTRACT

**Chloride intracellular channel 1 (CLIC1) is highly expressed and secreted by human glioblastoma cells and cell lines such as U87, initiating cell migration and tumor growth. Here, we examined whether CLIC1 could be transferred to human primary microvascular endothelial cells (HMEC). We previously reported that the oncogenic microRNA, miR-5096, increased the release of extracellular vesicles (EVs) by which it increased its own transfer from U87 to surrounding cells. Thus, we also examined its effect on the CLIC1 transfer. In homotypic cultures, miR-5096 did not increase the expression of CLIC1 in U87 nor in HMEC. However, the endothelial CLIC1 level increased after exposure to EVs released by U87, and even more by miR-5096-loaded U87. The EVs-transferred CLIC1 was active in HMEC, promoting endothelial sprouting in matrigel. Cell exposure to EVs induced cytosolic Ca<sup>2+</sup> spikes which were dependent on the transient receptor potential melastatin member 7 (TRPM7). TRPM7 silencing prevented Ca<sup>2+</sup> spikes and the subsequent CLIC1 delivery into HMEC. Our data suggest that the vesicular transfer of CLIC1 between cells requires TRPM7 expression in recipient endothelial cells. How the vesicular transfer of CLIC1 is modulated in cancer therapy is a future challenge.**

### INTRODUCTION

Extracellular vesicles (EVs) are membrane-enclosed particles released from either endosomes or the cell surface [1–3]. EVs are composed of an array of proteins, nucleic acids, lipids, and other metabolites that reflect the cell of origin. They offer an intercellular route to transfer oncogenic material that change the functions of non-malignant cells, i.e. proliferation, invasion, and angiogenesis [2]. Their secretion is correlated to the cell's ability to produce invadopodia (actin-rich cellular protrusions with proteolytic activity); i.e., inhibition of invadopodia formation decreased exosome release [3–5]. Importantly, glioblastoma (GBM)-derived EVs can cross

the brain–blood-barrier and are detectable in the systemic blood circulation [6]. Profiling the composition of GBM-derived EVs may, therefore, offer a non-invasive means of assessing tumors *in situ* [4].

Studies have described extensive RNA expression analyses of GBM-derived EVs, however, proteomic profiles are currently limited [4, 7]. Among the vesicular proteins, one study identify the chloride intracellular channels (CLIC) carried by exosomes between GBM cells [8]. The CLIC family form a class of proteins that do not fit the paradigm set by classical ion channels (for review see; [9–11]). They can exist as both soluble globular proteins and integral membrane proteins with ion channel function. The first member of CLIC, namely

CLIC1 (also known as NCC27), holds pathological implications in a variety of tumors, being involved in cell proliferation, motility, and angiogenesis [12–15]. CLIC1 is overexpressed in glioblastoma (GBM), with highest expression in patients with poor prognosis [13]. CLIC1 is also secreted in extracellular vesicles (EVs) by cancer cells [8] and is detected in biological fluids [8, 16, 17], fostering the hypothesis that secreted CLIC1 protein may increase GBM growth. Interestingly, Setti et al [8] have shown that the secretion of CLIC1 via EVs is common to all human GBM cell lines (U87MG, A172, LN405, U118MG, T98G, DBTRG-05MG and U373 MG). If the number of secreted EVs differs from one type of lineage to another, the membrane markers and biophysical properties of EVs are similar.

Using U87 GBM cell line, we have recently described that miR-5096 increases the outgrowth of filopodia in glioma cells, and promotes the extracellular release of EVs by U87 thereby promoting its own transfer to surrounding cells [18]. Here, we show that EVs also contain active CLIC1 whose amount is not significantly increased by miR-5096. The transfer of CLIC1 to human microvascular endothelial cells (HMEC) requires  $Ca^{2+}$  spikes and TRPM7 for their uptake, and contributes to endothelial sprouting [19, 20].

## RESULTS


### Extracellular vesicles from GBM cells transfer active CLIC1 to HMEC

Both U87 and HMEC expressed CLIC1 proteins, as already reported [12, 21]. Immunoblot analysis of whole cell lysates (WCL) from homotypic cultures revealed that the cell loading with miR-5096 mimic or inhibitor did not significantly change CLIC1 expression after 48h in both U87 and HMEC (Figure 1A). This is in agreement with the absence of miR-5096 effect on CLIC1 mRNA expression (not shown) and predictions from bioinformatics tools which failed to identify any target site for miR-5096 in CLIC1 gene and mRNA. However, the endothelial CLIC1 level was increased after 24h-exposure of HMEC to U87-conditioned media (Figure 1B). We next separated EVs from the effluent (soluble fraction) of culture media as described previously [18]. In all cases, EVs and effluents were adjusted to the same number of U87 (i.e.  $4 \times 10^6$  cells), then applied to homotypic HMEC cultures for 24h. Cell exposure to EVs released from miR-5096-loaded U87 significantly increased CLIC1 levels in HMEC, while the effluent (EVs-free) did not (Figure 1B). The immunoblot analysis of EVs showed an enrichment in the exosome specific protein tsg101 (tumor susceptibility gene 101) [8, 18] (Figure 1C). Clearly, EVs contained CLIC1 proteins and their level seemed to be higher in EVs from miR-loaded U87 than from empty-loaded U87. A possible explanation might be that miR5096 induced an increase

in EVs release [18], rather than a significant increase in CLIC1 vesicular content. To confirm the transfer of CLIC1 to HMEC, endogenous CLIC1 was silenced by using siRNA in a series of experiments (i.e. relative OD of  $0.406 \pm 0.061$  and  $0.015 \pm 0.007$ , respectively before and after CLIC1 silencing;  $P < 0.05$ ,  $n = 3$ ). As shown in Figure 1C, both cellular (WCL) and vesicular (EVs lysates) CLIC1 contents were suppressed in HMEC by CLIC1 siRNA. The CLIC1 immuno-labelling showed that CLIC1 was mostly found in perinuclear areas of control HMEC (Figure 1D). No labelling was observed after silencing CLIC1 in HMEC. After 24h of cell incubations with EVs from miR-5096 loaded U87, we detected CLIC1 in both the cytosol and the plasma membrane of control and silenced HMEC. We also overexpressed a fluorescent-tagged version of human CLIC1 in U87 and collected conditioned media after 48h (see Supplementary Figure 2). Exposure of HMEC to isolated EVs resulted to the fluorescent labelling of HMEC after 24h. Thus, the increase of CLIC1 in HMEC resulted more from a vesicular transfer of CLIC1 rather than an up-regulation of its endogenous expression in recipient HMEC. Are the transferred proteins active in the recipient cells? Using a 24-hour three-dimensional *in vitro* angiogenesis assay, we explored the ability of vesicular CLIC1 to induce endothelial spheroid sprouting [22]. As shown in Figure 1E, EVs stimulated HMEC sprouting even more when collected from miR-loaded U87 (M) (see also Supplementary Figure 1A). This effect was partially prevented by silencing CLIC1 in U87 (Msi). To confirm the contribution of vesicular CLIC1 to angiogenesis, EVs were also tested on branching morphogenesis *in vitro* [22]. HMEC control and CLIC1 silenced were plated in ECM gel and exposed or not (Co) to EVs collected from the same number of U87. Quantification of average number of processes per cell was performed after 12h (Figure 1F; see also Supplementary Figure 1B). Silencing CLIC1 in HMEC decreased the branching as expected for its contribution to *in vitro* angiogenesis [12]. Exposure to EVs stimulated the branching even more when collected from miR-5096-loaded U87 (M). This effect was partially prevented by silencing CLIC1 in secretory U87 (Msi). Thus, the vesicular CLIC1 was active in recipient HMEC and contributed to early steps of *in vitro* angiogenesis [12].

### EVs-mediated CLIC1 transfer to HMEC requires TRPM7-dependent $Ca^{2+}$ signaling

In order for EVs to elicit a signaling response from recipient cells, they can fuse with plasma membrane or are taken up via endocytosis or attach to the cell surface [23] (see Supplementary Figure 2). Since endocytosis, receptor internalization and trafficking are regulated by cytosolic  $Ca^{2+}$  level [24, 25], we determined whether the endothelial uptake of vesicular CLIC1 was associated with cytosolic  $Ca^{2+}$  fluctuations. Spatio-temporal  $Ca^{2+}$



**Figure 1: Active CLIC1 protein is transferred via vesicles from GBM to endothelial cells.** Immunoblot analysis of CLIC1 in whole cell lysates (WCL) from homotypic cultures of U87 and HMEC, 48 h after loading. Untreated cells were used as control (Co). Cells were loaded empty (E) or with 30nM miR5096 mimic (M) or inhibitor (I). β-actin as loading control (60μg proteins/lane). Numbers indicate mean values of optical densities (OD) of CLIC1 relative to β-actin (± SD;  $P > 0.05$  vs Co;  $n = 3$ ). (B) CLIC1 increased in HMEC after 24 h of incubation with EVs. Cell-conditioned media were collected from homotypic U87 miR-loaded (M) or not (E), 48h after loading. HMEC were exposed to EVs or effluent (soluble fraction) separated from U87-conditioned media. Numbers indicate mean OD values of CLIC1 relative to β-actin (± SD;  $P < 0.05$  vs Co;  $n = 3$ ). (C) EVs contained CLIC1. Lysates of EVs were immunoblotted for the marker tsq101. Homotypic U87 were loaded (M) or not (E) upon transfection of control siRNA or siRNA targeting CLIC1. Silencing CLIC1 was also tested in HMEC (WCL) and HMEC-released EVs (Hsc70 as loading control). Numbers indicate mean OD values of CLIC1 related to tsq101 for EVs lysates (± SD;  $P < 0.05$  vs Co (E);  $n = 4$ ). (D) Endothelial cell localization of CLIC1. HMEC were silenced by siRNA CLIC1 then exposed to EVs collected from homotypic U87 (M) ( $n = 3$ ). CLIC1 stained with alexa Fluor 594 (red) and nuclear DNA with Dapi (blue). (E) CLIC1 effect on the length of endothelial sprouts formed from spheroids in Matrigel for 24h, in the absence (Co) or the presence of EVs collected from homotypic U87 empty (E) or miR5096-loaded (M). When indicated by Msi, CLIC1 was silenced by siRNA in U87 (M). Data are means ± SD ( $P$ -values  $< 0.05$  vs control;  $n = 10$ ) in two independent experiments. (F) Contribution of CLIC1 to the branching morphogenesis in HMEC cultured in collagen ECM gel for 12 h, in the absence (Co) or presence of EVs. Histogram shows the average number of processes per cell. Control and CLIC1 siRNA HMEC are filled black and yellow, respectively. Data are means ± SD ( $P < 0.05$ ,  $^{**}P < 0.01$  vs Co;  $n = 10$ ) in two experiments. (G) EVs induced  $Ca^{2+}$  spikes in HMEC. Representative line scan images of cytosolic  $[Ca^{2+}]$  in Fluo-4-loaded HMEC exposed to the standard solution, to EGF (10 ng/ml) and to EVs (from U87) as indicated by arrows. Space and time ordinates are displayed in the horizontal and vertical directions, respectively (scan rate 22.3 μsec/line). Amplitudes of  $Ca^{2+}$  signal are expressed as the fluorescent rapport  $F/F_0$  (pseudo-colors) in a tridimensional histogram ( $F/F_0$  vs space/time). In all cases, the line scan crossed both cytosol and nuclei of 4 adjacent cells, as shown in the 1024x1024 pixel panel. Note that  $Ca^{2+}$  spikes were observed at the beginning of all recordings (due to the initial cell perfusion) and were not reproduced by reapplying the standard solution.


variations were recorded in HMEC loaded with Fluo-4 by using line scanning of confocal microscopy [26]. No  $\text{Ca}^{2+}$  spike was observed in standard external conditions (Figure 1G; upper panel). As a positive control, HMEC were exposed to epidermal growth factor (EGF), inducing a typical pattern of  $\text{Ca}^{2+}$  signal [27], i.e. a rapid increase in cytosolic  $\text{Ca}^{2+}$  which was maintained several minutes before decaying to the resting level, followed by a second transient increase observed about 6 min later. The endothelial cell exposure to EVs from U87 elicited a similar  $\text{Ca}^{2+}$  signal although with a lower amplitude than did EGF (i.e. max  $F/F_0$  of  $1000 \pm 500$  with EVs and  $3000 \pm 600$  with EGF;  $P < 0.05$ ,  $n = 6$ ). Of note, the lag time between successive  $\text{Ca}^{2+}$  waves was similar ( $6.61 \pm 1.25$  min;  $P > 0.05$ ;  $n = 6$ ). The well-known inhibitor of  $\text{Ca}^{2+}$  pathways, 2-APB [28–31], suppressed EVs-evoked  $\text{Ca}^{2+}$  signal (Figure 2A, lower panel) as well as the subsequently CLIC1 delivery to HMEC (Figure 2B). Indeed, incubations of 2-APB-treated HMEC with EVs for 24 h did not increase CLIC1 labelling, especially in CLIC1-silenced HMEC (Figure 2B). Among 2-APB-sensitive channels in plasma membranes, the melastatin-subfamily of TRP (TRPM7) is a non-specific divalent cation channel upregulated in GBM [29]. To estimate its contribution in both  $\text{Ca}^{2+}$  waves and CLIC1 delivery to HMEC, endogenous TRPM7 was silenced by using siRNA (Figure 2C, 2D). Cell exposure to EVs already produced cytosolic  $\text{Ca}^{2+}$  waves which were decreased by silencing TRPM7 (Figure 2E). Unfortunately, we could not knockdown both TRPM7 and CLIC1 since HMEC did not survive. After 24h of cell incubations with EVs, CLIC1 labeling was also decreased in cytosol or plasma membrane of TRPM7-silenced HMEC, attesting the partial contribution of TRPM7 in this process (Figure 2F). Of note, cell exposure to soluble fractions (EVs-free effluent) from U87-conditioned media did not increase TRPM7 levels in HMEC, while the miR5096 loading or Kir4.1 silencing did (Figure 2C, 2G). Thus, the vesicular transfer of CLIC1 to HMEC required  $\text{Ca}^{2+}$  signaling mediated, at least in part, by TRPM7.

## DISCUSSION

We report here that CLIC1 protein is transferred via EVs from the GBM cell line U87 to microvascular endothelial cells where it remains active, i.e. induces endothelial sprouting. When applied onto HMEC, EVs elicit  $\text{Ca}^{2+}$  “spikes” which can be prevented by 2-APB. Although 2-APB inhibits numerous channels including  $\text{IP}_3$  receptors [28], store-operated  $\text{Ca}^{2+}$  channels [30] and TRP channels [29, 31], silencing TRPM7 prevents  $\text{Ca}^{2+}$  spikes and the subsequent CLIC1 uptake by HMEC. Altogether, our data show that CLIC1 secreted by cancer cells via extracellular vesicles, modulates the activity of neighboring endothelial cells in a TRPM7 dependent manner, promoting tumor angiogenesis.

We previously reported that miR-5096 favors its own transfer from U87 to HMEC via an increased release of EVs, two days after its loading in U87 [18]. Here, we show that EVs also contain CLIC1 and mostly ensure its transfer to HMEC (Figure 1; see also Supplementary Figure 2). EVs are composed of an array of proteins, nucleic acids, lipids, and other metabolites that reflect the cell of origin [4]. We report that EVs, secreted by the same number of U87, produce a greater increase in active CLIC1 in the recipient HMEC when the donor U87 are previously loaded with miR-5096. The most likely explanation is that miR-5096 induces an increase in EVs release [18], rather than a significant increase in CLIC1 vesicular content. How miR-5096 exerts such an effect is currently unknown and not explored in our study. Nevertheless, evidence increasingly points to a connection between lipid metabolism and cancer, characterized by an alteration in the mechanisms that regulate cholesterol homeostasis [32]. It is known that the survival of GBM cells is dependent on uptake of cholesterol [33] in which some microRNAs are the fine tuners [34, 35]. Interestingly, cholesterol promotes the conversion of CLIC1 from cytosolic to transmembrane proteins [36], thus facilitates its docking to the membranes [37, 38]. Drawing on the data above, we propose a pure speculative model where miR-5096 increases cholesterol and CLIC1 is involved in recruiting EVs, leading to an increased secretion of EVs by U87 cells (see Supplementary Figure 3).

By overexpressing fluorescent-tagged CLIC1 proteins (CLIC1-OPF) in U87, we observe CLIC1-OPF inside the invadopodia (see Supplementary Figure 2B). Upon exposure to EVs, HMEC become fluorescent and change their morphology; i.e. showing invadopodia formation. Invadopodia act as multivesicular endosome docking sites and are a site of EVs release, meaning the cell's ability to form invadopodia determines their ability to release of EVs [4, 5]. In this process, CLIC1 would contribute to the formation of invadopodia in endothelial and tumor cells, by inducing integrin-mediated actomyosin dynamic [15]. Changes in CLIC1 location from cytosolic to transmembrane proteins are associated with malignant transformation [15]. Our study does not allow to distinguish the two forms of CLIC1 (i.e. soluble form and membrane-inserted chloride conducting pore). However, immuno-labeling of CLIC1 confirms its previously described nuclear location in steady HMEC [9]. Following exposure to EVs, CLIC1 is also detected in cytosol and weakly at the plasma membrane of HMEC within 24h. On the other hand, the endothelial sprouting in matrigel is increased by EVs within 24h. This effect is partially prevented by silencing CLIC1 in donor U87 and is not attributed to miR-5096 itself [39]. Our results are in agreement with the literature showing that a low CLIC1 expression in endothelium decreases capillary-like sprouting in matrigel [12, 14, 15]. We observe a functional difference between silencing all CLIC1 and preventing



**Figure 2: The vesicular transfer of CLIC1 requires cytosolic  $Ca^{2+}$  increases in HMEC.** (A) Line scan images of cytosolic  $[Ca^{2+}]$  increases in Fluo-4 loaded HMEC exposed to the same amount of EVs collected from the same homotypic U87 culture. HMEC were pre-treated with 2-APB (50  $\mu$ M; lower panel). Tridimensional histogram ( $F/F_0$  vs space/time) are representative of 3 experiments. (B) Transfer of vesicular CLIC1 was blocked by 2-APB (50  $\mu$ M). HMEC silenced by siRNA CLIC1 were exposed to EVs from U87 (n = 3). After 24h of incubation with EVs, HMEC were stained for CLIC1 (red) and nuclei (blue). (C) Expression of TRPM7 in HMEC. Homotypic HMEC were loaded (M) or not (E) with miR-5096 upon transfection of control siRNA or siRNA targeting TRPM7. Numbers indicate mean OD values of TRPM7 related to  $\beta$ -actin ( $\pm$  SD; n = 2; 80 $\mu$ g proteins/lane). (D) Spatially average  $Ca^{2+}$  profile showing the dynamic change of  $Ca^{2+}$  signals with time and induced by EVs (applied at the beginning of the records) then EGF (10 ng/ml) applied at the time indicated by arrow. Cytosolic  $Ca^{2+}$  store depletion was performed by the addition of thapsigargin (TSG, 5 $\mu$ M) at the end of recordings. Values are means of fluorescent ratio  $F/F_0 \pm$  SD; n = 3. (E) Silencing TRPM7 in HMEC reduced the  $Ca^{2+}$  signal induced by EVs collected from homotypic U87 for 48h. (F) Control and silenced TRPM7 HMEC were exposed to EVs and stained for CLIC1 (red) after 24 h of culture (representative of 3 experiments). (G) Expression of TRPM7 in homotypic HMEC upon transfection of control siRNA or siRNA targeting Kir4.1 [18]. HMEC were exposed to the effluent (soluble fraction) from homotypic U87. Numbers indicate mean OD values of TRPM7 related to  $\beta$ -actin ( $\pm$  SD; n = 2).

only the U87-derived CLIC1 delivery. This cannot be easily explained since EVs probably contain proangiogenic factors, miRNAs and extracellular proteases which are required by endothelial cells to proliferate, migrate, and organize into new tubular structures [4, 40]. For instance, EVs from xenografts of glioblastomas contain an oncogenic variant of the epidermal growth factor receptor (EGFRvIII), which can be transferred to endothelial cells, producing proliferation and tubulogenesis [41, 42]. A broad array of cell surface and signaling proteins is involved in tubulogenesis [43], and could explain why the perivascular invasion is more important in vascular endothelial growth factor (VEGF)-deficient glioblastoma cells and brain tumor xenografts treated with anti-VEGF blocking antibodies such as bevacizumab [44, 45].

We hypothesize that EVs bind to recipient endothelial cells (see Supplementary Figure 4). These EVs may remain at the plasma membrane [46] or may be internalized by endocytosis either mediated by clathrin [47, 48] or via caveolae and lipid rafts [49]. These mechanisms require  $Ca^{2+}$  increase at the submembrane level [50, 51]. While the precise mechanism of CLIC1 uptake and processing in HMEC remains unclear, we show for the first time that CLIC1 transfer requires an initial  $Ca^{2+}$  signaling in recipient cells within 1h. Moreover, the EVs-induced  $Ca^{2+}$  signal is suppressed in nominally  $Ca^{2+}$ -free standard solution (i.e. no  $CaCl_2$  added; data not shown), attesting the involvement of an external  $Ca^{2+}$  entry. Among the putative  $Ca^{2+}$  entry pathways, the presence of functional TRPM7 channels is known in human endothelial cells [52–55]. By using specific siRNA, we identify TRPM7 as a mediator for this  $Ca^{2+}$  entry needed for CLIC1 uptake by HMEC. Of note, TRPM7 contributes to the EGF-induced  $Ca^{2+}$  signal, without affecting the  $Ca^{2+}$  content of internal  $Ca^{2+}$  stores sensitive to thapsigargin (see Supplementary Figure 1C).

High CLIC1 expression is involved in the progression of GBM and other tumors [56–58] and correlates with a poor patient outcome [13]. Our data foster the hypothesis that CLIC1 transfer to endothelial cells via EVs contributes to GBM growth by promoting capillary formation [12, 14, 15, 56]. Moreover, the pharmacological inhibition or silencing of TRPM7 inhibits adhesion or invasion in cancer cell lines [19, 59–61] as well as migration of HMEC [53]. Of note, TRPM7 expression is increased in miR-5096 loaded U87 (see Supplementary Figure 1D). Because the silencing of potassium Kir4.1 channels [18] also produces this increase, this up-regulation of TRPM7 should result more from a membrane potential variation than from a direct effect of miR-5096 on TRPM7 gene or mRNA [62]. Nevertheless, it is still not clear whether other proteins and miRNAs could be transferred via EVs to modulate channels in recipient cells [63, 64]. Further investigations are required to fully resolve the functional capabilities of EVs [65–67].

## MATERIALS AND METHODS

### Cells

Human primary microvascular HMEC (HMVEC-D; Lonza) and U87-MG cells (ATCC HTB-14) were grown in DMEM plus 10% FCS (5%  $CO_2$ ; 37°C). Cells were incubated 48 h in FCS-free media before use.

### Reagents

Monoclonal anti-Tsg101, anti-Hsc70 and anti- $\beta$ -actin were purchased from Santa Cruz Biotech (Clinisciences, Fr). Monoclonal anti-CLIC1 (ab77214) and anti-TRPM7 (ab109438) were from Abcam. Fluo-4 acetomethyl (AM) ester was from Invitrogen (ThermoFisher). 2-Aminoethyl diphenylborinate (2-APB), thapsigargin (TSG) and other chemicals were from Sigma-Aldrich.

### Transfection

Cells were transfected by lipofectamine RNAiMAX according to the manufacturer's protocol (Invitrogen). Human hsa-miR-5096 mimic (mirVana TM miRNA, 4464066-MC22429) and inhibitor (4464084-MH22429) were purchased from Ambion (Invitrogen; ThermoFisher) [18]. Human TRPM7 siRNA (ID 1490) and CLIC1 siRNA (ID 145733) were purchased from (Ambion, AM51331). The sequences were: siRNA CLIC1 (5'-GAGCUUGUGUUGUGCUGAAtt-3' and 5'-UUCAGCACAAACAAGCUCtt-3'); siRNA TRPM7 (5'-GGACCCUCACAGAUGCCUUt-3' and 5'-AAGG CAUCUGUGAGGGUCCtt-3'). To downregulate Kir4.1, cells were transfected with human *KCNJ10* siRNA SMARTpool (30 nM) purchased from Dharmacon (ThermoFisher), as we described previously [18]. To overexpress fluorescent CLIC1 proteins, we transfected U87 cells with the human CLIC1/NCC27 gene ORF cDNA clone expression plasmid, C-OFPSpark (HG15242-ACR, Sino Biological Inc.; purchased from Interchim, Montluçon, Fr). Cells were used after 48h.

### Immunoblotting

Cells were lysed in RIPA buffer, and Western blots were performed as previously described [18]. EVs pellets were lysed in RIPA buffer containing protease inhibitor cocktail (Roche, Indianapolis, IN) then sonicated for 10 s. Insoluble material was pelleted by centrifugation for 15 min at 14,000 g at 4°C.

### Immunofluorescence

Cells were fixed in 4% PFA and permeabilized with 0.1% Triton X-100. Images were performed using a Leica SP2 RS confocal microscope (Z-series of 0.6  $\mu$ m-optical sections; 512x512 pixels).

## EVs isolation

After 48h of culture in FCS-free conditions, cell-conditioned media were collected and sequentially centrifuged at 300 g for 10 min (4°C) then at 2,000 g for 10 min to remove cell debris [18, 68]. EVs were collected by ultracentrifugation at 100,000 g for 90 min. Concentrations were adjusted to the same number of cells (i.e. corresponding to the secretion from  $4 \times 10^6$  cells).

## Cell sprouting assay in collagen gels

Sprouting of HMEC spheroids was performed as previously described [69]. For each gel, 8 spheroids (each containing 400 – 500 cells) were seeded into 0.7 ml collagen solution in 24-well plates (PromoCell GmbH) and incubated with the tested solutions for 24h (5% CO<sub>2</sub>; 37°C). The cumulative sprout length of 8 randomly selected spheroids was measured for each tested group.

## Endothelial tube formation assay in collagen gels

Control and silenced CLIC1 HMEC were plated in DMEM ECM gel, with or without EVs collected from U87, according to the manufacturer's instructions (from Cell Biolabs, Inc). After 12 hours of incubation at 37°C, 80 single cells were scored for the number of processes per cell. Each well is duplicated for each experiment, and each experiment was repeated three times.

## Calcium imaging

Spatiotemporal Ca<sup>2+</sup> variations were recorded in HMEC cultured on uncoated glass then loaded with 4μM Fluo4/AM in FCS-free conditions for 40 min at 37°C [26]. Cells were bathed in the standard solution containing (in mM): 136 NaCl, 5 KCl, 1 MgCl<sub>2</sub>, 1.8 CaCl<sub>2</sub>, 0.3 NaH<sub>2</sub>PO<sub>4</sub>, 10 Glucose, and 10 HEPES (pH 7.4). Measurements were performed by a line scan crossing 3-4 cells in a 1024x1024 pixel panel using a confocal microscope (Nikon C1Si) with 100x objective (Nikon, Melville, NY). Excitation was at 488 nm and emission-selected at 500-570 nm. Line scan images in pseudo-colors were acquired at a sampling rate of 22.3 μsec per line (32 lines/sec). To compare cytosolic [Ca<sup>2+</sup>] fluctuations, fluorescent measurements (F) were expressed as the F/F<sub>0</sub> ratio, where F<sub>0</sub> refers to the basal [Ca<sup>2+</sup>] fluorescence at rest [70]. The signal amplitudes were shown in a tridimensional histogram (F/F<sub>0</sub> as a function of time/length).

## Statistical analysis

Results are expressed as mean ± SD. A Mann-Whitney *U* test was used to compare data groups. Statistics were also made with Tanagra software using a Kruskal-Wallis 1-way ANOVA. In all cases, \**P* values < 0.05 were significant.

## ACKNOWLEDGMENTS

We thank greatly Dr Anne Cantereau (ImageUP, STIM CNRS ERL7003 Poitiers) and Dr André Bouchot (Cellmap/IFR100, Dijon) for their technical assistance.

## CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

## FUNDING

This work was supported by Centre National de la Recherche Scientifique (CNRS) and French National Research Agency ANR-11-LABX-0021 (Lipstic Labex). Gaetan Chanteloup is a fellow of Fondation Recherche Médicale (Grant ECO20160736090).

## REFERENCES

1. Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. *Cell Mol Life Sci.* 2018; 75:193-208.
2. Quezada C, Torres A, Niechi I, Uribe D, Contreras-Duarte S, Toledo F, San Martin R, Gutierrez J, Sobrevia L. Role of extracellular vesicles in glioma progression. *Mol Aspects Med.* 2018; 60:38-51.
3. Paterson EK, Courtneidge SA. Invadosomes are coming: new insights into function and disease relevance. *FEBS J.* 2018; 285:8-27.
4. Mallawaarachy DM, Hallal S, Russell B, Ly L, Ebrahimkhani S, Wei H, Christopherson RI, Buckland ME, Kaufman KL. Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. *J Neurooncol.* 2017; 131:233-244.
5. Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, Tyska MJ, Weaver AM. Exosome secretion is enhanced by invadopodia and drives invasive behavior. *Cell Rep.* 2013; 5:1159-1168.
6. Garcia-Romero N, Carrión-Navarro J, Esteban-Rubio S, Lázaro-Ibáñez E, Peris-Celda M, Alonso MM, Guzmán-De-Villoria J, Fernández-Carballal C, de Mendivil AO, García-Duque S, Escobedo-Lucea C, Prat-Acín R, Belda-Iniesta C, Ayuso-Sacido A. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. *Oncotarget.* 2017; 8:1416–28. <https://doi.org/10.18632/oncotarget.13635>.
7. Park J, Im H, Hong S, Castro CM, Weissleder R, Lee H. Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. *ACS Photonics.* 2018; 5:487-494.
8. Setti M, Osti D, Richichi C, Ortensi B, Del Bene M, Fomasari L, Beznoussenko G, Mironov A, Rappa G,

- Cuomo A, Faretta M, Bonaldi T, Lorico A, Pelicci G. Extracellular vesicle-mediated transfer of CLIC1 protein is a novel mechanism for the regulation of glioblastoma growth. *Oncotarget*. 2015; 6:31413–27. <https://doi.org/10.18632/oncotarget.5105>
9. Edwards JC, Kahl CR. Chloride channels of intracellular membranes. *FEBS Lett*. 2010; 584:2102-2111.
  10. Littler DR, Harrop SJ, Goodchild SC, Phang JM, Mynott AV, Jiang L, Valenziela SM, Mazzanti M, Brown LJ, Breit SN, Curmi PM. The enigma of the CLIC proteins: Ion channels, redox proteins, enzymes, scaffolding proteins? *FEBS Lett*. 2010; 584:2093-2101.
  11. Argenzio E, Moolenaar WH. Emerging biological roles of Cl<sup>-</sup> intracellular channel proteins. *J Cell Sci*. 2016; 129:4165-4174.
  12. Tung JJ, Kitajewski J. Chloride intracellular channel 1 functions in endothelial cell growth and migration. *J Angiogenesis Res*. 2010; 2:23.
  13. Wang L, He S, Tu Y, Ji P, Zong J, Zhang J, Feng F, Zhao J, Zhang Y, Gao G. Elevated expression of chloride intracellular channel 1 is correlated with poor prognosis in human gliomas. *J Exp Clin Cancer Res*. 2012; 31:44.
  14. Knowles LM, Malik G, Hood BL, Conrads TP, Pilch J. CLT1 targets angiogenic endothelium through CLIC1 and fibronectin. *Angiogenesis*. 2012; 15:115-129.
  15. Gurski LA, Knowles LM, Basse PH, Maranchie JK, Watkins SC, Pilch J. Relocation of CLIC1 promotes tumor cell invasion and colonization of fibrin. *Mol Cancer Res*. 2015; 13:273-280.
  16. Chang YH, Wu CC, Chang KP, Yu JS, Chang YC, Liao PC. Cell secretome analysis using hollow fiber culture system leads to the discovery of CLIC1 protein as a novel plasma marker for nasopharyngeal carcinoma. *J Proteome Res*. 2009; 8:5465-5474.
  17. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. *Proc Natl Acad Sci U S A*. 2004; 101:13368-13373.
  18. Thuringer D, Chanteloup G, Boucher J, Pemet N, Boudesco C, Jego G, Chatelier A, Bois P, Gobbo J, Cronier L, Solary E, Garrido C. Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells. *Oncotarget*. 2017; 8:37681–93. <https://doi.org/10.18632/oncotarget.16949>.
  19. Wong R, Turlova E, Feng ZP, Rutka JT, Sun HS. Activation of TRPM7 by naltriben enhances migration and invasion of glioblastoma cells. *Oncotarget*. 2017; 8:11239–48. <https://doi.org/10.18632/oncotarget.14496>.
  20. Gautier M, Perriere M, Monet M, Vanlaeys A, Korichneva I, Dhennin-Duthille I, Ouadid-Ahidouch H. Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme. *Curr Med Chem*. 2016; 23:4092-4107.
  21. Li H, Lei B, Xiang W, Wang H, Feng W, Liu Y, Qi S. Differences in Protein Expression between the U251 and U87 Cell Lines. *Turk Neurosurg*. 2017; 27:894-903.
  22. Thuringer D, Jego G, Wettstein G, Terrier O, Cronier L, Yousfi N, Hebrard S, Bouchot A, Hazoume A, Joly AL, Gleave M, Rosa-Calatrava M, Solary E, Garrido C. Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. *FASEB J*. 2013; 27:4169-4183.
  23. Edgar JR. Q&A: What are exosomes, exactly? *BMC Biol*. 2016; 14:46.
  24. Simard M, Nedergaard M. The neurobiology of glia in the context of water and ion homeostasis. *Neuroscience*. 2004; 129:877-896.
  25. Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium. *Physiol Rev*. 2001; 81:1415-1459.
  26. Cheng H, Lederer WJ. Calcium sparks. *Physiol Rev*. 2008; 88:1491-1545.
  27. Moccia F, Berra-Romani R, Tritto S, Signorelli S, Taglietti V, Tanzi F. Epidermal growth factor induces intracellular Ca<sup>2+</sup> oscillations in microvascular endothelial cells. *J Cell Physiol*. 2003; 194:139-150.
  28. Saleem H, Tovey SC, Molinski TF, Taylor CW. Interactions of antagonists with subtypes of inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptor. *Br J Pharmacol*. 2014; 171:3298-3312.
  29. Leng TD, Li MH, Shen JF, Liu ML, Li XB, Sun HW, Branigan D, Zeng Z, Si HF, Li J, Chen J, Xiong ZG. Suppression of TRPM7 inhibits proliferation, migration, and invasion of malignant human glioma cells. *CNS Neurosci Ther*. 2015; 21:252-261.
  30. Choi KJ, Kim KS, Kim SH, Kim DK, Park HS. Caffeine and 2-Aminoethoxydiphenyl Borate (2-APB) Have Different Ability to Inhibit Intracellular Calcium Mobilization in Pancreatic Acinar Cell. *Korean J Physiol Pharmacol*. 2010; 14:105-111.
  31. Chokshi R, Fruasaha P, Kozak JA. 2-aminoethyl diphenyl borinate (2-APB) inhibits TRPM7 channels through an intracellular acidification mechanism. *Channels (Austin)*. 2012; 6:362-369.
  32. Santos CR, Schulze A. Lipid metabolism in cancer. *FEBS J*. 2012; 279:2610-2623.
  33. Vïlla GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, et al. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. *Cancer Cell*. 2016; 30:683-693.
  34. Adlakha YK, Saini N. MicroRNA: a connecting road between apoptosis and cholesterol metabolism. *Tumour Biol*. 2016; 37:8529-8554.
  35. Loh WP, Yang Y, Lam KP. miR-92a enhances recombinant protein productivity in CHO cells by increasing intracellular cholesterol levels. *Biotechnol J*. 2017; 12:12.



36. Valenzuela SM, Alkhamici H, Brown LJ, Almond OC, Goodchild SC, Came S, Curmi PM, Holt SA, Cornell BA. Regulation of the membrane insertion and conductance activity of the metamorphic chloride intracellular channel protein CLIC1 by cholesterol. *PLoS One*. 2013; 8:e56948.
37. Jiang L, Phang JM, Yu J, Harrop SJ, Sokolova AV, Duff AP, Wilk KE, Alkhamici H, Breit SN, Valenzuela SM, Brown LJ, Curmi PM. CLIC proteins, ezrin, radixin, moesin and the coupling of membranes to the actin cytoskeleton: a smoking gun? *Biochim Biophys Acta*. 2014; 1838:643-657.
38. Hossain KR, Holt SA, Le Brun AP, Al Khamici H, Valenzuela SM. X-ray and Neutron Reflectivity Study Shows That CLIC1 Undergoes Cholesterol-Dependent Structural Reorganization in Lipid Monolayers. *Langmuir*. 2017; 33:12497-12509.
39. Thuringer D, Boucher J, Jegou G, Pernet N, Cronier L, Hammann A, Solary E, Garrido C. Transfer of functional microRNAs between glioblastoma and microvascular endothelial cells through gap junctions. *Oncotarget*. 2016; 7:73925-34. <https://doi.org/10.18632/oncotarget.12136>.
40. Khan IN, Ullah N, Hussein D, Saini KS. Current and emerging biomarkers in tumors of the central nervous system: Possible diagnostic, prognostic and therapeutic applications. *Semin Cancer Biol*. 2017 Jul 31. <https://doi.org/10.1016/j.semcancer.2017.07.004>. [Epub ahead of print].
41. D'Asti E, Chemmakrishnaiah S, Lee TH, Rak J. Extracellular Vesicles in Brain Tumor Progression. *Cell Mol Neurobiol*. 2016; 36:383-407.
42. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nat Cell Biol*. 2008; 10:619-624.
43. Tung JJ, Tattersall IW, Kitajewski J. Tips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesis. *Cold Spring Harb Perspect Med*. 2012; 2:a006601.
44. Carbonell WS, DeLay M, Jahangiri A, Park CC, Agbi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. *Cancer Res*. 2013; 73:3145-3154.
45. Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. *Neoplasia*. 2014; 16:543-561.
46. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J Cell Sci*. 2000; 113:3365-74.
47. Nakase I, Kobayashi NB, Takatani-Nakase T, Yoshida T. Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes. *Sci Rep*. 2015; 5:10300.
48. Tian T, Zhu YL, Zhou YY, Liang GF, Wang YY, Hu FH, Xiao ZD. Exosome uptake through clathrin-mediated endocytosis and macropinocytosis and mediating miR-21 delivery. *J Biol Chem*. 2014; 289:22258-22267.
49. Laulagnier K, Javalet C, Hemming FJ, Chivet M, Lachenal G, Blot B, Chatellard C, Sadoul R. Amyloid precursor protein products concentrate in a subset of exosomes specifically endocytosed by neurons. *Cell Mol Life Sci*. 2018; 75:757-773.
50. Shin W, Ge L, Arpino G, Villarreal SA, Hamid E, Liu H, Zhao WD, Wen PJ, Chiang HC, Wu LG. Visualization of Membrane Pore in Live Cells Reveals a Dynamic-Pore Theory Governing Fusion and Endocytosis. *Cell*. 2018; 173:934-945.e12.
51. Oh HG, Chun YS, Park CS, Kim TW, Park MK, Chung S. Regulation of basal autophagy by transient receptor potential melastatin 7 (TRPM7) channel. *Biochem Biophys Res Commun*. 2015; 463:7-12.
52. Inoue K, Xiong ZG. Silencing TRPM7 promotes growth/proliferation and nitric oxide production of vascular endothelial cells via the ERK pathway. *Cardiovasc Res*. 2009; 83:547-557.
53. Baldoli E, Maier JA. Silencing TRPM7 mimics the effects of magnesium deficiency in human microvascular endothelial cells. *Angiogenesis*. 2012; 15:47-57.
54. Zeng Z, Inoue K, Sun H, Leng T, Feng X, Zhu L, Xiong ZG. TRPM7 regulates vascular endothelial cell adhesion and tube formation. *Am J Physiol Cell Physiol*. 2015; 308:C308-318.
55. Visser D, Langeslag M, Kedziora KM, Klarenbeek J, Kamermans A, Horgen FD, Fleig A, van Leeuwen FN, Jalink K. TRPM7 triggers Ca<sup>2+</sup> sparks and invadosome formation in neuroblastoma cells. *Cell Calcium*. 2013; 54:404-415.
56. Wang P, Zhang C, Yu P, Tang B, Liu T, Cui H, Xu J. Regulation of colon cancer cell migration and invasion by CLIC1-mediated RVD. *Mol Cell Biochem*. 2012; 365:313-321.
57. Zhang S, Wang XM, Yin ZY, Zhao WX, Zhou JY, Zhao BX, Liu PG. Chloride intracellular channel 1 is overexpression in hepatic tumor and correlates with a poor prognosis. *APMIS*. 2013; 121:1047-1053.
58. Gritti M, Würth R, Angelini M, Barbieri F, Peretti M, Pizzi E, Pattarozzi A, Carra E, Siritto R, Daga A, Curmi PM, Mazzanti M, Florio T. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. *Oncotarget*. 2014; 5:11252-68. <https://doi.org/10.18632/oncotarget.2617>.
59. Chen WL, Barszczyk A, Turlova E, Deurloo M, Liu B, Yang BB, Rutka JT, Feng ZP, Sun HS. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell

- proliferation, migration and invasion. *Oncotarget*. 2015; 6:16321–40. <https://doi.org/10.18632/oncotarget.3872>
60. Sander P, Mostafa H, Soboh A, Schneider JM, Pala A, Baron AK, Moepps B, Wirtz CR, Georgieff M, Schneider M. Vacquinol-1 inducible cell death in glioblastoma multiforme is counter regulated by TRPM7 activity induced by exogenous ATP. *Oncotarget*. 2017; 8:35124–37. <https://doi.org/10.18632/oncotarget.16703>.
  61. Leng T, Lin S, Xiong Z, Lin J. Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels. *Int J Physiol Pathophysiol Pharmacol*. 2017; 9:8-15.
  62. Andres-Leon E, Cases I, Alonso S, Rojas AM. Novel miRNA-mRNA interactions conserved in essential cancer pathways. *Sci Rep*. 2017; 7:46101.
  63. Haug BH, Hald OH, Utnes P, Roth SA, Lokke C, Flaegstad T, Einvik C. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs. *Anticancer Res*. 2015; 35:2521-2530.
  64. Yee NS. Role of TRPM7 in Cancer: Potential as Molecular Biomarker and Therapeutic Target. *Pharmaceuticals (Basel)*. 2017; 10:39.
  65. Kamerkar S, LeBleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ, Kalluri R. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. *Nature*. 2017; 546:498-503.
  66. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol*. 2008; 10:1470-1476.
  67. Wang R, Gurguis CI, Gu W, Ko EA, Lim I, Bang H, Zhou T, Ko JH. Ion channel gene expression predicts survival in glioma patients. *Sci Rep*. 2015; 5:11593.
  68. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Prindal-Bengtson B, Dingli F, Loew D, Tkach M, Thery C. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci U S A*. 2016; 113:E968-977.
  69. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. *J Cell Biol*. 1998; 143:1341-1352.
  70. Guatimosim S, Guatimosim C, Song LS. Imaging calcium sparks in cardiac myocytes. *Methods Mol Biol*. 2011; 689:205-214.

## **ANNEXE 5**

### *Exosomes in cancer theranostic: Diamonds in the Rough*

Marine Cordonnier, Gaëtan Chanteloup, Nicolas Isambert, Renaud  
Seigneuric, Pierre Fumoleau, Carmen Garrido & Jessica Gobbo

*review*



## Exosomes in cancer theranostic: Diamonds in the rough

Marine Cordonnier, Gaëtan Chanteloup, Nicolas Isambert, Renaud Seigneuric, Pierre Fumoleau, Carmen Garrido & Jessica Gobbo

To cite this article: Marine Cordonnier, Gaëtan Chanteloup, Nicolas Isambert, Renaud Seigneuric, Pierre Fumoleau, Carmen Garrido & Jessica Gobbo (2017): Exosomes in cancer theranostic: Diamonds in the rough, Cell Adhesion & Migration, DOI: [10.1080/19336918.2016.1250999](https://doi.org/10.1080/19336918.2016.1250999)

To link to this article: <http://dx.doi.org/10.1080/19336918.2016.1250999>



Published online: 06 Feb 2017.



Submit your article to this journal [↗](#)



Article views: 95



View related articles [↗](#)



View Crossmark data [↗](#)

Full Terms & Conditions of access and use can be found at  
<http://www.tandfonline.com/action/journalInformation?journalCode=kcam20>

Download by: [Bibl de L'Univ de Bourgogne]

Date: 22 February 2017, At: 02:34

REVIEW

## Exosomes in cancer theranostic: Diamonds in the rough

Marine Cordonnier<sup>a,b,#</sup>, Gaëtan Chanteloup<sup>a,b,#</sup>, Nicolas Isambert<sup>a,b,c</sup>, Renaud Seigneuric<sup>a,b</sup>, Pierre Fumoleau<sup>c</sup>, Carmen Garrido<sup>a,b,c,d,#</sup>, and Jessica Gobbo<sup>a,b,c,#</sup>

<sup>a</sup>INSERM, UMR 866, Laboratoire d'Excellence LipSTIC, Dijon, France; <sup>b</sup>University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France; <sup>c</sup>Department of Medical Oncology, Georges-François Leclerc Centre, Dijon, France; <sup>d</sup>Equipe Labellisée par la Ligue Nationale Contre le Cancer, Paris, France

### ABSTRACT

During the last 10 years, exosomes, which are small vesicles of 50–200 nm diameter of endosomal origin, have aroused a great interest in the scientific and clinical community for their roles in intercellular communication in almost all physiological and pathological processes. Most cells can potentially release these nanovesicles that share with the parent cell a similar lipid bilayer with transmembrane proteins and a panel of enclosed soluble proteins such as heat shock proteins and genetic material, thus acting as potential nanoshuttles of biomarkers. Exosomes surface proteins allow their targeting and capture by recipient cells, while the exosomes' content can modify the physiological state of recipient cells. Tumor derived exosomes by interacting with other cells of the tumor microenvironment modulate tumor progression, angiogenic switch, metastasis, and immune escape. Targeting tumor-derived exosomes might be an interesting approach in cancer therapy. Furthermore, because a key issue to improve cancer patients' outcome relies on earlier cancer diagnosis (metastases, as opposed to the primary tumor, are responsible for most cancer deaths) exosomes have been put forward as promising biomarker candidates for cancer diagnosis and prognosis. This review summarizes the roles of exosomes in cancer and clinical interest, focusing on the importance of exosomal heat shock proteins (HSP). The challenges of clinical translation of HSP-exosomes as therapeutic targets and biomarkers for early cancer detection are also discussed.

### ARTICLE HISTORY

Received 15 August 2016  
Revised 13 October 2016  
Accepted 17 October 2016

### KEYWORDS

cancer diagnosis; cancer therapy; exosomes; heat shock proteins

### Introduction

For many years, researchers thought that intercellular communications were ensured only by hormones, cytokines or neurotransmitters. However, it is now well established that cells can communicate by means of extracellular vesicles (EVs). EVs are a generic name for all vesicles that are small spherical structures surrounded by a lipid bilayer (of similar structure to that of cell membranes) and that contain hydrophilic soluble components. Through the extracellular vesicles, cells can transfer information from the plasma membrane or internal compartments.<sup>1</sup> There are different EVs: (i) directly formed and released from the cells' plasma membrane e.g. microparticles,<sup>2</sup> microvesicles,<sup>3</sup> or ectosomes,<sup>4</sup> (ii) with an endocytic origin and release in the extracellular media by exocytosis called exosomes.<sup>5</sup> (iii) that present several characteristics of exosomes but differ by certain biophysical properties, i.e. exosomes-like vesicles,<sup>6,7</sup> (iv) release by cells in apoptosis and called apoptotic vesicles.<sup>8</sup> Recently, a new type of EVs have

been described in gastrointestinal stromal tumors called spherosomes.<sup>9</sup> All these vesicles types differ in their sub-cellular origin, their biophysical and/or biochemical properties, their receptors composition, and their content in soluble proteins and genetic material. As they contain some nanoliters of cytosol and expose at the outer space the same proteins than the parental cell, they are also considered as nanosized cells with a functional role in many biological processes. Among the different EVs, exosomes have been particularly studied since they have been shown to play a role in many physiological and pathological processes.<sup>10–12</sup> Exosomes are cup-shaped nanovesicles that represent a distinct class of membrane vesicles, with a density of 1.13–1.19 g/ml and a diameter of 50–200 nm. These vesicles form a bioactive cargo since they carry genetic material including DNA, mRNA and miRNA, and numerous proteins, notably heat shock proteins, known to play important roles in immunity and cancer.<sup>10,13,14</sup> The exosome, thanks to its a lipid bilayer, act like a nanoshuttle protecting these

**CONTACT** Jessica Gobbo  [jgobbo@cgfl.fr](mailto:jgobbo@cgfl.fr)  Georges-François Leclerc Center, 1 rue du Professeur Marion, 21079 Dijon, France.

Color versions of one or more of the figures in the article can be found online at [www.tandfonline.com/kcam](http://www.tandfonline.com/kcam).

\*These authors contributed equally to this work.

© 2017 Taylor & Francis

molecules from their degradation in the extracellular medium. In this review we provide a comprehensive overview of the interest of heat shock proteins contained in exosomes in cancer diagnosis and therapy.

### Discovery of exosomes


The term “exosomes” was first used in 1981 by Trams *et al.* to appoint small vesicles secreted by several cell types in the extracellular media.<sup>5</sup> In 1983, Johnstone *et al.* discovered with the help of electron microscopy that these vesicles derived from multivesicular bodies (MVBs) and have an endocytic origin.<sup>15</sup> At the time, exosomes generated a poor interest since they were considered as a mean to eliminate obsolete proteins.<sup>16</sup> But in 1996, Raposo *et al.* discovered for the first time that these nanovesicles secreted by antigen-presenting cells (APCs) bore functional peptide–MHC complexes.<sup>17</sup> This article opened a new field in the study of these interesting nanovesicles. Two years later, it was demonstrated the release of exosomes by dendritic cells (DCs) and the ability of tumor peptide-pulsed DC-derived exosomes to suppress growth tumor *in vivo*.<sup>18</sup> Following pioneer studies showing the potential role of exosomes in the regulation of

immune responses, myriad of articles have been published related to the immune function of exosomes<sup>10</sup> and their role in cancer.<sup>11</sup> Furthermore, in addition to immune cells, many other cell types have been described as exosome secretory cells such as epithelial cells,<sup>19</sup> neurons<sup>20</sup> and tumor cells.<sup>21</sup>

Exosomes can be isolated from cell culture supernatants and can be found in numerous body fluids such as blood,<sup>22,23</sup> urine,<sup>24</sup> saliva,<sup>25</sup> bronchoalveolar fluid,<sup>26</sup> seminal fluid,<sup>27</sup> amniotic fluid,<sup>28</sup> breast milk,<sup>29</sup> tumor effusions<sup>30</sup> and cerebrospinal fluid.<sup>31</sup>

### Biogenesis

The biogenesis of the exosome starts with the invagination of the plasma membrane leading to the endosome formation. Endosomes can differentiate in multi-vesicular bodies (MVBs), which are endocytic structures formed by the budding of an endosomal membrane into the lumen of the compartment.<sup>32</sup> This leads to the formation of small vesicles called intraluminal vesicles (ILVs), future exosomes. Then, the fusion of these MVBs with the plasma membrane provokes the release of the ILVs in extracellular space, and become exosomes (Fig. 1). Although the biological function of MVBs was



**Figure 1.** Scheme of exosomes biogenesis, composition and internalization. Biogenesis: the biogenesis of exosomes involves 4 different steps: (1) the membrane invagination; (2) endosome formation; (3) generation of the exosomes precursors, called intraluminal vesicles (ILVs), by inward budding of endosomes. These accumulations of ILVs is termed as multivesicular bodies (MVBs); (4) the fusion of MVBs with the plasma membrane release the ILVs in the extracellular space by exocytosis and become exosomes. Composition: Exosome are composed by different types of enzymes and proteins involved in: adhesion, traffic, intracellular signaling, immunostimulatory molecules, multivesicular body (MVB) formation and heat shock proteins (HSPs). Exosomes contain lipids such as (i) saturated phospholipids (phosphatidyl-ethanolamine, glycerophospholipids, phosphatidyl-choline and phosphatidyl-serine) (ii) sphingolipids (ceramides), (iii) cholesterol. Finally, exosomes contain nucleic acids, including miRNA, mRNA, DNA and small non coding RNA (snRNA, tRNA). Internalization: The exosome may, (i) elicit transduction of the signal via intracellular signaling pathways by direct contact through adhesion molecules like integrin or through a ligand-receptor interaction, (ii) be endocytosed via phagocytosis, macropinocytosis or receptor-mediated endocytosis, or (iii) fusion with the plasma membrane and transfer its content into the cytoplasm of the recipient cell.

interpreted for many years to be a late step in the degradation pathway toward lysosomes, we now know that MVBs have an alternative fate participating in the exocytic fusion of their external membrane with the plasma membrane. This phenomenon allows the excretion of exosomes by exocytosis into the extracellular space. The mechanisms underlying the sorting of the intraluminal vesicles are not yet fully understood, but 2 ways of exosome sorting have been proposed, dependent or independent on Endosomal Sorting Complex Required for Transport (ESCRT) signals.<sup>33</sup> This complex consists of 4 soluble protein ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III. ESCRT is involved in the process of membrane invagination to the formation of ILVs and in the selection of proteins integrating these vesicles.<sup>34</sup> Concerning ESCRT-independent signals that regulate exosome secretion we can name the ceramide pathway,<sup>35</sup> intracellular  $Ca^{2+}$  levels,<sup>36</sup> p53 status,<sup>37</sup> Rab protein family,<sup>38,39</sup> Syndecan-Syntenin-ALIX proteins,<sup>40</sup> high level of heparanase<sup>41</sup> and pH.<sup>42</sup>

How the exosome penetrates into the recipient cell is still a debated issue. Three mechanisms have been proposed based on indirect evidences and in vitro studies: (i) direct contact between surface molecules of vesicles and cells, (ii) endocytosis of exosomes, and (iii) fusion between the membranes of the cell and the exosome.<sup>10</sup> Once the exosome penetrates into the host cell, its content is released in the plasma membrane or in the cytoplasm (Fig. 1).

### Composition

The composition of exosomes allows their discrimination from other EVs' family members.<sup>43,44</sup> The exosome membrane composition is the same than that of the mother cell but present specific enrichments and they contain proteins, lipid and genetic material (Fig. 1). All exosome components described are listed in Exocarta website. Proteins present in exosomes include adhesion proteins such as tetraspanins (CD9, CD63, CD81) and integrins (LFA-1), immunostimulatory molecules (MHC I/II), cytoskeleton molecules (actin, myosin, tubulin), membrane trafficking proteins (Rab GTPases such as Rab 5 and annexin), proteins involved in MVB formation (ALIX, TSG101), intracellular signaling proteins ( $G\alpha$ , 14-3-3, syntenin), lipid raft associated proteins (flotillin-1), enzymes (pyruvate kinase, GAPDH), certain ligands such as FAS-L. Finally, several HSPs have been retrieved in exosomes lumen (HSP27, HSP60, HSP70, HSP90) and in exosome membrane (HSP70, HSP60 and HSP90). Some of these proteins are specifically enriched in exosomes compared to cell lysate and are classically used as exosome markers (CD9, CD63, CD81, ALIX,

TSG101).<sup>45</sup> Nevertheless, very recently, Kowal et al. compared the composition of EVs subtypes and revealed that although exosomes are enriched in CD9, CD63 and CD81, only TSG101 allows to distinguish exosomes from other EVs subtypes.<sup>46</sup> Finally, numerous studies have revealed that some proteins within the exosomes are dependent on the cell type secreting them while others are independent from the parental cell.<sup>47</sup> These different types of proteins become incorporated into exosomes during exosome formation and serve as cargo for cell-cell communication. Besides, protein exosomes are enriched in lipids such as saturated phospholipids (i.e., phosphatidyl-ethanolamin, phosphatidyl-serin, phosphatidyl-choline), sphingolipids (e.g. ceramids), and cholesterol. These lipid compositions confer to exosomes an exceptional rigidity compared to a plasma membrane.<sup>48</sup> Additional components are found in exosomes including genetic materials such as mRNA (mRNA), transcripts, microRNA (miRNA), and small non coding RNA (snRNA, tRNA).<sup>49</sup>

### Clinical interest of exosomes in cancer

Researches on exosomes have considerably increased over the past decade. Although different areas of research are interested in exosomes, most scientific publications are related to cancer. Exosomes have been reported to be involved in all stages in cancer development: (i) tumorigenic transformation, (ii) tumor growth, (iii) angiogenesis, (iv) modulation of immune responses, and (v) induction of mechanisms to acquire therapy resistance.<sup>50-53</sup> The impact of exosomes in clinical research is demonstrated by the fact that there are already 19 clinical trials ongoing (web site <https://clinicaltrials.gov/>). Among them, 13 involve the study of exosomes as cancer diagnosis biomarkers whereas the others use the exosomes for cancer therapy purposes. Thus, exosomes has emerged as potential biomarkers and therapeutic targets in cancer.

### Exosomes as biomarkers

It is well established that the earlier the cancer is diagnosed, the better the survival rate. Although numerous works have been consecrated to early cancer diagnosis, today there is not yet a reliable detection non-invasive method. The main reasons for this are: first of all, in general there is a poor patients compliance, which make difficult to draw any conclusions from the clinical studies. For example, in France, in 2014, the participation rate for breast cancer screening was only of 52.1%.<sup>54</sup> Secondly, actual detection methods, mainly based on medical imaging, have the limitation of tumor detection at an

early stage. Finally, certain publications have shown that some imaging approaches can have undesirable side effects and favor the appearance of tumors. For instance, mammography has been related to cancer apparition -about 1 to 20 for 100 000 mammograms.<sup>55</sup> For all these reasons, it is necessary to develop more performing diagnosis methods. Exosomes appear to be powerful circulating biomarkers.<sup>56-58</sup> These vesicles, reported to be stable and biologically active in human blood plasma up to 3 months, can reveal potential diagnostic information through their examination in body fluids, known as liquid biopsies.<sup>59</sup> They are great potential tools for providing noninvasive, sensitive and economically justifiable new diagnosis methods in oncology.<sup>60</sup> The main advantage of quantifying tumor-derived exosomes compared to circulating tumor cells (CTCs) is that exosomes are found in large amounts compared to CTCs (e.g :  $53.2 \pm 1.6 \times 10^8$  exosomes per  $10^6$  cells in the 24 h period, determined by Nanoparticle Tracking Analysis, Nano-sight LM10,<sup>61</sup> Furthermore, exosomes can be quantified non-invasively in urines and other human fluids.

During the last years, improvement in some techniques like mass spectrometry has allowed to better study exosome protein content. First, several studies indicate that tumor derived exosomes carry more proteins than healthy donors-derived exosomes, particularly when compared to patients with an advanced stage disease.<sup>62,63</sup> In 2012, Peinado's team defined a melanoma-specific exosome signature that included tyrosinase-related protein-2 (TYRP2), very late antigen 4 (VLA-4), heat-shock-protein 70 (HSP70), an HSP90 isoform and the MET oncoprotein.<sup>62</sup> Furthermore, TrkB (Tropomyosin receptor kinase B) expression was detected in exosomes isolated from plasma of glioblastoma patients, suggesting that this receptor may be considered also as a new biomarker for glioblastoma diagnosis.<sup>64</sup> It was latter on reported that certain proteins were differentially expressed dependently on the melanoma cells from which the exosomes were analyzed, revealing a specific signature for metastatic cell lines.<sup>65</sup> In this way, in exosomes from patients with metastatic melanoma, MIA (Melanoma Inhibitory Activity) and S100B can be detected, therefore their quantification presents diagnostic and prognostic utility.<sup>66</sup> In 2015, Hoshino et al. revealed that specific integrin expression in exosomes could be used to predict organ-specific metastasis.<sup>67</sup> In Non Small Cell Lung Cancer (NSCLC), leucine-rich  $\alpha$ -2-glycoprotein (LRG1) was found to be expressed at higher levels in urinary exosomes of NSCLC patients suggesting that LRG1 may be a candidate biomarker for non-invasive diagnosis of NSCLC in urine. (Li *et al.*,<sup>68</sup> 1) More recently, it has been determined a combination of several exosomal proteins (CD151, CD171 and tetraspanin 8)

that could be used as a promising diagnostic tool of lung cancer independently of its stage and histology.<sup>69</sup> In acute myeloid leukemia, TGF $\beta$ 1 expression seems to be useful to predict response to immunotherapy.<sup>70</sup> Finally, in urological malignancies, exosomes in the urine have been described as robust biomarkers and particularly those expressing survivin for early detection of prostate cancer.<sup>71</sup> Other proteins have been described as specific of cancer-derived exosomes compared to healthy donors and seem also candidates as cancer diagnosis tools. This is the case for Claudin, which is present only in exosomes derived from the plasma of women with ovarian cancer,<sup>72</sup> for Glypican-1 that appears to allow to distinguish an ovarian cancer with high specificity and sensitivity<sup>56</sup> or for CD9-CD147 that is embedded in colorectal cancer-derived exosomes.<sup>73</sup> It has also been reported that 80 percent of the exosomes isolated from NSCLC samples was positive for surface EGFR (epithelium growth factor receptor) by immune staining compared to only 2% of the exosomes in chronic inflammatory lung tissue.<sup>74</sup> Finally, as a general marker of cancer-derived exosomes, our team has recently proposed membrane HSP70 that is present in exosomes released by large panel of cancer cells but not by their normal counterparts<sup>50</sup>; see below.

New researches focus on miRNA potential because exosomes offer a miRNA protection from RNases contrary to free circulating miRNA. In 2007, Valadi *et al.* showed for the first time the transfer of functional miRNAs between 2 cells by means of exosomes.<sup>75</sup> miRNAs are a class of 21-25 small non coding but functional RNA that negatively regulates mRNA expression. These small non-coding RNAs plays important roles in cancer,<sup>76</sup> explaining why this discovery suggested a new regulatory role for exosomes in cancer. Today, numerous studies have identified different functional exosomal miRNAs and their role in cancer,<sup>77,78</sup> and proposed their use as diagnosis biomarkers.<sup>79,80,81</sup> For example, in lung cancer 2 miRNAs, miR-21 and miR-155 have been found to be significantly upregulated in recurrent tumors compared to primary tumors.

#### **Exosomes as immunotherapy agents**

Despite improvements in treatment and longer survival, cancer stays a principal cause of death in the world. Since the discovery of functional MHC-peptides complexes in DCs-derived exosomes,<sup>18</sup> many immune functions for exosomes have been described.<sup>10</sup> Researchers tend also to find a new way to modulate immune responses against cancer with the help of exosomes: it is called cell-free vaccines. A classical approach consists in loading exosomes derived from DCs with a tumor specific antigen to restore antitumor immunity. For example, André *et al.*



isolated exosomes from DCs following tumor peptide pulse and their administration in murine tumor models resulted in rejection of established tumors, an action mediated by T-cell activity.<sup>82</sup> It was later shown that vaccination with exosomes containing modified IL-2 could induce a significant regression of a pre-established tumor by targeting the antigen-specific Th1-polarized immune response and cytotoxic T lymphocytes (CTL).<sup>83</sup> More recently, it has been described an alternative approach to prepare exosomes GPI-IL-12 from fusion gene-modified renal cancer cells and to use them for immunization. This modified exosomes-based vaccine can induce an antigen-specific immune response and CTL more efficiently, resulting in more significant cytotoxic effects *in vitro*.<sup>84</sup>

Chaput *et al.* demonstrated that isolated DCs-derived exosomes pulsed with Mart1 (Melanoma antigen recognized by T-cells 1) peptides *in vitro* were able to activate CTL and in, combination with appropriate adjuvants, to induce an antitumor response.<sup>85</sup> In a sarcoma mice model, it was found that OVA (chicken egg ovalbumin) packaged-exosomes allowed a more efficient induction of antitumor immune responses than the native soluble OVA secreted form.<sup>86</sup>

Another way to modulate antitumor immune responses is to combine vaccination by exosomes with other molecules. It was found that ascite-derived exosomes combined to GM-CSF in the immunotherapy of colorectal cancer could induce an antitumor cytotoxic T lymphocyte response<sup>87</sup> whereas combined vaccination with tumor antigen loaded DC-derived exosomes with metronomic cyclophosphamide, which inhibit Treg function and restore T and NK cell effector functions, could boost NK cell mediated antitumor immunity in lung cancer patients.<sup>88</sup> Finally, recent several studies have shown that HSP-exosomes can also modulate the immune system. This part is discussed in more detail below.

### Exosomes as drug delivery cargos

From their characteristics and properties, exosomes have been used as natural drug delivery cargos. Indeed, exosomes offers several advantages: (i) from their composition, exosomes are capable to avoid immune response and are less immunogenic than any other drug delivery system,<sup>89</sup> (ii) exosomes can naturally and easily penetrate in a host cell by several means,<sup>10</sup> (iii) their nanometric size (50–200 nm) allows them to avoid phagocytosis by the circulating mononuclear phagocytic systems, and the easy extravasation through hyper-permeable blood vessels surrounding tumors, in order to reach tumor tissues<sup>90,91</sup> and (iv) exosomes' membrane protects their content from degradation and are very

stable. Several means of modifying exosomes composition exists.<sup>92</sup>

The vast majority of exosome-based drug delivery works and reviews describe the therapeutic transfer of interfering RNAs like synthetic siRNAs or miRNAs and therefore will not be discussed here. We will focus on chemical compound, drugs and proteins.

In a zebrafish brain cancer model, exosome-delivered anticancer drugs through the blood brain barrier decreased tumor growth markers and so could be potentially used as a carrier for brain delivery of anticancer drugs.<sup>93</sup> In 2014, Pascucci *et al.* showed that Mesenchymal Stem Cells (MSC) could incorporate and deliver Paclitaxel to recipient cells through exosomes with increased anti-tumor effects.<sup>94</sup> This study suggests that MSC-derived exosomes could be a new strategy for drug delivery in cancer treatment. Exosomes have also been used as cargos of paclitaxel to increase the effectiveness of the treatment in prostate cancer cells.<sup>95</sup> It has also been shown the effectiveness of targeted exosome-encapsulated doxorubicin for integrin-positive breast cancer cells in inhibition of tumor growth.<sup>96</sup> Recently, Fuhmann *et al.* found that exosomes loaded with hydrophilic porphyrins induced a stronger phototoxic effect than the free drug in a cancer cell model (Integrin-positive cancer cells).<sup>97</sup>

Zhang's research group used exosomes derived from different cell types to successfully delivered curcumin to activate myeloid cells, producing anti-inflammatory activity and apoptosis in monocytes.<sup>98</sup> Finally, genetically engineered exosomes expressing high levels of a suicide gene mRNA and protein-cytosine deaminase (CD) fused to uracil phosphoribosyltransferase (UPRT) have been used to treat pre-established nerve sheath tumors (schwannomas) in an orthotopic mouse model and led to tumor regression.<sup>99</sup>

Exosomes seem to be new actors in theranostic oncology. In this context, recent studies have validated a major role for heat shock proteins in exosomes.

### Heat shock proteins and exosomes

Heat shock proteins are stress proteins subdivided in several families according to their molecular weight: HSP110, HSP90, HSP70, HSP60 and small HSPs. These proteins, very well conserved during evolution, were first discovered in 1962. They represent about 2–3% of cellular proteins. In case of a cellular stress, several of these proteins are overexpressed. A wide variety of stress might induce HSPs expression such as hypoxia, infections, drugs and ischemia.<sup>100</sup> The induction of HSP genes require the activation and translocation to the nucleus of specific transcription factors called "Heat Shock Factors" (HSF). These HSF bind to DNA particular sequences

named “Heat Shock Elements” (HSE) in the promoter of HSP genes allowing their expression.<sup>101</sup>

HSPs have been retrieved in all cellular compartments including cytoplasm, nucleus, membrane, mitochondria or endoplasmic reticulum and act as molecular chaperones to maintain cellular homeostasis. HSPs allow the correct refolding of newly-synthesized proteins or incorrectly folded proteins, following physiological conditions or in response to stress.<sup>102,103</sup> If they can't refold correctly the abnormal protein, HSPs can facilitate their proteasomal degradation.<sup>104</sup> In case of a cell death stimulus, HSPs are overexpressed and have strong anti-apoptotic properties by associating to different key proteins of the apoptosis transduction signaling pathway.<sup>105</sup>

HSPs can also be extracellular (membrane-bound or free after secretion).<sup>106,107</sup> HSP27,<sup>108</sup> HSP70<sup>109</sup> and HSP90<sup>110</sup> have been found secreted in the extracellular media, and some of them, as already mentioned above, have been shown to be present in extracellular vesicles, notably in exosomes.<sup>111-113</sup>

HSPs have an important function in cancer by acting at different levels. First, they can promote tumor growth by stabilizing oncogenic proteins. For example, HSP90 can stabilize c-Src, STAT3, Raf-1 or HER2/neu.<sup>114</sup> Certain HSPs, mainly HSP70 and HSP27, can also increase the resistance to chemotherapy by inhibiting apoptosis.<sup>115</sup> Further, some HSPs can promote angiogenesis such as HSP70 and HSP90 that can sequester HIF- $\alpha$ , which is necessary for VEGF production.<sup>116</sup> HSP90 is also involved in the VEGF synthesis and may be a potential novel target for anti-angiogenic therapy.<sup>117</sup> Moreover, HSPs play a role in metastasis formation; some clinical studies have shown a correlation between the expression of HSP27 and/or HSP70 and the metastatic potential.<sup>118-120</sup> Finally, extracellular HSPs can have immunosuppressive functions. Indeed, HSP70 secreted by colorectal cancer cells can activate myeloid-derived suppressor cells and inhibit T cells activation.<sup>121</sup>

During the last few years there have been a growing interest in extracellular HSPs because of the increasing evidences of their role in the induction of innate immune responses with immunostimulatory or immunosuppressive effects, depending on the nature of the HSP, its localization and cell type.<sup>122</sup> Among them, exosomal HSPs seems to modulate the immune response and play anti-tumor functions.<sup>13</sup> This is the rationale for the use of exosomal HSPs in cancer therapy and diagnosis.


Published data about extracellular HSPs can be confusing as the term “extracellular HSPs” is generally employed for both soluble, membrane-bound and exosomal HSPs. EV-associated HSPs are still quite new in the field of extracellular HSPs and therefore most papers do not unambiguously differentiate between the different

forms of extracellular HSPs. Moreover, very often, researchers write about HSPs in “extracellular vesicles” without given any precision about which subtypes of vesicles they are analyzing. To overcome this problem, in this review, we will summarize mainly data about clearly established exosomal HSPs (i.e. studies in which HSPs are determined from previously isolated exosomes -from human body fluids or culture supernatants).

### **HSP-exosomes in cancer therapy**

Several studies have shown that certain exosomal HSPs could modulate the immune system (Fig. 2). HSP70-exosomes could stimulate natural killer cells (NK) reactivity.<sup>123</sup> When preincubated with HSP70 surface-positive exosomes, NK cells initiated colon tumor cells apoptosis through granzyme B release.<sup>123</sup> It was later on discovered that extracellular HSP70 could also activate macrophages and that this immune modulator effect depended on the ability of HSP70, present on the cell surface, to translocate into the plasma membrane.<sup>124</sup> It was suggested that HSP70, release through exosomes derived from stressed cells, constitute a form of intercellular communication in order to inform macrophages and to induce innate immune responses.<sup>125</sup> These studies suggested that exosomal HSPs could be used in cancer therapy. In 2006, Chen al. tested the vaccination with exosomes presenting HSP60 and HSP90, derived from lymphoma cells. Researchers found an increase in the antitumor immune response involving the induction of IFN production and the activation/maturation of dendritic cells.<sup>126</sup> Several years later, myeloma cell derived exosomes were genetically modified to express endogenous P1A tumor antigen and a transgenic form of membrane-bound HSP70. These HSP70-modified exosomes were able to stimulate *in vitro* DC maturation more efficiently. The researchers used them as a vaccine and found that they stimulate type 1 CD4(+) helper T (Th1) cell responses, P1A-specific CD8(+) CTL responses and antitumor immunity.<sup>127</sup> More recently, Li-Hong et al. demonstrated that exosomes derived from resistant anticancer drug-treated Hepatocellular Carcinoma (HCC) cells conferred a higher antitumor response by inducing HSP-specific NK cell responses *in vitro* and suggested HSP-bearing exosomes could be used as an efficient vaccine for hepatocellular carcinoma immunotherapy.<sup>128</sup>

In apparent contrast with these results, we discovered an immunosuppressive function of HSP70 at the surface of exosomes. We have shown that all cancer cells analyzed so far have the ability to secrete exosomes with HSP70 in their membrane while normal “non cancerous” cells do not. These tumor-derived exosomes, through membrane-anchored HSP70, can activate Myeloid Derived Suppressor Cells (MDSCs),<sup>121,50</sup> which are abundant cells in a cancer context that restrain antitumor immunity and promote



**Figure 2.** Exosomal heat shock proteins: theranostic oncology tools. HSP60 and HSP70 are proposed as potential cancer biomarkers because of their presence only in exosomes derived from cancer cells. Exosomal HSP70 can act in 2 different ways in the modulation of the immune system. Indeed, it can play an immunosuppressive role through the activation of MDSCs that block the anti-tumor response. But it can have an opposite effect by activating immune cells such as macrophages, dendritic cells (DC) or natural killer cells (NK) which may lead to anti-tumor response. Furthermore, HSP90 may represent a therapeutic target because of their ability to respectively increase tumor cell motility (activation of plasmin tPA).

tumor expansion. At the molecular level, the extracellular domain of membrane HSP70 binds to the Toll-Like Receptor 2 at the surface of MDSCs thus activating them. This interaction triggers NF- $\kappa$ B signaling pathway allowing the expression of the inflammatory cytokine IL-6, which binds to its receptor IL-6R in an autocrine manner. This interaction leads to STAT3 phosphorylation via JAK2 pathway, activating survival genes in MDSCs that could exert their immunosuppressive functions.

Recently, our team has confirmed the release of HSP70-exosomes by cancer cells and their ability to activate MDSC in a small cohort of colon cancer patients. Further, we have developed a peptide aptamer (A8) that binds to the extracellular domain of membrane-bound HSP70, called "TKD."<sup>129</sup> Membrane HSP70 binds with much higher affinity to A8 than to the TLR2 receptor in the MDSC. As a result, A8 block the capacity of these tumor-derived exosomes to activate MDSC. Thereby, *in vivo* and *in vitro*, A8 induce the development of an efficient anti-tumor immune response that was associated to an inhibition of MDSC.<sup>50</sup> In line with our results proposing an HSP70 inhibitor -A8- as an agent that can boost the anti-cancer immune response, HSP90-exosomes have been described as to be involved in the activation of plasmin and cancer cells' motility in several cancer

models. Thus, targeting HSP90 could also represent a way to limit tumor invasion by inhibiting a growing number of proteins that are involved in tumor cell motility.<sup>130</sup>

#### HSP-exosomes in cancer diagnosis

The detection and quantification of exosomal HSPs can provide useful information for establishing new circulating and non-invasive biomarkers (Fig. 2). Our team suggests the use of HSP70-exosomes as a cancer marker because they seem a general feature of cancer cells (but not of "normal" non-cancerous cells) and we have demonstrated that they can be measured in large amounts in biological fluids from cancer patients but not from healthy individuals where they are hardly detected.<sup>50</sup> We have patented an interference biolayer protocol to easily capture HSP70-exosomes isolated from human fluids using as a high affinity ligand our peptide aptamer A8 (WO2015/189395<sup>131</sup>). To move beyond the proof of principle that these tumor-derived exosomes (HSP70-exosomes) can be quantified and might be interesting to follow up cancer patients, we have started a prospective study with the anticancer Center Georges-François Leclerc (CGFL, Dijon, France) in breast, ovarian and

lung cancer aiming at determining whether the presence of HSP70-exosomes is predictive of the patients' outcome and whether their detection precedes CTCs and the apparition of metastases.

Finally, HSP60 have also been localized at the membrane of exosomes isolated from blood patients suffering from large bowel cancer, before surgery, but was absent after surgery and in healthy controls. Because of its presence in tumor cells but not in healthy cells, HSP60-exosomes seem to be also interesting biomarkers in cancer, at least for large bowel cancer diagnosis.<sup>13,2</sup>

### Concluding remarks

In conclusion, there are no doubts that even if there are still many questions remaining to be answered, the relatively young field of exosomes in cancer is gaining greater interest within the scientific and medical communities. There are 2 main limitations in the discussion of the works presented in this review. The first and most important is the lack of standardized protocols for isolation of tumor-derived exosomes; the second is the still partial understanding of the mechanisms involving exosomes functions in cancer. Indeed, there is a Janus faced implication of exosomes in cancer biology explained by the fact that exosomes can transfer both tumor-promoting molecules (e.g., oncoproteins) and tumor suppressors and can either induce or suppress an immune response. We believed these debated issues could be solved with more precise protocols to isolate cancer exosomes and taking into account the *in vivo* cancer environmental context.

The available data on exosomes strongly suggest that these diamonds in the rough might represent a revolution in cancer diagnosis and toward a more personalized medicine. Exosomes can be a fingerprint of the parental cell type and of its status. Moreover, they are abundant in body fluids such as blood and urine, therefore representing a precious biomedical tool for non-invasive approaches in cancer diagnosis and cancer patients' follow up. Furthermore, as nanoshuttles of biomarkers and/or anti-tumor drugs, exosomes open new avenues for the clinical management of cancer.

### Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

### Funding

This work is supported by the "Investissements d'Avenir" (ANR-11-LABX-0021), the Fondation pour la Recherche Médicale (FRM grant number ECO20160736090 to GC), the Ligue Nationale Contre le Cancer, the Association pour la

Recherche sur le Cancer, l'Institut National du Cancer, Centre Georges-François Leclerc, Cancéropole Grand-Est and FEDER.

### References

- [1] Hurley JH, Boura E, Carlson L-A, Rózycki B Membrane budding. *Cell* 2010; 143:875-87; PMID:21145455; <http://dx.doi.org/10.1016/j.cell.2010.11.030>
- [2] Marzesco A-M, Janich P, Wilsch-Bräuninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. *J Cell Sci* 2005; 118:2849-58; PMID:15976444; <http://dx.doi.org/10.1242/jcs.02439>
- [3] Borges FT, Reis LA, Schor N Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. *Braz J Med Biol Res Rev Bras Pesqui Médicas E Biológicas Soc Bras Biofísica* 2013; 46:824-830.
- [4] Gasser O, Hess C, Miot S, Deon C, Sanchez J-C, Schiffrerli JA Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. *Exp Cell Res* 2003; 285:243-57; PMID:12706119; [http://dx.doi.org/10.1016/S0014-4827\(03\)00055-7](http://dx.doi.org/10.1016/S0014-4827(03)00055-7)
- [5] Trams EG, Lauter CJ, Salem N, Heine U Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. *Biochim Biophys Acta* 1981; 645:63-70; PMID:6266476; [http://dx.doi.org/10.1016/0005-2736\(81\)90512-5](http://dx.doi.org/10.1016/0005-2736(81)90512-5)
- [6] Hawari FI, Rouhani FN, Cui X, Yu Z-X, Buckley C, Kaler M, Levine SJ Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. *Proc Natl Acad Sci U S A* 2004; 101:1297-302; PMID:14745008; <http://dx.doi.org/10.1073/pnas.0307981100>
- [7] Ristorcelli E, Beraud E, Verrando P, Villard C, Lafitte D, Sbarra V, Lombardo D, Verine A Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. *FASEB J Off Publ Fed Am Soc Exp Biol* 2008; 22:3358-69.
- [8] Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. *J Immunol Baltim Md 1950* 2001; 166:7309-18.
- [9] Junquera C, Castiella T, Muñoz G, Fernández-Pacheco R, Luesma MJ, Monzón M Biogenesis of a new type of extracellular vesicles in gastrointestinal stromal tumors: ultrastructural profiles of spherosomes. *Histochem. Cell Biol* 2016
- [10] Théry C, Ostrowski M, Segura E Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 2009a; 9:581-93; <http://dx.doi.org/10.1038/nri2567>
- [11] Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W Exosomes in cancer: small particle, big player. *J Hematol Oncol J Hematol Oncol* 2015; 8:83; <http://dx.doi.org/10.1186/s13045-015-0181-x>
- [12] Soung YH, Nguyen T, Cao H, Lee J, Chung J. Emerging roles of exosomes in cancer invasion and metastasis. *BMB Rep* 2016; 49:18-25.
- [13] Campanella C, Bavisotto CC, Gammazza AM, Nikolic D, Rappa F, David S, Cappello F, Bucchieri F, Fais S Exosomal Heat Shock Proteins as New Players in

- Tumour Cell-to-cell Communication. *J Circ Biomark* 2014; 1; <http://dx.doi.org/10.5772/58721>
- [14] De Maio A, Vazquez D Extracellular heat shock proteins: a new location, a new function. *Shock* August 2013a; 40:239-246; <http://dx.doi.org/10.1097/SHK.0b013e3182a185ab>
- [15] Pan BT, Johnstone RM Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. *Cell* 1983; 33:967-78; PMID:6307529; [http://dx.doi.org/10.1016/0092-8674\(83\)90040-5](http://dx.doi.org/10.1016/0092-8674(83)90040-5)
- [16] Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J Biol Chem* 1987; 262:9412-20; PMID:3597417
- [17] Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ B lymphocytes secrete antigen-presenting vesicles. *J Exp Med* 1996; 183:1161-72; PMID:8642258; <http://dx.doi.org/10.1084/jem.183.3.1161>
- [18] Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. *Nat Med* 1998; 4:594-600; PMID:9585234; <http://dx.doi.org/10.1038/nm0598-594>
- [19] van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N, Heyman M Intestinal epithelial cells secrete exosome-like vesicles. *Gastroenterology* 2001; 121:337-49; PMID:11487543; <http://dx.doi.org/10.1053/gast.2001.26263>
- [20] Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, et al. Exosomes are released by cultured cortical neurones. *Mol Cell Neurosci* 2006; 31:642-8; <http://dx.doi.org/10.1016/j.mcn.2005.12.003>
- [21] Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. *Nat Med* 2001; 7:297-303; PMID:11231627; <http://dx.doi.org/10.1038/85438>
- [22] Taylor DD, Akyol S, Gerceel-Taylor C Pregnancy-associated exosomes and their modulation of T cell signaling. *J Immunol* Baltimore Md 2006; 1950 176:1534-42.
- [23] Caby M-P, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomal-like vesicles are present in human blood plasma. *Int Immunol* 2005; 17:879-887.
- [24] Pisitkun T, Shen R-F, Knepper MA Identification and proteomic profiling of exosomes in human urine. *Proc Natl Acad Sci U S A* 2004; 101:13368-73; PMID:15326289; <http://dx.doi.org/10.1073/pnas.0403453101>
- [25] Ogawa Y, Kanai-Azuma M, Akimoto Y, Kawakami H, Yanoshita R Exosome-like vesicles with dipeptidyl peptidase IV in human saliva. *Biol Pharm Bull* 2008; 31:1059-62; PMID:18520029; <http://dx.doi.org/10.1248/bpb.31.1059>
- [26] Admyre C, Grunewald J, Thyberg J, Gripenbäck S, Tornling G, Eklund A, Scheynius A, Gabriellson S Exosomes with major histocompatibility complex class II and costimulatory molecules are present in human BAL fluid. *Eur Respir J* 2003; 22:578-83; PMID:14582906; <http://dx.doi.org/10.1183/09031936.03.00041703>
- [27] Gatti J-L, Métayer S, Belghazi M, Dacheux F, Dacheux J-L Identification, proteomic profiling, and origin of ram epididymal fluid exosome-like vesicles. *Biol Reprod* 2005; 72:1452-65; PMID:15635128; <http://dx.doi.org/10.1095/biolreprod.104.036426>
- [28] Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, Hager H-D, Abdel-Bakky MS, Gutwein P, Altevogt P CD24 is a marker of exosomes secreted into urine and amniotic fluid. *Kidney Int* 2007; 72:1095-102; PMID:17700640; <http://dx.doi.org/10.1038/sj.ki.5002486>
- [29] Admyre C, Johansson SM, Qazi KR, Filén J-J, Lahesmaa R, Norman M, Neve EPA, Scheynius A, Gabriellson S Exosomes with immune modulatory features are present in human breast milk. *J Immunol* Baltimore Md 1950 2007; 179:1969-78.
- [30] Andre F, Scharz NEC, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, et al. Malignant effusions and immunogenic tumour-derived exosomes. *Lancet* Lond Engl 2002; 360:295-305; [http://dx.doi.org/10.1016/S0140-6736\(02\)09552-1](http://dx.doi.org/10.1016/S0140-6736(02)09552-1)
- [31] Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, Chalmers RTA, Webb DJ, Dear JW Identification and proteomic profiling of exosomes in human cerebrospinal fluid. *J Transl Med* 2012; 10:5; PMID:22221959; <http://dx.doi.org/10.1186/1479-5876-10-5>
- [32] Duijvesz D, Luider T, Bangma CH, Jenster G Exosomes as biomarker treasure chests for prostate cancer. *Eur Urol* 2011; 59:823-31; PMID:21196075; <http://dx.doi.org/10.1016/j.eururo.2010.12.031>
- [33] Hurley JH ESCRT complexes and the biogenesis of multivesicular bodies. *Curr Opin Cell Biol* 2008; 20:4-11; PMID:18222686; <http://dx.doi.org/10.1016/j.ceb.2007.12.002>
- [34] Williams RL, Urbé S. The emerging shape of the ESCRT machinery. *Nat Rev Mol Cell Biol* 2007; 8:355-368.
- [35] Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brügger B, Simons M Ceramide triggers budding of exosome vesicles into multivesicular endosomes. *Science* 2008; 319:1244-7; PMID:18309083; <http://dx.doi.org/10.1126/science.1153124>
- [36] Savina A, Furlan M, Vidal M, Colombo MI Exosome release is regulated by a calcium-dependent mechanism in K562 cells. *J Biol Chem* 2003; 278:20083-90; PMID:12639953; <http://dx.doi.org/10.1074/jbc.M301642200>
- [37] Feng Z p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. *Cold Spring Harb Perspect Biol* 2010; 2:a001057; PMID:20182617; <http://dx.doi.org/10.1101/cshperspect.a001057>
- [38] Hsu C, Morohashi Y, Yoshimura S-I, Manrique-Hoyos N, Jung S, Lauterbach MA, Bakhti M, Gronborg M, Möbius W, Rhee J, Barr FA, et al. Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A-C. *J Cell Biol* 2010; 189:223-32; PMID:20404108; <http://dx.doi.org/10.1083/jcb.200911018>
- [39] Ostrowski M, Carmo NB, Krumeich S, Fangel I, Raposo G, Savina A, Moita CF, Schauer K, Hume AN, Freitas RP, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat Cell Biol* 2010; 12:19-30-13; PMID:19966785; <http://dx.doi.org/10.1038/ncb2000>

- [40] Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, Ivarsson Y, Depoortere F, Coomans C, Vermeiren E, et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. *Nat Cell Biol* 2012; 14:677-85; PMID:22660413; <http://dx.doi.org/10.1038/ncb2502>
- [41] Thompson CA, Purushothaman A, Ramani VC, Vlodysky I, Sanderson RD Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. *J Biol Chem* 2013; 288:10093-9; PMID:23430739; <http://dx.doi.org/10.1074/jbc.C112.444562>
- [42] Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. *J Biol Chem* 2009; 284:34211-22; PMID:19801663; <http://dx.doi.org/10.1074/jbc.M109.041152>
- [43] Crescitelli R, Lässer C, Szabó TG, Kittel A, Eldh M, Dianzani I, Buzás EI, Lötvall J Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. *J Extracell Vesicles* 2013; 2; PMID:24223256; <http://dx.doi.org/10.3402/jev.v2i0.20677>
- [44] Raposo G, Stoorvogel W Extracellular vesicles: exosomes, microvesicles, and friends. *J Cell Biol* 2013; 200:373-83; PMID:23420871; <http://dx.doi.org/10.1083/jcb.201211138>
- [45] Logozzi M, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. *PLoS One* 2009; 4:e2519.
- [46] Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primal-Bengtson B, Dingli F, Loew D, Tkach M, Théry C Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. *Proc Natl Acad Sci* 2016; 113:E968-77; <http://dx.doi.org/10.1073/pnas.1521230113>
- [47] Hosseini-Beheshti E, Pham S, Adomat H, Li N, Tomlinson Guns ES. Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. *Mol Cell Proteomics* 2012; MCP 11:863-885.
- [48] Ibrahim A, Marban E. Exosomes: Fundamental Biology and Roles in Cardiovascular Physiology. *Annu Rev Physiol* 2016; 78:67-83; PMID:26667071
- [49] Mittelbrunn M, Sánchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. *Nat Rev Mol Cell Biol* 2012; 13:328-335.
- [50] Gobbo J, Marcion G, Cordonnier M, Dias AMM, Pernet N, Hammann A, Richaud S, Mjahed H, Isambert N, Clause V, et al. Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. *J Natl Cancer Inst* 2016; 108; PMID:26598503; <http://dx.doi.org/10.1093/jnci/djv330>
- [51] Crunkhorn S. Cancer: Cancer exosomes promote tumorigenesis. *Nat Rev Drug Discov* 2015; 14:16-16.
- [52] Raimondo S, Corrado C, Raimondi L, De Leo G, Alessandro R. Role of Extracellular Vesicles in Hematological Malignancies. *BioMed Res Int* 2015; 2015:821613.
- [53] Yu, D. et al. Exosomes in development, metastasis and drug resistance of breast cancer. *Cancer Sci* 2015; 106:959-964.
- [54] Santé publique France - InVS / Accueil. Available at <http://invs.santepubliquefrance.fr/> (Accessed: 4th November 2016)
- [55] Institut National Du Cancer - Accueil. Available at <http://www.e-cancer.fr/> (Accessed: 4th November 2016)
- [56] Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature* 2015; 523:177-82; PMID:26106858; <http://dx.doi.org/10.1038/nature14581>
- [57] Gumireddy K, Li A, Chang DH, Liu Q, Kossenkov AV, Yan J, Korst RJ, Nam BT, Xu H, Zhang L, et al. AKAP4 is a circulating biomarker for non-small cell lung cancer. *Oncotarget* 2015; 6:17637-47; PMID:26160834; <http://dx.doi.org/10.18632/oncotarget.3946>
- [58] Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. *Int. J. Cancer* 2015; 136:2616-27.
- [59] Kalra H, Adda CG, Liem M, Ang C-S, Mechler A, Simpson RJ, Hulett MD, Mathivanan S Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. *Proteomics* 2013; 13:3354-64; PMID:24115447; <http://dx.doi.org/10.1002/pmic.201300282>
- [60] Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. *Biochim Biophys Acta* 2014; 1846:539-46.
- [61] Riches A, Campbell E, Borger E, Powis S Regulation of exosome release from mammary epithelial and breast cancer cells – A new regulatory pathway. *Eur J Cancer* 2014; 50(5):1025-34; PMID:24462375; <http://dx.doi.org/10.1016/j.ejca.2013.12.019>
- [62] Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. *Nat Med* 2012; 18:883-91; PMID:22635005; <http://dx.doi.org/10.1038/nm.2753>
- [63] Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, Szperek D, Nowakowski A, Spaczynski M, Baranowski W, et al. Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy. *Gynecol Obstet Sunnyvale Calif Suppl* 2013; 4:3
- [64] Pinet S, Bessette B, Vedrenne N, Lacroix A, Richard L, Jauberteau M-O, Battu S & Lalloué F. TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells. *Oncotarget* 2016; 7:6349-50364; PMID:27385098
- [65] Lazar I, Clement E, Ducoux-Petit M, Denat L, Soldan V, Dauvillier S, Balor S, Burret-Schiltz O, Larue L, Muller C, et al. Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. *Pigment Cell Melanoma Res* 2015; 28:464-75; PMID:25950383; <http://dx.doi.org/10.1111/pcmr.12380>
- [66] Alegre E, Zubiri L, Perez-Gracia JL, González-Cao M, Soria L, Martín-Algarra S, González A Circulating melanoma exosomes as diagnostic and prognosis biomarkers.

- Clin Chim Acta 2016; 454:28-32; PMID:26724367; <http://dx.doi.org/10.1016/j.cca.2015.12.031>
- [67] Hoshino A, Costa-Silva B, Shen T-L, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al. Tumour exosome integrins determine organotropic metastasis. *Nature* 2015; 527:329-35; PMID:26524530; <http://dx.doi.org/10.1038/nature15756>
- [68] Li Y, Zhang Y, Qiu F, Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. *Electrophoresis* 2011; 32:1976-83; PMID:21557262; <http://dx.doi.org/10.1002/elps.201000598>
- [69] Sandfeld-Paulsen B, Jakobsen KR, Bæk R, Folkersen BH, Rasmussen TR, Meldgaard P, Varming K, Jørgensen MM, Sorensen BS. Exosomal Proteins as a Diagnostic Biomarkers in Lung Cancer. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* 2016; 11:1701-1710; <http://dx.doi.org/10.1016/j.jtho.2016.05.034>
- [70] Hong C-S, Muller L, Whiteside TL, Boyiadzis M. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. *Front Immunol* 2014; 5:160; PMID:24782865; <http://dx.doi.org/10.3389/fimmu.2014.00160>
- [71] Khan S, Jutzy JMS, Valenzuela MMA, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. *PLoS One* 2012; 7:e46737; PMID:23091600; <http://dx.doi.org/10.1371/journal.pone.0046737>
- [72] Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. *BMC Cancer* 2009; 9:244; PMID:19619303; <http://dx.doi.org/10.1186/1471-2407-9-244>
- [73] Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. *Nat Commun* 2014; 5:3591; PMID:24710016; <http://dx.doi.org/10.1038/ncomms4591>
- [74] Huang S-H, Li Y, Zhang J, Rong J, Ye S. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T cells. *Cancer Invest* 2013; 31:330-5; PMID:23614656; <http://dx.doi.org/10.3109/07357907.2013.789905>
- [75] Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007; 9:654-9; PMID:17486113; <http://dx.doi.org/10.1038/ncb1596>
- [76] Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer* 2006; 6:259-69; PMID:16557279; <http://dx.doi.org/10.1038/nrc1840>
- [77] Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell* 2014; 26:707-21; PMID:25446899; <http://dx.doi.org/10.1016/j.ccr.2014.09.005>
- [78] Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor STF, Chin AR, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer Cell* 2014; 25:501-15; PMID:24735924; <http://dx.doi.org/10.1016/j.ccr.2014.03.007>
- [79] Chiam K, Wang T, Watson DI, Mayne GC, Irvine TS, Bright T, Smith L, White IA, Bowen JM, Keefe D, et al. Circulating Serum Exosomal miRNAs As Potential Biomarkers for Esophageal Adenocarcinoma. *J Gastrointest Surg Off J Soc Surg Aliment Tract* 2015; 19:1208-15; <http://dx.doi.org/10.1007/s11605-015-2829-9>
- [80] Munagala R, Aqil F, Gupta RC. Exosomal miRNAs as biomarkers of recurrent lung cancer. *Tumour Biol J Int Soc Oncodevelopmental Biol Med* 2016; <http://dx.doi.org/10.1007/s13277-016-4939-8>
- [81] Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol* 2008; 110:13-21.
- [82] André F, Chaput N, Scharz NEC, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu D-H, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. *J Immunol Baltim Md* 1950 2004; 172:2126-36.
- [83] Yang Y, Xiu F, Cai Z, Wang J, Wang Q, Fu Y, Cao X. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. *J Cancer Res Clin Oncol* 2007; 133:389-99; PMID:17219198; <http://dx.doi.org/10.1007/s00432-006-0184-7>
- [84] Zhang Y, Luo C-L, He B-C, Zhang J-M, Cheng G, Wu X-H. Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific anti-tumor response in vitro: a novel vaccine for renal cell carcinoma. *Int J Oncol* 2010; 36:133-40; PMID:19956842
- [85] Chaput N, Scharz NEC, André F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. *J Immunol Baltim Md* 1950 2004; 172:2137-46
- [86] Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, Delcayre A, Le Pecq J-B, Combadière B, Amigorena S, et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. *Cancer Res* 2008; 68:1228-35; PMID:18281500; <http://dx.doi.org/10.1158/0008-5472.CAN-07-3163>
- [87] Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, Li G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. *Mol Ther J Am Soc Gene Ther* 2008; 16:782-90; <http://dx.doi.org/10.1038/mt.2008.1>
- [88] Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. *Oncoimmunology* 2016; 5:e1071008; PMID:27141373; <http://dx.doi.org/10.1080/2162402X.2015.1071008>
- [89] van den Boorn JG, Schlee M, Coch C, Hartmann G. siRNA delivery with exosome nanoparticles. *Nat Biotechnol* 2011; 29:325-6; PMID:21478846; <http://dx.doi.org/10.1038/nbt.1830>

- [90] Lee J, Kim J, Jeong M, Lee H, Goh U, Kim H, Kim B, Park J-H Liposome-Based Engineering of Cells To Package Hydrophobic Compounds in Membrane Vesicles for Tumor Penetration. *Nano Lett* 2015; 15:2938-44; PMID:25806671; <http://dx.doi.org/10.1021/nl5047494>
- [91] Srivastava A, Babu A, Filant J, Moxley KM, Ruskin R, Dhanasekaran D, Sood AK, McMeekin S, Ramesh R Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. *J Biomed Nanotechnol* 2016; 12:1159-73; PMID:27319211; <http://dx.doi.org/10.1166/jbn.2016.2205>
- [92] Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M A comprehensive overview of exosomes as drug delivery vehicles — Endogenous nanocarriers for targeted cancer therapy. *Biochim Biophys Acta BBA - Rev Cancer* 2014; 1846:75-87; <http://dx.doi.org/10.1016/j.bbcan.2014.04.005>
- [93] Yang T, Martin P, Fogarty B, Brown A, Schurman K, Phipps R, Yin VP, Lockman P, Bai S Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. *Pharm Res* 2015; 32:2003-14; PMID:25609010; <http://dx.doi.org/10.1007/s11095-014-1593-y>
- [94] Pascucci L, Cocchè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G & Pessina A Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. *J Control Release Off J Control Release Soc* 2014; 192:262-70; <http://dx.doi.org/10.1016/j.jconrel.2014.07.042>
- [95] Saari H, Lázaro-Ibáñez E, Viitala T, Vuorimaa-Laukkainen E, Siljander P, Yliperttula M Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. *J Control Release Off J Control Release Soc* 2015; 220:727-37; <http://dx.doi.org/10.1016/j.jconrel.2015.09.031>
- [96] Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J, Nie G A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. *Biomaterials* 2014; 35:2383-90; PMID:24345736; <http://dx.doi.org/10.1016/j.biomaterials.2013.11.083>
- [97] Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. *J Control Release Off J Control Release Soc* 2015; 205:35-44; <http://dx.doi.org/10.1016/j.jconrel.2014.11.029>
- [98] Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang H-G A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. *Mol Ther J Am Soc Gene Ther* 2010; 18:1606-14; <http://dx.doi.org/10.1038/mt.2010.105>
- [99] Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. *Mol Ther J Am Soc Gene Ther* 2013; 21:101-8; <http://dx.doi.org/10.1038/mt.2012.161>
- [100] Pace, A. et al. Hsp60, a novel target for antitumor therapy: structure-function features and prospective drugs design. *Curr Pharm Des* 2013; 19:2757-2764.
- [101] Akerfelt M, Morimoto RI, Sistonen L Heat shock factors: integrators of cell stress, development and lifespan. *Nat Rev Mol Cell Biol* 2010; 11:545-55; PMID:20628411; <http://dx.doi.org/10.1038/nrm2938>
- [102] Beckmann RP, Mizzen LE, Welch WJ Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. *Science* 1990; 248:850-4; PMID:2188360; <http://dx.doi.org/10.1126/science.2188360>
- [103] Gething MJ, Sambrook J Protein folding in the cell. *Nature* 1992; 355:33-45; PMID:1731198; <http://dx.doi.org/10.1038/355033a0>
- [104] Lanneau D, Wettstein G, Bonniaud P, Garrido C Heat shock proteins: cell protection through protein triage. *ScientificWorldJournal* 2010; 10:1543-52; PMID:20694452; <http://dx.doi.org/10.1100/tsw.2010.152>
- [105] Lanneau D, de Thonel A, Maurel S, Didelot C, Garrido C Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27. *Prion* 2007; 1:53-60; PMID:19164900; <http://dx.doi.org/10.4161/pri.1.1.4059>
- [106] De Maio A Extracellular Hsp70: export and function. *Curr Protein Pept Sci* 2014; 15:225-31; PMID:24694368; <http://dx.doi.org/10.2174/1389203715666140331113057>
- [107] Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W, Issels RD A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. *Int J Cancer* 1995; 61:272-9; PMID:7705958; <http://dx.doi.org/10.1002/ijc.2910610222>
- [108] Liao W-C, Wu M-S, Wang H-P, Tien Y-W, Lin J-T Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. *Pancreas* 2009; 38:422-6; PMID:19214136; <http://dx.doi.org/10.1097/MPA.0b013e318198281d>
- [109] De Maio A, Vazquez D Extracellular heat shock proteins: a new location, a new function. *Shock Augusta Ga* 2013b; 40:239-46; <http://dx.doi.org/10.1097/SHK.0b013e3182a185ab>
- [110] Sidera K, Patsavoudi E Extracellular HSP90: conquering the cell surface. *Cell Cycle Georget Tex* 2008; 7:1564-8; <http://dx.doi.org/10.4161/cc.7.11.6054>
- [111] Campanella C, Bucchieri F, Merendino AM, Fucarino A, Burgio G, Corona DFV, Barbieri G, David S, Farina F, Zummo G, et al. The odyssey of Hsp60 from tumor cells to other destinations includes plasma membrane-associated stages and Golgi and exosomal protein-trafficking modalities. *PLoS One* 2012; 7:e42008; PMID:22848686; <http://dx.doi.org/10.1371/journal.pone.0042008>
- [112] Schorey JS, Bhatnagar S Exosome function: from tumor immunology to pathogen biology. *Traffic Cph Den* 2008; 9:871-81; <http://dx.doi.org/10.1111/j.1600-0854.2008.00734.x>
- [113] Théry C, Ostrowski M, Segura E Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol* 2009b; 9:581-93; <http://dx.doi.org/10.1038/nri2567>
- [114] Blagosklonny MV Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.



- Leukemia 2002; 16:455-62; PMID:11960322; <http://dx.doi.org/10.1038/sj.leu.2402415>
- [115] Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. *Cell Cycle Georget Tex* 2006; 5:2592-601.
- [116] Neckers L, Ivy SP Heat shock protein 90. *Curr Opin Oncol* 2003; 15:419-24; PMID:14624223; <http://dx.doi.org/10.1097/00001622-200311000-00003>
- [117] Sun J, Liao JK Induction of Angiogenesis by Heat Shock Protein 90 Mediated by Protein Kinase Akt and Endothelial Nitric Oxide Synthase. *Arterioscler Thromb Vasc Biol* 2004; 24:2238-44; PMID:15486309; <http://dx.doi.org/10.1161/01.ATV.0000147894.22300.4c>
- [118] Calderwood SK, Gong J Heat Shock Proteins Promote Cancer: It's a Protection Racket. *Trends Biochem Sci* 2016; 41:311-23; PMID:26874923; <http://dx.doi.org/10.1016/j.tibs.2016.01.003>
- [119] Gibert B, Eckel B, Gonin V, Goldschneider D, Fombonne J, Deux B, Mehlen P, Arrigo A-P, Clézardin P, Diaz-Latoud C Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. *Br J Cancer* 2012; 107:63-70; PMID:22627320; <http://dx.doi.org/10.1038/bjc.2012.188>
- [120] Gong J, Weng D, Eguchi T, Murshid A, Sherman MY, Song B, Calderwood SK Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis. *Oncogene* 2015; 34:5460-71; PMID:25659585; <http://dx.doi.org/10.1038/onc.2015.1>
- [121] Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin J-P, Boireau W, Rouleau A, Simon B, Lanneau D, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. *J Clin Invest* 2010; 120:457-71; PMID:20093776
- [122] Tamura Y, Torigoe T, Kutomi G, Hirata K, Sato N New paradigm for intrinsic function of heat shock proteins as endogenous ligands in inflammation and innate immunity. *Curr Mol Med* 2012; 12:1198-206; PMID:22804242; <http://dx.doi.org/10.2174/156652412803306710>
- [123] Gastpar R, Gehrman M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. *Cancer Res* 2005; 65:5238-47; PMID:15958569; <http://dx.doi.org/10.1158/0008-5472.CAN-04-3804>
- [124] Vega VL, Rodriguez-Silva M, Frey T, Gehrman M, Diaz JC, Steinem C, Multhoff G, Arispe N, De Maio A Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. *J Immunol Baltim Md* 1950 2008; 180:4299-307
- [125] De Maio A Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. *Cell Stress Chaperones* 2011; 16:235-49; PMID:20963644; <http://dx.doi.org/10.1007/s12192-010-0236-4>
- [126] Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q, Cao X Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. *Eur J Immunol* 2006; 36:1598-607; PMID:16708399; <http://dx.doi.org/10.1002/eji.200535501>
- [127] Xie Y, Bai O, Zhang H, Yuan J, Zong S, Chibbar R, Slatery K, Qureshi M, Wei Y, Deng Y, et al. Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8(+) CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70. *J Cell Mol Med* 2010; 14:2655-66; PMID:19627400; <http://dx.doi.org/10.1111/j.1582-4934.2009.00851.x>
- [128] Lv L-H, Wan Y-L, Lin Y, Zhang W, Yang M, Li G-L, Lin H-M, Shang C-Z, Chen Y-J, Min J Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. *J Biol Chem* 2012; 287:15874-85; PMID:22396543; <http://dx.doi.org/10.1074/jbc.M112.340588>
- [129] Stangl S, Varga J, Freysoldt B, Trajkovic-Arsic M, Siveke JT, Greten FR, Ntziachristos V, Multhoff G Selective in vivo imaging of syngeneic, spontaneous, and xenograft tumors using a novel tumor cell-specific hsp70 peptide-based probe. *Cancer Res* 2014; 74:6903-12; PMID:25300920; <http://dx.doi.org/10.1158/0008-5472.CAN-14-0413>
- [130] McCready J, Sims JD, Chan D, Jay DG Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. *BMC Cancer* 2010; 10:294; PMID:20553606; <http://dx.doi.org/10.1186/1471-2407-10-294>
- [131] WO2015/189395. "HSP70 peptide aptamers: Methods and compositions for diagnosis, monitoring and treating cancer."
- [132] Campanella C, Rappa F, Sciumè C, Marino Gammazza A, Barone R, Bucchieri F, David S, Curcurù G, Caruso Bavisotto C, et al. Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery. *Cancer* 2015; 121:3230-9; PMID:26060090; <http://dx.doi.org/10.1002/cncr.29499>

## **ANNEXE 6**

*Liste des publications et des participations à un congrès*

## Liste des publications

### [Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study](#)

GAËTAN CHANTELOUP, Marine Cordonnier, Nicolas Isambert, Aurélie Bertaut, Alice Hervieu, Audrey Hennequin, Maxime Luu, Sylvie Zanetta, Bruno Coudert, Leila Bengrine, Isabelle Desmoulins, Laure Favier, Aurélie Lagrange, Pierre-Benoit Pages, Ivan Gutierrez, Jeanine Lherminier, Laure Avoscan, Clémentine Jankowski, Cédric Rébé, Angélique Chevriaux, Marie-Martine Padeano, Charles Coutant, Sylvain Ladoire, Sylvain Causeret, Laurent Arnould, Céline Charon-Barra, Vanessa Cottet, Julie Blanc, Christine Biquet, Marc Bardou, Carmen Garrido & Jessica Gobbo, **J Extracell Vesicles**, 2020 May 20.

### [Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients](#)

Cordonnier M\*, Nardin C\*, CHANTELOUP G, Derangere V, Algros M, Arnould L, Garrido C\*\*, Aubin F\*\*, Gobbo J\*\*. **J Extracell Vesicles**, 2020 Jan 7.

### [Membrane-anchored heat-shock protein 70 \(Hsp70\) in Cancer](#)

Elmallah MIY, Cordonnier M, Vautrot V, CHANTELOUP G, Garrido C, Gobbo J. **Cancer Lett**, 2019 Oct 25.

### [Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer](#)

Vautrot V, CHANTELOUP G, Elmallah M, Cordonnier M, Aubin F, Garrido C, Gobbo J. **J Oncol**, 2019 Oct 13

### [Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer's disease: Clinical and FDG-PET Correlation.](#)

CHANTELOUP G\*, Cordonnier M\*, Moreno-Ramos T, Pytel V, Matías-Guiu J, Gobbo J, Cabrera-Martín MN, Gómez-Pinedo U, Garrido C, Matías-Guiu JA. **J Alzheimers Dis**. 2019.

### [Increased levels of IL-17a exosomes in psoriasis](#)

Jacquin-Porretaz C, Cordonnier M, Nardin C, Boullerot L, CHANTELOUP G, Vautrot V, Adotevi O, Garrido C, Gobbo J, Aubin F. **ActaDV**, 2019.

### [HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells.](#)

Causse S.Z., Marcion G., CHANTELOUP G., Boudesco C., Grigorash B.B., Uyanik B., Douhard R., Dias A., Dumetier B., Dondaine L., Gozzi G., Moussay E., Paggetti J., Mirjolet C, de Thonel A., Dubrez L., Demidov O.N., Gobbo J., Garrido C. **Oncogene**, 2019.

### [The vesicular transfer of CLIC1 from glioblastoma to microvascular endothelial cells requires TRPM7.](#)

Thuringer D, CHANTELOUP G, Wrinckler P, Garrido C, **Oncotarget**, 2018.

### [HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.](#)

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, CHANTELOUP G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, I Plo, Garrido C, F Girodon, A de Thonel. **Nat Commun**. 2018 Apr 12.

[Modulation of the inwardly rectifying potassium channel Kir4.1 by the pro-invasive miR-5096 in glioblastoma cells.](#)

Thüringer D, CHANTELOUP G, Boucher J, Pernet N, Boudesco C, Jegou G, Chatelier A, Bois P, Gobbo J, Cronier L, Solary E, Garrido C. **Oncotarget**, 2017 Jun 6.

[Exosomes in cancer theranostic: Diamonds in the rough.](#)

Cordonnier M\*, CHANTELOUP G\*, Isambert N, Seigneuric R, Fumoleau P, Garrido C, Gobbo J. **Cell Adh Migr**, 2017 Mar 4.

[Visualization of RNA-Quadruplexes in Live Cells.](#)

Laguerre A, Hukezalie K, Winckler P, Katranji F, CHANTELOUP G, Pirrotta M, Perrier-Cornet JM, Wong JM, Monchaud D. **J Am Chem Soc**, 2015 Jul 8.

## Liste des participations à un congrès

### Communication orale :

[Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study](#), Tumor Liquid Biopsy Symposium, Nancy, 2017.

[Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer's disease: Clinical and FDG-PET Correlation](#), CALM, Montpellier, 2019.

### Communication affichée :

[Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients](#), ISEV, Tokyo, 2019.

[Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients](#), ASCO, Chicago, 2019.

[Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study](#), OncoTrans, Besançon, 2016.

## Résumé

Le cancer est aujourd'hui une maladie qui fait malheureusement partie de notre quotidien, et bien qu'il soit de mieux en mieux traité, de plus en plus de gens en sont atteints. La recherche s'oriente sur deux pans : la thérapie et le diagnostic. Les nouvelles thérapies présentent des résultats spectaculaires jamais atteints à ce jour, mais l'amélioration du diagnostic peut aussi sauver des vies. Il est établi que plus un cancer est diagnostiqué tôt, plus le patient a de chances de guérir. Idem pour le suivi de la maladie. Dans ce contexte de précision et de précocité, la biopsie liquide émerge et possède un avenir très prometteur. Elle consiste en l'étude d'analytes présents dans les fluides corporels, particulièrement la circulation sanguine. On y retrouve principalement, mais pas exclusivement, l'ADN tumoral circulant, les cellules tumorales circulantes (CTCs) et les exosomes.

Ce manuscrit a pour objectif de replacer mon travail de recherche, qui porte sur les exosomes, dans le contexte de la biopsie liquide, afin de laisser libre court aux comparaisons et à la compréhension de leur potentiel diagnostic. Les exosomes sont des nanovésicules libérées par les cellules dans le sang. Elles contiennent du matériel génétique, des lipides et des protéines. Une étape clé pour leur utilisation en tant que biomarqueur est de différencier les exosomes dérivés de tumeur de ceux dérivés d'autres cellules de l'organisme.

La protéine de stress Heat shock protein-70 (HSP70) a été décrite comme étant surexprimée dans les cellules cancéreuses et associée à un mauvais pronostic. Nous avons précédemment démontré que seuls les exosomes dérivés de cellules cancéreuses portaient HSP70 à la membrane. Dans ce travail, nous avons ouvert une étude clinique pilote prospective incluant des patients atteints d'un cancer du sein et du poumon afin de déterminer s'il était possible de détecter et quantifier les HSP70-exosomes dans le sang de patients atteints de tumeurs solides malignes.

Nous avons montré que le taux de HSP70 dans les exosomes, contrairement à la forme soluble, reflétait le contenu en HSP70 dans la biopsie tumorale. Le taux de HSP70-exosomes circulants est augmenté chez les patients atteints d'un cancer à un stade métastatique comparé aux non-métastatique et aux donneurs sains. Nous avons ensuite démontré que les niveaux de HSP70-exosomes étaient corrélés au statut de la maladie, et étaient potentiellement de meilleurs marqueurs que les CTCs. Enfin, nous avons indiqué que le taux de HSP70-exosomes étaient inversement corrélés à la réponse au traitement, et, par conséquent, que le suivi du taux de HSP70 dans les exosomes pourrait être utile dans la prédiction de la réponse au traitement.